{"39fc372b376adbbd26dc6127a907c0a54c1a4f3f": [["BackgroundIn early stages of slowly progressive spasticity of the legs, establishing a diagnosis may be challenging as symptoms are often limited to just one region.", [["legs", "ANATOMY", 66, 70], ["spasticity", "DISEASE", 48, 58], ["legs", "ORGANISM_SUBDIVISION", 66, 70], ["slowly progressive spasticity of the legs", "PROBLEM", 29, 70], ["symptoms", "PROBLEM", 119, 127], ["early stages", "OBSERVATION_MODIFIER", 13, 25], ["slowly", "OBSERVATION_MODIFIER", 29, 35], ["progressive", "OBSERVATION_MODIFIER", 36, 47], ["spasticity", "OBSERVATION", 48, 58], ["legs", "ANATOMY", 66, 70]]], ["The diagnosis of motor neuron diseases like amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia and primary lateral sclerosis relies on the exclusion of spinal stenosis and inflammatory diseases of the central nervous system.", [["motor neuron", "ANATOMY", 17, 29], ["primary lateral sclerosis", "ANATOMY", 115, 140], ["spinal", "ANATOMY", 168, 174], ["central nervous system", "ANATOMY", 217, 239], ["motor neuron diseases", "DISEASE", 17, 38], ["amyotrophic lateral sclerosis", "DISEASE", 44, 73], ["ALS", "DISEASE", 75, 78], ["hereditary spastic paraplegia", "DISEASE", 81, 110], ["primary lateral sclerosis", "DISEASE", 115, 140], ["spinal stenosis", "DISEASE", 168, 183], ["diseases of the central nervous system", "DISEASE", 201, 239], ["motor neuron", "CANCER", 17, 29], ["amyotrophic lateral sclerosis", "CANCER", 44, 73], ["spinal stenosis", "PATHOLOGICAL_FORMATION", 168, 183], ["central nervous system", "ANATOMICAL_SYSTEM", 217, 239], ["motor neuron diseases", "PROBLEM", 17, 38], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 44, 79], ["hereditary spastic paraplegia", "PROBLEM", 81, 110], ["primary lateral sclerosis", "PROBLEM", 115, 140], ["spinal stenosis", "PROBLEM", 168, 183], ["inflammatory diseases of the central nervous system", "PROBLEM", 188, 239], ["motor neuron diseases", "OBSERVATION", 17, 38], ["amyotrophic", "OBSERVATION_MODIFIER", 44, 55], ["lateral", "OBSERVATION_MODIFIER", 56, 63], ["sclerosis", "OBSERVATION", 64, 73], ["hereditary", "OBSERVATION_MODIFIER", 81, 91], ["spastic", "OBSERVATION_MODIFIER", 92, 99], ["paraplegia", "OBSERVATION", 100, 110], ["primary", "OBSERVATION_MODIFIER", 115, 122], ["lateral", "OBSERVATION_MODIFIER", 123, 130], ["sclerosis", "OBSERVATION", 131, 140], ["spinal", "ANATOMY", 168, 174], ["stenosis", "OBSERVATION", 175, 183], ["inflammatory", "OBSERVATION", 188, 200], ["central", "ANATOMY_MODIFIER", 217, 224], ["nervous system", "ANATOMY", 225, 239]]], ["This clinical scenario is reflected by the category \"clinically possible ALS\" according to the El Escorial criteria, defined by clinical evidence of upper and lower motor neuron dysfunction in one region only [1] .", [["lower motor neuron", "ANATOMY", 159, 177], ["ALS", "DISEASE", 73, 76], ["upper", "ORGANISM_SUBDIVISION", 149, 154], ["ALS", "PROBLEM", 73, 76], ["upper and lower motor neuron dysfunction", "PROBLEM", 149, 189], ["upper", "ANATOMY_MODIFIER", 149, 154], ["lower", "ANATOMY_MODIFIER", 159, 164], ["motor neuron dysfunction", "OBSERVATION", 165, 189]]], ["Patterns and time course of progression of motor neuron diseases show a considerable variation and cannot be sufficiently predicted to date [2] .", [["motor neuron", "ANATOMY", 43, 55], ["motor neuron diseases", "DISEASE", 43, 64], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 43, 55], ["motor neuron diseases", "PROBLEM", 43, 64], ["progression", "OBSERVATION_MODIFIER", 28, 39], ["motor neuron diseases", "OBSERVATION", 43, 64]]], ["Thus, while early diagnosis is an important prerequisite to initiate the correct type of treatment (e.g., riluzole, immunomodulation or surgery), slowly progressive upper motor neuron syndromes may remain unresolved during initial follow-up [3] .", [["upper motor neuron", "ANATOMY", 165, 183], ["riluzole", "CHEMICAL", 106, 114], ["upper motor neuron syndromes", "DISEASE", 165, 193], ["riluzole", "CHEMICAL", 106, 114], ["riluzole", "SIMPLE_CHEMICAL", 106, 114], ["treatment", "TREATMENT", 89, 98], ["riluzole", "TREATMENT", 106, 114], ["immunomodulation", "TREATMENT", 116, 132], ["surgery", "TREATMENT", 136, 143], ["slowly progressive upper motor neuron syndromes", "PROBLEM", 146, 193], ["upper", "ANATOMY_MODIFIER", 165, 170], ["motor neuron syndromes", "OBSERVATION", 171, 193]]], ["Moreover, clear-cut clinical signs or progression markers of upper motor neuron dysfunction are often lacking [4] .BackgroundWe herein report the case of a male patient with thoracic anterior spinal cord herniation (aSCH) who initially presented with monomelic spasticity and weakness leading to a suspected diagnosis of motor neuron disease.BackgroundWith a comprehensive demonstration of the long-term course of MRI and motor/ sensory evoked potentials, we provide a detailed description of potential early indications for this rare mimic of motor neuron disease.Case presentationA 51-year-old patient presented in 2004 with pain of the right side of the trunk.", [["upper motor neuron", "ANATOMY", 61, 79], ["thoracic anterior spinal cord", "ANATOMY", 174, 203], ["aSCH", "ANATOMY", 216, 220], ["motor neuron", "ANATOMY", 321, 333], ["motor neuron", "ANATOMY", 544, 556], ["trunk", "ANATOMY", 657, 662], ["upper motor neuron dysfunction", "DISEASE", 61, 91], ["thoracic anterior spinal cord herniation", "DISEASE", 174, 214], ["aSCH", "DISEASE", 216, 220], ["spasticity", "DISEASE", 261, 271], ["weakness", "DISEASE", 276, 284], ["motor neuron disease", "DISEASE", 321, 341], ["motor neuron disease", "DISEASE", 544, 564], ["pain", "DISEASE", 627, 631], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 67, 79], ["patient", "ORGANISM", 161, 168], ["cord", "ORGAN", 199, 203], ["motor neuron", "CANCER", 321, 333], ["motor neuron disease", "CANCER", 544, 564], ["patient", "ORGANISM", 596, 603], ["trunk", "ORGANISM_SUBDIVISION", 657, 662], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 596, 603], ["progression markers", "PROBLEM", 38, 57], ["upper motor neuron dysfunction", "PROBLEM", 61, 91], ["thoracic anterior spinal cord herniation", "PROBLEM", 174, 214], ["monomelic spasticity", "PROBLEM", 251, 271], ["weakness", "PROBLEM", 276, 284], ["motor neuron disease", "PROBLEM", 321, 341], ["MRI", "TEST", 414, 417], ["motor/ sensory evoked potentials", "TEST", 422, 454], ["motor neuron disease", "PROBLEM", 544, 564], ["pain", "PROBLEM", 627, 631], ["clear", "OBSERVATION", 10, 15], ["upper", "ANATOMY_MODIFIER", 61, 66], ["motor neuron", "ANATOMY", 67, 79], ["thoracic", "ANATOMY", 174, 182], ["anterior", "ANATOMY_MODIFIER", 183, 191], ["spinal cord", "ANATOMY", 192, 203], ["herniation", "OBSERVATION", 204, 214], ["weakness", "OBSERVATION", 276, 284], ["motor neuron disease", "OBSERVATION", 321, 341], ["motor neuron disease", "OBSERVATION", 544, 564], ["pain", "OBSERVATION", 627, 631], ["right", "ANATOMY_MODIFIER", 639, 644], ["trunk", "ANATOMY", 657, 662]]], ["Neurological examination and Fig. 1 Longitudinal course of anterior spinal cord herniation. a Magnifications of the Th2/Th3 segment obtained in T2-weighted sagittal imaging at different visits.", [["anterior spinal cord", "ANATOMY", 59, 79], ["cord herniation", "DISEASE", 75, 90], ["anterior spinal cord", "ORGAN", 59, 79], ["Th2/Th3 segment", "DNA", 116, 131], ["Neurological examination", "TEST", 0, 24], ["anterior spinal cord herniation", "PROBLEM", 59, 90], ["a Magnifications of the Th2/Th3 segment", "TEST", 92, 131], ["sagittal imaging", "TEST", 156, 172], ["Longitudinal", "OBSERVATION_MODIFIER", 36, 48], ["course", "OBSERVATION_MODIFIER", 49, 55], ["anterior", "ANATOMY_MODIFIER", 59, 67], ["spinal cord", "ANATOMY", 68, 79], ["herniation", "OBSERVATION", 80, 90], ["Th2", "ANATOMY", 116, 119]]], ["Arrowheads highlight evolving anterior spinal cord herniation and a postoperative myelopathy signal.", [["anterior spinal cord", "ANATOMY", 30, 50], ["cord herniation", "DISEASE", 46, 61], ["myelopathy", "DISEASE", 82, 92], ["Arrowheads", "CELLULAR_COMPONENT", 0, 10], ["anterior spinal cord", "ORGAN", 30, 50], ["evolving anterior spinal cord herniation", "PROBLEM", 21, 61], ["a postoperative myelopathy signal", "PROBLEM", 66, 99], ["anterior", "ANATOMY_MODIFIER", 30, 38], ["spinal cord", "ANATOMY", 39, 50], ["herniation", "OBSERVATION", 51, 61], ["postoperative myelopathy", "OBSERVATION", 68, 92]]], ["The red arrow highlights the early subtle sign of ventral spinal cord misplacement and posterior indentation. b Corresponding axial images of Th2/3. c MEP including transcranial (lines 1-2) and lumbar stimulation (lines 3-4) to the right (R) and to the left (L) tibialis anterior muscle.", [["ventral spinal cord", "ANATOMY", 50, 69], ["lumbar", "ANATOMY", 194, 200], ["right", "ANATOMY", 232, 237], ["left (L) tibialis anterior muscle", "ANATOMY", 253, 286], ["ventral spinal cord", "MULTI-TISSUE_STRUCTURE", 50, 69], ["tibialis anterior muscle", "TISSUE", 262, 286], ["ventral spinal cord misplacement", "PROBLEM", 50, 82], ["posterior indentation", "PROBLEM", 87, 108], ["Corresponding axial images", "TEST", 112, 138], ["transcranial (lines", "TREATMENT", 165, 184], ["lumbar stimulation (lines", "TREATMENT", 194, 219], ["red arrow", "OBSERVATION", 4, 13], ["early", "OBSERVATION_MODIFIER", 29, 34], ["subtle", "OBSERVATION_MODIFIER", 35, 41], ["ventral", "ANATOMY_MODIFIER", 50, 57], ["spinal cord", "ANATOMY", 58, 69], ["misplacement", "OBSERVATION", 70, 82], ["posterior", "ANATOMY_MODIFIER", 87, 96], ["indentation", "OBSERVATION", 97, 108], ["lumbar", "ANATOMY", 194, 200], ["right", "ANATOMY_MODIFIER", 232, 237], ["left", "ANATOMY_MODIFIER", 253, 257], ["L", "ANATOMY_MODIFIER", 259, 260], ["tibialis", "ANATOMY", 262, 270], ["anterior", "ANATOMY_MODIFIER", 271, 279], ["muscle", "ANATOMY", 280, 286]]], ["Central motor conductance was pathological after 8 years follow-up (arrow; amplitude R 1.27 mV, L 2.88 mV).", [["amplitude", "TEST", 75, 84], ["mV", "TEST", 92, 94], ["motor conductance", "OBSERVATION", 8, 25]]], ["After 11 years, spasticity had progressed to the left leg, along with affection of the left leg central motor conductance (arrow; R 1.0 mV, L 2.47 mV).", [["left leg", "ANATOMY", 49, 57], ["left leg", "ANATOMY", 87, 95], ["spasticity", "DISEASE", 16, 26], ["leg", "ORGANISM_SUBDIVISION", 54, 57], ["leg", "ORGANISM_SUBDIVISION", 92, 95], ["spasticity", "PROBLEM", 16, 26], ["affection of the left leg", "PROBLEM", 70, 95], ["left", "ANATOMY_MODIFIER", 49, 53], ["leg", "ANATOMY", 54, 57], ["affection", "OBSERVATION", 70, 79], ["left", "ANATOMY_MODIFIER", 87, 91], ["leg", "ANATOMY", 92, 95], ["central", "ANATOMY_MODIFIER", 96, 103], ["motor conductance", "OBSERVATION", 104, 121]]], ["Six months after neurosurgery, there were no significant changes in MEP (R 0.68 mV, L 3.02 mV).", [["significant changes in MEP", "PROBLEM", 45, 71], ["mV", "TEST", 80, 82], ["no", "UNCERTAINTY", 42, 44], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["changes", "OBSERVATION", 57, 64]]], ["Five years after neurosurgery, cortical MEP were absent to the right leg (arrow; R -, L 2.59 mV), despite unchanged MRI. d SEP-recordings during follow-up visits, obtained from stimulation of the right (R) and left (L) tibial nerve.", [["cortical", "ANATOMY", 31, 39], ["right leg", "ANATOMY", 63, 72], ["right", "ANATOMY", 196, 201], ["left (L) tibial nerve", "ANATOMY", 210, 231], ["cortical MEP", "MULTI-TISSUE_STRUCTURE", 31, 43], ["leg", "ORGANISM_SUBDIVISION", 69, 72], ["tibial nerve", "MULTI-TISSUE_STRUCTURE", 219, 231], ["cortical MEP", "TEST", 31, 43], ["R", "TEST", 81, 82], ["unchanged MRI", "TEST", 106, 119], ["right", "ANATOMY_MODIFIER", 63, 68], ["leg", "ANATOMY", 69, 72], ["right", "ANATOMY_MODIFIER", 196, 201], ["left", "ANATOMY_MODIFIER", 210, 214], ["L", "ANATOMY_MODIFIER", 216, 217], ["tibial nerve", "ANATOMY", 219, 231]]], ["At 8 years follow-up, SEP P40-latency was prolonged bilaterally (R 51.8 ms, L 52.0 ms).", [["P40", "GENE_OR_GENE_PRODUCT", 26, 29], ["P40", "PROTEIN", 26, 29], ["SEP P40", "TEST", 22, 29], ["prolonged bilaterally", "PROBLEM", 42, 63], ["bilaterally", "ANATOMY_MODIFIER", 52, 63]]], ["At presentation with Brown-S\u00e9quard syndrome involving right-sided hypesthesia, SEP from the right was absent (arrow; R -, L 50.8 ms).", [["Brown-S\u00e9quard syndrome", "DISEASE", 21, 43], ["Brown-S\u00e9quard syndrome", "PROBLEM", 21, 43], ["right-sided hypesthesia", "PROBLEM", 54, 77], ["SEP", "TEST", 79, 82], ["S\u00e9quard syndrome", "OBSERVATION", 27, 43], ["right", "ANATOMY_MODIFIER", 54, 59], ["sided", "ANATOMY_MODIFIER", 60, 65], ["hypesthesia", "OBSERVATION", 66, 77], ["right", "ANATOMY_MODIFIER", 92, 97], ["absent", "OBSERVATION", 102, 108]]], ["Six months after neurosurgery, SEP from the right gradually improved (arrow; R 51.2 ms, L 51.2 ms).", [["SEP", "TEST", 31, 34], ["R", "TEST", 77, 78], ["ms", "TEST", 84, 86], ["right", "ANATOMY_MODIFIER", 44, 49]]], ["Five years after neurosurgery, SEP from the right leg was absent again (arrow; R -, L 53.6 ms), despite unchanged MRI.", [["right leg", "ANATOMY", 44, 53], ["right leg", "ORGANISM_SUBDIVISION", 44, 53], ["SEP from the right leg", "TEST", 31, 53], ["unchanged MRI", "TEST", 104, 117], ["right", "ANATOMY_MODIFIER", 44, 49], ["leg", "ANATOMY", 50, 53]]], ["Scale: C, 20 ms/ Div. and 2000 \u03bcV/ Div.; D, 20 ms/ Div. and 1.0 \u03bcV/ Div. f/u follow-up, n/a not available spinal MRI (Fig. 1a) were normal.", [["spinal", "ANATOMY", 106, 112], ["spinal MRI", "TEST", 106, 116], ["spinal", "ANATOMY", 106, 112], ["normal", "OBSERVATION", 132, 138]]], ["Symptoms resolved over a course of several weeks after physiotherapy and analgesics.", [["Symptoms", "PROBLEM", 0, 8], ["physiotherapy", "TREATMENT", 55, 68], ["analgesics", "TREATMENT", 73, 83]]], ["Eight years later, in 2012, the patient developed progressive spastic paresis of the right leg, associated with a positive Babinski sign.", [["right leg", "ANATOMY", 85, 94], ["spastic paresis of the right leg", "DISEASE", 62, 94], ["patient", "ORGANISM", 32, 39], ["right leg", "ORGANISM_SUBDIVISION", 85, 94], ["patient", "SPECIES", 32, 39], ["progressive spastic paresis of the right leg", "PROBLEM", 50, 94], ["a positive Babinski sign", "PROBLEM", 112, 136], ["progressive", "OBSERVATION_MODIFIER", 50, 61], ["spastic", "OBSERVATION_MODIFIER", 62, 69], ["paresis", "OBSERVATION", 70, 77], ["right", "ANATOMY_MODIFIER", 85, 90], ["leg", "ANATOMY", 91, 94], ["positive", "OBSERVATION_MODIFIER", 114, 122], ["Babinski", "OBSERVATION", 123, 131]]], ["Spinal MRI showed a lumbar disk protrusion bilaterally contacting S1 nerve roots, but was otherwise reported normal (Fig. 1a) .", [["Spinal", "ANATOMY", 0, 6], ["lumbar", "ANATOMY", 20, 26], ["nerve roots", "ANATOMY", 69, 80], ["nerve roots", "MULTI-TISSUE_STRUCTURE", 69, 80], ["Spinal MRI", "TEST", 0, 10], ["a lumbar disk protrusion bilaterally", "PROBLEM", 18, 54], ["lumbar", "ANATOMY", 20, 26], ["disk", "ANATOMY_MODIFIER", 27, 31], ["protrusion", "OBSERVATION", 32, 42], ["bilaterally", "ANATOMY_MODIFIER", 43, 54], ["S1", "ANATOMY_MODIFIER", 66, 68], ["nerve roots", "ANATOMY", 69, 80], ["normal", "OBSERVATION", 109, 115]]], ["Motor evoked potentials (MEP, Fig. 1c ) indicated central motor conductance pathology to the right leg only.", [["right leg", "ANATOMY", 93, 102], ["leg", "ORGANISM_SUBDIVISION", 99, 102], ["Motor evoked potentials", "TEST", 0, 23], ["MEP, Fig. 1c", "TEST", 25, 37], ["central motor conductance pathology", "PROBLEM", 50, 85], ["central", "ANATOMY_MODIFIER", 50, 57], ["motor conductance", "OBSERVATION", 58, 75], ["right", "ANATOMY_MODIFIER", 93, 98], ["leg", "ANATOMY", 99, 102]]], ["Somatosensory evoked potentials (SEP, Fig. 1d ) were normal.", [["Somatosensory evoked potentials", "TEST", 0, 31], ["SEP", "TEST", 33, 36], ["normal", "OBSERVATION", 53, 59]]], ["Electromyography revealed fasciculations and chronic neurogenic changes in muscles innervated by nerve roots L4-S1 on the right side.", [["muscles", "ANATOMY", 75, 82], ["nerve roots", "ANATOMY", 97, 108], ["fasciculations", "DISEASE", 26, 40], ["muscles", "ORGAN", 75, 82], ["Electromyography", "TEST", 0, 16], ["fasciculations", "PROBLEM", 26, 40], ["chronic neurogenic changes in muscles", "PROBLEM", 45, 82], ["fasciculations", "OBSERVATION", 26, 40], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["neurogenic", "OBSERVATION", 53, 63], ["muscles", "ANATOMY", 75, 82], ["innervated", "ANATOMY_MODIFIER", 83, 93], ["nerve roots", "ANATOMY", 97, 108], ["L4", "ANATOMY_MODIFIER", 109, 111], ["S1", "ANATOMY_MODIFIER", 112, 114], ["right", "ANATOMY_MODIFIER", 122, 127]]], ["Cerebrospinal fluid analysis was unremarkable.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["Cerebrospinal fluid analysis", "TEST", 0, 28], ["fluid", "OBSERVATION", 14, 19], ["unremarkable", "OBSERVATION", 33, 45]]], ["Accordingly, we diagnosed a degenerative upper motor neuron syndrome.", [["upper motor neuron", "ANATOMY", 41, 59], ["degenerative upper motor neuron syndrome", "DISEASE", 28, 68], ["upper motor neuron", "CANCER", 41, 59], ["a degenerative upper motor neuron syndrome", "PROBLEM", 26, 68], ["degenerative", "OBSERVATION_MODIFIER", 28, 40], ["upper", "ANATOMY_MODIFIER", 41, 46], ["motor neuron syndrome", "OBSERVATION", 47, 68]]], ["Due to denervation patterns in EMG readings, differential diagnosis included early stages of ALS; furthermore, spastic paraplegia and primary lateral sclerosis were considered.Case presentationThree years later, right-sided hypesthesia involving dermatomes Th4-S1 emerged subacutely, now matching with a Brown-S\u00e9quard syndrome.", [["primary lateral sclerosis", "ANATOMY", 134, 159], ["dermatomes", "ANATOMY", 246, 256], ["ALS", "DISEASE", 93, 96], ["spastic paraplegia", "DISEASE", 111, 129], ["primary lateral sclerosis", "DISEASE", 134, 159], ["hypesthesia", "DISEASE", 224, 235], ["Brown-S\u00e9quard syndrome", "DISEASE", 304, 326], ["denervation patterns", "PROBLEM", 7, 27], ["EMG readings", "TEST", 31, 43], ["early stages of ALS", "PROBLEM", 77, 96], ["spastic paraplegia", "PROBLEM", 111, 129], ["primary lateral sclerosis", "PROBLEM", 134, 159], ["right-sided hypesthesia involving dermatomes", "PROBLEM", 212, 256], ["a Brown-S\u00e9quard syndrome", "PROBLEM", 302, 326], ["denervation", "OBSERVATION", 7, 18], ["early stages", "OBSERVATION_MODIFIER", 77, 89], ["spastic", "OBSERVATION_MODIFIER", 111, 118], ["paraplegia", "OBSERVATION", 119, 129], ["primary", "OBSERVATION_MODIFIER", 134, 141], ["lateral", "OBSERVATION_MODIFIER", 142, 149], ["sclerosis", "OBSERVATION", 150, 159], ["right", "ANATOMY_MODIFIER", 212, 217], ["sided", "ANATOMY_MODIFIER", 218, 223], ["hypesthesia", "OBSERVATION", 224, 235], ["dermatomes", "ANATOMY", 246, 256], ["syndrome", "OBSERVATION", 318, 326]]], ["Follow-up spinal MRI showed an aSCH at Th2/3 ( Fig. 1a-b) .", [["spinal", "ANATOMY", 10, 16], ["spinal", "ORGAN", 10, 16], ["Th2", "PROTEIN", 39, 42], ["Follow-up spinal MRI", "TEST", 0, 20], ["spinal", "ANATOMY", 10, 16]]], ["In retrospect, subtle signs of aSCH were already detectable in 2012: The spinal cord was ventrally displaced, appeared attached to the ventral dura and showed a posterior indentation at Th2/3 (Fig. 1a, red arrow) .", [["spinal cord", "ANATOMY", 73, 84], ["ventral dura", "ANATOMY", 135, 147], ["aSCH", "DISEASE", 31, 35], ["aSCH", "CANCER", 31, 35], ["spinal cord", "ORGAN", 73, 84], ["ventral dura", "MULTI-TISSUE_STRUCTURE", 135, 147], ["subtle signs of aSCH", "PROBLEM", 15, 35], ["ventrally displaced", "PROBLEM", 89, 108], ["a posterior indentation at Th2", "PROBLEM", 159, 189], ["spinal cord", "ANATOMY", 73, 84], ["ventrally", "OBSERVATION_MODIFIER", 89, 98], ["displaced", "OBSERVATION", 99, 108], ["ventral", "ANATOMY_MODIFIER", 135, 142], ["dura", "ANATOMY", 143, 147], ["posterior", "OBSERVATION_MODIFIER", 161, 170], ["indentation", "OBSERVATION", 171, 182]]], ["Due to the chronically progressive motor and sensory deficits, neurosurgery was performed.", [["chronically progressive motor and sensory deficits", "DISEASE", 11, 61], ["the chronically progressive motor and sensory deficits", "PROBLEM", 7, 61], ["chronically", "OBSERVATION_MODIFIER", 11, 22], ["progressive", "OBSERVATION_MODIFIER", 23, 34], ["sensory deficits", "OBSERVATION", 45, 61]]], ["The neurosurgical treatment aimed at relocating the spinal cord into its normal intradural position with closure of the ventral dural defect to prevent reherniation.", [["spinal cord", "ANATOMY", 52, 63], ["intradural", "ANATOMY", 80, 90], ["ventral dural", "ANATOMY", 120, 133], ["dural defect", "DISEASE", 128, 140], ["reherniation", "DISEASE", 152, 164], ["spinal cord", "ORGAN", 52, 63], ["ventral dural", "MULTI-TISSUE_STRUCTURE", 120, 133], ["The neurosurgical treatment", "TREATMENT", 0, 27], ["closure", "TREATMENT", 105, 112], ["the ventral dural defect", "PROBLEM", 116, 140], ["reherniation", "PROBLEM", 152, 164], ["spinal cord", "ANATOMY", 52, 63], ["normal", "OBSERVATION", 73, 79], ["intradural position", "OBSERVATION", 80, 99], ["closure", "OBSERVATION", 105, 112], ["ventral", "ANATOMY_MODIFIER", 120, 127], ["dural", "ANATOMY", 128, 133], ["defect", "OBSERVATION", 134, 140], ["reherniation", "OBSERVATION", 152, 164]]], ["To gain sufficient access, the spinal cord was mobilized on the right side by applying sutures to the dentate ligaments (Fig. 2a) .", [["spinal cord", "ANATOMY", 31, 42], ["dentate ligaments", "ANATOMY", 102, 119], ["spinal cord", "ORGAN", 31, 42], ["dentate ligaments", "MULTI-TISSUE_STRUCTURE", 102, 119], ["sutures", "TREATMENT", 87, 94], ["spinal cord", "ANATOMY", 31, 42], ["mobilized", "OBSERVATION", 47, 56], ["right", "ANATOMY_MODIFIER", 64, 69], ["sutures", "OBSERVATION", 87, 94], ["dentate ligaments", "ANATOMY", 102, 119]]], ["Part of the herniated cord could be lifted out of Fig. 2 Intraoperative images.", [["herniated cord", "ANATOMY", 12, 26], ["herniated cord", "ORGAN", 12, 26], ["the herniated cord", "PROBLEM", 8, 26], ["Intraoperative images", "TEST", 57, 78], ["herniated", "OBSERVATION", 12, 21], ["cord", "ANATOMY", 22, 26]]], ["The intraoperative images demonstrate the defect in the anterior dural sac (arrowheads in a) after gently mobilizing the spinal cord with a suture applied to the dentate ligament (arrows in a and b) and closure of the defect with a dura patch (arrowheads in b).", [["anterior dural sac", "ANATOMY", 56, 74], ["spinal cord", "ANATOMY", 121, 132], ["dentate ligament", "ANATOMY", 162, 178], ["dura", "ANATOMY", 232, 236], ["anterior dural sac", "MULTI-TISSUE_STRUCTURE", 56, 74], ["spinal cord", "ORGAN", 121, 132], ["dentate ligament", "TISSUE", 162, 178], ["The intraoperative images", "TEST", 0, 25], ["the defect in the anterior dural sac", "PROBLEM", 38, 74], ["gently mobilizing the spinal cord", "TREATMENT", 99, 132], ["a suture", "TREATMENT", 138, 146], ["a and b)", "TREATMENT", 190, 198], ["closure", "TREATMENT", 203, 210], ["the defect", "PROBLEM", 214, 224], ["a dura patch", "TREATMENT", 230, 242], ["defect", "OBSERVATION", 42, 48], ["anterior", "ANATOMY_MODIFIER", 56, 64], ["dural sac", "ANATOMY", 65, 74], ["spinal cord", "ANATOMY", 121, 132], ["suture", "OBSERVATION", 140, 146], ["dentate ligament", "ANATOMY", 162, 178], ["defect", "OBSERVATION", 218, 224]]], ["The herniated part of the spinal cord appears dysplastic (SC in B).", [["herniated part", "ANATOMY", 4, 18], ["spinal cord", "ANATOMY", 26, 37], ["SC", "ANATOMY", 58, 60], ["herniated part", "MULTI-TISSUE_STRUCTURE", 4, 18], ["spinal cord", "ORGAN", 26, 37], ["B", "CANCER", 64, 65], ["The herniated part of the spinal cord", "PROBLEM", 0, 37], ["dysplastic", "PROBLEM", 46, 56], ["herniated", "OBSERVATION", 4, 13], ["spinal cord", "ANATOMY", 26, 37], ["appears", "UNCERTAINTY", 38, 45], ["dysplastic", "OBSERVATION", 46, 56]]], ["SC spinal cord the defect easily, while the caudal part required sharp dissection before it could be mobilized.", [["SC spinal cord", "ANATOMY", 0, 14], ["caudal part", "ANATOMY", 44, 55], ["SC spinal cord", "TISSUE", 0, 14], ["caudal part", "MULTI-TISSUE_STRUCTURE", 44, 55], ["SC spinal cord the defect", "PROBLEM", 0, 25], ["sharp dissection", "TREATMENT", 65, 81], ["spinal cord", "ANATOMY", 3, 14], ["defect", "OBSERVATION", 19, 25], ["sharp", "OBSERVATION_MODIFIER", 65, 70], ["dissection", "OBSERVATION", 71, 81]]], ["Finally, the defect was closed by muscle and fibrin glue.", [["muscle", "ANATOMY", 34, 40], ["muscle", "TISSUE", 34, 40], ["fibrin", "GENE_OR_GENE_PRODUCT", 45, 51], ["the defect", "PROBLEM", 9, 19], ["fibrin glue", "TREATMENT", 45, 56], ["defect", "OBSERVATION", 13, 19], ["closed", "OBSERVATION", 24, 30], ["muscle", "ANATOMY", 34, 40], ["fibrin glue", "OBSERVATION", 45, 56]]], ["To prevent adhesions between cord and the closed dura defect, a goretexpatch was placed to cover the former defect (Fig. 2b) .", [["adhesions", "ANATOMY", 11, 20], ["cord", "ANATOMY", 29, 33], ["dura", "ANATOMY", 49, 53], ["cord", "ORGAN", 29, 33], ["dura", "TISSUE", 49, 53], ["adhesions between cord", "PROBLEM", 11, 33], ["the closed dura defect", "PROBLEM", 38, 60], ["a goretexpatch", "TREATMENT", 62, 76], ["the former defect", "PROBLEM", 97, 114], ["adhesions", "OBSERVATION", 11, 20], ["cord", "ANATOMY", 29, 33], ["closed", "OBSERVATION_MODIFIER", 42, 48], ["dura defect", "OBSERVATION", 49, 60], ["defect", "OBSERVATION", 108, 114]]], ["During surgery, SEP and MEP were monitored [5] .", [["surgery", "TREATMENT", 7, 14], ["SEP and MEP", "TEST", 16, 27]]], ["Postoperative MRI confirmed the corrected position of the spinal cord in the dural sac, and showed profound intramedullary signal changes consistent with a myelopathy at the level of former herniation (Fig. 1b) .", [["spinal cord", "ANATOMY", 58, 69], ["dural sac", "ANATOMY", 77, 86], ["myelopathy", "DISEASE", 156, 166], ["herniation", "DISEASE", 190, 200], ["spinal cord", "ORGAN", 58, 69], ["dural sac", "MULTI-TISSUE_STRUCTURE", 77, 86], ["Postoperative MRI", "TEST", 0, 17], ["profound intramedullary signal changes", "PROBLEM", 99, 137], ["a myelopathy", "PROBLEM", 154, 166], ["former herniation", "PROBLEM", 183, 200], ["spinal cord", "ANATOMY", 58, 69], ["dural sac", "ANATOMY", 77, 86], ["profound", "OBSERVATION_MODIFIER", 99, 107], ["intramedullary signal", "OBSERVATION", 108, 129], ["consistent with", "UNCERTAINTY", 138, 153], ["myelopathy", "OBSERVATION", 156, 166], ["former", "OBSERVATION_MODIFIER", 183, 189], ["herniation", "OBSERVATION", 190, 200]]], ["Six months after surgery, amplitudes and latencies of MEP were unchanged, whereas SEP was slightly improved (Fig. 1c, d) .", [["surgery", "TREATMENT", 17, 24], ["amplitudes", "TEST", 26, 36], ["latencies of MEP", "TEST", 41, 57], ["unchanged", "OBSERVATION_MODIFIER", 63, 72]]], ["Clinically, symptoms improved partially over the course of 5 years after surgery.", [["symptoms", "PROBLEM", 12, 20], ["surgery", "TREATMENT", 73, 80]]], ["Spasticity of both legs was decreased (reduction of the modified Ashworth score of adductors from 2 to 1 on both sides) and the maximum walking distance was increased from 500 to 2000 m.", [["legs", "ANATOMY", 19, 23], ["Spasticity", "DISEASE", 0, 10], ["legs", "ORGANISM_SUBDIVISION", 19, 23], ["Spasticity of both legs", "PROBLEM", 0, 23], ["both", "ANATOMY_MODIFIER", 14, 18], ["legs", "ANATOMY", 19, 23], ["decreased", "OBSERVATION_MODIFIER", 28, 37]]], ["The sensory deficit improved, but persisted in the right trunk (dermatomes Th2-L1).", [["right trunk", "ANATOMY", 51, 62], ["dermatomes", "ANATOMY", 64, 74], ["sensory deficit", "DISEASE", 4, 19], ["trunk", "ORGANISM_SUBDIVISION", 57, 62], ["The sensory deficit", "PROBLEM", 0, 19], ["sensory deficit", "OBSERVATION", 4, 19], ["improved", "OBSERVATION_MODIFIER", 20, 28], ["right", "ANATOMY_MODIFIER", 51, 56], ["trunk", "ANATOMY", 57, 62], ["dermatomes", "ANATOMY_MODIFIER", 64, 74], ["L1", "ANATOMY", 79, 81]]], ["At the latest follow-up in 2020, the patient reported recurring stiffness and pain of both legs probably related to cessation of physical therapy due to COVID-19 pandemic restrictions.", [["legs", "ANATOMY", 91, 95], ["stiffness", "DISEASE", 64, 73], ["pain", "DISEASE", 78, 82], ["patient", "ORGANISM", 37, 44], ["legs", "ORGANISM_SUBDIVISION", 91, 95], ["patient", "SPECIES", 37, 44], ["recurring stiffness", "PROBLEM", 54, 73], ["pain of both legs", "PROBLEM", 78, 95], ["physical therapy", "TREATMENT", 129, 145], ["COVID", "TEST", 153, 158], ["recurring", "OBSERVATION_MODIFIER", 54, 63], ["stiffness", "OBSERVATION", 64, 73], ["pain", "OBSERVATION", 78, 82], ["both", "ANATOMY_MODIFIER", 86, 90], ["legs", "ANATOMY", 91, 95]]], ["Interestingly, while MRI showed no signs of progression at this point, MEP correlated with the clinical increase in spasticity (Fig. 1c, d) .Discussion and ConclusionsASCH is a rare cause of myelopathy which may be missed on imaging during early stages of the disease [6] .Discussion and ConclusionsWhereas Brown-S\u00e9quard syndrome is initially observed in the majority of aSCH cases, about 20% present with pure motor symptoms accompanied by spasticity and paresis of one or both legs [6] .", [["legs", "ANATOMY", 479, 483], ["spasticity", "DISEASE", 116, 126], ["myelopathy", "DISEASE", 191, 201], ["Brown-S\u00e9quard syndrome", "DISEASE", 307, 329], ["aSCH", "DISEASE", 371, 375], ["spasticity", "DISEASE", 441, 451], ["paresis", "DISEASE", 456, 463], ["aSCH", "CANCER", 371, 375], ["legs", "ORGANISM_SUBDIVISION", 479, 483], ["MRI", "TEST", 21, 24], ["progression", "PROBLEM", 44, 55], ["the clinical increase in spasticity", "PROBLEM", 91, 126], ["myelopathy", "PROBLEM", 191, 201], ["imaging", "TEST", 225, 232], ["the disease", "PROBLEM", 256, 267], ["S\u00e9quard syndrome", "PROBLEM", 313, 329], ["pure motor symptoms", "PROBLEM", 406, 425], ["spasticity", "PROBLEM", 441, 451], ["paresis", "PROBLEM", 456, 463], ["no signs of", "UNCERTAINTY", 32, 43], ["progression", "OBSERVATION_MODIFIER", 44, 55], ["myelopathy", "OBSERVATION", 191, 201], ["spasticity", "OBSERVATION", 441, 451], ["paresis", "OBSERVATION", 456, 463], ["legs", "ANATOMY", 479, 483]]], ["In retrospect, specific signs merit attention as early indicators of a symptomatic spinal cause of lower limb spasticity: (i) Although the patient exhibited an isolated motor syndrome without sensory symptoms, the history of lateralized pain of the trunk should prompt the careful revision of MRI. (ii) Ventral displacement and posterior indentation of the spinal cord on the sagittal plane are indicative for aSCH and should trigger additional axial imaging (Fig. 1a, red arrow) .Discussion and ConclusionsIn the patient presented, coexisting multisegmental lumbar radiculopathy caused additional lower motor neuron pathology.", [["spinal", "ANATOMY", 83, 89], ["lower limb", "ANATOMY", 99, 109], ["trunk", "ANATOMY", 249, 254], ["Ventral", "ANATOMY", 303, 310], ["spinal cord", "ANATOMY", 357, 368], ["sagittal plane", "ANATOMY", 376, 390], ["lumbar", "ANATOMY", 559, 565], ["lower motor neuron", "ANATOMY", 598, 616], ["spasticity", "DISEASE", 110, 120], ["pain", "DISEASE", 237, 241], ["radiculopathy", "DISEASE", 566, 579], ["spinal", "ORGANISM_SUBDIVISION", 83, 89], ["lower limb", "ORGANISM_SUBDIVISION", 99, 109], ["patient", "ORGANISM", 139, 146], ["trunk", "ORGANISM_SUBDIVISION", 249, 254], ["spinal cord", "ORGAN", 357, 368], ["patient", "ORGANISM", 514, 521], ["patient", "SPECIES", 139, 146], ["patient", "SPECIES", 514, 521], ["a symptomatic spinal cause of lower limb spasticity", "PROBLEM", 69, 120], ["an isolated motor syndrome", "PROBLEM", 157, 183], ["sensory symptoms", "PROBLEM", 192, 208], ["lateralized pain of the trunk", "PROBLEM", 225, 254], ["MRI", "TEST", 293, 296], ["Ventral displacement and posterior indentation of the spinal cord", "PROBLEM", 303, 368], ["aSCH", "PROBLEM", 410, 414], ["additional axial imaging", "TEST", 434, 458], ["coexisting multisegmental lumbar radiculopathy", "PROBLEM", 533, 579], ["additional lower motor neuron pathology", "PROBLEM", 587, 626], ["symptomatic", "OBSERVATION_MODIFIER", 71, 82], ["spinal", "ANATOMY", 83, 89], ["lower limb", "ANATOMY", 99, 109], ["spasticity", "OBSERVATION", 110, 120], ["motor syndrome", "OBSERVATION", 169, 183], ["trunk", "ANATOMY", 249, 254], ["Ventral", "ANATOMY_MODIFIER", 303, 310], ["displacement", "OBSERVATION", 311, 323], ["posterior", "ANATOMY_MODIFIER", 328, 337], ["indentation", "OBSERVATION", 338, 349], ["spinal cord", "ANATOMY", 357, 368], ["indicative for", "UNCERTAINTY", 395, 409], ["multisegmental", "ANATOMY_MODIFIER", 544, 558], ["lumbar", "ANATOMY", 559, 565], ["radiculopathy", "OBSERVATION", 566, 579], ["lower", "ANATOMY_MODIFIER", 598, 603], ["motor neuron pathology", "OBSERVATION", 604, 626]]], ["Consequently, an early stage of motor neuron disease (ALS) could not be excluded at this point.", [["motor neuron", "ANATOMY", 32, 44], ["motor neuron disease", "DISEASE", 32, 52], ["ALS", "DISEASE", 54, 57], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 32, 44], ["motor neuron disease (ALS)", "PROBLEM", 32, 58], ["early", "OBSERVATION_MODIFIER", 17, 22], ["stage", "OBSERVATION_MODIFIER", 23, 28], ["motor neuron disease", "OBSERVATION", 32, 52], ["could not be excluded", "UNCERTAINTY", 59, 80]]], ["SEP were prolonged bilaterally in this patient, but the finding of pathological SEP is not uncommon in ALS and did not preclude a diagnosis of ALS [7] .", [["ALS", "DISEASE", 103, 106], ["ALS", "DISEASE", 143, 146], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["prolonged bilaterally", "PROBLEM", 9, 30], ["pathological SEP", "PROBLEM", 67, 83], ["ALS", "PROBLEM", 143, 146], ["prolonged", "OBSERVATION_MODIFIER", 9, 18], ["bilaterally", "OBSERVATION_MODIFIER", 19, 30]]], ["One patient with concomitant ALS and aSCH has been reported previously, but this single case may also have been coincidental and further follow-up of our patient clearly ruled out ALS [8] .Discussion and ConclusionsSo far, there is no widely accepted pathophysiological concept for these ventral dural defects.", [["ventral dural", "ANATOMY", 288, 301], ["ALS", "DISEASE", 29, 32], ["aSCH", "DISEASE", 37, 41], ["ALS", "DISEASE", 180, 183], ["ventral dural defects", "DISEASE", 288, 309], ["patient", "ORGANISM", 4, 11], ["aSCH", "CANCER", 37, 41], ["patient", "ORGANISM", 154, 161], ["ventral dural", "MULTI-TISSUE_STRUCTURE", 288, 301], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 154, 161], ["concomitant ALS", "PROBLEM", 17, 32], ["aSCH", "PROBLEM", 37, 41], ["ALS", "PROBLEM", 180, 183], ["these ventral dural defects", "PROBLEM", 282, 309], ["concomitant", "OBSERVATION_MODIFIER", 17, 28], ["ALS", "OBSERVATION", 29, 32], ["ventral", "ANATOMY_MODIFIER", 288, 295], ["dural", "ANATOMY", 296, 301], ["defects", "OBSERVATION", 302, 309]]], ["Degenerative changes, developmental defects, and spinal trauma may predispose to aSCH, but MRI studies prior to symptom onset are lacking [9] .", [["spinal", "ANATOMY", 49, 55], ["developmental defects", "DISEASE", 22, 43], ["spinal trauma", "DISEASE", 49, 62], ["aSCH", "DISEASE", 81, 85], ["Degenerative changes", "PROBLEM", 0, 20], ["developmental defects", "PROBLEM", 22, 43], ["spinal trauma", "PROBLEM", 49, 62], ["MRI studies", "TEST", 91, 102], ["symptom", "PROBLEM", 112, 119], ["developmental", "OBSERVATION_MODIFIER", 22, 35], ["defects", "OBSERVATION", 36, 43], ["spinal", "ANATOMY", 49, 55], ["trauma", "OBSERVATION", 56, 62]]], ["Our imaging study reveals a gradual herniation of the spinal cord into a dural defect over a course of at least 3 years.", [["spinal cord", "ANATOMY", 54, 65], ["dural", "ANATOMY", 73, 78], ["herniation of the spinal cord", "DISEASE", 36, 65], ["dural defect", "DISEASE", 73, 85], ["spinal cord", "ORGAN", 54, 65], ["dural defect", "PATHOLOGICAL_FORMATION", 73, 85], ["Our imaging study", "TEST", 0, 17], ["a gradual herniation of the spinal cord", "PROBLEM", 26, 65], ["a dural defect", "PROBLEM", 71, 85], ["gradual", "OBSERVATION_MODIFIER", 28, 35], ["herniation", "OBSERVATION", 36, 46], ["spinal cord", "ANATOMY", 54, 65], ["dural", "ANATOMY", 73, 78], ["defect", "OBSERVATION", 79, 85]]], ["The present course suggests that the increasing dural defect was related to degenerative changes.", [["dural", "ANATOMY", 48, 53], ["dural defect", "DISEASE", 48, 60], ["dural", "PATHOLOGICAL_FORMATION", 48, 53], ["the increasing dural defect", "PROBLEM", 33, 60], ["degenerative changes", "PROBLEM", 76, 96], ["increasing", "OBSERVATION_MODIFIER", 37, 47], ["dural defect", "OBSERVATION", 48, 60], ["degenerative", "OBSERVATION", 76, 88]]], ["These include small bony spurs or calcified osteochondroses that may cause dural tears leading to larger defects and cord herniation [10] .", [["bony spurs", "ANATOMY", 20, 30], ["osteochondroses", "ANATOMY", 44, 59], ["dural", "ANATOMY", 75, 80], ["cord", "ANATOMY", 117, 121], ["osteochondroses", "DISEASE", 44, 59], ["dural tears", "DISEASE", 75, 86], ["cord herniation", "DISEASE", 117, 132], ["dural tears", "PATHOLOGICAL_FORMATION", 75, 86], ["cord", "ORGAN", 117, 121], ["small bony spurs", "PROBLEM", 14, 30], ["calcified osteochondroses", "PROBLEM", 34, 59], ["dural tears", "PROBLEM", 75, 86], ["larger defects", "PROBLEM", 98, 112], ["cord herniation", "PROBLEM", 117, 132], ["small", "OBSERVATION_MODIFIER", 14, 19], ["bony", "ANATOMY", 20, 24], ["spurs", "OBSERVATION", 25, 30], ["calcified", "OBSERVATION_MODIFIER", 34, 43], ["osteochondroses", "OBSERVATION", 44, 59], ["may cause", "UNCERTAINTY", 65, 74], ["dural tears", "OBSERVATION", 75, 86], ["larger", "OBSERVATION_MODIFIER", 98, 104], ["defects", "OBSERVATION", 105, 112], ["cord", "ANATOMY", 117, 121], ["herniation", "OBSERVATION", 122, 132]]], ["This view is supported by the fact that the defects tend to be at the level of intervertebral spaces and that large calcified thoracic disc herniations tend to perforate the dura [11] [12] [13] .", [["intervertebral", "ANATOMY", 79, 93], ["thoracic disc herniations", "ANATOMY", 126, 151], ["disc herniations", "DISEASE", 135, 151], ["intervertebral", "MULTI-TISSUE_STRUCTURE", 79, 93], ["the defects", "PROBLEM", 40, 51], ["large calcified thoracic disc herniations", "PROBLEM", 110, 151], ["defects", "OBSERVATION", 44, 51], ["intervertebral spaces", "ANATOMY", 79, 100], ["large", "OBSERVATION_MODIFIER", 110, 115], ["calcified", "OBSERVATION_MODIFIER", 116, 125], ["thoracic disc", "ANATOMY", 126, 139], ["herniations", "OBSERVATION", 140, 151], ["dura", "ANATOMY", 174, 178]]], ["However, degenerative changes of the corresponding disc are not a regular feature in aSCH and were also not observed in the presented patient.", [["disc", "ANATOMY", 51, 55], ["disc", "ORGAN", 51, 55], ["aSCH", "CANCER", 85, 89], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["degenerative changes of the corresponding disc", "PROBLEM", 9, 55], ["degenerative", "OBSERVATION", 9, 21], ["disc", "ANATOMY", 51, 55]]], ["It is also not known why aSCH almost exlusively affects the thoracic spine.", [["thoracic spine", "ANATOMY", 60, 74], ["aSCH", "CANCER", 25, 29], ["thoracic spine", "MULTI-TISSUE_STRUCTURE", 60, 74], ["thoracic spine", "ANATOMY", 60, 74]]], ["Therefore, many authors consider these defects as a congenital disposition.Discussion and ConclusionsIn case, symptoms progress or are associated with a functional impairment, neurosurgical intervention is indicated to halt worsening of the herniation in order to limit the functional deficit.", [["functional impairment", "DISEASE", 153, 174], ["herniation", "DISEASE", 241, 251], ["these defects", "PROBLEM", 33, 46], ["a congenital disposition", "PROBLEM", 50, 74], ["symptoms", "PROBLEM", 110, 118], ["a functional impairment", "PROBLEM", 151, 174], ["neurosurgical intervention", "TREATMENT", 176, 202], ["the herniation", "PROBLEM", 237, 251], ["the functional deficit", "PROBLEM", 270, 292], ["defects", "OBSERVATION", 39, 46], ["congenital", "OBSERVATION", 52, 62], ["herniation", "OBSERVATION", 241, 251]]], ["In most cases, functional improvement was reported up to several years after neurosurgical intervention [6] .", [["neurosurgical intervention", "TREATMENT", 77, 103]]], ["However, improvement depends on the affected fiber tracts (Fig. 3) .", [["fiber tracts", "ANATOMY", 45, 57], ["improvement", "OBSERVATION_MODIFIER", 9, 20]]], ["Functional impairment is caused by different mechanisms which include pressure/ traction forces, hypoperfusion, secondary swelling, and tissue remodeling [14] .", [["tissue", "ANATOMY", 136, 142], ["Functional impairment", "DISEASE", 0, 21], ["hypoperfusion", "DISEASE", 97, 110], ["swelling", "DISEASE", 122, 130], ["tissue", "TISSUE", 136, 142], ["Functional impairment", "PROBLEM", 0, 21], ["different mechanisms", "PROBLEM", 35, 55], ["pressure/ traction forces", "PROBLEM", 70, 95], ["hypoperfusion", "PROBLEM", 97, 110], ["secondary swelling", "PROBLEM", 112, 130], ["tissue remodeling", "PROBLEM", 136, 153], ["impairment", "OBSERVATION", 11, 21], ["pressure", "OBSERVATION_MODIFIER", 70, 78], ["traction forces", "OBSERVATION", 80, 95], ["hypoperfusion", "OBSERVATION", 97, 110], ["secondary", "OBSERVATION_MODIFIER", 112, 121], ["swelling", "OBSERVATION", 122, 130], ["tissue", "ANATOMY", 136, 142]]], ["This explains the severe phenotype although only a part of the spinal cord is herniated.", [["spinal cord", "ANATOMY", 63, 74], ["spinal cord", "ORGAN", 63, 74], ["the severe phenotype", "PROBLEM", 14, 34], ["herniated", "PROBLEM", 78, 87], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["phenotype", "OBSERVATION", 25, 34], ["spinal cord", "ANATOMY", 63, 74], ["herniated", "OBSERVATION", 78, 87]]], ["Segmental symptoms caused by anterior horn pathology at the Th2/3 level (e.g., intercostal weakness) were not observed, most likely due to the overlapping myotomic organization of the thoracic segments [15] .Discussion and ConclusionsPostoperative segmental myelopathy, as seen in the presented patient, is commonly observed after spinal cord surgery.", [["anterior horn", "ANATOMY", 29, 42], ["intercostal", "ANATOMY", 79, 90], ["thoracic segments", "ANATOMY", 184, 201], ["spinal cord", "ANATOMY", 331, 342], ["intercostal weakness", "DISEASE", 79, 99], ["myelopathy", "DISEASE", 258, 268], ["anterior horn", "MULTI-TISSUE_STRUCTURE", 29, 42], ["3", "GENE_OR_GENE_PRODUCT", 64, 65], ["intercostal", "ORGANISM_SUBDIVISION", 79, 90], ["patient", "ORGANISM", 295, 302], ["spinal cord", "ORGAN", 331, 342], ["patient", "SPECIES", 295, 302], ["Segmental symptoms", "PROBLEM", 0, 18], ["anterior horn pathology", "PROBLEM", 29, 52], ["intercostal weakness", "PROBLEM", 79, 99], ["the overlapping myotomic organization of the thoracic segments", "PROBLEM", 139, 201], ["Postoperative segmental myelopathy", "PROBLEM", 234, 268], ["spinal cord surgery", "TREATMENT", 331, 350], ["anterior", "ANATOMY_MODIFIER", 29, 37], ["horn", "OBSERVATION_MODIFIER", 38, 42], ["pathology", "OBSERVATION", 43, 52], ["Th2", "ANATOMY_MODIFIER", 60, 63], ["intercostal", "ANATOMY", 79, 90], ["weakness", "OBSERVATION", 91, 99], ["most likely due to", "UNCERTAINTY", 120, 138], ["overlapping", "OBSERVATION_MODIFIER", 143, 154], ["myotomic", "OBSERVATION", 155, 163], ["thoracic segments", "ANATOMY", 184, 201], ["segmental", "OBSERVATION_MODIFIER", 248, 257], ["myelopathy", "OBSERVATION", 258, 268], ["spinal cord", "ANATOMY", 331, 342], ["surgery", "OBSERVATION", 343, 350]]], ["It is most likely caused by decompression or loss of traction forces acting on the myelon [6, 16] .", [["myelon", "ANATOMY", 83, 89], ["decompression", "TREATMENT", 28, 41], ["loss of traction forces", "PROBLEM", 45, 68], ["most likely caused", "UNCERTAINTY", 6, 24], ["decompression", "OBSERVATION", 28, 41], ["loss", "OBSERVATION_MODIFIER", 45, 49], ["traction forces", "OBSERVATION", 53, 68]]], ["As the myelopathy was stable over several years and there was no spinal cord atrophy, we did not suspect other causes of myelopathy (e.g., inflammatory, neurodegenerative) [17] .", [["spinal cord", "ANATOMY", 65, 76], ["myelopathy", "DISEASE", 7, 17], ["cord atrophy", "DISEASE", 72, 84], ["myelopathy", "DISEASE", 121, 131], ["spinal cord", "ORGAN", 65, 76], ["the myelopathy", "PROBLEM", 3, 17], ["spinal cord atrophy", "PROBLEM", 65, 84], ["myelopathy", "PROBLEM", 121, 131], ["inflammatory, neurodegenerative)", "PROBLEM", 139, 171], ["myelopathy", "OBSERVATION", 7, 17], ["stable", "OBSERVATION_MODIFIER", 22, 28], ["no", "UNCERTAINTY", 62, 64], ["spinal cord", "ANATOMY", 65, 76], ["atrophy", "OBSERVATION", 77, 84], ["myelopathy", "OBSERVATION", 121, 131], ["inflammatory", "OBSERVATION_MODIFIER", 139, 151]]], ["Levels of vitamin B12 and folic acid remained within normal limits during the postoperative course.Discussion and ConclusionsIn summary, our patient illustrates the importance of careful longitudinal follow-up with repeated imaging studies in atypical clinical courses of suspected degenerative upper motor neuron syndromes.", [["upper motor neuron", "ANATOMY", 295, 313], ["vitamin B12", "CHEMICAL", 10, 21], ["folic acid", "CHEMICAL", 26, 36], ["degenerative upper motor neuron syndromes", "DISEASE", 282, 323], ["vitamin B12", "CHEMICAL", 10, 21], ["folic acid", "CHEMICAL", 26, 36], ["vitamin B12", "SIMPLE_CHEMICAL", 10, 21], ["folic acid", "SIMPLE_CHEMICAL", 26, 36], ["patient", "ORGANISM", 141, 148], ["upper motor neuron", "CANCER", 295, 313], ["patient", "SPECIES", 141, 148], ["Levels", "TEST", 0, 6], ["vitamin B12", "TEST", 10, 21], ["folic acid", "TEST", 26, 36], ["repeated imaging studies", "TEST", 215, 239], ["degenerative upper motor neuron syndromes", "PROBLEM", 282, 323], ["normal limits", "OBSERVATION", 53, 66], ["degenerative", "OBSERVATION_MODIFIER", 282, 294], ["upper", "ANATOMY_MODIFIER", 295, 300], ["motor neuron syndromes", "OBSERVATION", 301, 323]]]], "PMC7319603": [], "286db1744e15a42fa837fab01bd5311b80bc089e": [["IntroductionCovid-19 has severely tested our public health systems.", [["IntroductionCovid", "TREATMENT", 0, 17]]], ["Recovering from Covid-19 will soon test our economic systems.", [["Covid", "TEST", 16, 21]]], ["Innovation will have an important role to play in recovering from the aftermath of the coronavirus.", [["coronavirus", "DISEASE", 87, 98], ["coronavirus", "ORGANISM", 87, 98], ["the coronavirus", "PROBLEM", 83, 98]]], ["This article discusses both how to manage innovation as part of that recovery, and also derives some lessons from how we have responded to the virus so far, and what those lessons imply for managing innovation during the recovery.IntroductionCovid-19's assault has prompted a number of encouraging developments.", [["IntroductionCovid", "TREATMENT", 230, 247]]], ["One development has been the rapid mobilization of scientists, pharmaceutical companies and government officials to launch a variety of scientific initiatives to find an effective response to the virus.", [["scientific initiatives", "TREATMENT", 136, 158], ["the virus", "PROBLEM", 192, 201], ["rapid", "OBSERVATION_MODIFIER", 29, 34], ["mobilization", "OBSERVATION_MODIFIER", 35, 47]]], ["As of the time of this writing, there are tests underway of more than 50 different compounds as possible vaccines against the virus.", [["tests", "TEST", 42, 47], ["vaccines", "TREATMENT", 105, 113], ["the virus", "PROBLEM", 122, 131]]], ["1 Most of these will ultimately fail, but the severity of the crisis demands that we investigate every plausible candidate.", [["the crisis demands", "PROBLEM", 58, 76]]], ["We need rapid, parallel experimentation, and it must be the test data that select our vaccine, not internal political or bureaucratic processes.IntroductionA second development has been the release of copious amounts of information about the virus, its spread, and human responses to various public health measures.", [["human", "ORGANISM", 265, 270], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["the test data", "TEST", 56, 69], ["our vaccine", "TREATMENT", 82, 93], ["internal political or bureaucratic processes", "PROBLEM", 99, 143], ["the virus", "PROBLEM", 238, 247], ["rapid", "OBSERVATION_MODIFIER", 8, 13], ["bureaucratic processes", "OBSERVATION", 121, 143]]], ["The Gates Foundation, working with the Chan-Zuckerberg Foundation and the White House Office of Science and Technology Policy have joined forces to publish all of the known medical literature on the coronavirus, in machine-readable form 2 .", [["coronavirus", "DISEASE", 199, 210], ["coronavirus", "ORGANISM", 199, 210], ["the coronavirus", "PROBLEM", 195, 210]]], ["This was done with the intent to accelerate the analysis of the existing research to identify possible new avenues of attack against Covid-19.", [["Covid", "TEST", 133, 138]]], ["The coronavirus itself was synthesized early on in the outbreak by scientists in China, providing the genetic sequence of the virus, and showing where it differed from earlier viruses such as SARS and MERS.", [["SARS", "DISEASE", 192, 196], ["coronavirus", "ORGANISM", 4, 15], ["the virus", "PROBLEM", 122, 131], ["earlier viruses", "PROBLEM", 168, 183], ["SARS", "PROBLEM", 192, 196], ["coronavirus", "OBSERVATION", 4, 15], ["early", "OBSERVATION_MODIFIER", 39, 44]]], ["At the same time, GITHUB and the Humanitarian Data Exchange each have an accumulating series of datasets on the geography of the spread of the disease (including positive test cases, hospitalizations, and deaths).", [["deaths", "DISEASE", 205, 211], ["the disease", "PROBLEM", 139, 150], ["disease", "OBSERVATION", 143, 150]]], ["Opening up mobilizes knowledge from many different places, causing our learning to advance and our progress against the disease to accelerate.", [["the disease", "PROBLEM", 116, 127]]], ["Openness leverages the human capital available in the world to tackle the disease, and also accesses the physical capital (such as plant and equipment) already in place to launch rapid testing of possible solutions.", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["the disease", "PROBLEM", 70, 81], ["rapid testing", "TEST", 179, 192], ["disease", "OBSERVATION", 74, 81]]], ["The Covid-19 disease appears to be doubling every 3-5 days, so a delay of just a few weeks in the search for a new vaccine (they normally take 1-2 years to develop, or more) might witness multiple doublings of size of the population infected with the disease.", [["The Covid-19 disease", "PROBLEM", 0, 20], ["a new vaccine", "TREATMENT", 109, 122], ["the disease", "PROBLEM", 247, 258], ["disease", "OBSERVATION", 13, 20], ["size", "OBSERVATION_MODIFIER", 210, 214], ["population", "OBSERVATION_MODIFIER", 222, 232], ["infected", "OBSERVATION", 233, 241], ["disease", "OBSERVATION", 251, 258]]], ["It is for this reason that Bill Gates is providing funds to construct facilities in advance for producing https://doi.org/10.1016/j.indmarman.2020.04.010 the leading vaccine candidates 4 .", [["the leading vaccine candidates", "TREATMENT", 154, 184]]], ["Though the facilities for the losing candidates will not be used, it will save precious time to make the winning vaccine in high volume, once it is found.Open innovation in medical scienceOpen innovation can help speed things up.", [["the winning vaccine", "TREATMENT", 101, 120], ["Open innovation in medical scienceOpen innovation", "TREATMENT", 154, 203]]], ["The availability of the gene sequencing of the coronavirus establishes a clear target to all of us.", [["coronavirus", "ORGANISM", 47, 58], ["the coronavirus", "PROBLEM", 43, 58]]], ["The 50+ vaccine candidates being considered are all already-approved drugs for other medical uses.", [["The 50+ vaccine candidates", "TREATMENT", 0, 26]]], ["This means that each candidate's basic safety dosage levels in humans have already been established.", [["humans", "ORGANISM", 63, 69], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69]]], ["This allows the testing to start in the middle of the usual drug development process, with the Phase 1 safety protocols already completed.", [["the testing", "TEST", 12, 23]]], ["And not just professional researchers and scientists, but also amateur researchers who have a passion and a hunch to test.Open innovation in medical scienceThis openness in the scientific domain will likely help us find a vaccine sooner.", [["a vaccine", "TREATMENT", 220, 229]]], ["Many powerful new technologies lack a clear and obvious way to create business value (think of artificial intelligence, or IoT, or blockchain).", [["artificial intelligence", "PROBLEM", 95, 118]]], ["Instead, set up the tests, and let the resulting data guide your decision.", [["the tests", "TEST", 16, 25]]], ["And notice that many of these experiments can be done by others, with their own money, people, and equipment.", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93]]], ["So practicing more openness in the science and technology that undergirds your business is well worth your consideration.Open innovation in medical scienceBut finding a vaccine is not enough.", [["a vaccine", "TREATMENT", 167, 176]]], ["There are now more than a million confirmed cases of Covid-19, with tens of thousands people in serious or critical condition in hospitals to be treated (a number that is doubling every 3-5 days).", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["Covid", "TEST", 53, 58], ["serious", "OBSERVATION_MODIFIER", 96, 103]]], ["There has been a shortage of personal protective equipment (PPE) for medical staff to protect themselves against the virus, including masks, gowns, and gloves.", [["personal protective equipment", "TREATMENT", 29, 58], ["medical staff", "TREATMENT", 69, 82], ["the virus", "PROBLEM", 113, 122], ["gloves", "TREATMENT", 152, 158]]], ["What if mask manufacturers like 3 M opened up their mask designs and IP temporarily, so that anyone in the world with a 3D printer could print a mask?Open innovation in medical scienceThere also is a severe shortage of ventilators in this crisis.", [["a mask", "TREATMENT", 143, 149], ["a severe shortage of ventilators", "PROBLEM", 198, 230], ["this crisis", "PROBLEM", 234, 245], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["shortage", "OBSERVATION_MODIFIER", 207, 215]]], ["For example, given the shortage of ventilators that are needed for the intensive care for some COVID-19 patients, ventilator manufacturers are forming partnerships with carmakers, aerospace firms and others to boost output as fast as possible.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["ventilators", "TREATMENT", 35, 46], ["the intensive care", "TREATMENT", 67, 85], ["some COVID", "TREATMENT", 90, 100], ["ventilator manufacturers", "TREATMENT", 114, 138], ["carmakers", "TREATMENT", 169, 178]]], ["6 Companies that make ventilators could also do more.", [["ventilators", "TREATMENT", 22, 33]]], ["7 Moreover, the company will post the mechanical designs of its ventilators, so that others can not only see the patents, but can use the actual designs to shorten the time needed to build more ventilators.How open innovation works: outside in and inside outTo understand better how open innovation works, it helps to compare and contrast some of its principal mechanisms in normal times to our present crisis.", [["the mechanical designs of its ventilators", "TREATMENT", 34, 75], ["patents", "OBSERVATION", 113, 120]]], ["Open innovation is defined as \"a distributed innovation process involving purposive knowledge flows across organizational boundaries for monetary or non-monetary reasons\" (Chesbrough & Bogers, 2014) .", [["Open innovation", "TREATMENT", 0, 15], ["a distributed innovation process", "PROBLEM", 31, 63]]], ["It has two principal directions on knowledge flow: outside in, and inside out.", [["two", "OBSERVATION_MODIFIER", 7, 10], ["principal", "OBSERVATION_MODIFIER", 11, 20], ["directions", "OBSERVATION_MODIFIER", 21, 31]]], ["In the Covid-19 crisis, the White House Office of Science and Technology policy published all of the relevant research on Covid-19 and the underlying SARS-Cov2 virus, to encourage collaborators to work on solutions.", [["SARS", "DISEASE", 150, 154], ["SARS-Cov2 virus", "ORGANISM", 150, 165], ["SARS-Cov2 virus", "SPECIES", 150, 165], ["Covid", "TEST", 122, 127], ["the underlying SARS", "PROBLEM", 135, 154], ["Cov2 virus", "PROBLEM", 155, 165]]], ["In Covid-19, we are seeing similar crowdsourcing for therapies for managing the disease, plus ways to design and make masks, hand sanitizers, and even modifying a ventilator to support 2 patients at a time.How open innovation works: outside in and inside outFor inside-out knowledge flows in the b2b context, Amazon famously offered its internal IT infrastructure to host external customers' websites and IT needs (Huckman, Pisano, & Kind, 2008) .", [["hand", "ANATOMY", 125, 129], ["hand", "ORGANISM_SUBDIVISION", 125, 129], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["therapies", "TREATMENT", 53, 62], ["the disease", "PROBLEM", 76, 87], ["masks, hand sanitizers", "TREATMENT", 118, 140], ["a ventilator", "TREATMENT", 161, 173]]], ["In the Covid-19 pandemic, Medtronic has opened up its ventilator design for anyone to make, posted its internal design drawings for the ventilator, and waived its IP rights to the design.", [["Covid-19 pandemic", "SPECIES", 7, 24], ["Medtronic", "TREATMENT", 26, 35], ["the ventilator", "TREATMENT", 132, 146]]], ["In the b2c context for inside-out knowledge flows, Lego allowed users and teachers to modify its Lego Mindstorms product to create a whole program of robotics instruction in middle schools (Afari & Khine, 2017) .", [["robotics instruction", "TREATMENT", 150, 170]]], ["In the Covid-19 pandemic, many companies are converting part of their manufacturing processes to produce scarce supplies like hand sanitizer.Open innovation in crisis managementThis openness could go still further.", [["hand", "ANATOMY", 126, 130], ["hand", "ORGANISM_SUBDIVISION", 126, 130], ["Covid-19 pandemic", "SPECIES", 7, 24], ["Open innovation", "TREATMENT", 141, 156], ["crisis management", "TREATMENT", 160, 177], ["hand", "ANATOMY", 126, 130], ["sanitizer", "OBSERVATION", 131, 140]]], ["We have a severe shortage of hospital beds.", [["severe", "OBSERVATION_MODIFIER", 10, 16]]], ["We also have a lockdown on non-essential business travel, causing most business hotel rooms to go empty.", [["empty", "OBSERVATION", 98, 103]]], ["Could we devise ways to allow non-contagious patients in hospitals to migrate to these unused hotel rooms?", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["It is likely to be much cheaper than the fully allocated costs of inpatient hospital rooms.", [["likely to be", "UNCERTAINTY", 6, 18]]], ["And this infrastructure is already built, ready to be used.Open innovation in crisis managementUser innovation may have a role to play here as well (Von Hippel, 2005; Von Hippel, 2016) -because we know that solutions to complex problems may come for non-conventional sources, particularly when the users themselves stand to benefit from the solution.", [["Open innovation", "TREATMENT", 59, 74], ["crisis management", "TREATMENT", 78, 95]]], ["Users can make their own masks, which will both reduce transmission of the disease to them and more importantly for society, reduce their transmission of the disease to others.", [["the disease", "PROBLEM", 71, 82], ["the disease", "PROBLEM", 154, 165], ["disease", "OBSERVATION", 75, 82]]], ["And these home-made masks will not deplete the scarce inventory of masks needed for front line medical staff.", [["masks", "TREATMENT", 20, 25]]], ["We are already seeing a version of this with hand sanitizers, as recipes for home-made hand sanitizers (usually featuring grain alcohol, and softeners like Aloe vera) abound on the internet.", [["hand", "ANATOMY", 45, 49], ["hand", "ANATOMY", 87, 91], ["alcohol", "CHEMICAL", 128, 135], ["Aloe vera", "DISEASE", 156, 165], ["alcohol", "CHEMICAL", 128, 135], ["hand", "ORGANISM_SUBDIVISION", 87, 91], ["Aloe vera", "SPECIES", 156, 165], ["hand sanitizers", "TREATMENT", 45, 60], ["hand sanitizers", "TREATMENT", 87, 102]]], ["With ventilators, there are reports of individual physicians modifying ventilators to serve multiple patients simultaneously.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["ventilators", "TREATMENT", 5, 16], ["ventilators", "TREATMENT", 71, 82]]], ["This is another lesson for innovation in the recovery: users can be a powerful source of innovative ideas and opportunities in your business as well.Open innovation in crisis managementThe pandemic is also stimulating innovation in the management of intellectual property (IP).", [["Open innovation", "TREATMENT", 149, 164], ["crisis management", "TREATMENT", 168, 185], ["pandemic", "OBSERVATION", 189, 197], ["stimulating", "OBSERVATION_MODIFIER", 206, 217], ["innovation", "OBSERVATION_MODIFIER", 218, 228]]], ["Some initiatives are now in place to encourage companies and universities to release portions their intellectual property (IP) in the fight against COVID-19.", [["COVID", "TEST", 148, 153]]], ["The World Health Organization (WHO) has offered a proposal to create a patent pool for all who are working on Covid-19 initiatives, providing access to all critical scientific information in return for agreeing to compulsory licensing for essential information.", [["patent", "OBSERVATION", 71, 77]]], ["Most patents in most large companies are neither used nor licensed.", [["most large", "OBSERVATION_MODIFIER", 16, 26], ["companies", "OBSERVATION", 27, 36]]], ["This is wasteful in the best of times, and is even harder to justify in times like now.Open innovation in the public sectorIn normal times, most companies take their regulatory environment as given.", [["Open innovation", "TREATMENT", 87, 102], ["wasteful", "OBSERVATION_MODIFIER", 8, 16], ["innovation", "OBSERVATION", 92, 102], ["normal times", "OBSERVATION_MODIFIER", 126, 138]]], ["In a pandemic, though, the regulators need to adapt as well.", [["pandemic", "OBSERVATION", 5, 13]]], ["While we search for an effective vaccine, regulators should allow compassionate use of promising (but not yet approved) medicines, particularly those whose safety profiles have already been vetted as noted above.", [["an effective vaccine", "TREATMENT", 20, 40], ["medicines", "TREATMENT", 120, 129]]], ["And vaccine candidate drugs that are already approved should not have to again undergo the initial safety tests that the FDA usually requires.", [["vaccine candidate drugs", "TREATMENT", 4, 27], ["the initial safety tests", "TEST", 87, 111]]], ["If regulators in Japan approve a ventilator during the crisis, that should imply provisional acceptance for that device in Spain or the US, so long as certain procedures were followed and, importantly, the Japanese regulator shared the underlying data that justified the approval.", [["a ventilator", "TREATMENT", 31, 43], ["the US", "TEST", 132, 138]]], ["Transparency offers society protection against poor or shoddy offerings, so regulatory studies themselves need to be widely shared in these times of crisis.Open innovation in the public sectorIn order to do achieve an effective response from these various open initiatives, we need to agree upon mechanisms of coordination for the open platforms that collect the initiatives and their underlying data.", [["society protection", "TREATMENT", 20, 38], ["poor or shoddy offerings", "PROBLEM", 47, 71], ["regulatory studies", "TEST", 76, 94], ["crisis", "PROBLEM", 149, 155], ["Open innovation", "TREATMENT", 156, 171], ["the open platforms", "TEST", 327, 345], ["innovation", "OBSERVATION", 161, 171]]], ["Openness can help build trust, which is an essential ingredient in fighting a pandemic, and a critical part of sustaining your brand image in more ordinary times.Open innovation in the public sectorOther public constraints also require attention in these times.", [["your brand image", "TEST", 122, 138], ["Open innovation", "TREATMENT", 162, 177], ["innovation", "OBSERVATION", 167, 177]]], ["Product liability laws may need to be suspended temporarily, and/or public indemnification for companies from litigation may be needed to speed up the rapid development and manufacture of critical equipment, diagnostics, vaccines, and so on.", [["vaccines", "TREATMENT", 221, 229]]], ["Society should be willing to accept somewhat higher riskstill insisting on transparency in the process of developmentduring this crisis period, if it results in faster availability of these items in market.Open innovation in the public sectorIf and when the crisis begins to abate in the developed countries, it sadly seems quite likely that there will be an extension of the pandemic in less developed countries.", [["Open innovation", "TREATMENT", 206, 221], ["the crisis", "PROBLEM", 254, 264], ["innovation", "OBSERVATION", 211, 221], ["pandemic", "OBSERVATION_MODIFIER", 376, 384]]], ["The openness provisions sketched here must enable those impacted countries to quickly access all of the data, techniques, vaccines, and other technologies they will need to combat the virus (along with the human, physical and financial resources they will need).", [["human", "ORGANISM", 206, 211], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["vaccines", "TREATMENT", 122, 130], ["the virus", "PROBLEM", 180, 189]]], ["This is not only just and humane, it is also enlightened selfinterest.", [["not only", "UNCERTAINTY", 8, 16]]], ["Absent such assistance, people from those countries might otherwise ignite a global revival of the virus, or give rise to a viral mutation that evades our treatments, forcing us to start the pandemic cycle all over again.Managerial implications for recovery from the crisisThere are lessons here for us for managing innovation even after the crisis has finally passed.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["the virus", "PROBLEM", 95, 104], ["a viral mutation", "PROBLEM", 122, 138], ["the pandemic cycle", "TREATMENT", 187, 205], ["the crisis", "PROBLEM", 263, 273], ["managing innovation", "TREATMENT", 307, 326], ["the crisis", "PROBLEM", 338, 348], ["crisis", "OBSERVATION", 267, 273]]], ["Openness is essential to respond to the pandemic.", [["the pandemic", "PROBLEM", 36, 48]]], ["This will sharpen their own knowledge and provide additional validation for prospective innovations being considered in your company.", [["prospective innovations", "TREATMENT", 76, 99]]], ["2) Many of your most challenging problems might benefit from solutions from others in different places around the world.", [["your most challenging problems", "PROBLEM", 11, 41]]], ["Share some of these problems, along with their relevant scientific and technical data, on open platforms, so that anyone with the interest and knowledge can offer their ideas on how best to address the problem.", [["problems", "OBSERVATION", 20, 28]]], ["3) Work with your legal team to manage your internal IP more creatively and openly.", [["your internal IP", "TREATMENT", 39, 55]]], ["Instead, separate your IP into three buckets: a) the Crown Jewels, that will be protected as before; b) the Middle group that can be shared selectively with key customers, suppliers, and/or partners for mutual business benefit; and c) the Long Tail of IP that should be opened up to everyone (thus enabling others to innovate more, and saving on patent renewal fees).", [["the Long Tail of IP", "TREATMENT", 235, 254]]], ["Only now there is an entire new market waiting for the improved product, built up from the earlier generation of licensing.ConclusionGood ideas can come from anywhere, making openness is an imperative in these times of crisis.", [["crisis", "PROBLEM", 219, 225], ["entire", "OBSERVATION_MODIFIER", 21, 27], ["new", "OBSERVATION_MODIFIER", 28, 31], ["market", "OBSERVATION", 32, 38]]], ["This is one of the many lessons we are learning as we struggle to meet the challenge of our times.ConclusionThis openness contrasts sharply with some of the rising nationalist trends we are seeing.", [["the rising nationalist trends", "PROBLEM", 153, 182], ["many", "OBSERVATION_MODIFIER", 19, 23], ["lessons", "OBSERVATION", 24, 31]]], ["Excluding entire countries from access to vaccines, or ventilators, or masks, or tests, or other critical equipment will undermine the ability to enlist the creative minds and imaginations of us all to address the crisis.", [["vaccines", "TREATMENT", 42, 50], ["ventilators", "TREATMENT", 55, 66], ["masks", "TREATMENT", 71, 76], ["tests", "TEST", 81, 86], ["the crisis", "PROBLEM", 210, 220]]], ["Moreover, it is short-sighted in the extreme, as shifting the pandemic out of one country in the short term will only cause it to return later, possibly in a mutated form.", [["short", "OBSERVATION_MODIFIER", 16, 21]]]], "PMC4058655": [["IntroductionA large number of medical biomarkers are expressed at the surface of human cells or infectious pathogens such as viruses, bacteria, fungi or parasites.", [["surface", "ANATOMY", 70, 77], ["cells", "ANATOMY", 87, 92], ["surface", "CELLULAR_COMPONENT", 70, 77], ["human", "ORGANISM", 81, 86], ["cells", "CELL", 87, 92], ["human cells", "CELL_TYPE", 81, 92], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["medical biomarkers", "TEST", 30, 48], ["human cells", "PROBLEM", 81, 92], ["infectious pathogens", "PROBLEM", 96, 116], ["viruses", "PROBLEM", 125, 132], ["bacteria", "PROBLEM", 134, 142], ["fungi", "PROBLEM", 144, 149], ["parasites", "PROBLEM", 153, 162], ["large", "OBSERVATION_MODIFIER", 14, 19], ["number", "OBSERVATION_MODIFIER", 20, 26], ["infectious", "OBSERVATION", 96, 106]]], ["The composition and dynamics of the cell surface determine how a cell or a pathogen can interact with its environment and are crucial to send and receive chemical signals, to transport metabolites, ions, or larger molecules, to attach to neighboring cells and the extracellular matrix, etc. In the context of disease, a mutation, deletion or over-expression of cell surface proteins is associated with many pathological states and membrane proteins are currently the target for more than half of the approved drugs [1].", [["cell surface", "ANATOMY", 36, 48], ["cell", "ANATOMY", 65, 69], ["cells", "ANATOMY", 250, 255], ["extracellular matrix", "ANATOMY", 264, 284], ["cell surface", "ANATOMY", 361, 373], ["membrane", "ANATOMY", 431, 439], ["cell surface", "CELLULAR_COMPONENT", 36, 48], ["cell", "CELL", 65, 69], ["ions", "SIMPLE_CHEMICAL", 198, 202], ["cells", "CELL", 250, 255], ["extracellular matrix", "CELLULAR_COMPONENT", 264, 284], ["cell", "CELL", 361, 365], ["membrane", "CELLULAR_COMPONENT", 431, 439], ["neighboring cells", "CELL_TYPE", 238, 255], ["cell surface proteins", "PROTEIN", 361, 382], ["membrane proteins", "PROTEIN", 431, 448], ["a pathogen", "PROBLEM", 73, 83], ["chemical signals", "TEST", 154, 170], ["disease", "PROBLEM", 309, 316], ["a mutation", "PROBLEM", 318, 328], ["deletion", "PROBLEM", 330, 338], ["cell surface proteins", "PROBLEM", 361, 382], ["many pathological states", "PROBLEM", 402, 426], ["membrane proteins", "PROBLEM", 431, 448], ["extracellular matrix", "ANATOMY", 264, 284], ["disease", "OBSERVATION", 309, 316]]], ["Hence, there is a high demand for specific ligands against cell surface targets for fundamental research, but also for diagnosis, monitoring and treatment of diseases.", [["cell surface", "ANATOMY", 59, 71], ["cell", "CELL", 59, 63], ["a high demand", "PROBLEM", 16, 29], ["cell surface targets", "TREATMENT", 59, 79], ["monitoring", "TEST", 130, 140], ["diseases", "PROBLEM", 158, 166], ["diseases", "OBSERVATION", 158, 166]]], ["So far, most of these ligands have been developed against proteins whereas only a few exist against carbohydrates and lipids.", [["carbohydrates", "CHEMICAL", 100, 113], ["carbohydrates", "SIMPLE_CHEMICAL", 100, 113], ["lipids", "SIMPLE_CHEMICAL", 118, 124], ["lipids", "TREATMENT", 118, 124]]], ["Two types of ligands have been developed: (1) small molecule drugs which are predominantly designed to bind the intracellular catalytic domain of membrane proteins, and (2) peptide-based ligands or antibodies which are designed to bind both intracellular and extracellular domains.IntroductionAmong the existing ligands, antibodies are extensively used to profile the expression of cell surface biomarkers and to study their role.", [["intracellular", "ANATOMY", 112, 125], ["membrane", "ANATOMY", 146, 154], ["intracellular", "ANATOMY", 241, 254], ["extracellular", "ANATOMY", 259, 272], ["cell surface", "ANATOMY", 382, 394], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 241, 254], ["extracellular domains", "CELLULAR_COMPONENT", 259, 280], ["cell", "CELL", 382, 386], ["intracellular catalytic domain", "PROTEIN", 112, 142], ["membrane proteins", "PROTEIN", 146, 163], ["antibodies", "PROTEIN", 198, 208], ["intracellular and extracellular domains", "PROTEIN", 241, 280], ["antibodies", "PROTEIN", 321, 331], ["small molecule drugs", "PROBLEM", 46, 66], ["membrane proteins", "TEST", 146, 163], ["peptide-based ligands", "TEST", 173, 194], ["antibodies", "PROBLEM", 198, 208], ["antibodies", "TREATMENT", 321, 331], ["cell surface biomarkers", "TEST", 382, 405], ["ligands", "OBSERVATION", 13, 20], ["small", "OBSERVATION_MODIFIER", 46, 51], ["molecule drugs", "OBSERVATION", 52, 66], ["intracellular", "ANATOMY_MODIFIER", 241, 254], ["extracellular domains", "OBSERVATION", 259, 280]]], ["Such antibodies have led to the development of the cluster of differentiation (CD) nomenclature initially used for phenotyping cells of the immune system but now extended to many other cell types (http://www.hcdm.org/MoleculeInformation/tabid/54/Default.aspx).", [["cells", "ANATOMY", 127, 132], ["immune system", "ANATOMY", 140, 153], ["cell", "ANATOMY", 185, 189], ["cells", "CELL", 127, 132], ["cell", "CELL", 185, 189], ["antibodies", "PROTEIN", 5, 15], ["Such antibodies", "PROBLEM", 0, 15], ["phenotyping cells of the immune system", "PROBLEM", 115, 153], ["cluster", "OBSERVATION_MODIFIER", 51, 58], ["cell types", "OBSERVATION", 185, 195]]], ["However, it can be challenging to identify antibodies recognizing membrane proteins as they exist in their natural environment on the cell surface.", [["membrane", "ANATOMY", 66, 74], ["cell surface", "ANATOMY", 134, 146], ["membrane", "CELLULAR_COMPONENT", 66, 74], ["cell surface", "CELLULAR_COMPONENT", 134, 146], ["antibodies", "PROTEIN", 43, 53], ["membrane proteins", "PROTEIN", 66, 83], ["antibodies recognizing membrane proteins", "PROBLEM", 43, 83]]], ["Indeed, it is difficult to present membrane proteins to the immune system in their native conformation and for many such targets standard immunization approaches so far have been applied with limited success.", [["membrane", "ANATOMY", 35, 43], ["immune system", "ANATOMY", 60, 73], ["membrane", "CELLULAR_COMPONENT", 35, 43], ["membrane proteins", "PROTEIN", 35, 52], ["standard immunization approaches", "TREATMENT", 129, 161]]], ["Hence, whereas the predicted number of human transmembrane proteins is very high (\u223c13,000), antibodies have been identified against only 364 CD antigens.IntroductionNucleic acid-based ligands, named aptamers, appear as appealing new ligands in this field and more than one hundred aptamers have been selected against cell surface targets during the past 10-15 years.", [["transmembrane", "ANATOMY", 45, 58], ["cell surface", "ANATOMY", 317, 329], ["Nucleic acid", "CHEMICAL", 165, 177], ["human", "ORGANISM", 39, 44], ["transmembrane", "CELLULAR_COMPONENT", 45, 58], ["CD antigens", "GENE_OR_GENE_PRODUCT", 141, 152], ["Nucleic acid", "SIMPLE_CHEMICAL", 165, 177], ["cell", "CELL", 317, 321], ["human transmembrane proteins", "PROTEIN", 39, 67], ["antibodies", "PROTEIN", 92, 102], ["364 CD antigens", "PROTEIN", 137, 152], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["human transmembrane proteins", "TEST", 39, 67], ["antibodies", "TEST", 92, 102], ["Nucleic acid", "TEST", 165, 177]]], ["This technique is usually named SELEX (Systematic Evolution of Ligands by EXponential enrichment) and consists of repetitive cycles of selection and amplification (Figure 1).", [["This technique", "TREATMENT", 0, 14], ["repetitive cycles of selection", "TREATMENT", 114, 144]]], ["During each cycle, oligonucleotides with affinity for a desired target are retained and amplified, leading to their enrichment in the pool which is finally sequenced to identify the aptamers.", [["oligonucleotides", "TREATMENT", 19, 35]]], ["Since 1990, this strategy has been used to identify aptamers against a wide variety of targets from small molecules to peptides, proteins, nucleic acid-based structures (for reviews, see [4,5]).", [["nucleic acid", "CHEMICAL", 139, 151], ["small molecules to peptides", "PROBLEM", 100, 127]]], ["In many cases, aptamers have been shown to present high specificity and affinity as well as inhibitory or modulatory activity towards their targets [6].", [["aptamers", "TREATMENT", 15, 23]]], ["Moreover, they seem to lack immunogenicity and can be chemically modified in order to improve their stability against nucleases, modify their pharmacokinetics or allow labelling.", [["nucleases", "PROTEIN", 118, 127]]], ["Due to their unique advantages, aptamers have been used in several applications from basic to applied research.", [["aptamers", "TREATMENT", 32, 40]]], ["For instance, aptamers have been used to study natural interactions between RNA and proteins, to regulate gene expression, to develop biosensors, to purify specific molecules, to inhibit the function of a protein and to develop drugs (for reviews, see [7-10]).IntroductionAptamers recognize the three-dimensional structure of their targets with high specificity and the affinity is often highly dependent on the chosen conditions applied during the selection.", [["aptamers", "TREATMENT", 14, 22]]], ["It is therefore very important to perform the SELEX against the native conformation of the target and as much as possible in a near natural environment.", [["the SELEX", "TREATMENT", 42, 51]]], ["Such conditions are easily provided for soluble targets but more difficult to achieve for membrane proteins whose structures are inextricably linked to their inclusion in lipidic bi-layers as well as their interaction with the intra- and extracellular matrix.", [["membrane", "ANATOMY", 90, 98], ["extracellular matrix", "ANATOMY", 238, 258], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["extracellular matrix", "CELLULAR_COMPONENT", 238, 258], ["membrane proteins", "PROTEIN", 90, 107], ["soluble targets", "TREATMENT", 40, 55], ["membrane proteins", "PROBLEM", 90, 107], ["extracellular matrix", "ANATOMY", 238, 258]]], ["Although several aptamers have been successfully selected against purified cell surface carbohydrates or recombinant ectodomains of membrane proteins, the three-dimensional structure of a purified cell surface biomarker can be rather different from the one found in the context of a plasma membrane.", [["cell surface", "ANATOMY", 75, 87], ["membrane", "ANATOMY", 132, 140], ["cell surface", "ANATOMY", 197, 209], ["plasma membrane", "ANATOMY", 283, 298], ["carbohydrates", "CHEMICAL", 88, 101], ["cell", "CELL", 75, 79], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["cell", "CELL", 197, 201], ["plasma membrane", "CELLULAR_COMPONENT", 283, 298], ["recombinant ectodomains", "PROTEIN", 105, 128], ["membrane proteins", "PROTEIN", 132, 149], ["purified cell surface carbohydrates", "TREATMENT", 66, 101], ["recombinant ectodomains of membrane proteins", "PROBLEM", 105, 149], ["a purified cell surface biomarker", "TEST", 186, 219], ["purified cell surface", "OBSERVATION", 188, 209], ["plasma membrane", "OBSERVATION", 283, 298]]], ["Therefore, aptamers selected against purified domains of membrane proteins are sometimes unable to bind the natural protein expressed at the cell surface.", [["membrane", "ANATOMY", 57, 65], ["cell surface", "ANATOMY", 141, 153], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["cell surface", "CELLULAR_COMPONENT", 141, 153], ["purified domains", "PROTEIN", 37, 53], ["membrane proteins", "PROTEIN", 57, 74], ["natural protein", "PROTEIN", 108, 123], ["aptamers", "TREATMENT", 11, 19], ["purified domains of membrane proteins", "PROBLEM", 37, 74], ["cell surface", "OBSERVATION", 141, 153]]], ["To bypass this drawback, several new methods of SELEX have been developed to allow aptamer selection under conditions as close as possible to the natural situation (Figures 1 and 2).", [["bypass", "TREATMENT", 3, 9], ["several new methods of SELEX", "TREATMENT", 25, 53], ["bypass", "OBSERVATION", 3, 9], ["new", "OBSERVATION_MODIFIER", 33, 36]]], ["The present review describes the different strategies that have been developed to select aptamers against cell surface biomarkers.SELEX Directed against Purified Cell Surface BiomarkersThe first SELEX against a membrane protein was performed against L-Selectin by NeXstar Pharmaceuticals Inc. (Boulder, CO, USA) in 1996 [20].", [["cell surface", "ANATOMY", 106, 118], ["Cell", "ANATOMY", 162, 166], ["membrane", "ANATOMY", 211, 219], ["cell", "CELL", 106, 110], ["membrane", "CELLULAR_COMPONENT", 211, 219], ["L-Selectin", "SIMPLE_CHEMICAL", 250, 260], ["membrane protein", "PROTEIN", 211, 227], ["L-Selectin", "PROTEIN", 250, 260], ["cell surface biomarkers", "TEST", 106, 129], ["SELEX", "TREATMENT", 130, 135], ["Purified Cell Surface Biomarkers", "TEST", 153, 185], ["a membrane protein", "TEST", 209, 227]]], ["The L-selectin is a calcium-dependent cell surface lectin that is constitutively expressed on most leukocytes and mediates their adhesion to endothelial cells through interaction with cell-specific carbohydrates.", [["cell surface", "ANATOMY", 38, 50], ["leukocytes", "ANATOMY", 99, 109], ["endothelial cells", "ANATOMY", 141, 158], ["cell", "ANATOMY", 184, 188], ["calcium", "CHEMICAL", 20, 27], ["calcium", "CHEMICAL", 20, 27], ["carbohydrates", "CHEMICAL", 198, 211], ["L-selectin", "GENE_OR_GENE_PRODUCT", 4, 14], ["calcium", "SIMPLE_CHEMICAL", 20, 27], ["cell", "CELL", 38, 42], ["leukocytes", "CELL", 99, 109], ["endothelial cells", "CELL", 141, 158], ["cell", "CELL", 184, 188], ["L-selectin", "PROTEIN", 4, 14], ["calcium-dependent cell surface lectin", "PROTEIN", 20, 57], ["leukocytes", "CELL_TYPE", 99, 109], ["endothelial cells", "CELL_TYPE", 141, 158], ["a calcium-dependent cell surface lectin", "PROBLEM", 18, 57], ["L-selectin", "OBSERVATION", 4, 14], ["calcium-dependent", "OBSERVATION_MODIFIER", 20, 37], ["cell", "OBSERVATION", 38, 42], ["surface lectin", "OBSERVATION", 43, 57], ["most leukocytes", "OBSERVATION_MODIFIER", 94, 109], ["endothelial cells", "OBSERVATION", 141, 158]]], ["A pool of nuclease-stabilized 2\u2032-aminopyrimidine RNA library was selected at 4 and 22 \u00b0C against a human L-selectin-Ig chimera immobilized on Protein A-Sepharose beads.", [["2\u2032-aminopyrimidine", "CHEMICAL", 30, 48], ["2\u2032-aminopyrimidine", "CHEMICAL", 30, 48], ["2\u2032-aminopyrimidine", "SIMPLE_CHEMICAL", 30, 48], ["human", "ORGANISM", 99, 104], ["L-selectin", "GENE_OR_GENE_PRODUCT", 105, 115], ["Ig", "GENE_OR_GENE_PRODUCT", 116, 118], ["nuclease-stabilized 2\u2032-aminopyrimidine RNA library", "DNA", 10, 60], ["L-selectin", "PROTEIN", 105, 115], ["Ig chimera", "PROTEIN", 116, 126], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["nuclease", "TEST", 10, 18], ["aminopyrimidine RNA library", "TREATMENT", 33, 60], ["a human L-selectin-Ig chimera", "TREATMENT", 97, 126], ["Protein A-Sepharose beads", "TREATMENT", 142, 167], ["Sepharose beads", "OBSERVATION", 152, 167]]], ["After extensive washing, bound oligonucleotides were eluted with 5 mM EDTA.", [["EDTA", "CHEMICAL", 70, 74], ["EDTA", "SIMPLE_CHEMICAL", 70, 74], ["extensive washing", "TREATMENT", 6, 23], ["bound oligonucleotides", "TREATMENT", 25, 47]]], ["This SELEX identified aptamers with high affinity at 4 and 22 \u00b0C but they had much lower affinity at 37 \u00b0C. To isolate aptamers with improved thermal stability, the same group performed the same SELEX at higher selection temperatures (either 22 or 37 \u00b0C) using a DNA library [11].", [["DNA", "CELLULAR_COMPONENT", 263, 266], ["This SELEX", "TEST", 0, 10], ["high affinity", "PROBLEM", 36, 49], ["much lower affinity", "PROBLEM", 78, 97], ["improved thermal stability", "PROBLEM", 133, 159], ["a DNA library", "TREATMENT", 261, 274]]], ["These results highlight that aptamers have to be selected as close as possible to physiological conditions (i.e. 37 \u00b0C) in order to be potentially usable in vivo.SELEX Directed against Purified Cell Surface BiomarkersTwo years later a SELEX was performed against the full length extracellular domain of CD4 produced from a mammalian expression system and immobilized on beads [12].", [["Cell", "ANATOMY", 194, 198], ["extracellular", "ANATOMY", 279, 292], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 279, 292], ["CD4", "GENE_OR_GENE_PRODUCT", 303, 306], ["full length extracellular domain", "PROTEIN", 267, 299], ["CD4", "PROTEIN", 303, 306], ["SELEX", "TREATMENT", 162, 167], ["Purified Cell Surface Biomarkers", "TEST", 185, 217], ["a SELEX", "TREATMENT", 233, 240], ["a mammalian expression system", "TREATMENT", 321, 350]]], ["To remove sequences with ability to bind to other sites than CD4 in the selection matrix, the library was in each round of the selection pre-exposed to beads lacking CD4, and furthermore, two types of beads were used during selection.", [["CD4", "GENE_OR_GENE_PRODUCT", 61, 64], ["matrix", "CELLULAR_COMPONENT", 82, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 166, 169], ["CD4", "PROTEIN", 61, 64], ["CD4", "PROTEIN", 166, 169], ["sequences", "TREATMENT", 10, 19], ["beads", "TREATMENT", 201, 206], ["beads", "OBSERVATION", 201, 206]]], ["The first six rounds were performed against biotinylated CD4 captured on beads coated with streptavidin.", [["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["streptavidin", "GENE_OR_GENE_PRODUCT", 91, 103], ["biotinylated CD4", "PROTEIN", 44, 60], ["streptavidin", "PROTEIN", 91, 103], ["biotinylated CD4", "TREATMENT", 44, 60], ["streptavidin", "TREATMENT", 91, 103]]], ["Subsequently, another six rounds were performed against CD4 captured onto beads coated with a monoclonal anti-CD4 antibody.", [["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 105, 113], ["CD4", "PROTEIN", 56, 59], ["monoclonal anti-CD4 antibody", "PROTEIN", 94, 122], ["CD4", "PROBLEM", 56, 59], ["a monoclonal anti-CD4 antibody", "TREATMENT", 92, 122], ["monoclonal anti-CD4 antibody", "OBSERVATION", 94, 122]]], ["Interestingly, the selected aptamers were not only able to bind the recombinant ectodomain of CD4 but also the entire protein expressed on the surface of a mouse T cell line after transfection.", [["surface", "ANATOMY", 143, 150], ["T cell line", "ANATOMY", 162, 173], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["surface", "CELLULAR_COMPONENT", 143, 150], ["mouse", "ORGANISM", 156, 161], ["T cell line", "CELL", 162, 173], ["recombinant ectodomain", "PROTEIN", 68, 90], ["CD4", "PROTEIN", 94, 97], ["mouse T cell line", "CELL_LINE", 156, 173], ["mouse", "SPECIES", 156, 161], ["mouse", "SPECIES", 156, 161], ["a mouse T cell line", "TREATMENT", 154, 173], ["CD4", "OBSERVATION", 94, 97], ["cell line", "OBSERVATION", 164, 173]]], ["In contrast, no measurable binding was observed for the non-transfected cell line lacking the expression of CD4.", [["cell line", "ANATOMY", 72, 81], ["cell line", "CELL", 72, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 108, 111], ["non-transfected cell line", "CELL_LINE", 56, 81], ["CD4", "PROTEIN", 108, 111], ["measurable binding", "PROBLEM", 16, 34], ["the non-transfected cell line", "TREATMENT", 52, 81], ["no", "UNCERTAINTY", 13, 15], ["non-transfected cell line", "OBSERVATION", 56, 81]]], ["Hence, aptamers selected against a purified ectodomain of a membrane protein may also be able to recognize the protein in its native environment.", [["membrane", "ANATOMY", 60, 68], ["membrane", "CELLULAR_COMPONENT", 60, 68], ["purified ectodomain", "PROTEIN", 35, 54], ["membrane protein", "PROTEIN", 60, 76], ["aptamers", "TREATMENT", 7, 15], ["a membrane protein", "TREATMENT", 58, 76]]], ["Similar SELEX experiments have been performed successfully against other types of membrane proteins including G Protein Coupled-Receptors (GPCRs), Receptor Tyrosine Kinases (RTKs), and Tumour Necrosis Factor (TNF) receptors (see Table 1).", [["membrane", "ANATOMY", 82, 90], ["Tyrosine", "CHEMICAL", 156, 164], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["G Protein Coupled-Receptors", "GENE_OR_GENE_PRODUCT", 110, 137], ["Receptor Tyrosine Kinases", "GENE_OR_GENE_PRODUCT", 147, 172], ["RTKs", "GENE_OR_GENE_PRODUCT", 174, 178], ["Tumour Necrosis Factor (TNF) receptors", "GENE_OR_GENE_PRODUCT", 185, 223], ["see Table 1", "GENE_OR_GENE_PRODUCT", 225, 236], ["membrane proteins", "PROTEIN", 82, 99], ["G Protein Coupled-Receptors", "PROTEIN", 110, 137], ["GPCRs", "PROTEIN", 139, 144], ["Receptor Tyrosine Kinases", "PROTEIN", 147, 172], ["RTKs", "PROTEIN", 174, 178], ["Tumour Necrosis Factor (TNF) receptors", "PROTEIN", 185, 223], ["Similar SELEX experiments", "PROBLEM", 0, 25], ["membrane proteins", "PROBLEM", 82, 99], ["G Protein Coupled", "TREATMENT", 110, 127], ["Receptors (GPCRs", "TREATMENT", 128, 144], ["Receptor Tyrosine Kinases", "TEST", 147, 172], ["RTKs", "TEST", 174, 178], ["Tumour Necrosis Factor (TNF) receptors", "PROBLEM", 185, 223], ["SELEX", "OBSERVATION", 8, 13], ["Tumour Necrosis", "OBSERVATION", 185, 200]]], ["In addition, similar strategies have also been applied to select aptamers against proteins from the surface of bacteria and parasites as well as from the envelope or capsid of viruses (see Table 1).SELEX Directed against Purified Cell Surface BiomarkersA few aptamer selections have targeted cell surface-associated carbohydrates which represent an important class of cell surface biomarkers as well.", [["surface", "ANATOMY", 100, 107], ["Cell", "ANATOMY", 230, 234], ["cell surface", "ANATOMY", 292, 304], ["cell surface", "ANATOMY", 368, 380], ["carbohydrates", "CHEMICAL", 316, 329], ["surface", "CELLULAR_COMPONENT", 100, 107], ["Cell", "CELL", 230, 234], ["cell", "CELL", 292, 296], ["cell", "CELL", 368, 372], ["bacteria", "PROBLEM", 111, 119], ["parasites", "PROBLEM", 124, 133], ["capsid of viruses", "PROBLEM", 166, 183], ["SELEX", "TREATMENT", 198, 203], ["Purified Cell Surface Biomarkers", "TEST", 221, 253], ["A few aptamer selections", "PROBLEM", 253, 277], ["cell surface biomarkers", "TEST", 368, 391], ["bacteria", "OBSERVATION", 111, 119], ["parasites", "OBSERVATION", 124, 133], ["viruses", "OBSERVATION", 176, 183], ["cell surface", "OBSERVATION", 368, 380]]], ["The first anti-carbohydrate aptamer was selected against Sialyl Lewis X (sLeX) which is known to be a ligand for the selectin proteins and to be over-expressed at the surface of several types of tumor cells [13].", [["surface", "ANATOMY", 167, 174], ["tumor cells", "ANATOMY", 195, 206], ["tumor", "DISEASE", 195, 200], ["Sialyl Lewis X", "SIMPLE_CHEMICAL", 57, 71], ["selectin", "GENE_OR_GENE_PRODUCT", 117, 125], ["surface", "CELLULAR_COMPONENT", 167, 174], ["tumor cells", "CELL", 195, 206], ["selectin proteins", "PROTEIN", 117, 134], ["tumor cells", "CELL_TYPE", 195, 206], ["The first anti-carbohydrate aptamer", "TREATMENT", 0, 35], ["Sialyl Lewis", "TREATMENT", 57, 69], ["the selectin proteins", "TEST", 113, 134], ["tumor cells", "PROBLEM", 195, 206], ["several types", "OBSERVATION_MODIFIER", 178, 191], ["tumor cells", "OBSERVATION", 195, 206]]], ["The selected aptamers had a high affinity (KD around 10\u22129 to 10\u221211 M) for their target and for similar Lewis group sugars.", [["sugars", "CHEMICAL", 115, 121], ["a high affinity", "PROBLEM", 26, 41]]], ["In contrast, it demonstrated a 100 times lower affinity for unrelated sugars such as lactose.", [["lactose", "CHEMICAL", 85, 92], ["sugars", "CHEMICAL", 70, 76], ["lactose", "CHEMICAL", 85, 92], ["lactose", "SIMPLE_CHEMICAL", 85, 92], ["unrelated sugars", "PROBLEM", 60, 76], ["lactose", "TREATMENT", 85, 92]]], ["As carbohydrates are often anionic, this could represent a limitation for the selection of aptamers which are themselves negatively charged.", [["carbohydrates", "CHEMICAL", 3, 16], ["carbohydrates", "SIMPLE_CHEMICAL", 3, 16], ["the selection of aptamers", "TREATMENT", 74, 99]]], ["To solve this problem, chemically modified aptamers have been developed containing cationic protonated amino groups at the C5 position of thymidines.", [["thymidines", "CHEMICAL", 138, 148], ["amino", "CHEMICAL", 103, 108], ["thymidines", "CHEMICAL", 138, 148], ["cationic protonated amino groups", "SIMPLE_CHEMICAL", 83, 115], ["thymidines", "SIMPLE_CHEMICAL", 138, 148], ["chemically modified aptamers", "TREATMENT", 23, 51], ["cationic protonated amino groups", "TREATMENT", 83, 115]]], ["This strategy was applied successfully to identify aptamers against sialyllactose which is strongly anionic [14].", [["sialyllactose", "CHEMICAL", 68, 81], ["sialyllactose", "CHEMICAL", 68, 81], ["sialyllactose", "SIMPLE_CHEMICAL", 68, 81], ["This strategy", "TREATMENT", 0, 13]]], ["As for \u201cclassical\u201d SELEX against purified soluble proteins, different methods have been used to partition the sequences with affinity for the target from the rest of the pool (see Table 1 and Gopinath et al. for a review of these different methods [15]).SELEX Directed against Purified Cell Surface BiomarkersIn most cases, the selection of aptamers has been performed against the ectodomain of proteins immobilized on a support (magnetic beads, plastic plate or SPR biosensor).", [["Cell", "ANATOMY", 286, 290], ["purified soluble proteins", "PROTEIN", 33, 58], ["ectodomain", "PROTEIN", 381, 391], ["classical\u201d SELEX", "TREATMENT", 8, 24], ["purified soluble proteins", "TREATMENT", 33, 58], ["different methods", "TREATMENT", 60, 77], ["SELEX", "TREATMENT", 254, 259], ["Purified Cell Surface Biomarkers", "TEST", 277, 309], ["the ectodomain of proteins", "PROBLEM", 377, 403], ["a support (magnetic beads", "TREATMENT", 419, 444], ["plastic plate or SPR biosensor", "TREATMENT", 446, 476]]], ["The production and purification of a membrane protein ectodomain is often much easier than it is for the whole protein.", [["membrane", "ANATOMY", 37, 45], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["membrane protein ectodomain", "PROTEIN", 37, 64], ["a membrane protein ectodomain", "PROBLEM", 35, 64]]], ["Furthermore, ectodomains have a higher chance of conserving their proper folding outside the lipid bi-layer.", [["lipid bi-layer", "ANATOMY", 93, 107], ["ectodomains", "PROTEIN", 13, 24]]], ["However, in some cases, aptamers identified using this strategy was unable to bind their target in its native form and environment on the cell surface (Table 1 [16-18]).", [["cell surface", "ANATOMY", 138, 150], ["cell surface", "CELLULAR_COMPONENT", 138, 150], ["this strategy", "TREATMENT", 50, 63]]], ["For instance, aptamers selected against the ectodomain of the EGFRvIII protein produced in E. coli, were unable to bind the same target produced from an eukaryotic system possessing post-translational modifications [18].", [["EGFRvIII", "GENE_OR_GENE_PRODUCT", 62, 70], ["E. coli", "ORGANISM", 91, 98], ["ectodomain", "PROTEIN", 44, 54], ["EGFRvIII protein", "PROTEIN", 62, 78], ["E. coli", "SPECIES", 91, 98], ["E. coli", "SPECIES", 91, 98], ["aptamers", "TREATMENT", 14, 22], ["the EGFRvIII protein", "TEST", 58, 78], ["E. coli", "PROBLEM", 91, 98], ["E. coli", "OBSERVATION", 91, 98]]], ["This work demonstrates that the glycosylation state of a protein is a crucial aspect to consider when using recombinant purified protein as a target for SELEX.", [["recombinant purified protein", "PROTEIN", 108, 136], ["recombinant purified protein", "TREATMENT", 108, 136]]], ["However, using the glycosylated purified ectodomain is still not a guaranty for obtaining aptamers to the native form.", [["glycosylated purified ectodomain", "PROTEIN", 19, 51], ["the glycosylated purified ectodomain", "TREATMENT", 15, 51]]], ["For instance, we found in our group that aptamers selected against the glycosylated ectodomain of the RETC634Y transmembrane receptor were unable to bind their target on the surface of cells although the purified ectodomain was confirmed to bind its natural ligands (GDNF and GFR\u03b11) [16,19].", [["surface", "ANATOMY", 174, 181], ["cells", "ANATOMY", 185, 190], ["RETC634Y", "GENE_OR_GENE_PRODUCT", 102, 110], ["surface", "CELLULAR_COMPONENT", 174, 181], ["cells", "CELL", 185, 190], ["GDNF", "GENE_OR_GENE_PRODUCT", 267, 271], ["GFR\u03b11", "GENE_OR_GENE_PRODUCT", 276, 281], ["glycosylated ectodomain", "PROTEIN", 71, 94], ["RETC634Y transmembrane receptor", "PROTEIN", 102, 133], ["purified ectodomain", "PROTEIN", 204, 223], ["GDNF", "PROTEIN", 267, 271], ["GFR\u03b11", "PROTEIN", 276, 281], ["the RETC634Y transmembrane receptor", "TREATMENT", 98, 133], ["the purified ectodomain", "PROBLEM", 200, 223], ["GFR", "TEST", 276, 279]]], ["These results demonstrate that, in some cases, aptamers selected against purified ectodomain proteins may be unable to bind the same target expressed on the surface of cells, even if the purified ectodomain displays a glycosylation pattern and functionality similar to the native protein.", [["surface", "ANATOMY", 157, 164], ["cells", "ANATOMY", 168, 173], ["surface", "CELLULAR_COMPONENT", 157, 164], ["cells", "CELL", 168, 173], ["purified ectodomain proteins", "PROTEIN", 73, 101], ["purified ectodomain", "PROTEIN", 187, 206], ["native protein", "PROTEIN", 273, 287], ["aptamers", "TREATMENT", 47, 55], ["purified ectodomain proteins", "PROBLEM", 73, 101]]], ["To solve this problem, new SELEX procedures have been developed.SELEX Directed against Membrane CompartmentsIn order to select aptamers against membrane proteins in a more physiological environment, SELEX has been performed directly against purified plasma membranes (see Table 2).", [["Membrane Compartments", "ANATOMY", 87, 108], ["membrane", "ANATOMY", 144, 152], ["plasma membranes", "ANATOMY", 250, 266], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["plasma membranes", "CELLULAR_COMPONENT", 250, 266], ["Membrane Compartments", "PROTEIN", 87, 108], ["membrane proteins", "PROTEIN", 144, 161], ["new SELEX procedures", "TREATMENT", 23, 43], ["membrane proteins", "TREATMENT", 144, 161], ["new", "OBSERVATION_MODIFIER", 23, 26], ["SELEX", "OBSERVATION", 27, 32]]], ["However, in this case, aptamer selection is conducted towards a mixture of targets present in the plasma membrane.", [["plasma membrane", "ANATOMY", 98, 113], ["plasma membrane", "CELLULAR_COMPONENT", 98, 113], ["aptamer selection", "TREATMENT", 23, 40], ["plasma membrane", "OBSERVATION", 98, 113]]], ["The first SELEX against such a complex mixture of targets was performed using human red blood cell (RBC) ghosts in 1998 [50].SELEX Directed against Membrane CompartmentsAfter 25 rounds of selection using a filtration method to recover the sequences bound to RBC membranes, aptamers with high affinity for RBCs were identified.", [["red blood cell", "ANATOMY", 84, 98], ["RBC", "ANATOMY", 100, 103], ["Membrane", "ANATOMY", 148, 156], ["RBC membranes", "ANATOMY", 258, 271], ["RBCs", "ANATOMY", 305, 309], ["human", "ORGANISM", 78, 83], ["red blood cell", "CELL", 84, 98], ["RBC", "CELL", 100, 103], ["RBC membranes", "CELLULAR_COMPONENT", 258, 271], ["RBCs", "CELL", 305, 309], ["human red blood cell (RBC) ghosts", "CELL_TYPE", 78, 111], ["RBCs", "CELL_TYPE", 305, 309], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["human red blood cell", "TEST", 78, 98], ["a filtration method", "TREATMENT", 204, 223], ["RBC membranes", "TEST", 258, 271], ["high affinity", "PROBLEM", 287, 300], ["RBCs", "PROBLEM", 305, 309]]], ["UV-crosslinking experiments demonstrated that this kind of SELEX results in aptamers against several different membrane proteins.", [["membrane", "ANATOMY", 111, 119], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["membrane proteins", "PROTEIN", 111, 128], ["aptamers", "TREATMENT", 76, 84], ["several different membrane proteins", "PROBLEM", 93, 128]]], ["To direct the SELEX against a target of interest, specific elution of aptamers using natural ligands of the target has been proposed.", [["the SELEX", "TREATMENT", 10, 19], ["aptamers", "TREATMENT", 70, 78], ["natural ligands", "TREATMENT", 85, 100]]], ["This approach was used to select aptamers against several receptors of the nervous system using membrane extracts of brain homogenates from rats [51], T. Californica electric organ [52] or a HEK293 cell line expressing the GluR2 glutamate receptor channel [53] (Table 2).", [["nervous system", "ANATOMY", 75, 89], ["membrane extracts", "ANATOMY", 96, 113], ["brain homogenates", "ANATOMY", 117, 134], ["organ", "ANATOMY", 175, 180], ["HEK293 cell line", "ANATOMY", 191, 207], ["glutamate", "CHEMICAL", 229, 238], ["glutamate", "CHEMICAL", 229, 238], ["nervous system", "ANATOMICAL_SYSTEM", 75, 89], ["membrane extracts", "ORGANISM_SUBSTANCE", 96, 113], ["brain homogenates", "ORGANISM_SUBSTANCE", 117, 134], ["rats", "ORGANISM", 140, 144], ["T. Californica", "ORGANISM", 151, 165], ["organ", "ORGAN", 175, 180], ["HEK293 cell line", "CELL", 191, 207], ["GluR2 glutamate receptor", "GENE_OR_GENE_PRODUCT", 223, 247], ["HEK293 cell line", "CELL_LINE", 191, 207], ["GluR2 glutamate receptor channel", "PROTEIN", 223, 255], ["rats", "SPECIES", 140, 144], ["T. Californica", "SPECIES", 151, 165], ["T. Californica", "SPECIES", 151, 165], ["membrane extracts", "TREATMENT", 96, 113], ["a HEK293 cell line", "TREATMENT", 189, 207], ["the GluR2 glutamate receptor channel", "TREATMENT", 219, 255], ["nervous system", "ANATOMY", 75, 89], ["brain", "ANATOMY", 117, 122]]], ["During the selections, bound aptamers were eluted using a ligand of the receptor after removal of unbound aptamers by filtration.", [["bound aptamers", "TEST", 23, 37], ["a ligand of the receptor", "TREATMENT", 56, 80], ["removal of unbound aptamers", "TREATMENT", 87, 114]]], ["In addition to selecting aptamers that are specific for a target, this strategy also resulted in aptamers that were potent competitors of the natural ligands of the receptors.SELEX Directed against Whole Living Cells, Bacteria, Viruses and ParasitesAlthough proteins in plasma membrane extracts are in a more physiological environment compared with purified ectodomains, it is well known that the plasma membrane is a dynamic system composed of membrane constituents that are in close contact with each other as well as with the intra- and/or extra-cellular matrix.", [["Cells", "ANATOMY", 211, 216], ["plasma membrane extracts", "ANATOMY", 270, 294], ["plasma membrane", "ANATOMY", 397, 412], ["membrane constituents", "ANATOMY", 445, 466], ["extra-cellular matrix", "ANATOMY", 543, 564], ["Cells", "CELL", 211, 216], ["Bacteria", "CELL", 218, 226], ["Parasites", "CELL", 240, 249], ["plasma", "ORGANISM_SUBSTANCE", 270, 276], ["membrane extracts", "ORGANISM_SUBSTANCE", 277, 294], ["plasma membrane", "CELLULAR_COMPONENT", 397, 412], ["membrane constituents", "CELLULAR_COMPONENT", 445, 466], ["extra-cellular matrix", "CELLULAR_COMPONENT", 543, 564], ["purified ectodomains", "PROTEIN", 349, 369], ["selecting aptamers", "TREATMENT", 15, 33], ["SELEX", "TREATMENT", 175, 180], ["Whole Living Cells", "PROBLEM", 198, 216], ["Bacteria", "PROBLEM", 218, 226], ["Viruses", "PROBLEM", 228, 235], ["Parasites", "PROBLEM", 240, 249], ["proteins in plasma membrane extracts", "PROBLEM", 258, 294], ["purified ectodomains", "PROBLEM", 349, 369], ["membrane constituents", "PROBLEM", 445, 466], ["Viruses", "OBSERVATION", 228, 235], ["plasma membrane", "OBSERVATION_MODIFIER", 270, 285], ["plasma membrane", "OBSERVATION", 397, 412], ["membrane constituents", "OBSERVATION", 445, 466], ["extra-cellular matrix", "ANATOMY", 543, 564]]], ["This kind of SELEX was performed for the first time against Trypanosoma brucei parasites and Bacillus anthracis spores in 1999 [55,56].", [["Trypanosoma brucei parasites", "DISEASE", 60, 88], ["Trypanosoma brucei parasites", "ORGANISM", 60, 88], ["Bacillus anthracis", "ORGANISM", 93, 111], ["Trypanosoma brucei", "SPECIES", 60, 78], ["Bacillus anthracis", "SPECIES", 93, 111], ["Trypanosoma brucei", "SPECIES", 60, 78], ["Bacillus anthracis", "SPECIES", 93, 111], ["SELEX", "TREATMENT", 13, 18], ["Trypanosoma brucei parasites", "PROBLEM", 60, 88], ["Bacillus anthracis spores", "PROBLEM", 93, 118], ["SELEX", "OBSERVATION", 13, 18], ["brucei parasites", "OBSERVATION", 72, 88]]], ["In both cases, the partitioning of bound from unbound sequences was done by centrifugation of parasites or bacteria spores.", [["spores", "ANATOMY", 116, 122], ["unbound sequences", "TEST", 46, 63], ["parasites", "PROBLEM", 94, 103], ["bacteria spores", "PROBLEM", 107, 122], ["bacteria spores", "OBSERVATION", 107, 122]]], ["Interestingly, the SELEX against Trypanosoma brucei resulted in only a few types of aptamers in spite of the numerous potential targets present on the surface of the parasite suggesting the existence of dominant epitopes.", [["surface", "ANATOMY", 151, 158], ["Trypanosoma brucei", "DISEASE", 33, 51], ["Trypanosoma brucei", "ORGANISM", 33, 51], ["surface", "CELLULAR_COMPONENT", 151, 158], ["dominant epitopes", "PROTEIN", 203, 220], ["Trypanosoma brucei", "SPECIES", 33, 51], ["Trypanosoma brucei", "SPECIES", 33, 51], ["the SELEX", "TREATMENT", 15, 24], ["Trypanosoma brucei", "PROBLEM", 33, 51], ["dominant epitopes", "PROBLEM", 203, 220], ["Trypanosoma brucei", "OBSERVATION", 33, 51], ["few", "OBSERVATION_MODIFIER", 71, 74], ["aptamers", "OBSERVATION", 84, 92], ["numerous", "OBSERVATION_MODIFIER", 109, 117], ["potential", "OBSERVATION_MODIFIER", 118, 127], ["targets", "OBSERVATION", 128, 135], ["suggesting the existence of", "UNCERTAINTY", 175, 202], ["dominant", "OBSERVATION_MODIFIER", 203, 211], ["epitopes", "OBSERVATION", 212, 220]]], ["Aptamers were predominantly selected against a target specifically localized in the flagellar pocket of the trypanosome while no aptamer was selected against the VSG protein, which is the most abundant polypeptide on the trypanosome surface.", [["flagellar pocket", "ANATOMY", 84, 100], ["surface", "ANATOMY", 233, 240], ["VSG", "GENE_OR_GENE_PRODUCT", 162, 165], ["trypanosome surface", "CELLULAR_COMPONENT", 221, 240], ["VSG protein", "PROTEIN", 162, 173], ["Aptamers", "TREATMENT", 0, 8], ["the trypanosome", "PROBLEM", 104, 119], ["the VSG protein", "TEST", 158, 173], ["flagellar", "ANATOMY_MODIFIER", 84, 93], ["pocket", "OBSERVATION_MODIFIER", 94, 100], ["trypanosome", "OBSERVATION_MODIFIER", 221, 232], ["surface", "OBSERVATION_MODIFIER", 233, 240]]], ["In 2000, SELEX was performed against the human cytomegalovirus using filtration [57].", [["human", "ORGANISM", 41, 46], ["cytomegalovirus", "ORGANISM", 47, 62], ["human", "SPECIES", 41, 46], ["human cytomegalovirus", "SPECIES", 41, 62], ["SELEX", "TREATMENT", 9, 14]]], ["In that case, aptamers were predominantly selected against the glycoprotein B and H, which represent the most abundant and exposed envelope proteins of the virus.SELEX Directed against Whole Living Cells, Bacteria, Viruses and ParasitesIn 2001, SELEX was performed for the first time on a whole living mammalian cell line [58].", [["Cells", "ANATOMY", 198, 203], ["cell line", "ANATOMY", 312, 321], ["glycoprotein B", "GENE_OR_GENE_PRODUCT", 63, 77], ["H", "GENE_OR_GENE_PRODUCT", 82, 83], ["Cells", "CELL", 198, 203], ["Bacteria", "CELL", 205, 213], ["mammalian cell line [58", "CELL", 302, 325], ["glycoprotein B", "PROTEIN", 63, 77], ["H", "PROTEIN", 82, 83], ["envelope proteins", "PROTEIN", 131, 148], ["mammalian cell line", "CELL_LINE", 302, 321], ["aptamers", "TREATMENT", 14, 22], ["the virus", "PROBLEM", 152, 161], ["SELEX", "TREATMENT", 162, 167], ["Bacteria", "PROBLEM", 205, 213], ["ParasitesIn", "TREATMENT", 227, 238], ["SELEX", "TREATMENT", 245, 250], ["a whole living mammalian cell line", "TREATMENT", 287, 321], ["cell line", "OBSERVATION", 312, 321]]], ["During the SELEX, the library was counter-selected in each round against N9 microglial cells before selecting against rat YPEN-1 endothelial cells.", [["N9 microglial cells", "ANATOMY", 73, 92], ["YPEN-1 endothelial cells", "ANATOMY", 122, 146], ["N9 microglial cells", "CELL", 73, 92], ["rat", "ORGANISM", 118, 121], ["YPEN-1 endothelial cells", "CELL", 122, 146], ["SELEX", "DNA", 11, 16], ["N9 microglial cells", "CELL_LINE", 73, 92], ["rat YPEN-1 endothelial cells", "CELL_LINE", 118, 146], ["rat", "SPECIES", 118, 121], ["rat", "SPECIES", 118, 121], ["N9 microglial cells", "PROBLEM", 73, 92], ["rat YPEN", "TEST", 118, 126], ["microglial cells", "OBSERVATION", 76, 92], ["endothelial cells", "OBSERVATION", 129, 146]]], ["As the two cell types were non-adhering cells, unbound sequences were removed by centrifugation.", [["cell", "ANATOMY", 11, 15], ["cells", "ANATOMY", 40, 45], ["cell", "CELL", 11, 15], ["cells", "CELL", 40, 45], ["non-adhering cells", "CELL_TYPE", 27, 45], ["unbound sequences", "TEST", 47, 64]]], ["The counter-selection was performed to favour aptamers against targets whose expression is linked to the endothelial phenotype.", [["endothelial", "ANATOMY", 105, 116], ["endothelial", "CELL", 105, 116], ["The counter-selection", "TREATMENT", 0, 21], ["endothelial", "ANATOMY", 105, 116]]], ["The pool was fluorescently labeled during the SELEX, which allowed the monitoring of enrichment of cell-binding aptamers using flow cytometry.", [["cell", "ANATOMY", 99, 103], ["cell", "CELL", 99, 103], ["the SELEX", "TREATMENT", 42, 51], ["cell-binding aptamers", "TREATMENT", 99, 120], ["flow cytometry", "TEST", 127, 141]]], ["After sequencing, most of the individual sequences tested showed affinity for the YPEN-1 EC cell line by flow cytometry, and some of them could bind microvessels in cryostat tissue sections of rat brain glioblastomas.", [["YPEN-1 EC cell line", "ANATOMY", 82, 101], ["microvessels", "ANATOMY", 149, 161], ["tissue sections", "ANATOMY", 174, 189], ["brain glioblastomas", "ANATOMY", 197, 216], ["brain glioblastomas", "DISEASE", 197, 216], ["YPEN-1 EC cell line", "CELL", 82, 101], ["microvessels", "TISSUE", 149, 161], ["cryostat tissue sections", "TISSUE", 165, 189], ["rat", "ORGANISM", 193, 196], ["brain glioblastomas", "CANCER", 197, 216], ["YPEN-1 EC cell line", "CELL_LINE", 82, 101], ["rat", "SPECIES", 193, 196], ["rat", "SPECIES", 193, 196], ["the individual sequences", "TEST", 26, 50], ["the YPEN", "TEST", 78, 86], ["flow cytometry", "TEST", 105, 119], ["cryostat tissue sections", "TEST", 165, 189], ["rat brain glioblastomas", "PROBLEM", 193, 216], ["cell line", "OBSERVATION", 92, 101], ["flow cytometry", "OBSERVATION", 105, 119], ["cryostat tissue", "OBSERVATION", 165, 180], ["brain", "ANATOMY", 197, 202], ["glioblastomas", "OBSERVATION", 203, 216]]], ["Since then, several aptamer selections have been conducted with living cells and the strategy has been named cell-SELEX.", [["cells", "ANATOMY", 71, 76], ["cell", "ANATOMY", 109, 113], ["cells", "CELL", 71, 76], ["cell", "CELL", 109, 113], ["several aptamer selections", "TREATMENT", 12, 38], ["living cells", "TREATMENT", 64, 76]]], ["While centrifugation is the partitioning method of choice for non-adherent cells, in the case of adherent cells, gentle plate washing is used.", [["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 106, 111], ["cells", "CELL", 75, 80], ["cells", "CELL", 106, 111], ["non-adherent cells", "CELL_TYPE", 62, 80], ["adherent cells", "CELL_TYPE", 97, 111], ["non-adherent cells", "PROBLEM", 62, 80], ["adherent cells", "PROBLEM", 97, 111], ["gentle plate washing", "TREATMENT", 113, 133], ["adherent cells", "OBSERVATION", 97, 111], ["plate washing", "OBSERVATION", 120, 133]]], ["However, recently another method was described by Raddatz et al. who used fluorescence-activated cell sorting (FACS) to perform the partitioning of bound from unbound sequences [59].", [["cell", "ANATOMY", 97, 101], ["cell", "CELL", 97, 101], ["unbound sequences", "TEST", 159, 176]]], ["The study demonstrated that FACS was a powerful method for selecting aptamers against living Burkitt lymphoma B cells particularly because it allows the elimination of dead cells, which usually display high non-specific binding for nucleic acids.SELEX Directed against Whole Living Cells, Bacteria, Viruses and ParasitesAs mentioned previously for SELEX against membrane compartments, SELEX against a living biological system often also results in the identification of aptamers for an unknown target.", [["Burkitt lymphoma B cells", "ANATOMY", 93, 117], ["cells", "ANATOMY", 173, 178], ["Cells", "ANATOMY", 282, 287], ["membrane compartments", "ANATOMY", 362, 383], ["Burkitt lymphoma", "DISEASE", 93, 109], ["nucleic acids", "CHEMICAL", 232, 245], ["Burkitt lymphoma B cells", "CELL", 93, 117], ["cells", "CELL", 173, 178], ["nucleic acids", "SIMPLE_CHEMICAL", 232, 245], ["Cells", "CELL", 282, 287], ["Bacteria", "CELL", 289, 297], ["Burkitt lymphoma B cells", "CELL_LINE", 93, 117], ["dead cells", "CELL_TYPE", 168, 178], ["The study", "TEST", 0, 9], ["selecting aptamers", "TREATMENT", 59, 77], ["living Burkitt lymphoma B cells", "PROBLEM", 86, 117], ["dead cells", "PROBLEM", 168, 178], ["high non-specific binding for nucleic acids", "PROBLEM", 202, 245], ["SELEX", "TREATMENT", 246, 251], ["Bacteria", "PROBLEM", 289, 297], ["Viruses", "PROBLEM", 299, 306], ["ParasitesAs", "PROBLEM", 311, 322], ["SELEX against membrane compartments", "TREATMENT", 348, 383], ["SELEX", "TREATMENT", 385, 390], ["aptamers", "TREATMENT", 470, 478], ["Burkitt lymphoma", "OBSERVATION", 93, 109], ["dead cells", "OBSERVATION", 168, 178], ["Viruses", "OBSERVATION", 299, 306]]], ["It can be difficult to identify the unknown target of an aptamer, but it opens a new avenue for the application of SELEX within biomarker identification and cell phenotyping.", [["cell", "ANATOMY", 157, 161], ["cell", "CELL", 157, 161], ["SELEX", "TREATMENT", 115, 120], ["biomarker identification", "TEST", 128, 152], ["cell phenotyping", "TEST", 157, 173], ["cell phenotyping", "OBSERVATION", 157, 173]]], ["For example, the subtractive cell-based method described for the SELEX against the YPEN-1 endothelial cell line allowed the identification of aptamers against targets that are differentially expressed between different cell types.", [["cell", "ANATOMY", 29, 33], ["YPEN-1 endothelial cell line", "ANATOMY", 83, 111], ["cell", "ANATOMY", 219, 223], ["cell", "CELL", 29, 33], ["YPEN-1 endothelial cell line", "CELL", 83, 111], ["cell", "CELL", 219, 223], ["YPEN-1 endothelial cell line", "CELL_LINE", 83, 111], ["the SELEX", "TREATMENT", 61, 70], ["the YPEN", "TEST", 79, 87], ["1 endothelial cell line", "TREATMENT", 88, 111], ["endothelial", "ANATOMY", 90, 101], ["cell line", "OBSERVATION", 102, 111], ["different cell types", "OBSERVATION", 209, 229]]], ["Furthermore, aptamers have also been selected with ability to distinguish cells on the basis of differentiation state [60], distinguish cancer cells or virus infected cells from normal cells of the same origin [61-63] and discriminate for instance different lineages of hematopoietic cancers [64,65] (see Table 3).", [["cells", "ANATOMY", 74, 79], ["cancer cells", "ANATOMY", 136, 148], ["cells", "ANATOMY", 167, 172], ["cells", "ANATOMY", 185, 190], ["hematopoietic cancers", "ANATOMY", 270, 291], ["cancer", "DISEASE", 136, 142], ["hematopoietic cancers", "DISEASE", 270, 291], ["cells", "CELL", 74, 79], ["cancer cells", "CELL", 136, 148], ["cells", "CELL", 167, 172], ["cells", "CELL", 185, 190], ["hematopoietic cancers", "CANCER", 270, 291], ["cancer cells", "CELL_TYPE", 136, 148], ["virus infected cells", "CELL_TYPE", 152, 172], ["normal cells", "CELL_TYPE", 178, 190], ["cancer cells", "PROBLEM", 136, 148], ["virus infected cells", "PROBLEM", 152, 172], ["hematopoietic cancers", "PROBLEM", 270, 291], ["cancer cells", "OBSERVATION", 136, 148], ["normal cells", "OBSERVATION", 178, 190], ["hematopoietic cancers", "OBSERVATION", 270, 291]]], ["For such aptamers, target identification can lead to the identification or validation of cell specific biomarkers.", [["cell", "ANATOMY", 89, 93], ["cell", "CELL", 89, 93], ["the identification", "TEST", 53, 71], ["cell specific biomarkers", "TEST", 89, 113]]], ["The strategy has been named AptaBiD for Aptamer-facilated Biomarker Discovery [66].", [["AptaBiD", "SIMPLE_CHEMICAL", 28, 35], ["Aptamer", "SIMPLE_CHEMICAL", 40, 47]]], ["Several protocols have been used to isolate and identify the target protein of aptamers selected using cell-SELEX [58,67-70].", [["cell", "ANATOMY", 103, 107], ["cell", "CELL", 103, 107], ["Several protocols", "TREATMENT", 0, 17]]], ["Basically, affinity chromatography is performed using biotinylated aptamer pre-incubated with a membrane protein extract, a total protein extract, or alternatively with living cells followed by cell lysis.", [["membrane", "ANATOMY", 96, 104], ["extract", "ANATOMY", 113, 120], ["extract", "ANATOMY", 138, 145], ["cells", "ANATOMY", 176, 181], ["cell", "ANATOMY", 194, 198], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["cells", "CELL", 176, 181], ["cell", "CELL", 194, 198], ["affinity chromatography", "TEST", 11, 34], ["biotinylated aptamer", "TREATMENT", 54, 74], ["a membrane protein extract", "TREATMENT", 94, 120], ["a total protein extract", "TREATMENT", 122, 145], ["living cells", "TREATMENT", 169, 181], ["cell lysis", "TREATMENT", 194, 204], ["cell lysis", "OBSERVATION", 194, 204]]], ["Bound protein is subsequently recovered and separated or not by SDS-PAGE electrophoresis before being identified by mass spectrometry.SELEX Directed against a Specific Biomarker in a Complex MixtureDifferent strategies have been developed to select aptamers against a specific cell surface target using living organisms or cells.", [["cell surface", "ANATOMY", 277, 289], ["cells", "ANATOMY", 323, 328], ["cell", "CELL", 277, 281], ["cells", "CELL", 323, 328], ["SELEX", "TREATMENT", 134, 139], ["a Complex MixtureDifferent strategies", "TREATMENT", 181, 218], ["a specific cell surface target", "TREATMENT", 266, 296]]], ["As previously described for SELEX against purified plasma membranes, displacement of aptamers using ligands of known biomarkers has been used, for example, to isolate aptamers against cell surface proteins of T. cruzi which interact with host cellular matrix components [93].", [["plasma membranes", "ANATOMY", 51, 67], ["cell surface", "ANATOMY", 184, 196], ["cellular matrix", "ANATOMY", 243, 258], ["plasma membranes", "CELLULAR_COMPONENT", 51, 67], ["cell", "CELL", 184, 188], ["T. cruzi", "ORGANISM", 209, 217], ["cellular", "CELL", 243, 251], ["cell surface proteins", "PROTEIN", 184, 205], ["T. cruzi", "SPECIES", 209, 217], ["T. cruzi", "SPECIES", 209, 217], ["SELEX", "TREATMENT", 28, 33], ["purified plasma membranes", "TREATMENT", 42, 67], ["displacement of aptamers", "TREATMENT", 69, 93], ["known biomarkers", "TEST", 111, 127], ["T. cruzi", "PROBLEM", 209, 217]]], ["Cell surface proteins of the extracellular matrix bind to the parasite surface and affect host cell invasion.", [["Cell surface", "ANATOMY", 0, 12], ["extracellular matrix", "ANATOMY", 29, 49], ["surface", "ANATOMY", 71, 78], ["cell", "ANATOMY", 95, 99], ["Cell", "CELL", 0, 4], ["extracellular matrix", "CELLULAR_COMPONENT", 29, 49], ["parasite surface", "CELLULAR_COMPONENT", 62, 78], ["host cell", "CELL", 90, 99], ["Cell surface proteins", "PROTEIN", 0, 21], ["Cell surface proteins", "TEST", 0, 21], ["the extracellular matrix bind", "TREATMENT", 25, 54], ["host cell invasion", "PROBLEM", 90, 108], ["extracellular", "ANATOMY_MODIFIER", 29, 42], ["matrix bind", "OBSERVATION", 43, 54], ["parasite", "OBSERVATION_MODIFIER", 62, 70], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["affect", "OBSERVATION_MODIFIER", 83, 89], ["host cell invasion", "OBSERVATION", 90, 108]]], ["For the selection of aptamers against the parasite, aptamer elution was performed using a mix of proteins from the extracellular matrix including laminin, fibronectin, heparan sulfate and thrombospondin in order to isolate high affinity aptamers with ability to compete with host cell matrix molecules for binding to T. cruzi cell surfaces.", [["extracellular matrix", "ANATOMY", 115, 135], ["cell matrix", "ANATOMY", 280, 291], ["cell", "ANATOMY", 326, 330], ["heparan sulfate", "CHEMICAL", 168, 183], ["extracellular matrix", "CELLULAR_COMPONENT", 115, 135], ["laminin", "GENE_OR_GENE_PRODUCT", 146, 153], ["fibronectin", "GENE_OR_GENE_PRODUCT", 155, 166], ["heparan sulfate", "SIMPLE_CHEMICAL", 168, 183], ["thrombospondin", "GENE_OR_GENE_PRODUCT", 188, 202], ["cell", "CELL", 280, 284], ["laminin", "PROTEIN", 146, 153], ["fibronectin", "PROTEIN", 155, 166], ["thrombospondin", "PROTEIN", 188, 202], ["host cell matrix molecules", "PROTEIN", 275, 301], ["T. cruzi", "SPECIES", 317, 325], ["T. cruzi", "SPECIES", 317, 325], ["aptamers", "TREATMENT", 21, 29], ["aptamer elution", "TREATMENT", 52, 67], ["a mix of proteins", "TREATMENT", 88, 105], ["the extracellular matrix including laminin", "TREATMENT", 111, 153], ["fibronectin", "TREATMENT", 155, 166], ["heparan sulfate", "TREATMENT", 168, 183], ["thrombospondin", "TREATMENT", 188, 202], ["high affinity aptamers", "PROBLEM", 223, 245], ["host cell matrix molecules", "TREATMENT", 275, 301], ["cruzi cell surfaces", "OBSERVATION", 320, 339]]], ["Furthermore, to select aptamers specific for the infective form of the parasite, a counter-selection step using non-infective epimastigote surfaces was applied in round seven of the SELEX experiment.SELEX Directed against a Specific Biomarker in a Complex MixtureIn our group, we developed a strategy for selection of aptamers to specific cell surface targets using transfected cells which over-express a protein of interest.", [["cell surface", "ANATOMY", 339, 351], ["cells", "ANATOMY", 378, 383], ["cell", "CELL", 339, 343], ["cells", "CELL", 378, 383], ["transfected cells", "CELL_LINE", 366, 383], ["a counter-selection step", "TREATMENT", 81, 105], ["non-infective epimastigote surfaces", "TREATMENT", 112, 147], ["selection of aptamers", "TREATMENT", 305, 326], ["specific cell surface targets", "TREATMENT", 330, 359], ["transfected cells", "PROBLEM", 366, 383], ["infective", "OBSERVATION", 49, 58], ["SELEX experiment", "OBSERVATION", 182, 198], ["transfected cells", "OBSERVATION", 366, 383]]], ["To validate the approach, we selected aptamers against transfected PC12 cells over-expressing the human mutated receptor tyrosine kinase RET (RETC634Y), which is constitutively activated in its dimeric form.", [["PC12 cells", "ANATOMY", 67, 77], ["tyrosine", "CHEMICAL", 121, 129], ["tyrosine", "CHEMICAL", 121, 129], ["PC12 cells", "CELL", 67, 77], ["human", "ORGANISM", 98, 103], ["receptor tyrosine kinase RET", "GENE_OR_GENE_PRODUCT", 112, 140], ["RETC634Y", "AMINO_ACID", 142, 150], ["PC12 cells", "CELL_LINE", 67, 77], ["human mutated receptor tyrosine kinase RET", "PROTEIN", 98, 140], ["RETC634Y", "PROTEIN", 142, 150], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["transfected PC12 cells", "TREATMENT", 55, 77]]], ["In each round, we performed counter-selection steps against mock-transfected PC12 cells and PC12 cells over-expressing a monomeric activated mutant of RET (RETM918T) [16].", [["PC12 cells", "ANATOMY", 77, 87], ["PC12 cells", "ANATOMY", 92, 102], ["PC12 cells", "CELL", 77, 87], ["PC12 cells", "CELL", 92, 102], ["RET", "GENE_OR_GENE_PRODUCT", 151, 154], ["PC12 cells", "CELL_LINE", 77, 87], ["PC12 cells", "CELL_LINE", 92, 102], ["monomeric activated mutant", "PROTEIN", 121, 147], ["RET", "PROTEIN", 151, 154], ["mock", "TEST", 60, 64], ["PC12 cells", "TEST", 92, 102]]], ["Using this strategy we were able to identify an aptamer that inhibits RET dimerization-dependent signaling pathways induced either by its natural ligand (GDNF) or by the C634Y activating mutation.", [["RET", "GENE_OR_GENE_PRODUCT", 70, 73], ["GDNF", "GENE_OR_GENE_PRODUCT", 154, 158], ["C634Y", "GENE_OR_GENE_PRODUCT", 170, 175], ["RET", "PROTEIN", 70, 73], ["natural ligand", "PROTEIN", 138, 152], ["GDNF", "PROTEIN", 154, 158], ["C634Y", "PROTEIN", 170, 175], ["this strategy", "TREATMENT", 6, 19], ["an aptamer", "PROBLEM", 45, 55], ["RET dimerization", "PROBLEM", 70, 86], ["dependent signaling pathways", "PROBLEM", 87, 115]]], ["However, the aptamer did not distinguish the dimeric form of RET from the monomer form in spite of counter-selection using RETM918T expressing cells.", [["cells", "ANATOMY", 143, 148], ["RET", "GENE_OR_GENE_PRODUCT", 61, 64], ["cells", "CELL", 143, 148], ["RET", "PROTEIN", 61, 64], ["RETM918T expressing cells", "CELL_LINE", 123, 148], ["counter-selection", "TREATMENT", 99, 116], ["RETM918T expressing cells", "TREATMENT", 123, 148]]], ["Furthermore, it represents a minority of the selected sequences (2 out of 67 sequences).", [["the selected sequences", "TEST", 41, 63]]], ["Similar strategies have also been used to identify aptamers against transforming growth factor-\u03b2 type III (TbRIII) and the HCV-E2 envelope glycoprotein [73,80].", [["transforming growth factor-\u03b2 type III", "GENE_OR_GENE_PRODUCT", 68, 105], ["TbRIII", "GENE_OR_GENE_PRODUCT", 107, 113], ["HCV-E2", "ORGANISM", 123, 129], ["transforming growth factor-\u03b2 type III", "PROTEIN", 68, 105], ["TbRIII", "PROTEIN", 107, 113], ["HCV-E2 envelope glycoprotein", "PROTEIN", 123, 151], ["HCV", "SPECIES", 123, 126], ["transforming growth factor", "PROBLEM", 68, 94], ["type III (TbRIII)", "PROBLEM", 97, 114], ["the HCV", "PROBLEM", 119, 126]]], ["Alternatively, aptamers against HER-2 were selected using SK-BR-3 known to over-express the membrane protein, while counter-selecting using the same cell line treated with HER-2 siRNA [81].SELEX Directed against a Specific Biomarker in a Complex MixtureAnother strategy involves an immuno-precipitation step and was developed to select aptamers against the Toll-like receptor 2 [82].", [["membrane", "ANATOMY", 92, 100], ["cell line", "ANATOMY", 149, 158], ["HER-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["SK-BR-3", "CELL", 58, 65], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["cell line", "CELL", 149, 158], ["HER-2", "GENE_OR_GENE_PRODUCT", 172, 177], ["Toll-like receptor 2", "GENE_OR_GENE_PRODUCT", 357, 377], ["HER-2", "PROTEIN", 32, 37], ["SK", "PROTEIN", 58, 60], ["membrane protein", "PROTEIN", 92, 108], ["cell line", "CELL_LINE", 149, 158], ["HER", "PROTEIN", 172, 175], ["Toll-like receptor 2", "PROTEIN", 357, 377], ["SK", "TEST", 58, 60], ["the same cell line", "TREATMENT", 140, 158], ["HER-2 siRNA", "TREATMENT", 172, 183], ["a Complex MixtureAnother strategy", "TREATMENT", 236, 269], ["cell line", "OBSERVATION", 149, 158]]], ["In this study, Toll-like receptor 2 fused to an Fc fragment was transiently expressed in HEK293T cells.", [["HEK293T cells", "ANATOMY", 89, 102], ["Toll-like receptor 2", "GENE_OR_GENE_PRODUCT", 15, 35], ["Fc", "GENE_OR_GENE_PRODUCT", 48, 50], ["HEK293T cells", "CELL", 89, 102], ["Toll-like receptor 2", "PROTEIN", 15, 35], ["Fc fragment", "DNA", 48, 59], ["HEK293T cells", "CELL_LINE", 89, 102], ["this study", "TEST", 3, 13], ["Toll-like receptor 2", "TREATMENT", 15, 35], ["an Fc fragment", "PROBLEM", 45, 59], ["Fc fragment", "OBSERVATION", 48, 59], ["HEK293T cells", "OBSERVATION", 89, 102]]], ["The DNA library was incubated with whole cells before lysis or directly to cell lysates and the sequences specifically bound to the receptor recovered using protein A beads.Cross-Over SELEXIn comparison to SELEX against purified targets, the selection of aptamers from a complex mixture of targets, as for example in cell-SELEX, is more difficult to direct towards specific proteins, however, in the latter case the membrane proteins are in an environment more close to the native situation.", [["cells", "ANATOMY", 41, 46], ["cell lysates", "ANATOMY", 75, 87], ["cell", "ANATOMY", 317, 321], ["membrane", "ANATOMY", 416, 424], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["cells", "CELL", 41, 46], ["cell lysates", "ORGANISM_SUBSTANCE", 75, 87], ["cell", "CELL", 317, 321], ["membrane", "CELLULAR_COMPONENT", 416, 424], ["DNA library", "DNA", 4, 15], ["membrane proteins", "PROTEIN", 416, 433], ["The DNA library", "TEST", 0, 15], ["whole cells", "TREATMENT", 35, 46], ["lysis", "TREATMENT", 54, 59], ["the sequences", "TEST", 92, 105], ["protein A beads", "TREATMENT", 157, 172], ["SELEX", "TREATMENT", 206, 211]]], ["To compile the advantages of both types of SELEX methods, cross-over strategies have been developed, in which, shifting between steps of SELEX against a purified protein and cells expressing the protein are performed.", [["cells", "ANATOMY", 174, 179], ["cells", "CELL", 174, 179], ["purified protein", "PROTEIN", 153, 169], ["SELEX methods", "TREATMENT", 43, 56], ["cross-over strategies", "TREATMENT", 58, 79], ["SELEX", "TREATMENT", 137, 142], ["the protein", "TEST", 191, 202]]], ["An aptamer for Tenascin-C was obtained using this kind of strategy [95].", [["Tenascin-C", "CHEMICAL", 15, 25], ["Tenascin-C", "CHEMICAL", 15, 25], ["Tenascin-C", "SIMPLE_CHEMICAL", 15, 25], ["Tenascin-C", "TREATMENT", 15, 25]]], ["After nine rounds of cell-SELEX, two rounds were performed against the purified protein improving the affinity of the pool for the protein 50-fold.", [["cell", "ANATOMY", 21, 25], ["cell", "CELL", 21, 25], ["purified protein", "PROTEIN", 71, 87], ["protein 50-fold", "PROTEIN", 131, 146], ["cell-SELEX", "TREATMENT", 21, 31], ["the purified protein", "TREATMENT", 67, 87], ["the protein", "TEST", 127, 138]]], ["In our group, we have showed that the same strategy allowed higher specific enrichment of aptamers for RET than cell-SELEX alone, but that the selected aptamers using pure whole-living cell-SELEX display a better apparent KD [19].Cross-Over SELEXMore recently, cross-over SELEX has been used to obtain aptamers directed against CD16\u03b1 protein [96].", [["cell", "ANATOMY", 112, 116], ["cell", "ANATOMY", 185, 189], ["RET", "GENE_OR_GENE_PRODUCT", 103, 106], ["cell", "CELL", 112, 116], ["cell", "CELL", 185, 189], ["CD16\u03b1", "GENE_OR_GENE_PRODUCT", 328, 333], ["RET", "DNA", 103, 106], ["CD16\u03b1 protein", "PROTEIN", 328, 341], ["RET than cell-SELEX", "TREATMENT", 103, 122], ["cross-over SELEX", "TREATMENT", 261, 277], ["aptamers", "TREATMENT", 302, 310], ["protein", "TEST", 334, 341]]], ["Nine rounds were performed against purified protein and then five rounds against cells overexpressing the protein of interest.", [["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["purified protein", "PROTEIN", 35, 51]]], ["More than 25 aptamers were found to bind the purified protein whereas only two of them bound CD16\u03b1 on recombinant Jurkat or NK cells.", [["Jurkat", "ANATOMY", 114, 120], ["NK cells", "ANATOMY", 124, 132], ["CD16\u03b1", "GENE_OR_GENE_PRODUCT", 93, 98], ["Jurkat", "CELL", 114, 120], ["NK cells", "CELL", 124, 132], ["purified protein", "PROTEIN", 45, 61], ["CD16\u03b1", "PROTEIN", 93, 98], ["recombinant Jurkat", "CELL_LINE", 102, 120], ["NK cells", "CELL_TYPE", 124, 132], ["NK cells", "PROBLEM", 124, 132], ["NK cells", "OBSERVATION", 124, 132]]], ["One of these aptamers was already present at the end of the selection against the purified protein whereas the other was present only in the population selected against both purified protein and cells overexpressing it.Cross-Over SELEXIn an aptamer selection for the P2X2 receptor, another strategy was applied, involving shifting between selection against plasma membrane extracts containing the membrane protein and selection against the purified form inserted in immobilized artificial membranes (IAMs) [97].", [["cells", "ANATOMY", 195, 200], ["plasma membrane extracts", "ANATOMY", 357, 381], ["membrane", "ANATOMY", 397, 405], ["membranes", "ANATOMY", 489, 498], ["IAMs", "ANATOMY", 500, 504], ["cells", "CELL", 195, 200], ["P2X2 receptor", "GENE_OR_GENE_PRODUCT", 267, 280], ["plasma", "ORGANISM_SUBSTANCE", 357, 363], ["membrane extracts", "ORGANISM_SUBSTANCE", 364, 381], ["membrane", "CELLULAR_COMPONENT", 397, 405], ["membranes", "CELLULAR_COMPONENT", 489, 498], ["purified protein", "PROTEIN", 82, 98], ["purified protein", "PROTEIN", 174, 190], ["P2X2 receptor", "PROTEIN", 267, 280], ["membrane protein", "PROTEIN", 397, 413], ["Cross-Over SELEXIn an aptamer selection", "TREATMENT", 219, 258], ["the P2X2 receptor", "TREATMENT", 263, 280], ["another strategy", "TREATMENT", 282, 298], ["plasma membrane extracts", "TREATMENT", 357, 381], ["the membrane protein", "TREATMENT", 393, 413], ["membrane protein", "OBSERVATION", 397, 413], ["artificial membranes", "OBSERVATION", 478, 498]]], ["IAMs have been used previously to immobilize various types of transmembrane proteins including transporters, carriers and receptors.", [["transmembrane", "ANATOMY", 62, 75], ["IAMs", "SIMPLE_CHEMICAL", 0, 4], ["IAMs", "PROTEIN", 0, 4], ["transmembrane proteins", "PROTEIN", 62, 84], ["transmembrane proteins", "TREATMENT", 62, 84]]], ["In all cases, the proteins retained the ability to bind their ligands and a setup with IAMs could be used to determine their pharmacological properties.", [["IAMs", "SIMPLE_CHEMICAL", 87, 91], ["a setup with IAMs", "TREATMENT", 74, 91]]], ["After three initial cycles of SELEX using plasma membrane preparations containing P2X2 receptor, the pool was loaded on a P2X2-IAM column for chromatographic selection of RNA molecules with binding affinity to the P2X2 receptor.", [["plasma membrane", "ANATOMY", 42, 57], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["P2X2 receptor", "GENE_OR_GENE_PRODUCT", 82, 95], ["P2X2", "SIMPLE_CHEMICAL", 122, 126], ["P2X2 receptor", "GENE_OR_GENE_PRODUCT", 214, 227], ["P2X2 receptor", "PROTEIN", 82, 95], ["P2X2", "PROTEIN", 122, 126], ["RNA molecules", "PROTEIN", 171, 184], ["P2X2 receptor", "PROTEIN", 214, 227], ["SELEX using plasma membrane preparations", "TREATMENT", 30, 70], ["P2X2 receptor", "TREATMENT", 82, 95], ["a P2X2-IAM column", "TREATMENT", 120, 137], ["chromatographic selection of RNA molecules", "TREATMENT", 142, 184], ["binding affinity", "TREATMENT", 190, 206], ["the P2X2 receptor", "TREATMENT", 210, 227], ["RNA molecules", "OBSERVATION", 171, 184]]], ["One round of IAM chromatography SELEX was able to improve the affinity of the pool to the receptor by 300%.Tissue Slide-Based SELEXRecently, SELEX has been performed directly against cancerous tissue [98].", [["Tissue", "ANATOMY", 107, 113], ["cancerous tissue", "ANATOMY", 183, 199], ["Tissue", "TISSUE", 107, 113], ["cancerous tissue", "TISSUE", 183, 199], ["IAM chromatography SELEX", "TREATMENT", 13, 37], ["Tissue Slide", "TEST", 107, 119], ["SELEX", "TREATMENT", 141, 146], ["round", "OBSERVATION_MODIFIER", 4, 9]]], ["Li et al. performed SELEX against paraffin-embedded tissue sections from infiltrating ductal carcinomas and counter-selection against the adjacent normal tissue from the same case.", [["tissue sections", "ANATOMY", 52, 67], ["infiltrating ductal carcinomas", "ANATOMY", 73, 103], ["tissue", "ANATOMY", 154, 160], ["Li", "CHEMICAL", 0, 2], ["ductal carcinomas", "DISEASE", 86, 103], ["paraffin", "CHEMICAL", 34, 42], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 52, 67], ["infiltrating ductal carcinomas", "CANCER", 73, 103], ["normal tissue", "TISSUE", 147, 160], ["SELEX against paraffin-embedded tissue sections", "TREATMENT", 20, 67], ["infiltrating ductal carcinomas", "PROBLEM", 73, 103], ["counter-selection", "TREATMENT", 108, 125], ["infiltrating", "OBSERVATION_MODIFIER", 73, 85], ["ductal", "ANATOMY", 86, 92], ["carcinomas", "OBSERVATION", 93, 103], ["normal tissue", "OBSERVATION", 147, 160]]], ["An advantage of this method is that it's possible to select aptamers to all fractions of tissue including extracellular matrix, membrane components and intracellular targets.", [["tissue", "ANATOMY", 89, 95], ["extracellular matrix", "ANATOMY", 106, 126], ["membrane components", "ANATOMY", 128, 147], ["intracellular", "ANATOMY", 152, 165], ["tissue", "TISSUE", 89, 95], ["extracellular matrix", "CELLULAR_COMPONENT", 106, 126], ["membrane components", "CELLULAR_COMPONENT", 128, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["extracellular matrix", "OBSERVATION", 106, 126], ["membrane components", "OBSERVATION", 128, 147], ["intracellular targets", "OBSERVATION", 152, 173]]], ["One aptamer, BC15, was identified to specifically recognize breast cancer cells from clinical tissue sections of different pathological types and breast cancer cell lines.", [["breast cancer cells", "ANATOMY", 60, 79], ["tissue sections", "ANATOMY", 94, 109], ["breast cancer cell lines", "ANATOMY", 146, 170], ["breast cancer", "DISEASE", 60, 73], ["breast cancer", "DISEASE", 146, 159], ["BC15", "SIMPLE_CHEMICAL", 13, 17], ["breast cancer cells", "CELL", 60, 79], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 94, 109], ["breast cancer cell lines", "CELL", 146, 170], ["BC15", "PROTEIN", 13, 17], ["breast cancer cells", "CELL_TYPE", 60, 79], ["breast cancer cell lines", "CELL_LINE", 146, 170], ["breast cancer cells", "PROBLEM", 60, 79], ["clinical tissue sections", "TEST", 85, 109], ["different pathological types", "PROBLEM", 113, 141], ["breast cancer cell lines", "PROBLEM", 146, 170], ["breast", "ANATOMY", 60, 66], ["cancer", "OBSERVATION", 67, 73], ["breast", "ANATOMY", 146, 152], ["cancer cell lines", "OBSERVATION", 153, 170]]], ["The target of this aptamer was identified to be the intracellular protein hnRNP A1.In Vivo SELEXAs mentioned previously, cell-SELEX can be performed to identify aptamers against specific cell surface biomarkers of a disease without any prior knowledge of the markers.", [["intracellular", "ANATOMY", 52, 65], ["cell", "ANATOMY", 121, 125], ["cell surface", "ANATOMY", 187, 199], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["hnRNP A1", "GENE_OR_GENE_PRODUCT", 74, 82], ["cell", "CELL", 121, 125], ["cell", "CELL", 187, 191], ["intracellular protein hnRNP A1", "PROTEIN", 52, 82], ["specific cell surface biomarkers", "TEST", 178, 210], ["a disease", "PROBLEM", 214, 223], ["disease", "OBSERVATION", 216, 223]]], ["However, the question remains whether cells in culture are relevant models for a disease.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["cells", "PROBLEM", 38, 43], ["culture", "TEST", 47, 54], ["a disease", "PROBLEM", 79, 88]]], ["With the purpose of adapting the SELEX procedure to a complete physiological environment, SELEX has recently been performed in vivo to select aptamers recognizing intrahepatic colorectal cancer metastasis [99].", [["intrahepatic colorectal cancer", "ANATOMY", 163, 193], ["intrahepatic colorectal cancer", "DISEASE", 163, 193], ["intrahepatic colorectal cancer", "CANCER", 163, 193], ["the SELEX procedure", "TREATMENT", 29, 48], ["SELEX", "TREATMENT", 90, 95], ["intrahepatic colorectal cancer metastasis", "PROBLEM", 163, 204], ["intrahepatic", "ANATOMY_MODIFIER", 163, 175], ["colorectal", "ANATOMY", 176, 186], ["cancer", "OBSERVATION", 187, 193]]], ["A 2\u2032F-Py RNA library was injected intravenously in a mouse bearing a previously implanted hepatic tumour.", [["intravenously", "ANATOMY", 34, 47], ["hepatic tumour", "ANATOMY", 90, 104], ["hepatic tumour", "DISEASE", 90, 104], ["mouse", "ORGANISM", 53, 58], ["hepatic tumour", "CANCER", 90, 104], ["2\u2032F-Py RNA library", "DNA", 2, 20], ["mouse", "SPECIES", 53, 58], ["mouse", "SPECIES", 53, 58], ["A 2\u2032F-Py RNA library", "TREATMENT", 0, 20], ["a mouse bearing a previously implanted hepatic tumour", "PROBLEM", 51, 104], ["implanted", "OBSERVATION_MODIFIER", 80, 89], ["hepatic", "ANATOMY", 90, 97], ["tumour", "OBSERVATION", 98, 104]]], ["Liver tumours were collected and RNA was subsequently extracted and amplified.", [["Liver tumours", "ANATOMY", 0, 13], ["Liver tumours", "CANCER", 0, 13], ["Liver tumours", "PROBLEM", 0, 13], ["tumours", "OBSERVATION", 6, 13]]], ["The new population of 2\u2032F-Py RNA was re-injected in a new mouse and the process repeated several times.", [["2\u2032F-Py", "CHEMICAL", 22, 28], ["2\u2032F-Py", "GENE_OR_GENE_PRODUCT", 22, 28], ["mouse", "ORGANISM", 58, 63], ["2\u2032F-Py RNA", "RNA", 22, 32], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["2\u2032F-Py RNA", "TREATMENT", 22, 32], ["new", "OBSERVATION_MODIFIER", 4, 7], ["population", "OBSERVATION_MODIFIER", 8, 18]]], ["Interestingly, evolved RNA pools demonstrated higher affinity for a tumour protein extract than a normal colon cell protein extract and the population of round 14 was cloned and sequenced.", [["tumour", "ANATOMY", 68, 74], ["extract", "ANATOMY", 83, 90], ["colon cell", "ANATOMY", 105, 115], ["extract", "ANATOMY", 124, 131], ["tumour", "DISEASE", 68, 74], ["tumour", "CANCER", 68, 74], ["colon cell", "CELL", 105, 115], ["RNA pools", "TEST", 23, 32], ["higher affinity", "PROBLEM", 46, 61], ["a tumour protein extract", "PROBLEM", 66, 90], ["higher affinity", "OBSERVATION_MODIFIER", 46, 61], ["colon", "ANATOMY", 105, 110], ["cell protein extract", "OBSERVATION", 111, 131]]], ["Interestingly, the target of one aptamer was determined to be p68, an intracellular RNA helicase known to be upregulated in colorectal cancer.Methods To Study the Binding of Aptamers on Living Organisms or CellsWhatever the SELEX method used, after sequencing the pool, the binding of individual aptamer clones has to be evaluated on living organisms or cells.", [["intracellular", "ANATOMY", 70, 83], ["colorectal cancer", "ANATOMY", 124, 141], ["cells", "ANATOMY", 354, 359], ["colorectal cancer", "DISEASE", 124, 141], ["p68", "GENE_OR_GENE_PRODUCT", 62, 65], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["colorectal cancer", "CANCER", 124, 141], ["cells", "CELL", 354, 359], ["p68", "PROTEIN", 62, 65], ["intracellular RNA helicase", "PROTEIN", 70, 96], ["aptamer clones", "CELL_LINE", 296, 310], ["an intracellular RNA helicase", "PROBLEM", 67, 96], ["colorectal cancer", "PROBLEM", 124, 141], ["Living Organisms", "TREATMENT", 186, 202], ["the SELEX method", "TREATMENT", 220, 236], ["individual aptamer clones", "PROBLEM", 285, 310], ["colorectal cancer", "OBSERVATION", 124, 141]]], ["During this evaluation, the affinity of the aptamer can be determined but also its specificity for its target, since it is found in a mix with many other biomarkers at the cell surface.", [["cell surface", "ANATOMY", 172, 184], ["cell surface", "CELLULAR_COMPONENT", 172, 184], ["this evaluation", "TEST", 7, 22], ["cell surface", "OBSERVATION", 172, 184]]], ["Several strategies have been presented for measuring the binding of aptamers to living cells.", [["cells", "ANATOMY", 87, 92], ["cells", "CELL", 87, 92], ["living cells", "CELL_TYPE", 80, 92]]], ["Basically, aptamers are incubated with cells at different concentrations and bound aptamer quantified after extensive washing.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["bound aptamer", "PROBLEM", 77, 90], ["extensive washing", "TREATMENT", 108, 125]]], ["Using Scatchard analysis, the KD and Cmax (apparent concentration of target at the cell surface) can be measured for a specific cell line.", [["cell surface", "ANATOMY", 83, 95], ["cell line", "ANATOMY", 128, 137], ["Cmax", "CHEMICAL", 37, 41], ["Cmax", "SIMPLE_CHEMICAL", 37, 41], ["cell surface", "CELLULAR_COMPONENT", 83, 95], ["cell line", "CELL", 128, 137], ["specific cell line", "CELL_LINE", 119, 137], ["Scatchard analysis", "TEST", 6, 24], ["a specific cell line", "TREATMENT", 117, 137], ["cell line", "OBSERVATION", 128, 137]]], ["When cells are adherent, a possibility is to incubate cells with 5\u2032-[32P]-radiolabeled aptamer and following a washing step, detect bound aptamer by scintillation counting [16,95].", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 54, 59], ["5\u2032-[32P", "CHEMICAL", 65, 72], ["cells", "CELL", 5, 10], ["cells", "CELL", 54, 59], ["5\u2032-[32P", "SIMPLE_CHEMICAL", 65, 72], ["radiolabeled aptamer", "TREATMENT", 74, 94], ["a washing step", "TEST", 109, 123], ["scintillation counting", "TEST", 149, 171]]], ["When cells are non-adhering, many studies apply fluorescent aptamers to perform similar analyses by flow cytometry.", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10], ["many studies", "TEST", 29, 41], ["fluorescent aptamers", "TREATMENT", 48, 68], ["flow cytometry", "TEST", 100, 114]]], ["The latter technique has also been applied as a tool for monitoring the progress of cell-SELEX experiments [62,64,65].", [["cell", "ANATOMY", 84, 88], ["cell", "CELL", 84, 88], ["The latter technique", "TREATMENT", 0, 20]]], ["The technique can also be used with adherent cells, but cells have to be put in suspension before flow cytometry analysis.", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 56, 61], ["cells", "CELL", 45, 50], ["cells", "CELL", 56, 61], ["adherent cells", "CELL_TYPE", 36, 50], ["The technique", "TREATMENT", 0, 13], ["adherent cells", "TREATMENT", 36, 50], ["flow cytometry analysis", "TEST", 98, 121]]], ["However, the presence of some proteins on plasma membranes may be affected by the procedures associated with detachment of adhering cells from the solid support of the culture plate.", [["plasma membranes", "ANATOMY", 42, 58], ["cells", "ANATOMY", 132, 137], ["plasma membranes", "CELLULAR_COMPONENT", 42, 58], ["cells", "CELL", 132, 137], ["adhering cells", "CELL_TYPE", 123, 137], ["some proteins on plasma membranes", "PROBLEM", 25, 58], ["the procedures", "TREATMENT", 78, 92], ["detachment", "PROBLEM", 109, 119], ["adhering cells", "PROBLEM", 123, 137], ["the solid support", "TREATMENT", 143, 160], ["the culture plate", "TEST", 164, 181], ["some", "OBSERVATION_MODIFIER", 25, 29], ["proteins", "OBSERVATION", 30, 38], ["plasma membranes", "OBSERVATION", 42, 58], ["detachment", "OBSERVATION", 109, 119]]], ["For instance, Li et al. demonstrated that the aptamer for Tenascin-C was not a good probe for flow cytometry analysis using U251 glioma cells whereas it labeled the same cells efficiently after adhesion using microscopy [100].", [["U251 glioma cells", "ANATOMY", 124, 141], ["cells", "ANATOMY", 170, 175], ["Li", "CHEMICAL", 14, 16], ["Tenascin-C", "CHEMICAL", 58, 68], ["Tenascin-C", "SIMPLE_CHEMICAL", 58, 68], ["U251 glioma cells", "CELL", 124, 141], ["cells", "CELL", 170, 175], ["U251 glioma cells", "CELL_LINE", 124, 141], ["flow cytometry analysis", "TEST", 94, 117], ["U251 glioma cells", "PROBLEM", 124, 141], ["microscopy", "TEST", 209, 219]]], ["Tenascin-C is an extracellular matrix glycoprotein and the authors hypothesized that the protein may be removed and degraded by the process of detachment using trypsin which was performed prior to flow cytometry analysis.Conclusions and PerspectivesDuring the past 10-15 years, there have been a growing number of reports describing the identification of aptamers against cell surface-associated targets.", [["extracellular matrix", "ANATOMY", 17, 37], ["cell surface", "ANATOMY", 372, 384], ["Tenascin-C", "CHEMICAL", 0, 10], ["Tenascin-C", "GENE_OR_GENE_PRODUCT", 0, 10], ["extracellular matrix", "CELLULAR_COMPONENT", 17, 37], ["trypsin", "GENE_OR_GENE_PRODUCT", 160, 167], ["cell", "CELL", 372, 376], ["Tenascin-C", "PROTEIN", 0, 10], ["extracellular matrix glycoprotein", "PROTEIN", 17, 50], ["trypsin", "PROTEIN", 160, 167], ["an extracellular matrix glycoprotein", "TREATMENT", 14, 50], ["detachment", "PROBLEM", 143, 153], ["trypsin", "TREATMENT", 160, 167], ["flow cytometry analysis", "TEST", 197, 220], ["detachment", "OBSERVATION", 143, 153]]], ["During this time, several different strategies for performing SELEX have also been developed to enable selection of aptamers of particularly membrane proteins under near-physiological conditions.", [["membrane", "ANATOMY", 141, 149], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["membrane proteins", "PROTEIN", 141, 158], ["performing SELEX", "TREATMENT", 51, 67], ["particularly membrane proteins", "PROBLEM", 128, 158]]], ["These advanced strategies increase the probability of selecting aptamers against membrane targets in their native form and natural environment on the cell surface.", [["membrane", "ANATOMY", 81, 89], ["cell surface", "ANATOMY", 150, 162], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["cell surface", "CELLULAR_COMPONENT", 150, 162], ["selecting aptamers", "TREATMENT", 54, 72], ["membrane targets", "TREATMENT", 81, 97], ["natural environment", "OBSERVATION", 123, 142], ["cell surface", "OBSERVATION", 150, 162]]], ["However, these new SELEX methods are not always straightforward compared with classical SELEX methods against purified targets.", [["new", "OBSERVATION_MODIFIER", 15, 18], ["SELEX", "OBSERVATION", 19, 24]]], ["Hence, some pitfalls of cell-SELEX have been described that can cause failure of the selection process.", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28], ["cell-SELEX", "TREATMENT", 24, 34], ["failure of the selection process", "PROBLEM", 70, 102], ["cell", "OBSERVATION", 24, 28]]], ["For instance, the presence of dead cells during selection can capture non-specifically a high number of oligonucleotides [59,104], counter-selection is not always efficient [16,19], and purification of DNA single strands using streptavidin beads can be imperfect [105].", [["cells", "ANATOMY", 35, 40], ["cells", "CELL", 35, 40], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["streptavidin beads", "SIMPLE_CHEMICAL", 227, 245], ["dead cells", "CELL_TYPE", 30, 40], ["dead cells", "PROBLEM", 30, 40], ["oligonucleotides", "TEST", 104, 120], ["DNA single strands using streptavidin beads", "TREATMENT", 202, 245], ["dead cells", "OBSERVATION", 30, 40]]], ["Furthermore, in vivo SELEX in small animals and tissue slide-based SELEX have not yet been reproduced two years after having been published for the first time, eventhough these SELEX methods are particularly promising.", [["tissue", "ANATOMY", 48, 54], ["tissue", "TISSUE", 48, 54], ["tissue slide", "TEST", 48, 60], ["these SELEX methods", "TREATMENT", 171, 190], ["small", "OBSERVATION_MODIFIER", 30, 35]]], ["Nevertheless, all these new methods are expected to be improved over the next decade and will lead to the selection of many aptamers.Conclusions and PerspectivesCell surface targeting aptamers can potentially be used for several applications.", [["Cell surface", "ANATOMY", 161, 173], ["Cell", "CELL", 161, 165], ["Cell surface targeting aptamers", "TREATMENT", 161, 192], ["new", "OBSERVATION_MODIFIER", 24, 27]]], ["For instance, aptamers that bind to membrane proteins involved in disease can often inhibit or activate their targets leading to the development of new drugs.", [["membrane", "ANATOMY", 36, 44], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["membrane proteins", "PROTEIN", 36, 53], ["aptamers", "TREATMENT", 14, 22], ["disease", "PROBLEM", 66, 73]]], ["For example, a neutralizing anti-nucleolin aptamer is currently in phase IIb clinical trials for the treatment of Acute Myeloid Leukemia (AML) in combination with cytarabine [101].", [["Acute Myeloid Leukemia", "ANATOMY", 114, 136], ["AML", "ANATOMY", 138, 141], ["Acute Myeloid Leukemia", "DISEASE", 114, 136], ["AML", "DISEASE", 138, 141], ["cytarabine", "CHEMICAL", 163, 173], ["cytarabine", "CHEMICAL", 163, 173], ["anti-nucleolin", "SIMPLE_CHEMICAL", 28, 42], ["Acute Myeloid Leukemia", "CANCER", 114, 136], ["AML", "CANCER", 138, 141], ["cytarabine", "SIMPLE_CHEMICAL", 163, 173], ["a neutralizing anti-nucleolin aptamer", "TREATMENT", 13, 50], ["the treatment", "TREATMENT", 97, 110], ["Acute Myeloid Leukemia", "PROBLEM", 114, 136], ["AML", "PROBLEM", 138, 141], ["cytarabine", "TREATMENT", 163, 173], ["Acute", "OBSERVATION_MODIFIER", 114, 119], ["Myeloid Leukemia", "OBSERVATION", 120, 136]]], ["Additionally, aptamers targeting cell surface proteins have been successfully used as targeting moieties to deliver contrast agents, nanoparticles encapsulating drugs, or siRNA to specific tissues in vivo [102,103].", [["cell surface", "ANATOMY", 33, 45], ["tissues", "ANATOMY", 189, 196], ["cell", "CELL", 33, 37], ["tissues", "TISSUE", 189, 196], ["cell surface proteins", "PROTEIN", 33, 54], ["aptamers targeting cell surface proteins", "TREATMENT", 14, 54], ["contrast agents", "TREATMENT", 116, 131], ["nanoparticles encapsulating drugs", "TREATMENT", 133, 166], ["siRNA", "TREATMENT", 171, 176]]], ["Furthermore, they are being used within the development of diagnostic assays in fields such as cancer, infectious disease, food safety and bioterrorism.", [["cancer", "ANATOMY", 95, 101], ["cancer", "DISEASE", 95, 101], ["infectious disease", "DISEASE", 103, 121], ["cancer", "CANCER", 95, 101], ["diagnostic assays", "TEST", 59, 76], ["cancer", "PROBLEM", 95, 101], ["infectious disease", "PROBLEM", 103, 121], ["bioterrorism", "PROBLEM", 139, 151], ["cancer", "OBSERVATION", 95, 101], ["infectious", "OBSERVATION", 103, 113]]], ["Finally, a more recent area of interest for aptamer selections against membrane proteins is the use of methods such as cell-SELEX within cell surface biomarker discovery and cell phenotyping.", [["membrane", "ANATOMY", 71, 79], ["cell", "ANATOMY", 119, 123], ["cell surface", "ANATOMY", 137, 149], ["cell", "ANATOMY", 174, 178], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["cell", "CELL", 119, 123], ["cell", "CELL", 137, 141], ["cell", "CELL", 174, 178], ["membrane proteins", "PROTEIN", 71, 88], ["aptamer selections", "TREATMENT", 44, 62], ["membrane proteins", "TREATMENT", 71, 88], ["methods", "TREATMENT", 103, 110], ["cell phenotyping", "TEST", 174, 190], ["cell phenotyping", "OBSERVATION", 174, 190]]], ["As a consequence, selections of aptamers against cell surface biomarkers have a high potential use not only for fundamental research, but also for diagnosis, monitoring and treatment of diseases.", [["cell surface", "ANATOMY", 49, 61], ["cell", "CELL", 49, 53], ["cell surface biomarkers", "TEST", 49, 72], ["monitoring", "TEST", 158, 168], ["diseases", "PROBLEM", 186, 194]]]], "PMC7318552": [["IntroductionIridoviruses are large icosahedral cytoplasmic DNA viruses with circularly permuted, terminally redundant, double-stranded DNA genomes (Qin et al., 2003).", [["cytoplasmic", "ANATOMY", 47, 58], ["Iridoviruses", "GENE_OR_GENE_PRODUCT", 12, 24], ["cytoplasmic", "ORGANISM_SUBSTANCE", 47, 58], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["double-stranded DNA genomes", "DNA", 119, 146], ["IntroductionIridoviruses", "TREATMENT", 0, 24], ["large icosahedral cytoplasmic DNA viruses", "PROBLEM", 29, 70], ["terminally redundant", "PROBLEM", 97, 117], ["double-stranded DNA genomes", "TREATMENT", 119, 146], ["large", "OBSERVATION_MODIFIER", 29, 34], ["icosahedral cytoplasmic", "OBSERVATION", 35, 58], ["DNA viruses", "OBSERVATION", 59, 70], ["terminally", "OBSERVATION_MODIFIER", 97, 107], ["redundant", "OBSERVATION_MODIFIER", 108, 117], ["double", "OBSERVATION_MODIFIER", 119, 125], ["stranded DNA", "OBSERVATION_MODIFIER", 126, 138]]], ["The family Iridoviridae includes six genera: Ranavirus, Iridovirus, Chloriridovirus, Lymphocystivirus, Megalocytivirus, and Decapodiridovirus (Chinchar and Duffus, 2019).", [["Iridovirus", "GENE_OR_GENE_PRODUCT", 56, 66], ["Ranavirus", "TREATMENT", 45, 54], ["Iridovirus", "TREATMENT", 56, 66], ["Chloriridovirus", "TREATMENT", 68, 83], ["Lymphocystivirus", "TREATMENT", 85, 101], ["Megalocytivirus", "TREATMENT", 103, 118], ["Decapodiridovirus", "TREATMENT", 124, 141]]], ["Singapore grouper iridovirus (SGIV) was first isolated from the grouper Epinephelus tauvina.", [["Singapore grouper iridovirus", "ORGANISM", 0, 28], ["SGIV", "ORGANISM", 30, 34], ["grouper", "ORGANISM", 64, 71], ["Epinephelus tauvina", "ORGANISM", 72, 91], ["grouper", "SPECIES", 64, 71], ["Epinephelus tauvina", "SPECIES", 72, 91], ["Singapore grouper iridovirus", "SPECIES", 0, 28], ["SGIV", "SPECIES", 30, 34], ["Epinephelus tauvina", "SPECIES", 72, 91], ["Singapore grouper iridovirus (SGIV)", "TREATMENT", 0, 35], ["the grouper Epinephelus tauvina", "TREATMENT", 60, 91], ["iridovirus", "OBSERVATION", 18, 28]]], ["It belongs to the genus Ranavirus and currently causes high economic losses in the mariculture industry (Qin et al., 2003; Xiao et al., 2019; Liu et al., 2020).", [["Ranavirus", "CHEMICAL", 24, 33], ["the genus Ranavirus", "PROBLEM", 14, 33], ["high economic losses", "PROBLEM", 55, 75], ["genus Ranavirus", "OBSERVATION", 18, 33], ["high", "OBSERVATION_MODIFIER", 55, 59], ["economic losses", "OBSERVATION", 60, 75], ["mariculture", "ANATOMY", 83, 94]]], ["Understanding the pathogenesis of SGIV is necessary to develop effective therapies against it (Yu et al., 2019a).", [["SGIV", "DISEASE", 34, 38], ["SGIV", "CANCER", 34, 38], ["effective therapies", "TREATMENT", 63, 82]]], ["Viral infection begins with its attachment to the host cell membrane, and it then enters the cell via specific endocytosis.", [["cell membrane", "ANATOMY", 55, 68], ["cell", "ANATOMY", 93, 97], ["Viral infection", "DISEASE", 0, 15], ["cell membrane", "CELLULAR_COMPONENT", 55, 68], ["cell", "CELL", 93, 97], ["Viral infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15], ["host cell membrane", "OBSERVATION", 50, 68], ["specific", "OBSERVATION_MODIFIER", 102, 110], ["endocytosis", "OBSERVATION", 111, 122]]], ["In the host cell, the SGIV is transported to the replication site, where the viral genes are expressed (Seisenberger et al., 2001).", [["cell", "ANATOMY", 12, 16], ["host cell", "CELL", 7, 16], ["SGIV", "GENE_OR_GENE_PRODUCT", 22, 26], ["SGIV", "PROTEIN", 22, 26], ["replication site", "DNA", 49, 65], ["viral genes", "DNA", 77, 88], ["host cell", "OBSERVATION", 7, 16], ["viral genes", "OBSERVATION", 77, 88]]], ["Many SGIV structural genes and non-structural genes have already been studied and are related to viral replication, pathogenesis, and host cell immunity (Chinchar et al., 2009; Chinchar and Duffus, 2019).", [["cell", "ANATOMY", 139, 143], ["SGIV", "GENE_OR_GENE_PRODUCT", 5, 9], ["host cell", "CELL", 134, 143], ["SGIV structural genes", "DNA", 5, 26], ["non-structural genes", "DNA", 31, 51], ["Many SGIV structural genes and non-structural genes", "PROBLEM", 0, 51], ["viral replication", "PROBLEM", 97, 114], ["pathogenesis", "PROBLEM", 116, 128], ["structural genes", "OBSERVATION", 10, 26], ["non-structural genes", "OBSERVATION", 31, 51], ["viral replication", "OBSERVATION", 97, 114], ["host cell immunity", "OBSERVATION", 134, 152]]], ["During infection, modifications appear in the host cell membranes (Verdaguer et al., 2014; Ab\u00f3s et al., 2015; Seeger and Mason, 2015; Yu et al., 2019a), which can potentially be used as important biomarkers of infection.", [["cell membranes", "ANATOMY", 51, 65], ["infection", "DISEASE", 7, 16], ["infection", "DISEASE", 210, 219], ["cell membranes", "CELLULAR_COMPONENT", 51, 65], ["infection", "PROBLEM", 7, 16], ["infection", "PROBLEM", 210, 219], ["infection", "OBSERVATION", 7, 16], ["host cell membranes", "OBSERVATION", 46, 65], ["infection", "OBSERVATION", 210, 219]]], ["Such biomarkers can be used to develop diagnostic tools and therapeutic approaches to virus infection (Yildirim et al., 2007; Ashcroft, 2019).", [["infection", "DISEASE", 92, 101], ["diagnostic tools", "TEST", 39, 55], ["virus infection", "PROBLEM", 86, 101]]], ["Membrane proteins account for about 30% of the total cellular proteins and have important roles in various physiological functions (Shangguan et al., 2008).", [["Membrane", "ANATOMY", 0, 8], ["cellular", "ANATOMY", 53, 61], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["cellular", "CELL", 53, 61], ["Membrane proteins", "PROTEIN", 0, 17], ["cellular proteins", "PROTEIN", 53, 70], ["Membrane proteins", "TEST", 0, 17], ["the total cellular proteins", "PROBLEM", 43, 70]]], ["Knowledge of these biomarkers will extend our understanding of viral pathogenesis.", [["these biomarkers", "TEST", 13, 29], ["viral pathogenesis", "PROBLEM", 63, 81]]], ["However, little is yet known about the mechanisms underlying the entry of these biomarkers into host cells.", [["cells", "ANATOMY", 101, 106], ["host cells", "CELL", 96, 106], ["host cells", "CELL_TYPE", 96, 106], ["host cells", "OBSERVATION", 96, 106]]], ["To address this limitation, we used aptamers to investigate the crucial events of biomarker endocytosis into SGIV-infected host cells during viral infection.IntroductionAptamers are selected by the systematic evolution of ligands with the exponential enrichment technology (SELEX) (Ellington and Szostak, 1990).", [["cells", "ANATOMY", 128, 133], ["viral infection", "DISEASE", 141, 156], ["SGIV", "GENE_OR_GENE_PRODUCT", 109, 113], ["host cells", "CELL", 123, 133], ["SGIV-infected host cells", "CELL_TYPE", 109, 133], ["aptamers", "TREATMENT", 36, 44], ["biomarker endocytosis", "PROBLEM", 82, 103], ["infected host cells", "PROBLEM", 114, 133], ["viral infection", "PROBLEM", 141, 156], ["IntroductionAptamers", "TREATMENT", 157, 177], ["infected host cells", "OBSERVATION", 114, 133], ["viral", "OBSERVATION_MODIFIER", 141, 146], ["infection", "OBSERVATION", 147, 156]]], ["Aptamers selected against different targets are synthetic oligonucleotides with different sequences and fold into distinct three-dimensional structures, binding their targets with high specificity and affinity (Yu et al., 2019b).", [["Aptamers", "TREATMENT", 0, 8], ["synthetic oligonucleotides", "TREATMENT", 48, 74], ["different sequences", "TEST", 80, 99]]], ["Although they resemble antibodies in this regard, aptamers have properties that make them more useful than antibodies, such as their ease in synthesis and modification, high reproducibility, and stability.", [["antibodies", "PROTEIN", 23, 33], ["antibodies", "PROTEIN", 107, 117], ["high reproducibility", "PROBLEM", 169, 189], ["high reproducibility", "OBSERVATION", 169, 189], ["stability", "OBSERVATION_MODIFIER", 195, 204]]], ["Based on these excellent qualities, aptamers are excellent molecular probes for pathogen diagnostics and therapeutics (Li et al., 2014, 2016; Wolter and Mayer, 2017; Kaur et al., 2018; Zhou et al., 2020).", [["pathogen diagnostics", "TEST", 80, 100]]], ["For example, aptamer A10 was selected against the coat protein of red-spotted grouper nervous necrosis virus (RGNNV) and was successfully used to develop an aptamer-based enzyme-linked apta-sorbent assay (ELASA) for the rapid and sensitive detection of RGNNV infection (Zhou et al., 2016, 2017).", [["nervous necrosis", "DISEASE", 86, 102], ["RGNNV infection", "DISEASE", 253, 268], ["red-spotted grouper nervous necrosis virus", "ORGANISM", 66, 108], ["RGNNV", "ORGANISM", 253, 258], ["coat protein", "PROTEIN", 50, 62], ["enzyme", "PROTEIN", 171, 177], ["grouper nervous necrosis virus", "SPECIES", 78, 108], ["red-spotted grouper nervous necrosis virus", "SPECIES", 66, 108], ["RGNNV", "SPECIES", 110, 115], ["RGNNV", "SPECIES", 253, 258], ["the coat protein", "TEST", 46, 62], ["red-spotted grouper nervous necrosis virus", "PROBLEM", 66, 108], ["an aptamer", "TEST", 154, 164], ["based enzyme", "TEST", 165, 177], ["the rapid", "TEST", 216, 225], ["RGNNV infection", "PROBLEM", 253, 268], ["grouper nervous necrosis", "OBSERVATION", 78, 102], ["infection", "OBSERVATION", 259, 268]]], ["Aptamers are also used as highly specific molecular probes in pathogen pathogenesis studies (Jin et al., 2016; Yu et al., 2019a).", [["Aptamers", "TREATMENT", 0, 8]]], ["They have been widely used to identify membrane protein biomarkers, such as alkaline phosphatase placental-like 2 (Dua et al., 2013), stress-induced phosphoprotein 1 (Van et al., 2014), and protein tyrosine kinase 7 (Shangguan et al., 2008).", [["membrane", "ANATOMY", 39, 47], ["tyrosine", "CHEMICAL", 198, 206], ["tyrosine", "CHEMICAL", 198, 206], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["phosphoprotein 1", "GENE_OR_GENE_PRODUCT", 149, 165], ["protein tyrosine kinase 7", "GENE_OR_GENE_PRODUCT", 190, 215], ["alkaline phosphatase", "PROTEIN", 76, 96], ["phosphoprotein 1", "PROTEIN", 149, 165], ["protein tyrosine kinase 7", "PROTEIN", 190, 215], ["membrane protein biomarkers", "TEST", 39, 66], ["alkaline phosphatase placental", "TEST", 76, 106], ["stress-induced phosphoprotein", "PROBLEM", 134, 163], ["protein tyrosine kinase", "TEST", 190, 213]]], ["According to several reports, after specifically binding to biomarkers in the cell membrane, some aptamers are actively internalized into the target cell.", [["cell membrane", "ANATOMY", 78, 91], ["cell", "ANATOMY", 149, 153], ["cell membrane", "CELLULAR_COMPONENT", 78, 91], ["cell", "CELL", 149, 153], ["target cell", "CELL_TYPE", 142, 153], ["cell membrane", "ANATOMY", 78, 91], ["target cell", "OBSERVATION", 142, 153]]], ["Consequently, they can be used as delivery vehicles for the targeted delivery of drugs (Sun and Zu, 2015).", [["delivery vehicles", "TREATMENT", 34, 51], ["the targeted delivery of drugs", "TREATMENT", 56, 86]]], ["For example, McNamara et al. (2006) reported the cell-type-specific delivery of small interfering RNAs (siRNA)-aptamer chimeras, which significantly increased the therapeutic efficacy of the siRNA against cancer cells.", [["cell", "ANATOMY", 49, 53], ["cancer cells", "ANATOMY", 205, 217], ["cancer", "DISEASE", 205, 211], ["cell", "CELL", 49, 53], ["cancer cells", "CELL", 205, 217], ["small interfering RNAs", "RNA", 80, 102], ["cancer cells", "CELL_TYPE", 205, 217], ["small interfering RNAs (siRNA)", "PROBLEM", 80, 110], ["aptamer chimeras", "PROBLEM", 111, 127], ["cancer cells", "PROBLEM", 205, 217], ["small", "OBSERVATION_MODIFIER", 80, 85], ["interfering RNAs", "OBSERVATION", 86, 102]]], ["Because aptamers are easy to synthesize, they have great potential utility in targeted therapies.", [["targeted therapies", "TREATMENT", 78, 96]]], ["However, little is yet known about the mechanisms of entry of these cell biomarkers into host cells.IntroductionIn a previous study, the aptamer Q5, which targets whole grouper-iridovirus-infected cells, was successfully generated with Cell-SELEX (Li et al., 2015).", [["cell", "ANATOMY", 68, 72], ["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 197, 202], ["cell", "CELL", 68, 72], ["host cells", "CELL", 89, 99], ["grouper", "ORGANISM", 169, 176], ["iridovirus", "GENE_OR_GENE_PRODUCT", 177, 187], ["cells", "CELL", 197, 202], ["Cell", "CELL", 236, 240], ["host cells", "CELL_TYPE", 89, 99], ["aptamer Q5", "PROTEIN", 137, 147], ["whole grouper-iridovirus-infected cells", "CELL_LINE", 163, 202], ["these cell biomarkers", "TEST", 62, 83], ["a previous study", "TEST", 115, 131], ["infected cells", "PROBLEM", 188, 202], ["host cells", "OBSERVATION", 89, 99], ["infected cells", "OBSERVATION", 188, 202]]], ["Aptamer Q5 has high binding affinity (24.35 nM) and recognizes SGIV-infected cells with high specificity.", [["cells", "ANATOMY", 77, 82], ["Aptamer", "CHEMICAL", 0, 7], ["SGIV", "GENE_OR_GENE_PRODUCT", 63, 67], ["cells", "CELL", 77, 82], ["Aptamer Q5", "PROTEIN", 0, 10], ["SGIV", "PROTEIN", 63, 67], ["high binding affinity", "PROBLEM", 15, 36], ["infected cells", "PROBLEM", 68, 82], ["infected cells", "OBSERVATION", 68, 82]]], ["The target protein of aptamer Q5 on the membrane of SGIV-infected host cells was identified as the major capsid protein (MCP) of the virus (Yu et al., 2019a).", [["membrane", "ANATOMY", 40, 48], ["cells", "ANATOMY", 71, 76], ["aptamer Q5", "GENE_OR_GENE_PRODUCT", 22, 32], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["SGIV", "GENE_OR_GENE_PRODUCT", 52, 56], ["host cells", "CELL", 66, 76], ["MCP", "GENE_OR_GENE_PRODUCT", 121, 124], ["aptamer Q5", "PROTEIN", 22, 32], ["SGIV-infected host cells", "CELL_TYPE", 52, 76], ["major capsid protein", "PROTEIN", 99, 119], ["MCP", "PROTEIN", 121, 124], ["The target protein", "TEST", 0, 18], ["infected host cells", "PROBLEM", 57, 76], ["the virus", "PROBLEM", 129, 138], ["infected host cells", "OBSERVATION", 57, 76]]], ["MCP is the predominant structural protein of iridovirus particles and comprises about 40%\u201345% of the iridovirus particle polypeptides.", [["MCP", "GENE_OR_GENE_PRODUCT", 0, 3], ["iridovirus particle polypeptides", "GENE_OR_GENE_PRODUCT", 101, 133], ["MCP", "PROTEIN", 0, 3], ["structural protein", "PROTEIN", 23, 41], ["iridovirus particle polypeptides", "PROTEIN", 101, 133], ["iridovirus particles", "PROBLEM", 45, 65], ["the iridovirus particle polypeptides", "TREATMENT", 97, 133], ["predominant", "OBSERVATION_MODIFIER", 11, 22], ["structural protein of iridovirus particles", "OBSERVATION", 23, 65], ["iridovirus particle", "OBSERVATION", 101, 120]]], ["MCP plays an important role in iridovirus pathogenesis, including in the formation of the iridovirus particle, the induction of the immune responses, virus\u2013host cell interactions, antigen recognition, and the transcription of viral genes (Fu et al., 2012).", [["iridovirus", "ANATOMY", 31, 41], ["cell", "ANATOMY", 161, 165], ["MCP", "GENE_OR_GENE_PRODUCT", 0, 3], ["iridovirus", "CANCER", 31, 41], ["virus\u2013host cell", "CELL", 150, 165], ["MCP", "PROTEIN", 0, 3], ["viral genes", "DNA", 226, 237], ["iridovirus pathogenesis", "PROBLEM", 31, 54], ["the iridovirus particle", "TREATMENT", 86, 109], ["antigen recognition", "TEST", 180, 199], ["iridovirus", "OBSERVATION", 31, 41], ["iridovirus particle", "OBSERVATION", 90, 109]]], ["After specifically binding to MCP in the cell membrane, aptamer Q5 is actively internalized into the target cells, indicating that MCP is transported by the vesicular transport system in the host cell during viral infection.", [["cell membrane", "ANATOMY", 41, 54], ["cells", "ANATOMY", 108, 113], ["vesicular", "ANATOMY", 157, 166], ["cell", "ANATOMY", 196, 200], ["viral infection", "DISEASE", 208, 223], ["MCP", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell membrane", "CELLULAR_COMPONENT", 41, 54], ["cells", "CELL", 108, 113], ["MCP", "GENE_OR_GENE_PRODUCT", 131, 134], ["vesicular", "MULTI-TISSUE_STRUCTURE", 157, 166], ["host cell", "CELL", 191, 200], ["MCP", "PROTEIN", 30, 33], ["aptamer Q5", "PROTEIN", 56, 66], ["target cells", "CELL_TYPE", 101, 113], ["MCP", "PROTEIN", 131, 134], ["viral infection", "PROBLEM", 208, 223], ["cell membrane", "ANATOMY", 41, 54], ["host cell", "OBSERVATION", 191, 200], ["viral", "OBSERVATION_MODIFIER", 208, 213], ["infection", "OBSERVATION", 214, 223]]], ["Therefore, aptamer Q5 can be used as a specific probe with which to investigate the trafficking mechanism and endocytotic pathway of MCP in host cells during SGIV infection (Wickner and Schekman, 2005; Yu et al., 2019a).", [["cells", "ANATOMY", 145, 150], ["SGIV", "ANATOMY", 158, 162], ["infection", "DISEASE", 163, 172], ["MCP", "GENE_OR_GENE_PRODUCT", 133, 136], ["host cells", "CELL", 140, 150], ["SGIV", "CELL", 158, 162], ["MCP", "PROTEIN", 133, 136], ["host cells", "CELL_TYPE", 140, 150], ["SGIV", "SPECIES", 158, 162], ["aptamer", "TREATMENT", 11, 18], ["SGIV infection", "PROBLEM", 158, 172], ["host cells", "OBSERVATION", 140, 150]]], ["Briefly, aptamer Q5 first binds to the target protein (MCP) on the cell surface, and the Q5\u2013MCP interaction activates the cellular signaling pathways, which internalize Q5\u2013MCP through one of several endocytotic mechanisms.", [["cell surface", "ANATOMY", 67, 79], ["cellular", "ANATOMY", 122, 130], ["MCP", "GENE_OR_GENE_PRODUCT", 55, 58], ["cell surface", "CELLULAR_COMPONENT", 67, 79], ["Q5", "GENE_OR_GENE_PRODUCT", 89, 91], ["\u2013MCP", "GENE_OR_GENE_PRODUCT", 91, 95], ["cellular", "CELL", 122, 130], ["Q5\u2013MCP", "GENE_OR_GENE_PRODUCT", 169, 175], ["aptamer Q5", "PROTEIN", 9, 19], ["target protein", "PROTEIN", 39, 53], ["MCP", "PROTEIN", 55, 58], ["Q5", "PROTEIN", 89, 91], ["\u2013MCP", "PROTEIN", 91, 95], ["Q5", "PROTEIN", 169, 171], ["MCP", "PROTEIN", 172, 175], ["the cell surface", "TREATMENT", 63, 79]]], ["These include clathrin-mediated endocytosis, caveolae/raft-dependent endocytosis, macropinocytosis, and non-clathrin\u2013caveolae/raft-dependent endocytosis (Wang et al., 2014; Huang et al., 2017).", [["caveolae", "ANATOMY", 45, 53], ["raft", "ANATOMY", 54, 58], ["raft", "ANATOMY", 126, 130], ["clathrin", "GENE_OR_GENE_PRODUCT", 14, 22], ["caveolae", "CELLULAR_COMPONENT", 45, 53], ["raft", "CELLULAR_COMPONENT", 54, 58], ["raft", "CELLULAR_COMPONENT", 126, 130], ["clathrin", "PROTEIN", 14, 22], ["clathrin-mediated endocytosis", "PROBLEM", 14, 43], ["caveolae/raft", "TEST", 45, 58], ["dependent endocytosis", "PROBLEM", 59, 80], ["macropinocytosis", "PROBLEM", 82, 98], ["non-clathrin\u2013caveolae/raft", "PROBLEM", 104, 130], ["dependent endocytosis", "PROBLEM", 131, 152], ["endocytosis", "OBSERVATION", 32, 43], ["raft", "ANATOMY_MODIFIER", 54, 58], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["endocytosis", "OBSERVATION", 69, 80], ["macropinocytosis", "OBSERVATION", 82, 98], ["raft", "ANATOMY_MODIFIER", 126, 130], ["dependent", "OBSERVATION_MODIFIER", 131, 140], ["endocytosis", "OBSERVATION", 141, 152]]], ["In this study, an aptamer (Q5)-based specific probe was used to investigate the trafficking mechanism and endocytotic pathway of MCP in host cells during SGIV infection.Virus, Cell Lines, and Cell Culture ::: Materials and MethodsGrouper spleen (GS) cells were grown in Leibovitz\u2019s L-15 medium (Gibco, Grand Island, NY, United States) containing 10% fetal bovine serum (Gibco) at 28\u00b0C. The grouper iridovirus strain (SGIV-Gx) used in this study was isolated from diseased hybrid grouper (Epinephelus fuscoguttatus\u2640 \u00d7 E. lanceolatus\u2642) in Guangxi Province, China, propagated in GS cells, and stored at \u221280\u00b0C in the laboratory (Xiao et al., 2019).Virus-Infected Cells ::: Materials and MethodsGrouper spleen cells were cultured to 100% confluence in 12-well plates or 35-mm glass-bottom dishes (Cellvis, Hangzhou, China; catalog number D35-14-1-N) at 28\u00b0C for 24 h.", [["cells", "ANATOMY", 141, 146], ["SGIV", "ANATOMY", 154, 158], ["Cell", "ANATOMY", 176, 180], ["Cell", "ANATOMY", 192, 196], ["spleen (GS) cells", "ANATOMY", 238, 255], ["fetal bovine serum", "ANATOMY", 350, 368], ["GS cells", "ANATOMY", 576, 584], ["Cells", "ANATOMY", 659, 664], ["spleen cells", "ANATOMY", 698, 710], ["infection", "DISEASE", 159, 168], ["SGIV-Gx", "CHEMICAL", 417, 424], ["D35-14-1-N", "CHEMICAL", 833, 843], ["MCP", "GENE_OR_GENE_PRODUCT", 129, 132], ["host cells", "CELL", 136, 146], ["SGIV", "CANCER", 154, 158], ["Virus", "CELL", 169, 174], ["Cell Lines", "CELL", 176, 186], ["Cell Culture", "CELL", 192, 204], ["MethodsGrouper spleen (GS) cells", "CELL", 223, 255], ["bovine", "ORGANISM", 356, 362], ["serum", "ORGANISM_SUBSTANCE", 363, 368], ["Gibco", "ORGANISM_SUBSTANCE", 370, 375], ["grouper", "ORGANISM", 390, 397], ["iridovirus strain", "ORGANISM", 398, 415], ["SGIV-Gx", "CELL", 417, 424], ["grouper", "ORGANISM", 479, 486], ["Epinephelus fuscoguttatus", "ORGANISM", 488, 513], ["GS cells", "CELL", 576, 584], ["C", "GENE_OR_GENE_PRODUCT", 604, 605], ["Virus", "ORGANISM", 644, 649], ["Cells", "CELL", 659, 664], ["MethodsGrouper spleen cells", "CELL", 683, 710], ["MCP", "PROTEIN", 129, 132], ["host cells", "CELL_TYPE", 136, 146], ["MethodsGrouper spleen (GS) cells", "CELL_LINE", 223, 255], ["GS cells", "CELL_TYPE", 576, 584], ["MethodsGrouper spleen cells", "CELL_LINE", 683, 710], ["bovine", "SPECIES", 356, 362], ["grouper", "SPECIES", 479, 486], ["Epinephelus fuscoguttatus", "SPECIES", 488, 513], ["SGIV", "SPECIES", 154, 158], ["bovine", "SPECIES", 356, 362], ["grouper iridovirus", "SPECIES", 390, 408], ["Epinephelus fuscoguttatus", "SPECIES", 488, 513], ["this study", "TEST", 3, 13], ["MCP in host cells", "PROBLEM", 129, 146], ["SGIV infection", "PROBLEM", 154, 168], ["Virus", "PROBLEM", 169, 174], ["Cell Lines", "TEST", 176, 186], ["Cell Culture", "TEST", 192, 204], ["MethodsGrouper spleen (GS) cells", "PROBLEM", 223, 255], ["Leibovitz", "TEST", 270, 279], ["10% fetal bovine serum", "TREATMENT", 346, 368], ["The grouper iridovirus strain", "PROBLEM", 386, 415], ["this study", "TEST", 434, 444], ["Virus", "TEST", 644, 649], ["Infected Cells", "PROBLEM", 650, 664], ["MethodsGrouper spleen cells", "TEST", 683, 710], ["host cells", "OBSERVATION", 136, 146], ["infection", "OBSERVATION", 159, 168], ["Cell Lines", "OBSERVATION", 176, 186], ["spleen", "ANATOMY", 238, 244], ["grouper iridovirus strain", "OBSERVATION", 390, 415], ["hybrid grouper", "OBSERVATION", 472, 486], ["Infected Cells", "OBSERVATION", 650, 664], ["spleen", "ANATOMY", 698, 704]]], ["After the cells were infected with SGIV-Gx at a multiplicity of infection (MOI) of 1 at 28\u00b0C for 6 h, they were then washed with phosphate-buffered saline (PBS: 10 mM Na2HPO4\u22c512H2O, 2 mM KH2PO4, 137 mM NaCl, 1% NaN3) and collected for further use (Yu et al., 2019a).Aptamer, Reagents, and Biochemical Inhibitors ::: Materials and MethodsThe aptamer Q5 was generated against SGIV-infected cells with Cell-SELEX in our previous study (Li et al., 2015).", [["cells", "ANATOMY", 10, 15], ["cells", "ANATOMY", 388, 393], ["Cell", "ANATOMY", 399, 403], ["SGIV-Gx", "CHEMICAL", 35, 42], ["multiplicity of infection", "DISEASE", 48, 73], ["phosphate", "CHEMICAL", 129, 138], ["NaCl", "CHEMICAL", 202, 206], ["phosphate", "CHEMICAL", 129, 138], ["Na2HPO4\u22c512H2O", "CHEMICAL", 167, 180], ["KH2PO4", "CHEMICAL", 187, 193], ["NaCl", "CHEMICAL", 202, 206], ["NaN3", "CHEMICAL", 211, 215], ["cells", "CELL", 10, 15], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 129, 154], ["NaN3", "SIMPLE_CHEMICAL", 211, 215], ["SGIV", "SIMPLE_CHEMICAL", 374, 378], ["cells", "CELL", 388, 393], ["Cell", "CELL", 399, 403], ["SGIV-infected cells", "CELL_LINE", 374, 393], ["SGIV", "SPECIES", 374, 378], ["SGIV", "TREATMENT", 35, 39], ["infection", "PROBLEM", 64, 73], ["phosphate-buffered saline", "TREATMENT", 129, 154], ["Na2HPO4", "TEST", 167, 174], ["2 mM KH2PO4", "TREATMENT", 182, 193], ["NaCl", "TREATMENT", 202, 206], ["1% NaN3", "TREATMENT", 208, 215], ["infected cells", "PROBLEM", 379, 393], ["our previous study", "TEST", 413, 431], ["infection", "OBSERVATION", 64, 73], ["infected cells", "OBSERVATION", 379, 393]]], ["Aptamer Q5 was synthesized by Life Technologies, and the 5\u2032 end of aptamer Q5 was labeled fluorescently with Cy5 (Cy5-Q5).", [["Cy5", "SIMPLE_CHEMICAL", 109, 112], ["Cy5-Q5", "SIMPLE_CHEMICAL", 114, 120], ["aptamer Q5", "PROTEIN", 67, 77], ["Cy5 (Cy5", "TREATMENT", 109, 117]]], ["Chlorpromazine (CPZ), methyl-\u03b2-cyclodextrin (M\u03b2CD), nystatin, genistein, dynasore, (N-ethyl-N-isopropyl)-amiloride (EIPA), ML-7, NSC23766, rottlerin, IPA-3, chloroquine (CQ), ammonia chloride (NH4Cl), cytochalasin D (cytoD), and nocodazole were purchased from Sigma-Aldrich (St. Louis, MO, United States).", [["Chlorpromazine", "CHEMICAL", 0, 14], ["CPZ", "CHEMICAL", 16, 19], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 22, 43], ["M\u03b2CD", "CHEMICAL", 45, 49], ["nystatin", "CHEMICAL", 52, 60], ["genistein", "CHEMICAL", 62, 71], ["dynasore", "CHEMICAL", 73, 81], ["N-ethyl-N-isopropyl)-amiloride", "CHEMICAL", 84, 114], ["EIPA", "CHEMICAL", 116, 120], ["ML-7, NSC23766", "CHEMICAL", 123, 137], ["rottlerin", "CHEMICAL", 139, 148], ["IPA-3,", "CHEMICAL", 150, 156], ["chloroquine", "CHEMICAL", 157, 168], ["CQ", "CHEMICAL", 170, 172], ["ammonia chloride", "CHEMICAL", 175, 191], ["NH4Cl", "CHEMICAL", 193, 198], ["cytochalasin D", "CHEMICAL", 201, 215], ["cytoD", "CHEMICAL", 217, 222], ["nocodazole", "CHEMICAL", 229, 239], ["Chlorpromazine", "CHEMICAL", 0, 14], ["CPZ", "CHEMICAL", 16, 19], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 22, 43], ["M\u03b2CD", "CHEMICAL", 45, 49], ["nystatin", "CHEMICAL", 52, 60], ["genistein", "CHEMICAL", 62, 71], ["dynasore", "CHEMICAL", 73, 81], ["(N-ethyl-N-isopropyl)-amiloride", "CHEMICAL", 83, 114], ["EIPA", "CHEMICAL", 116, 120], ["ML-7", "CHEMICAL", 123, 127], ["NSC23766", "CHEMICAL", 129, 137], ["rottlerin", "CHEMICAL", 139, 148], ["IPA-3", "CHEMICAL", 150, 155], ["chloroquine", "CHEMICAL", 157, 168], ["CQ", "CHEMICAL", 170, 172], ["ammonia chloride", "CHEMICAL", 175, 191], ["NH4Cl", "CHEMICAL", 193, 198], ["cytochalasin D", "CHEMICAL", 201, 215], ["cytoD", "CHEMICAL", 217, 222], ["nocodazole", "CHEMICAL", 229, 239], ["Chlorpromazine", "SIMPLE_CHEMICAL", 0, 14], ["CPZ", "SIMPLE_CHEMICAL", 16, 19], ["methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 22, 43], ["M\u03b2CD", "SIMPLE_CHEMICAL", 45, 49], ["nystatin", "SIMPLE_CHEMICAL", 52, 60], ["genistein", "SIMPLE_CHEMICAL", 62, 71], ["dynasore", "SIMPLE_CHEMICAL", 73, 81], ["(N-ethyl-N-isopropyl)-amiloride", "SIMPLE_CHEMICAL", 83, 114], ["EIPA", "SIMPLE_CHEMICAL", 116, 120], ["ML-7", "SIMPLE_CHEMICAL", 123, 127], ["NSC23766", "SIMPLE_CHEMICAL", 129, 137], ["rottlerin", "SIMPLE_CHEMICAL", 139, 148], ["IPA-3", "SIMPLE_CHEMICAL", 150, 155], ["chloroquine", "SIMPLE_CHEMICAL", 157, 168], ["CQ", "SIMPLE_CHEMICAL", 170, 172], ["ammonia chloride", "SIMPLE_CHEMICAL", 175, 191], ["NH4Cl", "SIMPLE_CHEMICAL", 193, 198], ["cytochalasin D", "SIMPLE_CHEMICAL", 201, 215], ["cytoD", "SIMPLE_CHEMICAL", 217, 222], ["nocodazole", "SIMPLE_CHEMICAL", 229, 239], ["Sigma-Aldrich", "ORGANISM", 260, 273], ["St. Louis", "ORGANISM", 275, 284], ["MO", "ORGANISM", 286, 288], ["Chlorpromazine (CPZ)", "TREATMENT", 0, 20], ["methyl-\u03b2-cyclodextrin (M\u03b2CD)", "TREATMENT", 22, 50], ["nystatin", "TREATMENT", 52, 60], ["genistein", "TREATMENT", 62, 71], ["dynasore", "TREATMENT", 73, 81], ["N-ethyl", "TREATMENT", 84, 91], ["isopropyl)", "TREATMENT", 94, 104], ["amiloride (EIPA)", "TREATMENT", 105, 121], ["rottlerin", "TREATMENT", 139, 148], ["IPA", "TREATMENT", 150, 153], ["chloroquine (CQ)", "TREATMENT", 157, 173], ["ammonia chloride (NH4Cl)", "TREATMENT", 175, 199], ["cytochalasin D (cytoD)", "TREATMENT", 201, 223], ["nocodazole", "TREATMENT", 229, 239]]], ["All reagents were stored and dissolved to specific concentrations according to the manufacturer\u2019s instructions.Analysis of the Safe Working Concentrations of Inhibitors With Cell Viability Assays ::: Materials and MethodsTo optimize the safe working concentration of each inhibitor, its cytotoxicity was evaluated as described previously (Liu et al., 2019).", [["Cell", "ANATOMY", 174, 178], ["Cell", "CELL", 174, 178], ["All reagents", "TREATMENT", 0, 12], ["Materials", "TREATMENT", 200, 209], ["Methods", "TREATMENT", 214, 221], ["the safe working concentration of each inhibitor", "TREATMENT", 233, 281]]], ["GS cells (1 \u00d7 104) were cultured in a 96-well plate (Corning, New York, United States) for 24 h at 28\u00b0C, and then incubated with different concentrations of each inhibitor (15 \u03bcM CPZ, 20 \u03bcM dynasore, 2 mM M\u03b2CD, 100 \u03bcM genistein, 40 \u03bcM EIPA, 20 \u03bcM IPA-3, 20 \u03bcM ML-7, 200 \u03bcM NSC23766, 1 \u03bcM rottlerin, 20 \u03bcM CQ, 400 mM NH4Cl, or 6 \u03bcM cytoD) at 28\u00b0C for 4 h.", [["GS cells", "ANATOMY", 0, 8], ["CPZ", "CHEMICAL", 179, 182], ["dynasore", "CHEMICAL", 190, 198], ["M\u03b2CD", "CHEMICAL", 205, 209], ["genistein", "CHEMICAL", 218, 227], ["EIPA", "CHEMICAL", 235, 239], ["IPA", "CHEMICAL", 247, 250], ["rottlerin", "CHEMICAL", 288, 297], ["CQ", "CHEMICAL", 305, 307], ["NH4Cl", "CHEMICAL", 316, 321], ["CPZ", "CHEMICAL", 179, 182], ["dynasore", "CHEMICAL", 190, 198], ["M\u03b2CD", "CHEMICAL", 205, 209], ["genistein", "CHEMICAL", 218, 227], ["EIPA", "CHEMICAL", 235, 239], ["IPA-3", "CHEMICAL", 247, 252], ["ML-7", "CHEMICAL", 260, 264], ["NSC23766", "CHEMICAL", 273, 281], ["rottlerin", "CHEMICAL", 288, 297], ["CQ", "CHEMICAL", 305, 307], ["NH4Cl", "CHEMICAL", 316, 321], ["cytoD", "CHEMICAL", 331, 336], ["GS cells", "CELL", 0, 8], ["CPZ", "SIMPLE_CHEMICAL", 179, 182], ["M\u03b2CD", "SIMPLE_CHEMICAL", 205, 209], ["genistein", "SIMPLE_CHEMICAL", 218, 227], ["EIPA", "SIMPLE_CHEMICAL", 235, 239], ["NSC23766", "SIMPLE_CHEMICAL", 273, 281], ["rottlerin", "SIMPLE_CHEMICAL", 288, 297], ["CQ", "SIMPLE_CHEMICAL", 305, 307], ["NH4Cl", "SIMPLE_CHEMICAL", 316, 321], ["GS cells", "CELL_LINE", 0, 8], ["GS cells", "TEST", 0, 8], ["each inhibitor", "TREATMENT", 157, 171], ["CPZ", "TREATMENT", 179, 182], ["20 \u03bcM dynasore", "TREATMENT", 184, 198], ["EIPA", "TEST", 235, 239], ["IPA", "TEST", 247, 250], ["rottlerin", "TREATMENT", 288, 297], ["NH4Cl", "TREATMENT", 316, 321]]], ["Untreated GS cells were used as the control group.", [["GS cells", "ANATOMY", 10, 18], ["GS cells", "CELL", 10, 18], ["GS cells", "CELL_LINE", 10, 18], ["Untreated GS cells", "PROBLEM", 0, 18], ["GS cells", "OBSERVATION", 10, 18]]], ["CCK-8 solution (20 \u03bcL; Beyotime, Shanghai, China) was added to the cells, and they were incubated at 28\u00b0C for 4 h.", [["cells", "ANATOMY", 67, 72], ["CCK-8", "CHEMICAL", 0, 5], ["CCK-8", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 67, 72], ["CCK", "TEST", 0, 3], ["Beyotime", "TREATMENT", 23, 31]]], ["The absorbance at 450 nm was measured with an enzyme-linked immunosorbent assay plate reader (Thermo, Waltham, MA, United States), according to the manufacturer\u2019s instructions.", [["The absorbance", "TEST", 0, 14], ["an enzyme", "TEST", 43, 52], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The working concentration of each inhibitor used in this study caused no significant cytotoxicity.Flow-Cytometric Analysis ::: Materials and MethodsA flow cytometer (Beckman MoFlo XDP, Brea, CA, United States) was used to analyze the specific interaction and internalization of the Q5-MCP complex (Li et al., 2015; Yu et al., 2019a).", [["Q5-MCP", "GENE_OR_GENE_PRODUCT", 282, 288], ["Q5", "PROTEIN", 282, 284], ["MCP complex", "PROTEIN", 285, 296], ["The working concentration of each inhibitor", "TREATMENT", 0, 43], ["this study", "TEST", 52, 62], ["significant cytotoxicity", "PROBLEM", 73, 97], ["Flow", "TEST", 98, 102], ["Cytometric Analysis", "TEST", 103, 122], ["Materials", "TEST", 127, 136], ["MethodsA flow cytometer", "TEST", 141, 164], ["Beckman", "TEST", 166, 173], ["no", "UNCERTAINTY", 70, 72], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["cytotoxicity", "OBSERVATION", 85, 97]]], ["GS cells (1 \u00d7 105) were cultured to 100% confluence in 12-well plates for 24 h and then infected with SGIV-Gx (MOI = 1).", [["GS cells", "ANATOMY", 0, 8], ["GS cells", "CELL", 0, 8], ["GS cells", "CELL_LINE", 0, 8], ["GS cells", "TEST", 0, 8], ["SGIV", "TEST", 102, 106], ["MOI", "TEST", 111, 114]]], ["At 6 h post-infection, the SGIV-infected GS cells were incubated with Cy5-Q5 (200 nM) at 4\u00b0C or 28\u00b0C. After the mixtures were washed three times with PBS, they were resuspended in 400 \u03bcL of PBS for flow-cytometric analysis, in which 20,000 events were counted.", [["GS cells", "ANATOMY", 41, 49], ["Cy5-Q5", "CHEMICAL", 70, 76], ["SGIV", "GENE_OR_GENE_PRODUCT", 27, 31], ["GS cells", "CELL", 41, 49], ["Cy5-Q5", "SIMPLE_CHEMICAL", 70, 76], ["SGIV-infected GS cells", "CELL_LINE", 27, 49], ["SGIV", "SPECIES", 27, 31], ["infection", "PROBLEM", 12, 21], ["the SGIV", "TEST", 23, 31], ["infected GS cells", "PROBLEM", 32, 49], ["Cy5", "TEST", 70, 73], ["the mixtures", "TREATMENT", 108, 120], ["PBS", "TREATMENT", 150, 153], ["PBS", "TREATMENT", 190, 193], ["flow-cytometric analysis", "TEST", 198, 222], ["infection", "OBSERVATION", 12, 21]]], ["Normal GS cells incubated with aptamer Cy5-Q5 (200 nM) were used as the control.", [["GS cells", "ANATOMY", 7, 15], ["Cy5-Q5", "CHEMICAL", 39, 45], ["GS cells", "CELL", 7, 15], ["Cy5-Q5", "SIMPLE_CHEMICAL", 39, 45], ["GS cells", "CELL_TYPE", 7, 15], ["aptamer Cy5", "TREATMENT", 31, 42], ["GS cells", "OBSERVATION", 7, 15]]], ["The results are presented as the means \u00b1 SD of three independent experiments.Confocal Fluorescence Imaging Analysis ::: Materials and MethodsFor live-cell fluorescent imaging, 1 \u00d7 104 GS cells were cultured in 35-mm glass-bottom dishes (Cellvis, Hangzhou, Zhejiang, China) and infected with SGIV-Gx (MOI = 1) for 6 h.", [["cell", "ANATOMY", 150, 154], ["GS cells", "ANATOMY", 184, 192], ["SGIV-Gx", "CHEMICAL", 291, 298], ["cell", "CELL", 150, 154], ["GS cells", "CELL", 184, 192], ["GS cells", "CELL_LINE", 184, 192], ["Confocal Fluorescence Imaging Analysis", "TEST", 77, 115], ["Methods", "TEST", 134, 141], ["live-cell fluorescent imaging", "TEST", 145, 174], ["GS cells", "TEST", 184, 192], ["bottom dishes", "PROBLEM", 222, 235], ["SGIV", "TREATMENT", 291, 295]]], ["The SGIV-infected cells were then incubated with aptamer Cy5-Q5 (200 nM) at 4\u00b0C or 28\u00b0C. After the cells were washed with serum-free phenol-red-free medium, their fluorescence was detected with laser scanning confocal microscopy (LSCM; Nikon, Tokyo, Japan).", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 99, 104], ["serum", "ANATOMY", 122, 127], ["Cy5-Q5", "CHEMICAL", 57, 63], ["phenol", "CHEMICAL", 133, 139], ["phenol", "CHEMICAL", 133, 139], ["SGIV", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 18, 23], ["Cy5-Q5", "SIMPLE_CHEMICAL", 57, 63], ["cells", "CELL", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["phenol", "SIMPLE_CHEMICAL", 133, 139], ["SGIV-infected cells", "CELL_LINE", 4, 23], ["The SGIV", "TREATMENT", 0, 8], ["infected cells", "PROBLEM", 9, 23], ["aptamer Cy5", "TREATMENT", 49, 60], ["serum", "TEST", 122, 127], ["laser scanning confocal microscopy", "TEST", 194, 228], ["LSCM", "TEST", 230, 234], ["infected cells", "OBSERVATION", 9, 23]]], ["Normal GS cells incubated with aptamer Cy5-Q5 (200 nM) were used as the control.Effects of Inhibitors on Aptamer Cy5-Q5 Binding to MCP in Membranes of SGIV-Infected Cells ::: Materials and MethodsWe analyzed the effects of various inhibitors on the binding of aptamer Cy5-Q5 to its target protein, MCP, in the membranes of SGIV-infected cells with flow cytometry.", [["GS cells", "ANATOMY", 7, 15], ["Membranes", "ANATOMY", 138, 147], ["Cells", "ANATOMY", 165, 170], ["membranes", "ANATOMY", 310, 319], ["cells", "ANATOMY", 337, 342], ["Cy5-Q5", "CHEMICAL", 39, 45], ["GS cells", "CELL", 7, 15], ["Cy5-Q5", "SIMPLE_CHEMICAL", 39, 45], ["MCP", "GENE_OR_GENE_PRODUCT", 131, 134], ["Cells", "CELL", 165, 170], ["Cy5-Q5", "SIMPLE_CHEMICAL", 268, 274], ["MCP", "GENE_OR_GENE_PRODUCT", 298, 301], ["membranes", "CELLULAR_COMPONENT", 310, 319], ["SGIV", "GENE_OR_GENE_PRODUCT", 323, 327], ["cells", "CELL", 337, 342], ["GS cells", "CELL_TYPE", 7, 15], ["Q5", "PROTEIN", 117, 119], ["MCP", "PROTEIN", 131, 134], ["SGIV-Infected Cells", "CELL_LINE", 151, 170], ["Q5", "PROTEIN", 272, 274], ["MCP", "PROTEIN", 298, 301], ["SGIV-infected cells", "CELL_LINE", 323, 342], ["aptamer Cy5", "TREATMENT", 31, 42], ["Inhibitors", "TREATMENT", 91, 101], ["Aptamer Cy5", "TREATMENT", 105, 116], ["MethodsWe", "TREATMENT", 189, 198], ["various inhibitors", "TREATMENT", 223, 241], ["aptamer Cy5", "TEST", 260, 271], ["MCP", "TEST", 298, 301], ["infected cells", "PROBLEM", 328, 342], ["flow cytometry", "TEST", 348, 362], ["GS cells", "OBSERVATION", 7, 15], ["Infected Cells", "OBSERVATION", 156, 170], ["infected cells", "OBSERVATION", 328, 342], ["flow cytometry", "OBSERVATION", 348, 362]]], ["GS cells (1 \u00d7 105) were cultured in 12-well plates at 28\u00b0C for 24 h and then infected with SGIV-Gx (MOI = 1) for 6 h.", [["GS cells", "ANATOMY", 0, 8], ["SGIV-Gx", "CHEMICAL", 91, 98], ["GS cells", "CELL", 0, 8], ["GS cells", "CELL_LINE", 0, 8], ["GS cells", "TEST", 0, 8], ["SGIV", "TEST", 91, 95], ["MOI", "TEST", 100, 103]]], ["After the safe working concentration of each inhibitor was applied to the cells for 1 h, the SGIV-infected cells were incubated with aptamer Cy5-Q5 (200 nM) in the presence of each inhibitors for 1 h at 4\u00b0C. The culture supernatants were then removed, and the cells were washed twice with PBS and collected for flow-cytometric analysis (20,000 events).", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 107, 112], ["supernatants", "ANATOMY", 220, 232], ["cells", "ANATOMY", 260, 265], ["Cy5-Q5", "CHEMICAL", 141, 147], ["cells", "CELL", 74, 79], ["SGIV", "GENE_OR_GENE_PRODUCT", 93, 97], ["cells", "CELL", 107, 112], ["Cy5-Q5", "SIMPLE_CHEMICAL", 141, 147], ["cells", "CELL", 260, 265], ["SGIV-infected cells", "CELL_LINE", 93, 112], ["the safe working concentration of each inhibitor", "TREATMENT", 6, 54], ["the SGIV", "TREATMENT", 89, 97], ["infected cells", "PROBLEM", 98, 112], ["aptamer Cy5", "TREATMENT", 133, 144], ["each inhibitors", "TREATMENT", 176, 191], ["The culture supernatants", "TEST", 208, 232], ["PBS", "TEST", 289, 292], ["flow-cytometric analysis", "TEST", 311, 335], ["infected cells", "OBSERVATION", 98, 112]]], ["Normal GS cells incubated with Cy5-Q5 (200 nM) were used as the negative control; SGIV-infected cells with no inhibitor treatment were incubated with Cy5-Q5 (200 nM) and used as the positive control.", [["GS cells", "ANATOMY", 7, 15], ["cells", "ANATOMY", 96, 101], ["Cy5-Q5", "CHEMICAL", 31, 37], ["Cy5-Q5", "CHEMICAL", 150, 156], ["GS cells", "CELL", 7, 15], ["Cy5-Q5", "SIMPLE_CHEMICAL", 31, 37], ["SGIV", "SIMPLE_CHEMICAL", 82, 86], ["cells", "CELL", 96, 101], ["Cy5-Q5", "SIMPLE_CHEMICAL", 150, 156], ["GS cells", "CELL_LINE", 7, 15], ["SGIV-infected cells", "CELL_LINE", 82, 101], ["Cy5", "TEST", 31, 34], ["SGIV", "TEST", 82, 86], ["infected cells", "PROBLEM", 87, 101], ["inhibitor treatment", "TREATMENT", 110, 129], ["Cy5", "TEST", 150, 153], ["the positive control", "TREATMENT", 178, 198], ["GS cells", "OBSERVATION", 7, 15], ["infected cells", "OBSERVATION", 87, 101]]], ["The results are presented as the means \u00b1 SD of three independent experiments.MCP Entry Assay ::: Materials and MethodsThe MCP entry efficiency was assessed with the protocol described by Huang et al. (2017), with some modifications.", [["MCP", "PROTEIN", 77, 80], ["MCP", "PROTEIN", 122, 125], ["the protocol", "TREATMENT", 161, 173]]], ["GS cells were cultured to 100% confluence in 12-well plates or 35-mm glass-bottom dishes at 28\u00b0C for 24 h and then infected with SGIV-Gx (MOI = 1) for 6 h.", [["GS cells", "ANATOMY", 0, 8], ["SGIV-Gx", "CHEMICAL", 129, 136], ["GS cells", "CELL", 0, 8], ["GS cells", "CELL_LINE", 0, 8], ["GS cells", "TEST", 0, 8], ["bottom dishes", "PROBLEM", 75, 88], ["SGIV", "TEST", 129, 133], ["MOI", "TEST", 138, 141]]], ["After pretreatment with each inhibitor at the safe working concentration for 1 h, the SGIV-infected cells were incubated with aptamer Cy5-Q5 (200 nM) in the presence of each inhibitor for 1 h at 4\u00b0C. The cultured cells were then transferred to 28\u00b0C to initiate MCP endocytosis into the SGIV-infected host cells.", [["cells", "ANATOMY", 100, 105], ["cells", "ANATOMY", 213, 218], ["cells", "ANATOMY", 305, 310], ["Cy5-Q5", "CHEMICAL", 134, 140], ["SGIV", "SIMPLE_CHEMICAL", 86, 90], ["cells", "CELL", 100, 105], ["Cy5-Q5", "SIMPLE_CHEMICAL", 134, 140], ["cells", "CELL", 213, 218], ["MCP", "GENE_OR_GENE_PRODUCT", 261, 264], ["SGIV", "GENE_OR_GENE_PRODUCT", 286, 290], ["host cells", "CELL", 300, 310], ["SGIV-infected cells", "CELL_LINE", 86, 105], ["cultured cells", "CELL_LINE", 204, 218], ["MCP", "PROTEIN", 261, 264], ["SGIV-infected host cells", "CELL_TYPE", 286, 310], ["pretreatment", "TREATMENT", 6, 18], ["each inhibitor", "TREATMENT", 24, 38], ["infected cells", "PROBLEM", 91, 105], ["aptamer Cy5", "TREATMENT", 126, 137], ["each inhibitor", "TREATMENT", 169, 183], ["The cultured cells", "TEST", 200, 218], ["MCP endocytosis", "TEST", 261, 276], ["infected host cells", "PROBLEM", 291, 310], ["infected cells", "OBSERVATION", 91, 105], ["infected", "OBSERVATION", 291, 299], ["host cells", "OBSERVATION", 300, 310]]], ["The internalization of the Q5-MCP complex was analyzed with flow cytometry and LSCM.", [["Q5-MCP", "GENE_OR_GENE_PRODUCT", 27, 33], ["Q5", "PROTEIN", 27, 29], ["MCP complex", "PROTEIN", 30, 41], ["flow cytometry", "TEST", 60, 74], ["LSCM", "TEST", 79, 83], ["flow cytometry", "OBSERVATION", 60, 74]]], ["Normal GS cells incubated with Cy5-Q5 (200 nM) were used as the negative control; SGIV-infected cells without any inhibitor were incubated with Cy5-Q5 (200 nM) and used as the positive control.", [["GS cells", "ANATOMY", 7, 15], ["cells", "ANATOMY", 96, 101], ["Cy5-Q5", "CHEMICAL", 31, 37], ["Cy5-Q5", "CHEMICAL", 144, 150], ["GS cells", "CELL", 7, 15], ["Cy5-Q5", "SIMPLE_CHEMICAL", 31, 37], ["SGIV", "SIMPLE_CHEMICAL", 82, 86], ["cells", "CELL", 96, 101], ["Cy5-Q5", "SIMPLE_CHEMICAL", 144, 150], ["GS cells", "CELL_LINE", 7, 15], ["SGIV-infected cells", "CELL_LINE", 82, 101], ["Cy5", "TEST", 31, 34], ["SGIV", "TEST", 82, 86], ["infected cells", "PROBLEM", 87, 101], ["any inhibitor", "TREATMENT", 110, 123], ["Cy5", "TEST", 144, 147], ["the positive control", "TREATMENT", 172, 192], ["GS cells", "OBSERVATION", 7, 15], ["infected cells", "OBSERVATION", 87, 101]]], ["Entry efficiency was calculated with the following equation: entry efficiency = (X \u2212 Control 1)/(Control 2 \u2212 Control 1) \u00d7 100%, where X is the flow-cytometric results for each sample of inhibitor-pretreated SGIV-infected cells incubated with Cy5-Q5 (200 nM) at 28\u00b0C; Control 1 is the flow-cytometric result for SGIV-infected cells incubated with Cy5-Q5 (200 nM) at 4\u00b0C, and Control 2 is the flow-cytometric result for SGIV-infected cells incubated with Cy5-Q5 (200 nM) at 28\u00b0C. The results of the MCP entry assay for each inhibitor are presented as the means \u00b1 SD of three independent experiments.Statistical Analysis ::: Materials and MethodsThe experimental data in the study are expressed as means \u00b1 SE.", [["cells", "ANATOMY", 221, 226], ["cells", "ANATOMY", 325, 330], ["cells", "ANATOMY", 432, 437], ["SGIV", "CHEMICAL", 207, 211], ["Cy5-Q5", "CHEMICAL", 242, 248], ["Cy5-Q5", "CHEMICAL", 346, 352], ["Cy5-Q5", "CHEMICAL", 453, 459], ["SE", "DISEASE", 703, 705], ["SGIV", "SIMPLE_CHEMICAL", 207, 211], ["cells", "CELL", 221, 226], ["Cy5-Q5", "SIMPLE_CHEMICAL", 242, 248], ["SGIV", "SIMPLE_CHEMICAL", 311, 315], ["cells", "CELL", 325, 330], ["Cy5-Q5", "SIMPLE_CHEMICAL", 346, 352], ["SGIV", "SIMPLE_CHEMICAL", 418, 422], ["cells", "CELL", 432, 437], ["Cy5-Q5", "SIMPLE_CHEMICAL", 453, 459], ["MCP", "GENE_OR_GENE_PRODUCT", 497, 500], ["inhibitor-pretreated SGIV-infected cells", "CELL_LINE", 186, 226], ["SGIV-infected cells", "CELL_LINE", 311, 330], ["SGIV-infected cells", "CELL_LINE", 418, 437], ["MCP", "PROTEIN", 497, 500], ["Entry efficiency", "PROBLEM", 0, 16], ["entry efficiency", "PROBLEM", 61, 77], ["(X \u2212 Control", "TREATMENT", 80, 92], ["inhibitor", "TREATMENT", 186, 195], ["infected cells", "PROBLEM", 212, 226], ["Cy5", "TEST", 242, 245], ["the flow", "TEST", 280, 288], ["SGIV", "PROBLEM", 311, 315], ["infected cells", "PROBLEM", 316, 330], ["Cy5", "TEST", 346, 349], ["the flow", "TEST", 387, 395], ["SGIV", "PROBLEM", 418, 422], ["infected cells", "PROBLEM", 423, 437], ["Cy5", "TEST", 453, 456], ["the MCP entry assay", "TEST", 493, 512], ["each inhibitor", "TREATMENT", 517, 531], ["the study", "TEST", 668, 677]]], ["Intergroup differences were analyzed with one-way analysis of variance (ANOVA), with the SPSS 13.0 statistical software (IBM, Armonk, NY, United States).", [["the SPSS", "TEST", 85, 93]]], ["A p value < 0.05 was considered statistically significant.Aptamer Cy5-Q5 Specifically Bound to SGIV-Infected Cells ::: ResultsConfocal fluorescence imaging showed that the Cy5-labeled aptamer Q5 (Cy5-Q5) specifically bound to the surfaces of SGIV-infected cells at 4\u00b0C, but not to normal GS cells.", [["Cells", "ANATOMY", 109, 114], ["cells", "ANATOMY", 256, 261], ["GS cells", "ANATOMY", 288, 296], ["Cy5", "CHEMICAL", 172, 175], ["Cy5-Q5", "CHEMICAL", 196, 202], ["Cells", "CELL", 109, 114], ["Cy5", "SIMPLE_CHEMICAL", 172, 175], ["aptamer Q5", "SIMPLE_CHEMICAL", 184, 194], ["Cy5-Q5", "SIMPLE_CHEMICAL", 196, 202], ["SGIV", "GENE_OR_GENE_PRODUCT", 242, 246], ["cells", "CELL", 256, 261], ["GS cells", "CELL", 288, 296], ["SGIV", "PROTEIN", 95, 99], ["SGIV-infected cells", "CELL_LINE", 242, 261], ["4\u00b0C", "CELL_LINE", 265, 268], ["normal GS cells", "CELL_TYPE", 281, 296], ["A p value", "TEST", 0, 9], ["Aptamer Cy5", "TREATMENT", 58, 69], ["ResultsConfocal fluorescence imaging", "TEST", 119, 155], ["the Cy5", "TEST", 168, 175], ["Cy5", "TEST", 196, 199], ["SGIV", "TEST", 242, 246], ["infected cells", "PROBLEM", 247, 261], ["Infected Cells", "OBSERVATION", 100, 114], ["infected cells", "OBSERVATION", 247, 261], ["GS cells", "OBSERVATION", 288, 296]]], ["When Cy5-Q5 was incubated with SGIV-infected cells at 4\u00b0C, the fluorescent signal was only visible around the cell plasma membrane, but not inside the cells (Figure 1A).", [["cells", "ANATOMY", 45, 50], ["cell plasma membrane", "ANATOMY", 110, 130], ["cells", "ANATOMY", 151, 156], ["Cy5-Q5", "CHEMICAL", 5, 11], ["Cy5-Q5", "SIMPLE_CHEMICAL", 5, 11], ["SGIV", "SIMPLE_CHEMICAL", 31, 35], ["cells", "CELL", 45, 50], ["cell", "CELLULAR_COMPONENT", 110, 114], ["plasma membrane", "CELLULAR_COMPONENT", 115, 130], ["cells", "CELL", 151, 156], ["Q5", "PROTEIN", 9, 11], ["SGIV-infected cells", "CELL_LINE", 31, 50], ["Cy5", "TEST", 5, 8], ["SGIV", "TEST", 31, 35], ["infected cells", "PROBLEM", 36, 50], ["the fluorescent signal", "TEST", 59, 81], ["the cell plasma membrane", "TEST", 106, 130], ["infected cells", "OBSERVATION", 36, 50], ["cell plasma membrane", "OBSERVATION", 110, 130]]], ["The specific binding properties of aptamer Cy5-Q5 were confirmed with a flow-cytometric analysis (Figure 1B).Kinetics of Q5-MCP Complex Entry Into SGIV-Infected Cells ::: ResultsAs reported previously, aptamer Q5 recognizes SGIV-infected cells with high specificity and affinity, and the protein detected on the target cell membrane is the viral MCP.", [["Cells", "ANATOMY", 161, 166], ["cells", "ANATOMY", 238, 243], ["cell membrane", "ANATOMY", 319, 332], ["Cy5-Q5", "SIMPLE_CHEMICAL", 43, 49], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 121, 127], ["Cells", "CELL", 161, 166], ["SGIV", "GENE_OR_GENE_PRODUCT", 224, 228], ["cells", "CELL", 238, 243], ["cell membrane", "CELLULAR_COMPONENT", 319, 332], ["MCP", "GENE_OR_GENE_PRODUCT", 346, 349], ["Q5", "PROTEIN", 121, 123], ["SGIV", "PROTEIN", 147, 151], ["aptamer Q5", "PROTEIN", 202, 212], ["SGIV", "PROTEIN", 224, 228], ["viral MCP", "PROTEIN", 340, 349], ["aptamer Cy5", "TEST", 35, 46], ["a flow-cytometric analysis", "TEST", 70, 96], ["ResultsAs", "TEST", 171, 180], ["aptamer", "TEST", 202, 209], ["SGIV", "TEST", 224, 228], ["infected cells", "PROBLEM", 229, 243], ["affinity", "TEST", 270, 278], ["the protein", "TEST", 284, 295], ["Infected Cells", "OBSERVATION", 152, 166], ["infected cells", "OBSERVATION", 229, 243], ["cell membrane", "OBSERVATION", 319, 332], ["viral MCP", "OBSERVATION", 340, 349]]], ["Therefore, aptamer Q5 can be used as a specific probe to investigate the trafficking mechanism and endocytotic pathway of MCP in host cells during SGIV infection (Yu et al., 2019a).", [["cells", "ANATOMY", 134, 139], ["SGIV", "ANATOMY", 147, 151], ["infection", "DISEASE", 152, 161], ["MCP", "GENE_OR_GENE_PRODUCT", 122, 125], ["host cells", "CELL", 129, 139], ["SGIV", "CELL", 147, 151], ["MCP", "PROTEIN", 122, 125], ["host cells", "CELL_TYPE", 129, 139], ["SGIV", "SPECIES", 147, 151], ["aptamer", "TREATMENT", 11, 18], ["a specific probe", "TREATMENT", 37, 53], ["MCP in host cells", "PROBLEM", 122, 139], ["SGIV infection", "PROBLEM", 147, 161]]], ["The kinetics of the entry of the Q5-MCP complex into SGIV-infected cells were analyzed with flow cytometry (Figure 2A) and LSCM (Figure 2B).", [["cells", "ANATOMY", 67, 72], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 33, 39], ["SGIV", "GENE_OR_GENE_PRODUCT", 53, 57], ["cells", "CELL", 67, 72], ["Q5", "PROTEIN", 33, 35], ["MCP complex", "PROTEIN", 36, 47], ["SGIV-infected cells", "CELL_LINE", 53, 72], ["infected cells", "PROBLEM", 58, 72], ["flow cytometry", "TEST", 92, 106], ["LSCM", "TEST", 123, 127], ["infected cells", "OBSERVATION", 58, 72], ["flow cytometry", "OBSERVATION", 92, 106]]], ["The active internalization of MCP was blocked at 4\u00b0C (Li et al., 2018).", [["MCP", "GENE_OR_GENE_PRODUCT", 30, 33], ["MCP", "PROTEIN", 30, 33], ["active", "OBSERVATION_MODIFIER", 4, 10], ["internalization", "OBSERVATION_MODIFIER", 11, 26]]], ["As shown in Figure 2A, after incubation with SGIV-infected cells at 4\u00b0C for different periods (0, 30, 60, 90, 120, or 180 min), no significant change in fluorescence was detected with flow cytometry, indicating that aptamer Cy5-Q5 only bound to the cell plasma membrane, but endocytosis did not occur (Figure 2A).", [["cells", "ANATOMY", 59, 64], ["cell plasma membrane", "ANATOMY", 249, 269], ["Cy5-Q5", "CHEMICAL", 224, 230], ["SGIV", "SIMPLE_CHEMICAL", 45, 49], ["cells", "CELL", 59, 64], ["C", "GENE_OR_GENE_PRODUCT", 70, 71], ["Cy5-Q5", "GENE_OR_GENE_PRODUCT", 224, 230], ["cell", "CELLULAR_COMPONENT", 249, 253], ["plasma membrane", "CELLULAR_COMPONENT", 254, 269], ["SGIV-infected cells", "CELL_LINE", 45, 64], ["Q5", "PROTEIN", 228, 230], ["SGIV", "TREATMENT", 45, 49], ["infected cells", "PROBLEM", 50, 64], ["significant change in fluorescence", "PROBLEM", 131, 165], ["flow cytometry", "TEST", 184, 198], ["aptamer Cy5", "TEST", 216, 227], ["the cell plasma membrane", "TEST", 245, 269], ["endocytosis", "PROBLEM", 275, 286], ["infected cells", "OBSERVATION", 50, 64], ["no", "UNCERTAINTY", 128, 130], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["change", "OBSERVATION", 143, 149]]], ["When the cells were transferred to 28\u00b0C, the entry of the Q5-MCP complex into the SGIV-infected cells was rapidly initiated.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 96, 101], ["cells", "CELL", 9, 14], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 58, 64], ["SGIV", "GENE_OR_GENE_PRODUCT", 82, 86], ["cells", "CELL", 96, 101], ["Q5", "PROTEIN", 58, 60], ["MCP complex", "PROTEIN", 61, 72], ["SGIV-infected cells", "CELL_LINE", 82, 101], ["infected cells", "PROBLEM", 87, 101], ["infected cells", "OBSERVATION", 87, 101]]], ["There was a time-dependent increase in the fluorescent signal within the cell cytoplasm, which peaked at 120 min (Figure 2A).", [["cell cytoplasm", "ANATOMY", 73, 87], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 73, 87], ["a time-dependent increase", "PROBLEM", 10, 35], ["the fluorescent signal within the cell cytoplasm", "PROBLEM", 39, 87], ["dependent", "OBSERVATION_MODIFIER", 17, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["fluorescent signal", "OBSERVATION", 43, 61], ["cell cytoplasm", "OBSERVATION", 73, 87]]], ["The cell-specific internalization of the Q5-MCP complex was also detected with LSCM (Figure 2B).", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 41, 47], ["Q5", "PROTEIN", 41, 43], ["MCP complex", "PROTEIN", 44, 55], ["LSCM", "TEST", 79, 83]]], ["After incubation at 28\u00b0C for 2 h, the fluorescent signal was observed inside the SGIV-infected cells, indicating the endocytosis of the Q5-MCP complex.", [["cells", "ANATOMY", 95, 100], ["SGIV", "GENE_OR_GENE_PRODUCT", 81, 85], ["cells", "CELL", 95, 100], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 136, 142], ["SGIV-infected cells", "CELL_LINE", 81, 100], ["Q5", "PROTEIN", 136, 138], ["MCP complex", "PROTEIN", 139, 150], ["the fluorescent signal", "TEST", 34, 56], ["infected cells", "PROBLEM", 86, 100], ["infected cells", "OBSERVATION", 86, 100]]], ["The control group of SGIV-infected cells treated with Cy5-library showed no fluorescence (Figure 2B).Inhibitors Had No Effect on Cy5-Q5 Binding to SGIV-Infected Cells ::: ResultsRelative to the control group of normal GS cells, the GS cells incubated with the safe working concentration of each inhibitor in L-15 medium retained their normal growth, and the cell viability rate exceeded 99%, indicating that the working concentrations of the inhibitors used in this study caused no significant cytotoxicity (Supplementary Figure S1).", [["cells", "ANATOMY", 35, 40], ["Cells", "ANATOMY", 161, 166], ["GS cells", "ANATOMY", 218, 226], ["GS cells", "ANATOMY", 232, 240], ["cell", "ANATOMY", 358, 362], ["SGIV", "ORGANISM", 21, 25], ["cells", "CELL", 35, 40], ["Cy5", "SIMPLE_CHEMICAL", 54, 57], ["Cy5-Q5", "SIMPLE_CHEMICAL", 129, 135], ["SGIV", "SIMPLE_CHEMICAL", 147, 151], ["Cells", "CELL", 161, 166], ["GS cells", "CELL", 218, 226], ["GS cells", "CELL", 232, 240], ["cell", "CELL", 358, 362], ["SGIV-infected cells", "CELL_LINE", 21, 40], ["SGIV", "PROTEIN", 147, 151], ["normal GS cells", "CELL_TYPE", 211, 226], ["GS cells", "CELL_LINE", 232, 240], ["SGIV", "SPECIES", 21, 25], ["infected cells", "PROBLEM", 26, 40], ["Cy5-library", "TEST", 54, 65], ["fluorescence", "PROBLEM", 76, 88], ["Inhibitors", "TREATMENT", 101, 111], ["Cy5", "TEST", 129, 132], ["the GS cells", "TEST", 228, 240], ["the cell viability rate", "TEST", 354, 377], ["the inhibitors", "TREATMENT", 438, 452], ["this study", "TEST", 461, 471], ["significant cytotoxicity", "PROBLEM", 482, 506], ["infected cells", "OBSERVATION", 26, 40], ["Infected Cells", "OBSERVATION", 152, 166], ["GS cells", "OBSERVATION", 218, 226], ["normal", "OBSERVATION", 335, 341], ["growth", "OBSERVATION_MODIFIER", 342, 348], ["no", "UNCERTAINTY", 479, 481], ["significant", "OBSERVATION_MODIFIER", 482, 493], ["cytotoxicity", "OBSERVATION", 494, 506]]], ["After pretreatment with each inhibitor at its safe working concentration for 1 h, SGIV-infected cells were incubated with Cy5-Q5 (200 nM) at 4\u00b0C for 1 h and then collected for flow-cytometric analysis.", [["cells", "ANATOMY", 96, 101], ["Cy5-Q5", "CHEMICAL", 122, 128], ["SGIV", "SIMPLE_CHEMICAL", 82, 86], ["cells", "CELL", 96, 101], ["Cy5-Q5", "SIMPLE_CHEMICAL", 122, 128], ["SGIV-infected cells", "CELL_LINE", 82, 101], ["SGIV", "SPECIES", 82, 86], ["pretreatment", "TREATMENT", 6, 18], ["each inhibitor", "TREATMENT", 24, 38], ["infected cells", "PROBLEM", 87, 101], ["Cy5", "TEST", 122, 125], ["flow-cytometric analysis", "TEST", 176, 200], ["infected cells", "OBSERVATION", 87, 101]]], ["The fluorescent signals did not differ significantly in the SGIV-infected cells pretreated with or without each inhibitor, indicating that the inhibitors did not interfere with the binding of Cy5-Q5 to its target on the plasma membranes of SGIV-infected cells (Figure 3).Clathrin-Mediated Endocytosis Mediates MCP Entry Into SGIV-Infected Cells ::: ResultsAccording to our previous studies, the Q5 aptamer ultimately accumulates around the nucleus after it is efficiently internalized into SGIV-infected cells (Li et al., 2015; Yu et al., 2019a).", [["cells", "ANATOMY", 74, 79], ["plasma membranes", "ANATOMY", 220, 236], ["cells", "ANATOMY", 254, 259], ["Cells", "ANATOMY", 339, 344], ["nucleus", "ANATOMY", 440, 447], ["cells", "ANATOMY", 504, 509], ["cells", "CELL", 74, 79], ["Cy5-Q5", "GENE_OR_GENE_PRODUCT", 192, 198], ["plasma membranes", "CELLULAR_COMPONENT", 220, 236], ["SGIV", "GENE_OR_GENE_PRODUCT", 240, 244], ["cells", "CELL", 254, 259], ["Clathrin", "GENE_OR_GENE_PRODUCT", 271, 279], ["MCP", "GENE_OR_GENE_PRODUCT", 310, 313], ["SGIV", "GENE_OR_GENE_PRODUCT", 325, 329], ["Cells", "CELL", 339, 344], ["nucleus", "CELLULAR_COMPONENT", 440, 447], ["SGIV", "GENE_OR_GENE_PRODUCT", 490, 494], ["cells", "CELL", 504, 509], ["SGIV-infected cells", "CELL_LINE", 60, 79], ["Q5", "PROTEIN", 196, 198], ["SGIV-infected cells", "CELL_TYPE", 240, 259], ["Clathrin", "PROTEIN", 271, 279], ["MCP", "PROTEIN", 310, 313], ["SGIV", "PROTEIN", 325, 329], ["Q5", "PROTEIN", 395, 397], ["SGIV-infected cells", "CELL_LINE", 490, 509], ["The fluorescent signals", "TEST", 0, 23], ["infected cells", "PROBLEM", 65, 79], ["each inhibitor", "TREATMENT", 107, 121], ["the inhibitors", "PROBLEM", 139, 153], ["Cy5", "TEST", 192, 195], ["infected cells", "PROBLEM", 245, 259], ["Clathrin", "TREATMENT", 271, 279], ["our previous studies", "TEST", 369, 389], ["infected cells", "OBSERVATION", 65, 79], ["infected cells", "OBSERVATION", 245, 259], ["Infected Cells", "OBSERVATION", 330, 344], ["nucleus", "ANATOMY", 440, 447], ["infected cells", "OBSERVATION", 495, 509]]], ["Therefore, the effective inhibitory agents could reduce the endocytosis of Q5 and Cy5 signals in target SGIV-infected cells.", [["cells", "ANATOMY", 118, 123], ["Q5", "GENE_OR_GENE_PRODUCT", 75, 77], ["Cy5", "SIMPLE_CHEMICAL", 82, 85], ["SGIV", "GENE_OR_GENE_PRODUCT", 104, 108], ["cells", "CELL", 118, 123], ["Q5", "PROTEIN", 75, 77], ["SGIV-infected cells", "CELL_LINE", 104, 123], ["the effective inhibitory agents", "TREATMENT", 11, 42], ["the endocytosis", "PROBLEM", 56, 71], ["Cy5 signals", "TEST", 82, 93], ["infected cells", "PROBLEM", 109, 123], ["infected cells", "OBSERVATION", 109, 123]]], ["Chlorpromazine (CPZ) prevents the assembly of coated pits on the cell surface, so different concentrations of CPZ were used to analyze the role of the clathrin-mediated endocytotic pathway in the entry of the Q5-MCP complex into SGIV-infected cells.", [["cell surface", "ANATOMY", 65, 77], ["cells", "ANATOMY", 243, 248], ["Chlorpromazine", "CHEMICAL", 0, 14], ["CPZ", "CHEMICAL", 16, 19], ["CPZ", "CHEMICAL", 110, 113], ["Chlorpromazine", "CHEMICAL", 0, 14], ["CPZ", "CHEMICAL", 16, 19], ["CPZ", "CHEMICAL", 110, 113], ["Chlorpromazine", "SIMPLE_CHEMICAL", 0, 14], ["CPZ", "SIMPLE_CHEMICAL", 16, 19], ["cell surface", "CELLULAR_COMPONENT", 65, 77], ["CPZ", "SIMPLE_CHEMICAL", 110, 113], ["clathrin", "GENE_OR_GENE_PRODUCT", 151, 159], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 209, 215], ["SGIV", "GENE_OR_GENE_PRODUCT", 229, 233], ["cells", "CELL", 243, 248], ["clathrin", "PROTEIN", 151, 159], ["Q5", "PROTEIN", 209, 211], ["MCP complex", "PROTEIN", 212, 223], ["SGIV-infected cells", "CELL_LINE", 229, 248], ["Chlorpromazine (CPZ)", "TREATMENT", 0, 20], ["coated pits", "PROBLEM", 46, 57], ["the cell surface", "TREATMENT", 61, 77], ["CPZ", "TREATMENT", 110, 113], ["infected cells", "PROBLEM", 234, 248], ["coated pits", "OBSERVATION", 46, 57], ["infected cells", "OBSERVATION", 234, 248]]], ["As shown in Figure 4A, CPZ significantly reduced the fluorescent signal inside the SGIV-infected cells compared with that in the control group of SGIV-infected cells incubated with Cy5-Q5 without CPZ.", [["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 160, 165], ["CPZ", "CHEMICAL", 23, 26], ["Cy5-Q5", "CHEMICAL", 181, 187], ["CPZ", "CHEMICAL", 196, 199], ["CPZ", "CHEMICAL", 23, 26], ["CPZ", "CHEMICAL", 196, 199], ["CPZ", "SIMPLE_CHEMICAL", 23, 26], ["SGIV", "GENE_OR_GENE_PRODUCT", 83, 87], ["cells", "CELL", 97, 102], ["SGIV", "CELL", 146, 150], ["cells", "CELL", 160, 165], ["Cy5-Q5", "SIMPLE_CHEMICAL", 181, 187], ["CPZ", "SIMPLE_CHEMICAL", 196, 199], ["SGIV-infected cells", "CELL_LINE", 83, 102], ["SGIV-infected cells", "CELL_LINE", 146, 165], ["SGIV", "SPECIES", 146, 150], ["CPZ", "PROBLEM", 23, 26], ["infected cells", "PROBLEM", 88, 102], ["infected cells", "PROBLEM", 151, 165], ["Cy5", "TEST", 181, 184], ["CPZ", "TREATMENT", 196, 199], ["infected cells", "OBSERVATION", 88, 102], ["infected cells", "OBSERVATION", 151, 165]]], ["The entry efficiency of the Q5-MCP complex also decreased significantly to 81.9% at when treated with 10 \u03bcM CPZ and to 72.7% with 15 \u03bcM CPZ, confirming the dose-dependent inhibitory effect of CPZ on Q5-MCP entry (Figure 4B).Clathrin-Mediated Endocytosis Mediates MCP Entry Into SGIV-Infected Cells ::: ResultsDynamin is a cellular GTPase that is essential for clathrin-coated vesicle formation and membrane budding in the late stage.", [["Cells", "ANATOMY", 292, 297], ["cellular", "ANATOMY", 322, 330], ["vesicle", "ANATOMY", 376, 383], ["membrane", "ANATOMY", 398, 406], ["CPZ", "CHEMICAL", 108, 111], ["CPZ", "CHEMICAL", 136, 139], ["CPZ", "CHEMICAL", 192, 195], ["ResultsDynamin", "CHEMICAL", 302, 316], ["CPZ", "CHEMICAL", 108, 111], ["CPZ", "CHEMICAL", 136, 139], ["CPZ", "CHEMICAL", 192, 195], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 28, 34], ["CPZ", "SIMPLE_CHEMICAL", 108, 111], ["CPZ", "SIMPLE_CHEMICAL", 136, 139], ["CPZ", "SIMPLE_CHEMICAL", 192, 195], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 199, 205], ["Clathrin", "GENE_OR_GENE_PRODUCT", 224, 232], ["MCP", "GENE_OR_GENE_PRODUCT", 263, 266], ["SGIV", "GENE_OR_GENE_PRODUCT", 278, 282], ["Cells", "CELL", 292, 297], ["ResultsDynamin", "GENE_OR_GENE_PRODUCT", 302, 316], ["cellular", "CELL", 322, 330], ["clathrin", "GENE_OR_GENE_PRODUCT", 360, 368], ["vesicle", "CELLULAR_COMPONENT", 376, 383], ["membrane", "CELLULAR_COMPONENT", 398, 406], ["Q5", "PROTEIN", 28, 30], ["MCP complex", "PROTEIN", 31, 42], ["MCP", "PROTEIN", 202, 205], ["Clathrin", "PROTEIN", 224, 232], ["MCP", "PROTEIN", 263, 266], ["SGIV", "PROTEIN", 278, 282], ["ResultsDynamin", "PROTEIN", 302, 316], ["cellular GTPase", "PROTEIN", 322, 337], ["clathrin", "PROTEIN", 360, 368], ["10 \u03bcM CPZ", "TREATMENT", 102, 111], ["15 \u03bcM CPZ", "TREATMENT", 130, 139], ["CPZ", "TREATMENT", 192, 195], ["Clathrin", "TREATMENT", 224, 232], ["a cellular GTPase", "PROBLEM", 320, 337], ["clathrin", "PROBLEM", 360, 368], ["coated vesicle formation", "PROBLEM", 369, 393], ["membrane budding", "PROBLEM", 398, 414], ["entry", "OBSERVATION_MODIFIER", 4, 9], ["efficiency", "OBSERVATION_MODIFIER", 10, 20], ["decreased", "OBSERVATION_MODIFIER", 48, 57], ["Infected Cells", "OBSERVATION", 283, 297], ["cellular GTPase", "OBSERVATION", 322, 337], ["coated vesicle formation", "OBSERVATION", 369, 393], ["membrane budding", "OBSERVATION", 398, 414], ["late stage", "OBSERVATION_MODIFIER", 422, 432]]], ["Dynasore is a specific inhibitor of dynamin and rapidly blocks the formation of clathrin-coated vesicles (Abban et al., 2008).", [["vesicles", "ANATOMY", 96, 104], ["Dynasore", "CHEMICAL", 0, 8], ["Dynasore", "CHEMICAL", 0, 8], ["Dynasore", "SIMPLE_CHEMICAL", 0, 8], ["dynamin", "GENE_OR_GENE_PRODUCT", 36, 43], ["clathrin", "GENE_OR_GENE_PRODUCT", 80, 88], ["vesicles", "CELLULAR_COMPONENT", 96, 104], ["dynamin", "PROTEIN", 36, 43], ["clathrin", "PROTEIN", 80, 88]]], ["Therefore, we used different concentrations of dynasore (10 and 20 \u03bcM) to confirm the role of dynamin in the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 156, 161], ["dynasore", "CHEMICAL", 47, 55], ["dynasore", "CHEMICAL", 47, 55], ["dynasore", "SIMPLE_CHEMICAL", 47, 55], ["dynamin", "GENE_OR_GENE_PRODUCT", 94, 101], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 122, 128], ["SGIV", "GENE_OR_GENE_PRODUCT", 142, 146], ["cells", "CELL", 156, 161], ["dynamin", "PROTEIN", 94, 101], ["Q5", "PROTEIN", 122, 124], ["MCP complex", "PROTEIN", 125, 136], ["SGIV-infected cells", "CELL_LINE", 142, 161], ["different concentrations of dynasore", "TREATMENT", 19, 55], ["infected cells", "PROBLEM", 147, 161], ["infected cells", "OBSERVATION", 147, 161]]], ["The fluorescent signal inside the SGIV-infected cells was significantly reduced in the dynasore-treated cells (Figure 5A), and the entry efficiency was greatly and dose-dependently reduced in the presence of dynasore (to 75.4% with 10 \u03bcM dynasore, to 55.9% with 20 \u03bcM dynasore) (Figure 5B).", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 104, 109], ["dynasore", "CHEMICAL", 87, 95], ["dynasore", "CHEMICAL", 208, 216], ["dynasore", "CHEMICAL", 238, 246], ["dynasore", "CHEMICAL", 208, 216], ["SGIV", "GENE_OR_GENE_PRODUCT", 34, 38], ["cells", "CELL", 48, 53], ["dynasore", "SIMPLE_CHEMICAL", 87, 95], ["cells", "CELL", 104, 109], ["dynasore", "SIMPLE_CHEMICAL", 208, 216], ["SGIV-infected cells", "CELL_LINE", 34, 53], ["dynasore-treated cells", "CELL_LINE", 87, 109], ["The fluorescent signal", "TEST", 0, 22], ["the SGIV", "TEST", 30, 38], ["infected cells", "PROBLEM", 39, 53], ["dynasore", "TEST", 208, 216], ["dynasore", "TEST", 238, 246], ["infected cells", "OBSERVATION", 39, 53], ["significantly", "OBSERVATION_MODIFIER", 58, 71], ["reduced", "OBSERVATION_MODIFIER", 72, 79], ["entry efficiency", "OBSERVATION", 131, 147], ["dependently", "OBSERVATION_MODIFIER", 169, 180], ["reduced", "OBSERVATION_MODIFIER", 181, 188]]], ["Therefore, MCP entered the SGIV-infected host cells via clathrin-mediated dynamin-dependent endocytosis.MCP Endocytosis Is Dependent on Membrane Cholesterol, but Not Caveolae/Raft-Dependent Endocytosis ::: ResultsThe inhibitor M\u03b2CD depletes cholesterol from the cell plasma membrane, and cholesterol plays a critical role in caveolae/raft-dependent endocytosis (Huang et al., 2017).", [["cells", "ANATOMY", 46, 51], ["Membrane", "ANATOMY", 136, 144], ["cell plasma membrane", "ANATOMY", 262, 282], ["caveolae", "ANATOMY", 325, 333], ["raft", "ANATOMY", 334, 338], ["M\u03b2CD", "CHEMICAL", 227, 231], ["cholesterol", "CHEMICAL", 241, 252], ["cholesterol", "CHEMICAL", 288, 299], ["Cholesterol", "CHEMICAL", 145, 156], ["M\u03b2CD", "CHEMICAL", 227, 231], ["cholesterol", "CHEMICAL", 241, 252], ["cholesterol", "CHEMICAL", 288, 299], ["MCP", "GENE_OR_GENE_PRODUCT", 11, 14], ["SGIV", "GENE_OR_GENE_PRODUCT", 27, 31], ["host cells", "CELL", 41, 51], ["clathrin", "GENE_OR_GENE_PRODUCT", 56, 64], ["dynamin", "GENE_OR_GENE_PRODUCT", 74, 81], ["MCP", "GENE_OR_GENE_PRODUCT", 104, 107], ["Cholesterol", "SIMPLE_CHEMICAL", 145, 156], ["Raft", "GENE_OR_GENE_PRODUCT", 175, 179], ["M\u03b2CD", "SIMPLE_CHEMICAL", 227, 231], ["cholesterol", "SIMPLE_CHEMICAL", 241, 252], ["cell", "CELLULAR_COMPONENT", 262, 266], ["plasma membrane", "CELLULAR_COMPONENT", 267, 282], ["cholesterol", "SIMPLE_CHEMICAL", 288, 299], ["caveolae", "CELLULAR_COMPONENT", 325, 333], ["raft", "CELLULAR_COMPONENT", 334, 338], ["MCP", "PROTEIN", 11, 14], ["SGIV-infected host cells", "CELL_TYPE", 27, 51], ["clathrin", "PROTEIN", 56, 64], ["dynamin", "PROTEIN", 74, 81], ["infected host cells", "PROBLEM", 32, 51], ["clathrin", "TEST", 56, 64], ["dependent endocytosis", "PROBLEM", 82, 103], ["MCP Endocytosis", "PROBLEM", 104, 119], ["Membrane Cholesterol", "TEST", 136, 156], ["Dependent Endocytosis", "PROBLEM", 180, 201], ["cholesterol", "TEST", 241, 252], ["the cell plasma membrane", "TEST", 258, 282], ["dependent endocytosis", "PROBLEM", 339, 360], ["infected host cells", "OBSERVATION", 32, 51], ["dynamin", "OBSERVATION", 74, 81], ["dependent endocytosis", "OBSERVATION", 82, 103], ["Endocytosis", "OBSERVATION", 108, 119], ["Dependent", "OBSERVATION_MODIFIER", 123, 132], ["Raft", "OBSERVATION", 175, 179], ["Dependent Endocytosis", "OBSERVATION", 180, 201], ["cell plasma membrane", "OBSERVATION", 262, 282], ["raft", "ANATOMY_MODIFIER", 334, 338], ["dependent", "OBSERVATION_MODIFIER", 339, 348], ["endocytosis", "OBSERVATION", 349, 360]]], ["Therefore, we used M\u03b2CD to analyze the role of cholesterol in the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 113, 118], ["cholesterol", "CHEMICAL", 47, 58], ["cholesterol", "CHEMICAL", 47, 58], ["M\u03b2CD", "SIMPLE_CHEMICAL", 19, 23], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 79, 85], ["SGIV", "GENE_OR_GENE_PRODUCT", 99, 103], ["cells", "CELL", 113, 118], ["M\u03b2CD", "PROTEIN", 19, 23], ["Q5", "PROTEIN", 79, 81], ["MCP complex", "PROTEIN", 82, 93], ["SGIV-infected cells", "CELL_LINE", 99, 118], ["M\u03b2CD", "TREATMENT", 19, 23], ["infected cells", "PROBLEM", 104, 118], ["infected cells", "OBSERVATION", 104, 118]]], ["As expected, M\u03b2CD (2 mM) significantly reduced the fluorescent signal inside the SGIV-infected cells, and most fluorescence was observed outside the M\u03b2CD-treated SGIV-infected cell membranes (Figure 6A).", [["cells", "ANATOMY", 95, 100], ["cell membranes", "ANATOMY", 176, 190], ["M\u03b2CD", "CHEMICAL", 13, 17], ["M\u03b2CD", "CHEMICAL", 149, 153], ["M\u03b2CD", "CHEMICAL", 13, 17], ["M\u03b2CD", "CHEMICAL", 149, 153], ["M\u03b2CD", "SIMPLE_CHEMICAL", 13, 17], ["SGIV", "GENE_OR_GENE_PRODUCT", 81, 85], ["cells", "CELL", 95, 100], ["M\u03b2CD", "SIMPLE_CHEMICAL", 149, 153], ["SGIV", "SIMPLE_CHEMICAL", 162, 166], ["cell membranes", "CELL", 176, 190], ["SGIV-infected cells", "CELL_LINE", 81, 100], ["M\u03b2CD-treated SGIV", "CELL_LINE", 149, 166], ["the fluorescent signal", "TEST", 47, 69], ["infected cells", "PROBLEM", 86, 100], ["infected cell membranes", "PROBLEM", 167, 190], ["infected cells", "OBSERVATION", 86, 100], ["infected cell membranes", "OBSERVATION", 167, 190]]], ["The entry efficiency of the Q5-MCP complex also decreased significantly to 73.5% after treatment with 1 mM M\u03b2CD and to 63.0% with 2 mM M\u03b2CD (Figure 6B).MCP Endocytosis Is Dependent on Membrane Cholesterol, but Not Caveolae/Raft-Dependent Endocytosis ::: ResultsCaveolar budding is regulated by reversible phosphorylation.", [["Membrane", "ANATOMY", 184, 192], ["M\u03b2CD", "CHEMICAL", 107, 111], ["M\u03b2CD", "CHEMICAL", 107, 111], ["M\u03b2CD", "CHEMICAL", 135, 139], ["Cholesterol", "CHEMICAL", 193, 204], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 28, 34], ["M\u03b2CD", "SIMPLE_CHEMICAL", 107, 111], ["Membrane Cholesterol", "SIMPLE_CHEMICAL", 184, 204], ["Raft", "GENE_OR_GENE_PRODUCT", 223, 227], ["Q5", "PROTEIN", 28, 30], ["MCP complex", "PROTEIN", 31, 42], ["MCP", "PROTEIN", 152, 155], ["Raft", "PROTEIN", 223, 227], ["the Q5-MCP complex", "TEST", 24, 42], ["treatment", "TREATMENT", 87, 96], ["1 mM M\u03b2CD", "TREATMENT", 102, 111], ["MCP Endocytosis", "PROBLEM", 152, 167], ["Membrane Cholesterol", "TEST", 184, 204], ["entry", "OBSERVATION_MODIFIER", 4, 9], ["efficiency", "OBSERVATION_MODIFIER", 10, 20], ["decreased", "OBSERVATION_MODIFIER", 48, 57], ["Endocytosis", "OBSERVATION", 156, 167], ["Dependent", "OBSERVATION_MODIFIER", 171, 180], ["Raft", "OBSERVATION", 223, 227], ["Dependent Endocytosis", "OBSERVATION", 228, 249], ["Caveolar budding", "OBSERVATION", 261, 277], ["reversible phosphorylation", "OBSERVATION", 294, 320]]], ["Genistein is a tyrosine kinase inhibitor that blocks caveolae/raft-dependent endocytosis (Nabi, 2003).", [["caveolae", "ANATOMY", 53, 61], ["raft", "ANATOMY", 62, 66], ["Genistein", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 15, 23], ["Genistein", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 15, 23], ["Genistein", "SIMPLE_CHEMICAL", 0, 9], ["tyrosine", "AMINO_ACID", 15, 23], ["caveolae", "CELLULAR_COMPONENT", 53, 61], ["raft", "CELLULAR_COMPONENT", 62, 66], ["Genistein", "TREATMENT", 0, 9], ["a tyrosine kinase inhibitor", "TREATMENT", 13, 40], ["dependent endocytosis", "PROBLEM", 67, 88], ["dependent", "OBSERVATION_MODIFIER", 67, 76], ["endocytosis", "OBSERVATION", 77, 88]]], ["Therefore, we tested whether genistein blocks the entry of the Q5-MCP complex.", [["genistein", "CHEMICAL", 29, 38], ["genistein", "CHEMICAL", 29, 38], ["genistein", "SIMPLE_CHEMICAL", 29, 38], ["Q5-MCP complex", "GENE_OR_GENE_PRODUCT", 63, 77], ["Q5", "PROTEIN", 63, 65], ["MCP complex", "PROTEIN", 66, 77]]], ["As shown in Figure 7, even at a high concentration (100 \u03bcM), genistein did not block the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 136, 141], ["genistein", "CHEMICAL", 61, 70], ["genistein", "CHEMICAL", 61, 70], ["genistein", "SIMPLE_CHEMICAL", 61, 70], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 102, 108], ["SGIV", "GENE_OR_GENE_PRODUCT", 122, 126], ["cells", "CELL", 136, 141], ["Q5", "PROTEIN", 102, 104], ["MCP complex", "PROTEIN", 105, 116], ["SGIV-infected cells", "CELL_LINE", 122, 141], ["infected cells", "PROBLEM", 127, 141], ["infected cells", "OBSERVATION", 127, 141]]], ["Therefore, the entry of MCP into SGIV-infected host cells is dependent on cholesterol and membrane fluidity, but does not involve caveolae/raft-dependent endocytosis.MCP Endocytosis Is Independent of Macropinocytosis ::: ResultsAs well as clathrin- and caveolae/raft-dependent endocytosis, macropinocytosis has drawn increasing attention (Wang et al., 2014).", [["cells", "ANATOMY", 52, 57], ["membrane", "ANATOMY", 90, 98], ["caveolae", "ANATOMY", 130, 138], ["raft", "ANATOMY", 139, 143], ["raft", "ANATOMY", 262, 266], ["cholesterol", "CHEMICAL", 74, 85], ["cholesterol", "CHEMICAL", 74, 85], ["MCP", "GENE_OR_GENE_PRODUCT", 24, 27], ["SGIV", "GENE_OR_GENE_PRODUCT", 33, 37], ["host cells", "CELL", 47, 57], ["cholesterol", "SIMPLE_CHEMICAL", 74, 85], ["membrane fluidity", "CELLULAR_COMPONENT", 90, 107], ["caveolae", "CELLULAR_COMPONENT", 130, 138], ["raft", "CELLULAR_COMPONENT", 139, 143], ["MCP", "GENE_OR_GENE_PRODUCT", 166, 169], ["clathrin", "GENE_OR_GENE_PRODUCT", 239, 247], ["caveolae", "CELLULAR_COMPONENT", 253, 261], ["raft", "CELLULAR_COMPONENT", 262, 266], ["MCP", "PROTEIN", 24, 27], ["SGIV-infected host cells", "CELL_TYPE", 33, 57], ["MCP", "PROTEIN", 166, 169], ["clathrin", "PROTEIN", 239, 247], ["infected host cells", "PROBLEM", 38, 57], ["cholesterol and membrane fluidity", "TEST", 74, 107], ["dependent endocytosis", "PROBLEM", 144, 165], ["MCP Endocytosis", "PROBLEM", 166, 181], ["ResultsAs", "TEST", 221, 230], ["clathrin", "TEST", 239, 247], ["caveolae/raft", "TREATMENT", 253, 266], ["dependent endocytosis", "PROBLEM", 267, 288], ["macropinocytosis", "PROBLEM", 290, 306], ["infected", "OBSERVATION", 38, 46], ["host cells", "OBSERVATION", 47, 57], ["dependent", "OBSERVATION_MODIFIER", 61, 70], ["membrane fluidity", "OBSERVATION", 90, 107], ["raft", "OBSERVATION", 139, 143], ["dependent", "OBSERVATION_MODIFIER", 144, 153], ["endocytosis", "OBSERVATION", 154, 165], ["Endocytosis", "OBSERVATION", 170, 181], ["Macropinocytosis", "OBSERVATION", 200, 216], ["caveolae", "ANATOMY", 253, 261], ["dependent endocytosis", "OBSERVATION", 267, 288]]], ["Macropinocytosis inhibitors, including the Na+/H+ exchanger inhibitor EIPA, the PAK1 inhibitor IPA-3, the myosin II inhibitor ML-7, the Rac1 GTPase inhibitor NSC23766, and the protein kinase C (PKC) inhibitor rottlerin, were used to analyze the role of macropinocytosis in the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 324, 329], ["Na+", "CHEMICAL", 43, 46], ["EIPA", "CHEMICAL", 70, 74], ["IPA", "CHEMICAL", 95, 98], ["NSC23766", "CHEMICAL", 158, 166], ["rottlerin", "CHEMICAL", 209, 218], ["Na+", "CHEMICAL", 43, 46], ["H+", "CHEMICAL", 47, 49], ["EIPA", "CHEMICAL", 70, 74], ["IPA-3", "CHEMICAL", 95, 100], ["ML-7", "CHEMICAL", 126, 130], ["rottlerin", "CHEMICAL", 209, 218], ["Na+/H+ exchanger", "GENE_OR_GENE_PRODUCT", 43, 59], ["EIPA", "SIMPLE_CHEMICAL", 70, 74], ["PAK1", "GENE_OR_GENE_PRODUCT", 80, 84], ["IPA-3", "GENE_OR_GENE_PRODUCT", 95, 100], ["myosin II", "GENE_OR_GENE_PRODUCT", 106, 115], ["ML-7", "GENE_OR_GENE_PRODUCT", 126, 130], ["Rac1", "GENE_OR_GENE_PRODUCT", 136, 140], ["NSC23766", "SIMPLE_CHEMICAL", 158, 166], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 176, 192], ["PKC", "GENE_OR_GENE_PRODUCT", 194, 197], ["rottlerin", "SIMPLE_CHEMICAL", 209, 218], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 290, 296], ["SGIV", "GENE_OR_GENE_PRODUCT", 310, 314], ["cells", "CELL", 324, 329], ["Na+/H+ exchanger", "PROTEIN", 43, 59], ["PAK1", "PROTEIN", 80, 84], ["myosin II", "PROTEIN", 106, 115], ["Rac1 GTPase", "PROTEIN", 136, 147], ["protein kinase C", "PROTEIN", 176, 192], ["PKC", "PROTEIN", 194, 197], ["Q5", "PROTEIN", 290, 292], ["MCP complex", "PROTEIN", 293, 304], ["SGIV-infected cells", "CELL_LINE", 310, 329], ["Macropinocytosis inhibitors", "PROBLEM", 0, 27], ["the Na+", "TEST", 39, 46], ["exchanger inhibitor EIPA", "TREATMENT", 50, 74], ["the PAK1 inhibitor IPA", "TEST", 76, 98], ["the myosin II inhibitor ML", "TREATMENT", 102, 128], ["the Rac1 GTPase inhibitor", "TEST", 132, 157], ["the protein kinase C", "TEST", 172, 192], ["PKC) inhibitor rottlerin", "TREATMENT", 194, 218], ["macropinocytosis", "PROBLEM", 253, 269], ["infected cells", "PROBLEM", 315, 329], ["macropinocytosis", "OBSERVATION", 253, 269], ["infected cells", "OBSERVATION", 315, 329]]], ["As shown in Figure 8, even at high concentrations (40 \u03bcM EIPA, 20 \u03bcM IPA-3, 20 \u03bcM ML-7, 200 \u03bcM NSC23766, and 1 \u03bcM rottlerin), the macropinocytosis inhibitors did not block the entry of the Q5-MCP complex into SGIV-infected cells (Figure 8).", [["cells", "ANATOMY", 223, 228], ["EIPA", "CHEMICAL", 57, 61], ["IPA", "CHEMICAL", 69, 72], ["NSC23766", "CHEMICAL", 95, 103], ["rottlerin", "CHEMICAL", 114, 123], ["EIPA", "CHEMICAL", 57, 61], ["IPA-3", "CHEMICAL", 69, 74], ["ML-7", "CHEMICAL", 82, 86], ["NSC23766", "CHEMICAL", 95, 103], ["rottlerin", "CHEMICAL", 114, 123], ["EIPA", "SIMPLE_CHEMICAL", 57, 61], ["NSC23766", "SIMPLE_CHEMICAL", 95, 103], ["rottlerin", "SIMPLE_CHEMICAL", 114, 123], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 189, 195], ["SGIV", "GENE_OR_GENE_PRODUCT", 209, 213], ["cells", "CELL", 223, 228], ["Q5", "PROTEIN", 189, 191], ["MCP complex", "PROTEIN", 192, 203], ["SGIV-infected cells", "CELL_LINE", 209, 228], ["EIPA", "TEST", 57, 61], ["IPA", "TEST", 69, 72], ["rottlerin", "TREATMENT", 114, 123], ["the macropinocytosis inhibitors", "PROBLEM", 126, 157], ["infected cells", "PROBLEM", 214, 228], ["infected cells", "OBSERVATION", 214, 228]]], ["Therefore, MCP enters SGIV-infected host cells independently of macropinocytosis.MCP Endocytosis Is pH Dependent ::: ResultsTo assess whether low pH interferes with the entry of the Q5-MCP complex, SGIV-infected cells were pretreated with various concentrations of chloroquine (CQ) or ammonia chloride (NH4Cl), which act as inhibitors of endosomal acidification (Wang et al., 2014).", [["cells", "ANATOMY", 41, 46], ["cells", "ANATOMY", 212, 217], ["endosomal", "ANATOMY", 338, 347], ["chloroquine", "CHEMICAL", 265, 276], ["CQ", "CHEMICAL", 278, 280], ["ammonia chloride", "CHEMICAL", 285, 301], ["NH4Cl", "CHEMICAL", 303, 308], ["chloroquine", "CHEMICAL", 265, 276], ["CQ", "CHEMICAL", 278, 280], ["ammonia chloride", "CHEMICAL", 285, 301], ["NH4Cl", "CHEMICAL", 303, 308], ["MCP", "GENE_OR_GENE_PRODUCT", 11, 14], ["SGIV", "GENE_OR_GENE_PRODUCT", 22, 26], ["host cells", "CELL", 36, 46], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 182, 188], ["SGIV", "GENE_OR_GENE_PRODUCT", 198, 202], ["cells", "CELL", 212, 217], ["chloroquine", "SIMPLE_CHEMICAL", 265, 276], ["CQ", "SIMPLE_CHEMICAL", 278, 280], ["ammonia chloride", "SIMPLE_CHEMICAL", 285, 301], ["NH4Cl", "SIMPLE_CHEMICAL", 303, 308], ["endosomal", "CELLULAR_COMPONENT", 338, 347], ["MCP", "PROTEIN", 11, 14], ["SGIV-infected host cells", "CELL_TYPE", 22, 46], ["Q5", "PROTEIN", 182, 184], ["MCP complex", "PROTEIN", 185, 196], ["SGIV-infected cells", "CELL_LINE", 198, 217], ["infected host cells", "PROBLEM", 27, 46], ["macropinocytosis", "PROBLEM", 64, 80], ["MCP Endocytosis", "PROBLEM", 81, 96], ["pH Dependent", "PROBLEM", 100, 112], ["low pH", "PROBLEM", 142, 148], ["SGIV", "PROBLEM", 198, 202], ["infected cells", "PROBLEM", 203, 217], ["chloroquine (CQ", "TREATMENT", 265, 280], ["ammonia chloride (NH4Cl)", "TREATMENT", 285, 309], ["endosomal acidification", "PROBLEM", 338, 361], ["infected host cells", "OBSERVATION", 27, 46], ["macropinocytosis", "OBSERVATION", 64, 80], ["Endocytosis", "OBSERVATION", 85, 96], ["pH Dependent", "OBSERVATION_MODIFIER", 100, 112], ["infected cells", "OBSERVATION", 203, 217]]], ["As shown in Figure 9A, both CQ and NH4Cl reduced the internalization of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 110, 115], ["CQ", "CHEMICAL", 28, 30], ["NH4Cl", "CHEMICAL", 35, 40], ["CQ", "CHEMICAL", 28, 30], ["NH4Cl", "CHEMICAL", 35, 40], ["CQ", "SIMPLE_CHEMICAL", 28, 30], ["NH4Cl", "SIMPLE_CHEMICAL", 35, 40], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 76, 82], ["SGIV", "GENE_OR_GENE_PRODUCT", 96, 100], ["cells", "CELL", 110, 115], ["Q5", "PROTEIN", 76, 78], ["MCP complex", "PROTEIN", 79, 90], ["SGIV-infected cells", "CELL_LINE", 96, 115], ["NH4Cl", "TREATMENT", 35, 40], ["infected cells", "PROBLEM", 101, 115], ["infected cells", "OBSERVATION", 101, 115]]], ["The entry efficiency was greatly reduced in the presence of CQ (to 65.4% with 15 \u03bcM, to 60.3% with 20 \u03bcM) (Figure 9B) or NH4Cl (to 30.8% with 200 mM NH4Cl, to 23.5% with 400 mM NH4Cl) (Figure 9C).", [["CQ", "CHEMICAL", 60, 62], ["NH4Cl", "CHEMICAL", 121, 126], ["NH4Cl", "CHEMICAL", 149, 154], ["NH4Cl", "CHEMICAL", 177, 182], ["CQ", "CHEMICAL", 60, 62], ["NH4Cl", "CHEMICAL", 121, 126], ["NH4Cl", "CHEMICAL", 149, 154], ["NH4Cl", "CHEMICAL", 177, 182], ["CQ", "SIMPLE_CHEMICAL", 60, 62], ["NH4Cl", "SIMPLE_CHEMICAL", 121, 126], ["NH4Cl", "SIMPLE_CHEMICAL", 149, 154], ["NH4Cl", "SIMPLE_CHEMICAL", 177, 182], ["CQ", "TEST", 60, 62], ["Figure 9B", "TEST", 107, 116], ["NH4Cl", "TEST", 121, 126], ["NH4Cl", "TEST", 149, 154], ["NH4Cl", "TEST", 177, 182], ["entry efficiency", "OBSERVATION", 4, 20], ["reduced", "OBSERVATION_MODIFIER", 33, 40]]], ["Therefore, MCP endocytosis during SGIV infection is dependent upon a low endosomal pH.MCP Endocytosis Is Dependent on Cytoskeletal Actin Filaments ::: ResultsTo determine the role of actin filaments in MCP endocytosis, the chemical inhibitor cytoD was used to inhibit the elongation of actin filaments (Wang et al., 2014).", [["endosomal", "ANATOMY", 73, 82], ["filaments", "ANATOMY", 189, 198], ["filaments", "ANATOMY", 292, 301], ["infection", "DISEASE", 39, 48], ["MCP", "GENE_OR_GENE_PRODUCT", 11, 14], ["SGIV", "GENE_OR_GENE_PRODUCT", 34, 38], ["actin", "GENE_OR_GENE_PRODUCT", 183, 188], ["MCP", "GENE_OR_GENE_PRODUCT", 202, 205], ["cytoD", "SIMPLE_CHEMICAL", 242, 247], ["actin", "GENE_OR_GENE_PRODUCT", 286, 291], ["MCP", "PROTEIN", 11, 14], ["actin", "PROTEIN", 183, 188], ["MCP", "PROTEIN", 202, 205], ["cytoD", "PROTEIN", 242, 247], ["actin", "PROTEIN", 286, 291], ["SGIV", "SPECIES", 34, 38], ["MCP endocytosis", "PROBLEM", 11, 26], ["SGIV infection", "PROBLEM", 34, 48], ["a low endosomal pH.MCP Endocytosis", "PROBLEM", 67, 101], ["MCP endocytosis", "TREATMENT", 202, 217], ["the chemical inhibitor cytoD", "TREATMENT", 219, 247], ["infection", "OBSERVATION", 39, 48], ["Cytoskeletal Actin Filaments", "OBSERVATION", 118, 146]]], ["As shown in Figure 10, the disruption of the actin dynamics by cytoD significantly reduced the fluorescent signals inside the SGIV-infected cells.", [["cells", "ANATOMY", 140, 145], ["actin", "GENE_OR_GENE_PRODUCT", 45, 50], ["cytoD", "GENE_OR_GENE_PRODUCT", 63, 68], ["SGIV", "GENE_OR_GENE_PRODUCT", 126, 130], ["cells", "CELL", 140, 145], ["actin", "PROTEIN", 45, 50], ["cytoD", "PROTEIN", 63, 68], ["SGIV-infected cells", "CELL_LINE", 126, 145], ["the fluorescent signals", "TEST", 91, 114], ["infected cells", "PROBLEM", 131, 145], ["infected cells", "OBSERVATION", 131, 145]]], ["The entry efficiency also decreased significantly to 82.9% with 3 \u03bcM cytoD and 44.9% with 6 \u03bcM cytoD.", [["The entry efficiency", "TEST", 0, 20], ["cytoD", "TEST", 69, 74], ["entry", "OBSERVATION_MODIFIER", 4, 9], ["efficiency", "OBSERVATION_MODIFIER", 10, 20], ["decreased", "OBSERVATION_MODIFIER", 26, 35]]], ["Therefore, MCP endocytosis into SGIV-infected cells was inhibited by the inhibitor cytoD, indicating that MCP endocytosis during SGIV infection is dependent on cytoskeletal actin filaments.DiscussionDuring viral infection, modifications appear in the host cell membranes and are transported by the vesicular transport system of the host cell (Wickner and Schekman, 2005; Yu et al., 2019a).", [["cells", "ANATOMY", 46, 51], ["cytoskeletal", "ANATOMY", 160, 172], ["filaments", "ANATOMY", 179, 188], ["cell membranes", "ANATOMY", 256, 270], ["vesicular", "ANATOMY", 298, 307], ["cell", "ANATOMY", 337, 341], ["infection", "DISEASE", 134, 143], ["viral infection", "DISEASE", 206, 221], ["MCP", "GENE_OR_GENE_PRODUCT", 11, 14], ["SGIV", "GENE_OR_GENE_PRODUCT", 32, 36], ["cells", "CELL", 46, 51], ["cytoD", "GENE_OR_GENE_PRODUCT", 83, 88], ["MCP", "GENE_OR_GENE_PRODUCT", 106, 109], ["SGIV", "GENE_OR_GENE_PRODUCT", 129, 133], ["cytoskeletal", "CELLULAR_COMPONENT", 160, 172], ["actin", "GENE_OR_GENE_PRODUCT", 173, 178], ["filaments", "CELLULAR_COMPONENT", 179, 188], ["cell membranes", "CELLULAR_COMPONENT", 256, 270], ["host cell", "CELL", 332, 341], ["MCP", "PROTEIN", 11, 14], ["SGIV-infected cells", "CELL_LINE", 32, 51], ["cytoD", "PROTEIN", 83, 88], ["MCP", "PROTEIN", 106, 109], ["SGIV", "SPECIES", 129, 133], ["MCP endocytosis into SGIV", "PROBLEM", 11, 36], ["infected cells", "PROBLEM", 37, 51], ["the inhibitor cytoD", "TEST", 69, 88], ["MCP endocytosis", "PROBLEM", 106, 121], ["SGIV infection", "PROBLEM", 129, 143], ["viral infection", "PROBLEM", 206, 221], ["infected cells", "OBSERVATION", 37, 51], ["MCP endocytosis", "OBSERVATION", 106, 121], ["infection", "OBSERVATION", 134, 143], ["cytoskeletal actin filaments", "OBSERVATION", 160, 188], ["viral", "OBSERVATION_MODIFIER", 206, 211], ["infection", "OBSERVATION", 212, 221], ["host cell membranes", "OBSERVATION", 251, 270], ["host cell", "OBSERVATION", 332, 341]]], ["These modifications are associated with viral replication and host cell immunity and play critical roles in various physiological functions (Ab\u00f3s et al., 2015; Chinchar and Duffus, 2019).", [["cell", "ANATOMY", 67, 71], ["host cell", "CELL", 62, 71], ["viral replication", "TREATMENT", 40, 57], ["host cell immunity", "TREATMENT", 62, 80], ["associated with", "UNCERTAINTY", 24, 39], ["viral replication", "OBSERVATION", 40, 57], ["host cell immunity", "OBSERVATION", 62, 80]]], ["Studying the entry pathways of modifications is important in understanding viral pathogenesis and the development of diagnostic tools and therapeutic approaches to the very early critical steps of viral infection.DiscussionBecause aptamers specifically recognize and bind their target molecules, they are excellent molecular probes for various biological applications, such as pathogen detection, disease diagnosis, and viral pathogenesis research (Sun and Zu, 2015; Kaur et al., 2018).", [["viral infection", "DISEASE", 197, 212], ["viral pathogenesis", "PROBLEM", 75, 93], ["diagnostic tools", "TEST", 117, 133], ["therapeutic approaches", "TREATMENT", 138, 160], ["viral infection", "PROBLEM", 197, 212], ["viral", "OBSERVATION_MODIFIER", 197, 202], ["infection", "OBSERVATION", 203, 212]]], ["Aptamer Q5 recognizes SGIV-infected cells with high specificity and affinity, and its target protein on the target cell membrane is SGIV MCP.", [["cells", "ANATOMY", 36, 41], ["cell membrane", "ANATOMY", 115, 128], ["SGIV", "GENE_OR_GENE_PRODUCT", 22, 26], ["cells", "CELL", 36, 41], ["cell membrane", "CELLULAR_COMPONENT", 115, 128], ["SGIV MCP", "GENE_OR_GENE_PRODUCT", 132, 140], ["Q5", "PROTEIN", 8, 10], ["SGIV-infected cells", "CELL_LINE", 22, 41], ["target protein", "PROTEIN", 86, 100], ["SGIV MCP", "PROTEIN", 132, 140], ["infected cells", "PROBLEM", 27, 41], ["infected cells", "OBSERVATION", 27, 41], ["cell membrane", "OBSERVATION", 115, 128]]], ["The specific interaction between Q5 and MCP activates cellular signaling pathways, which results in the active internalization of the Q5-MCP complex via endocytotic mechanisms (Yu et al., 2019a).", [["cellular", "ANATOMY", 54, 62], ["Q5", "GENE_OR_GENE_PRODUCT", 33, 35], ["MCP", "GENE_OR_GENE_PRODUCT", 40, 43], ["cellular", "CELL", 54, 62], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 134, 140], ["Q5", "PROTEIN", 33, 35], ["MCP", "PROTEIN", 40, 43], ["Q5", "PROTEIN", 134, 136], ["MCP complex", "PROTEIN", 137, 148], ["active", "OBSERVATION_MODIFIER", 104, 110]]], ["Therefore, aptamer Q5 can be used as a specific probe to investigate the trafficking mechanism and endocytotic pathway of MCP in host cells during SGIV infection.", [["cells", "ANATOMY", 134, 139], ["SGIV", "ANATOMY", 147, 151], ["infection", "DISEASE", 152, 161], ["MCP", "GENE_OR_GENE_PRODUCT", 122, 125], ["host cells", "CELL", 129, 139], ["SGIV", "CANCER", 147, 151], ["MCP", "PROTEIN", 122, 125], ["host cells", "CELL_TYPE", 129, 139], ["SGIV", "SPECIES", 147, 151], ["aptamer", "TREATMENT", 11, 18], ["a specific probe", "TREATMENT", 37, 53], ["MCP in host cells", "PROBLEM", 122, 139], ["SGIV infection", "PROBLEM", 147, 161], ["host cells", "OBSERVATION", 129, 139], ["infection", "OBSERVATION", 152, 161]]], ["As demonstrated with Cy5-Q5, the entry of MCP into SGIV-infected cells was rapidly initiated at a temperature of 28\u00b0C and was followed by a time-dependent increase in the fluorescent signal inside the cells.", [["cells", "ANATOMY", 65, 70], ["cells", "ANATOMY", 201, 206], ["Cy5-Q5", "CHEMICAL", 21, 27], ["Cy5-Q5", "SIMPLE_CHEMICAL", 21, 27], ["MCP", "GENE_OR_GENE_PRODUCT", 42, 45], ["SGIV", "GENE_OR_GENE_PRODUCT", 51, 55], ["cells", "CELL", 65, 70], ["C", "GENE_OR_GENE_PRODUCT", 116, 117], ["cells", "CELL", 201, 206], ["MCP", "PROTEIN", 42, 45], ["SGIV-infected cells", "CELL_LINE", 51, 70], ["Cy5", "TEST", 21, 24], ["infected cells", "PROBLEM", 56, 70], ["a temperature", "TEST", 96, 109], ["infected cells", "OBSERVATION", 56, 70], ["dependent", "OBSERVATION_MODIFIER", 145, 154], ["increase", "OBSERVATION_MODIFIER", 155, 163], ["cells", "ANATOMY", 201, 206]]], ["This signal accumulated around the nucleus.", [["nucleus", "ANATOMY", 35, 42], ["nucleus", "CELLULAR_COMPONENT", 35, 42], ["accumulated", "OBSERVATION_MODIFIER", 12, 23], ["nucleus", "ANATOMY_MODIFIER", 35, 42]]], ["The fluorescence intensity reached its maximum within 120 min, indicating that the entry of all M in the SGIV-infected cell membrane was completed within 120 min.DiscussionThe endocytotic pathways predominantly include clathrin-mediated endocytosis, caveolae/raft-dependent endocytosis, macropinocytosis, non-clathrin\u2013caveolae/raft-dependent endocytosis, and some other still poorly characterized mechanisms (Huang et al., 2017).", [["cell membrane", "ANATOMY", 119, 132], ["caveolae", "ANATOMY", 250, 258], ["raft", "ANATOMY", 259, 263], ["raft", "ANATOMY", 327, 331], ["SGIV", "GENE_OR_GENE_PRODUCT", 105, 109], ["cell membrane", "MULTI-TISSUE_STRUCTURE", 119, 132], ["clathrin", "GENE_OR_GENE_PRODUCT", 219, 227], ["caveolae", "CELLULAR_COMPONENT", 250, 258], ["raft", "CELLULAR_COMPONENT", 259, 263], ["raft", "CELLULAR_COMPONENT", 327, 331], ["SGIV", "PROTEIN", 105, 109], ["clathrin", "PROTEIN", 219, 227], ["The fluorescence intensity", "TEST", 0, 26], ["infected cell membrane", "TREATMENT", 110, 132], ["clathrin-mediated endocytosis", "PROBLEM", 219, 248], ["caveolae/raft", "TEST", 250, 263], ["dependent endocytosis", "PROBLEM", 264, 285], ["macropinocytosis", "PROBLEM", 287, 303], ["non-clathrin\u2013caveolae/raft", "PROBLEM", 305, 331], ["dependent endocytosis", "PROBLEM", 332, 353], ["intensity", "OBSERVATION_MODIFIER", 17, 26], ["infected cell membrane", "OBSERVATION", 110, 132], ["raft", "ANATOMY_MODIFIER", 259, 263], ["dependent", "OBSERVATION_MODIFIER", 264, 273], ["endocytosis", "OBSERVATION", 274, 285], ["macropinocytosis", "OBSERVATION_MODIFIER", 287, 303], ["raft", "OBSERVATION_MODIFIER", 327, 331], ["dependent", "OBSERVATION_MODIFIER", 332, 341], ["endocytosis", "OBSERVATION", 342, 353], ["poorly characterized", "OBSERVATION_MODIFIER", 376, 396]]], ["Clathrin-mediated endocytosis is the classical endocytotic mechanism and also the best-characterized pathway.", [["Clathrin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Clathrin", "PROTEIN", 0, 8], ["endocytosis", "OBSERVATION", 18, 29]]], ["Some viruses are reported to invade their host cells via clathrin-mediated endocytosis, such as Betanodavirus (Huang et al., 2017), SGIV (Wang et al., 2014), and African swine fever virus (Hernaez and Alonso, 2010).", [["cells", "ANATOMY", 47, 52], ["swine fever", "DISEASE", 170, 181], ["cells", "CELL", 47, 52], ["clathrin", "GENE_OR_GENE_PRODUCT", 57, 65], ["African swine fever virus", "ORGANISM", 162, 187], ["host cells", "CELL_TYPE", 42, 52], ["clathrin", "PROTEIN", 57, 65], ["swine fever virus", "SPECIES", 170, 187], ["African swine fever virus", "SPECIES", 162, 187], ["Some viruses", "PROBLEM", 0, 12], ["mediated endocytosis", "PROBLEM", 66, 86], ["African swine fever virus", "PROBLEM", 162, 187], ["viruses", "OBSERVATION", 5, 12], ["host cells", "OBSERVATION", 42, 52], ["endocytosis", "OBSERVATION", 75, 86]]], ["During clathrin-mediated endocytosis, clathrin is assembled on the plasma membrane to form clathrin-coated pits (CCPs), which invaginate to form clathrin-coated vesicles containing the internalized material.", [["plasma membrane", "ANATOMY", 67, 82], ["CCPs", "ANATOMY", 113, 117], ["vesicles", "ANATOMY", 161, 169], ["clathrin", "GENE_OR_GENE_PRODUCT", 7, 15], ["clathrin", "GENE_OR_GENE_PRODUCT", 38, 46], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["clathrin-coated pits", "SIMPLE_CHEMICAL", 91, 111], ["clathrin", "GENE_OR_GENE_PRODUCT", 145, 153], ["vesicles", "CELLULAR_COMPONENT", 161, 169], ["clathrin", "PROTEIN", 7, 15], ["clathrin", "PROTEIN", 38, 46], ["clathrin", "PROTEIN", 91, 99], ["CCPs", "PROTEIN", 113, 117], ["clathrin", "PROTEIN", 145, 153], ["clathrin", "TREATMENT", 38, 46], ["the plasma membrane", "TREATMENT", 63, 82], ["clathrin-coated pits (CCPs", "TREATMENT", 91, 117], ["endocytosis", "OBSERVATION", 25, 36]]], ["CPZ is a cationic amphiphilic agent that causes the misassembly of CCPs, so it was used to determine the role of the clathrin-mediated endocytosis pathway in the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 209, 214], ["CPZ", "CHEMICAL", 0, 3], ["CPZ", "CHEMICAL", 0, 3], ["CPZ", "SIMPLE_CHEMICAL", 0, 3], ["clathrin", "GENE_OR_GENE_PRODUCT", 117, 125], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 175, 181], ["SGIV", "GENE_OR_GENE_PRODUCT", 195, 199], ["cells", "CELL", 209, 214], ["CCPs", "PROTEIN", 67, 71], ["clathrin", "PROTEIN", 117, 125], ["Q5", "PROTEIN", 175, 177], ["MCP complex", "PROTEIN", 178, 189], ["SGIV-infected cells", "CELL_LINE", 195, 214], ["CPZ", "TREATMENT", 0, 3], ["a cationic amphiphilic agent", "TREATMENT", 7, 35], ["infected cells", "PROBLEM", 200, 214], ["cationic amphiphilic agent", "OBSERVATION", 9, 35], ["infected cells", "OBSERVATION", 200, 214]]], ["In this study, the entry efficiency of the Q5-MCP complex decreased significantly and dose-dependently after CPZ treatment.", [["CPZ", "CHEMICAL", 109, 112], ["CPZ", "CHEMICAL", 109, 112], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 43, 49], ["CPZ", "SIMPLE_CHEMICAL", 109, 112], ["Q5", "PROTEIN", 43, 45], ["MCP complex", "PROTEIN", 46, 57], ["this study", "TEST", 3, 13], ["the Q5-MCP complex", "TREATMENT", 39, 57], ["CPZ treatment", "TREATMENT", 109, 122], ["complex", "OBSERVATION_MODIFIER", 50, 57], ["decreased", "OBSERVATION", 58, 67]]], ["Therefore, we conclude that MCP endocytosis during SGIV infection is dependent on clathrin-mediated endocytosis.DiscussionAnother well-characterized endocytotic pathway is caveolae/raft-dependent endocytosis, which is an alternative to clathrin-mediated endocytosis.", [["caveolae", "ANATOMY", 172, 180], ["raft", "ANATOMY", 181, 185], ["infection", "DISEASE", 56, 65], ["MCP", "GENE_OR_GENE_PRODUCT", 28, 31], ["SGIV", "GENE_OR_GENE_PRODUCT", 51, 55], ["clathrin", "GENE_OR_GENE_PRODUCT", 82, 90], ["caveolae", "CELLULAR_COMPONENT", 172, 180], ["raft", "CELLULAR_COMPONENT", 181, 185], ["clathrin", "GENE_OR_GENE_PRODUCT", 236, 244], ["MCP", "PROTEIN", 28, 31], ["clathrin", "PROTEIN", 82, 90], ["clathrin", "PROTEIN", 236, 244], ["SGIV", "SPECIES", 51, 55], ["MCP endocytosis", "PROBLEM", 28, 43], ["SGIV infection", "PROBLEM", 51, 65], ["mediated endocytosis", "PROBLEM", 91, 111], ["dependent endocytosis", "PROBLEM", 186, 207], ["mediated endocytosis", "PROBLEM", 245, 265], ["infection", "OBSERVATION", 56, 65], ["dependent endocytosis", "OBSERVATION", 186, 207], ["endocytosis", "OBSERVATION", 254, 265]]], ["In this mechanism, the extracellular substance first binds to the specialized membrane domain called the \u201ccaveola,\u201d which is composed of caveolin and associated with high levels of cholesterol.", [["extracellular", "ANATOMY", 23, 36], ["membrane", "ANATOMY", 78, 86], ["cholesterol", "CHEMICAL", 181, 192], ["cholesterol", "CHEMICAL", 181, 192], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 36], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["caveola", "GENE_OR_GENE_PRODUCT", 106, 113], ["caveolin", "GENE_OR_GENE_PRODUCT", 137, 145], ["cholesterol", "SIMPLE_CHEMICAL", 181, 192], ["membrane domain", "PROTEIN", 78, 93], ["caveolin", "PROTEIN", 137, 145], ["high levels of cholesterol", "PROBLEM", 166, 192]]], ["The signal cascade caused by the activation of tyrosine kinases ultimately results in the slow but efficient internalization of the substance (Doherty and McMahon, 2009).", [["tyrosine", "CHEMICAL", 47, 55], ["tyrosine", "CHEMICAL", 47, 55], ["tyrosine", "AMINO_ACID", 47, 55], ["tyrosine kinases", "PROTEIN", 47, 63], ["The signal cascade", "PROBLEM", 0, 18], ["the activation of tyrosine kinases", "PROBLEM", 29, 63], ["tyrosine kinases", "OBSERVATION", 47, 63], ["slow", "OBSERVATION_MODIFIER", 90, 94]]], ["Some viruses, such as the tiger frog virus (Guo et al., 2011), infectious spleen and kidney necrosis virus (ISKNV) (Guo et al., 2012), and coronaviruses (Nomura et al., 2004), invade cells via caveola-dependent endocytosis but not clathrin-mediated endocytosis.", [["spleen", "ANATOMY", 74, 80], ["kidney", "ANATOMY", 85, 91], ["cells", "ANATOMY", 183, 188], ["infectious spleen and kidney necrosis", "DISEASE", 63, 100], ["tiger", "ORGANISM", 26, 31], ["frog virus", "ORGANISM", 32, 42], ["spleen", "ORGAN", 74, 80], ["kidney", "ORGAN", 85, 91], ["necrosis virus", "ORGANISM", 92, 106], ["cells", "CELL", 183, 188], ["caveola", "SIMPLE_CHEMICAL", 193, 200], ["clathrin", "GENE_OR_GENE_PRODUCT", 231, 239], ["clathrin", "PROTEIN", 231, 239], ["tiger frog virus", "SPECIES", 26, 42], ["kidney necrosis virus", "SPECIES", 85, 106], ["tiger frog virus", "SPECIES", 26, 42], ["kidney necrosis virus", "SPECIES", 85, 106], ["ISKNV", "SPECIES", 108, 113], ["Some viruses", "PROBLEM", 0, 12], ["the tiger frog virus", "PROBLEM", 22, 42], ["infectious spleen", "PROBLEM", 63, 80], ["kidney necrosis virus", "PROBLEM", 85, 106], ["Guo et al.", "TEST", 116, 126], ["coronaviruses", "PROBLEM", 139, 152], ["invade cells", "PROBLEM", 176, 188], ["caveola", "TEST", 193, 200], ["dependent endocytosis", "PROBLEM", 201, 222], ["clathrin", "PROBLEM", 231, 239], ["mediated endocytosis", "PROBLEM", 240, 260], ["viruses", "OBSERVATION", 5, 12], ["infectious", "OBSERVATION_MODIFIER", 63, 73], ["spleen", "ANATOMY", 74, 80], ["kidney", "ANATOMY", 85, 91], ["necrosis", "OBSERVATION", 92, 100], ["dependent endocytosis", "OBSERVATION", 201, 222], ["endocytosis", "OBSERVATION", 249, 260]]], ["As reported previously, cholesterol plays a critical role in caveolae/raft-dependent endocytosis (Huang et al., 2017).", [["caveolae", "ANATOMY", 61, 69], ["raft", "ANATOMY", 70, 74], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "SIMPLE_CHEMICAL", 24, 35], ["caveolae", "CELLULAR_COMPONENT", 61, 69], ["raft", "CELLULAR_COMPONENT", 70, 74], ["dependent endocytosis", "PROBLEM", 75, 96], ["raft", "ANATOMY_MODIFIER", 70, 74], ["dependent", "OBSERVATION_MODIFIER", 75, 84], ["endocytosis", "OBSERVATION", 85, 96]]], ["In this study, M\u03b2CD was used to deplete cholesterol from the plasma membrane of the host cell.", [["plasma membrane", "ANATOMY", 61, 76], ["cell", "ANATOMY", 89, 93], ["M\u03b2CD", "CHEMICAL", 15, 19], ["cholesterol", "CHEMICAL", 40, 51], ["M\u03b2CD", "CHEMICAL", 15, 19], ["cholesterol", "CHEMICAL", 40, 51], ["M\u03b2CD", "SIMPLE_CHEMICAL", 15, 19], ["cholesterol", "SIMPLE_CHEMICAL", 40, 51], ["plasma membrane", "CELLULAR_COMPONENT", 61, 76], ["host cell", "CELL", 84, 93], ["M\u03b2CD", "PROTEIN", 15, 19], ["host cell", "CELL_TYPE", 84, 93], ["this study", "TEST", 3, 13], ["M\u03b2CD", "TREATMENT", 15, 19], ["plasma membrane", "OBSERVATION", 61, 76], ["host cell", "OBSERVATION", 84, 93]]], ["As expected, M\u03b2CD significantly reduced the cholesterol during the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 114, 119], ["M\u03b2CD", "CHEMICAL", 13, 17], ["cholesterol", "CHEMICAL", 44, 55], ["M\u03b2CD", "CHEMICAL", 13, 17], ["cholesterol", "CHEMICAL", 44, 55], ["M\u03b2CD", "SIMPLE_CHEMICAL", 13, 17], ["cholesterol", "SIMPLE_CHEMICAL", 44, 55], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 80, 86], ["SGIV", "GENE_OR_GENE_PRODUCT", 100, 104], ["cells", "CELL", 114, 119], ["Q5", "PROTEIN", 80, 82], ["MCP complex", "PROTEIN", 83, 94], ["SGIV-infected cells", "CELL_LINE", 100, 119], ["the cholesterol", "TEST", 40, 55], ["infected cells", "PROBLEM", 105, 119], ["infected cells", "OBSERVATION", 105, 119]]], ["However, the effect was insufficient to conclude that the internalization of the Q5-MCP complex is dependent upon caveolae-mediated endocytosis.", [["caveolae", "ANATOMY", 114, 122], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 81, 87], ["caveolae", "CELLULAR_COMPONENT", 114, 122], ["Q5", "PROTEIN", 81, 83], ["MCP complex", "PROTEIN", 84, 95], ["mediated endocytosis", "PROBLEM", 123, 143], ["endocytosis", "OBSERVATION", 132, 143]]], ["According to the latest reports, cholesterol is also an essential factor in clathrin-mediated endocytosis because it regulates the fluidity of the plasma membrane, which may affect the formation of clathrin-coated vesicles (Huang et al., 2017).", [["plasma membrane", "ANATOMY", 147, 162], ["vesicles", "ANATOMY", 214, 222], ["cholesterol", "CHEMICAL", 33, 44], ["cholesterol", "CHEMICAL", 33, 44], ["cholesterol", "SIMPLE_CHEMICAL", 33, 44], ["clathrin", "GENE_OR_GENE_PRODUCT", 76, 84], ["plasma membrane", "CELLULAR_COMPONENT", 147, 162], ["clathrin", "GENE_OR_GENE_PRODUCT", 198, 206], ["vesicles", "CELLULAR_COMPONENT", 214, 222], ["clathrin", "PROTEIN", 76, 84], ["clathrin", "PROTEIN", 198, 206], ["mediated endocytosis", "PROBLEM", 85, 105], ["plasma membrane", "ANATOMY", 147, 162]]], ["Some viruses, including rhesus rhadinovirus (Zhang et al., 2010), Betanodavirus (Huang et al., 2017), Japanese encephalitis virus (Das et al., 2010), and Chikungunya virus (Hoornweg et al., 2016), are reported to invade their host cells through cholesterol-dependent clathrin-mediated endocytosis.", [["cells", "ANATOMY", 231, 236], ["Japanese encephalitis", "DISEASE", 102, 123], ["Chikungunya virus", "DISEASE", 154, 171], ["cholesterol", "CHEMICAL", 245, 256], ["cholesterol", "CHEMICAL", 245, 256], ["rhesus rhadinovirus", "ORGANISM", 24, 43], ["Japanese encephalitis virus", "ORGANISM", 102, 129], ["Chikungunya virus", "ORGANISM", 154, 171], ["cells", "CELL", 231, 236], ["cholesterol", "SIMPLE_CHEMICAL", 245, 256], ["clathrin", "GENE_OR_GENE_PRODUCT", 267, 275], ["host cells", "CELL_TYPE", 226, 236], ["clathrin", "PROTEIN", 267, 275], ["rhesus rhadinovirus", "SPECIES", 24, 43], ["Japanese encephalitis virus", "SPECIES", 102, 129], ["Chikungunya virus", "SPECIES", 154, 171], ["rhesus rhadinovirus", "SPECIES", 24, 43], ["Japanese encephalitis virus", "SPECIES", 102, 129], ["Chikungunya virus", "SPECIES", 154, 171], ["Some viruses", "PROBLEM", 0, 12], ["rhesus rhadinovirus", "PROBLEM", 24, 43], ["Japanese encephalitis virus", "PROBLEM", 102, 129], ["Chikungunya virus", "PROBLEM", 154, 171], ["cholesterol", "TEST", 245, 256], ["dependent clathrin", "PROBLEM", 257, 275], ["mediated endocytosis", "PROBLEM", 276, 296], ["viruses", "OBSERVATION", 5, 12], ["host cells", "OBSERVATION", 226, 236], ["dependent clathrin", "OBSERVATION", 257, 275], ["endocytosis", "OBSERVATION", 285, 296]]], ["Therefore, whether the entry of SGIV MCP into its host cells involves caveolae/raft-dependent endocytosis warranted clarification.DiscussionCaveolae/raft-dependent endocytosis not only is sensitive to cholesterol depletion but also regulated by reversible phosphorylation (Nabi, 2003).", [["cells", "ANATOMY", 55, 60], ["caveolae", "ANATOMY", 70, 78], ["raft", "ANATOMY", 79, 83], ["raft", "ANATOMY", 149, 153], ["cholesterol", "CHEMICAL", 201, 212], ["cholesterol", "CHEMICAL", 201, 212], ["SGIV MCP", "GENE_OR_GENE_PRODUCT", 32, 40], ["cells", "CELL", 55, 60], ["caveolae", "CELLULAR_COMPONENT", 70, 78], ["raft", "CELLULAR_COMPONENT", 79, 83], ["Caveolae", "GENE_OR_GENE_PRODUCT", 140, 148], ["raft", "CELLULAR_COMPONENT", 149, 153], ["cholesterol", "SIMPLE_CHEMICAL", 201, 212], ["SGIV MCP", "PROTEIN", 32, 40], ["host cells", "CELL_TYPE", 50, 60], ["caveolae/raft", "TEST", 70, 83], ["dependent endocytosis", "PROBLEM", 84, 105], ["DiscussionCaveolae/raft", "TEST", 130, 153], ["dependent endocytosis", "PROBLEM", 154, 175], ["cholesterol depletion", "PROBLEM", 201, 222], ["reversible phosphorylation", "PROBLEM", 245, 271], ["host cells", "OBSERVATION", 50, 60], ["raft", "OBSERVATION_MODIFIER", 79, 83], ["dependent", "OBSERVATION_MODIFIER", 84, 93], ["endocytosis", "OBSERVATION", 94, 105], ["cholesterol depletion", "OBSERVATION", 201, 222], ["reversible phosphorylation", "OBSERVATION", 245, 271]]], ["Genistein is a natural flavonoid compound with various bioactivities and is used in the treatment of tumors (Banerjee et al., 2008), diabetes (Behloul and Wu, 2013), and skin diseases (Toutfaire et al., 2017).", [["tumors", "ANATOMY", 101, 107], ["skin", "ANATOMY", 170, 174], ["Genistein", "CHEMICAL", 0, 9], ["tumors", "DISEASE", 101, 107], ["diabetes", "DISEASE", 133, 141], ["skin diseases", "DISEASE", 170, 183], ["Genistein", "CHEMICAL", 0, 9], ["flavonoid", "CHEMICAL", 23, 32], ["Genistein", "SIMPLE_CHEMICAL", 0, 9], ["tumors", "CANCER", 101, 107], ["skin", "ORGAN", 170, 174], ["tumors", "PROBLEM", 101, 107], ["diabetes", "PROBLEM", 133, 141], ["skin diseases", "PROBLEM", 170, 183], ["flavonoid compound", "OBSERVATION", 23, 41], ["tumors", "OBSERVATION", 101, 107], ["skin", "ANATOMY", 170, 174], ["diseases", "OBSERVATION", 175, 183]]], ["Genistein also acts as protein tyrosine kinase inhibitor.", [["Genistein", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 31, 39], ["Genistein", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 31, 39], ["Genistein", "SIMPLE_CHEMICAL", 0, 9], ["protein tyrosine kinase", "GENE_OR_GENE_PRODUCT", 23, 46], ["Genistein", "TREATMENT", 0, 9], ["protein tyrosine kinase inhibitor", "TREATMENT", 23, 56]]], ["Previous studies of tiger frog virus (Guo et al., 2011) and ISKNV (Guo et al., 2012) have shown that genistein regulates and blocks caveolar budding during caveolae/raft-mediated endocytosis through reversible phosphorylation.", [["caveolar", "ANATOMY", 132, 140], ["caveolae", "ANATOMY", 156, 164], ["raft", "ANATOMY", 165, 169], ["genistein", "CHEMICAL", 101, 110], ["genistein", "CHEMICAL", 101, 110], ["tiger frog virus", "ORGANISM", 20, 36], ["genistein", "SIMPLE_CHEMICAL", 101, 110], ["caveolar", "CELLULAR_COMPONENT", 132, 140], ["caveolae", "CELLULAR_COMPONENT", 156, 164], ["raft", "CELLULAR_COMPONENT", 165, 169], ["tiger frog virus", "SPECIES", 20, 36], ["tiger frog virus", "SPECIES", 20, 36], ["Previous studies", "TEST", 0, 16], ["tiger frog virus", "PROBLEM", 20, 36], ["genistein regulates", "PROBLEM", 101, 120], ["blocks caveolar budding", "PROBLEM", 125, 148], ["caveolae/raft", "TREATMENT", 156, 169], ["mediated endocytosis", "PROBLEM", 170, 190], ["reversible phosphorylation", "PROBLEM", 199, 225], ["genistein", "OBSERVATION", 101, 110], ["reversible phosphorylation", "OBSERVATION", 199, 225]]], ["Therefore, we used genistein to determine whether the entry of SGIV MCP into its host cells is dependent on caveolae/raft-dependent endocytosis.", [["cells", "ANATOMY", 86, 91], ["caveolae", "ANATOMY", 108, 116], ["raft", "ANATOMY", 117, 121], ["genistein", "CHEMICAL", 19, 28], ["genistein", "CHEMICAL", 19, 28], ["genistein", "SIMPLE_CHEMICAL", 19, 28], ["SGIV MCP", "GENE_OR_GENE_PRODUCT", 63, 71], ["host cells", "CELL", 81, 91], ["caveolae", "CELLULAR_COMPONENT", 108, 116], ["raft", "CELLULAR_COMPONENT", 117, 121], ["SGIV MCP", "PROTEIN", 63, 71], ["host cells", "CELL_TYPE", 81, 91], ["SGIV", "SPECIES", 63, 67], ["genistein", "TREATMENT", 19, 28], ["dependent endocytosis", "PROBLEM", 122, 143], ["host cells", "OBSERVATION", 81, 91], ["raft", "OBSERVATION_MODIFIER", 117, 121], ["dependent", "OBSERVATION_MODIFIER", 122, 131], ["endocytosis", "OBSERVATION", 132, 143]]], ["As shown in Figure 7, genistein treatment, even at a high concentration (100 \u03bcM), did not block the entry of the Q5-MCP complex into SGIV-infected cells.", [["cells", "ANATOMY", 147, 152], ["genistein", "CHEMICAL", 22, 31], ["genistein", "CHEMICAL", 22, 31], ["genistein", "SIMPLE_CHEMICAL", 22, 31], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 113, 119], ["SGIV", "GENE_OR_GENE_PRODUCT", 133, 137], ["cells", "CELL", 147, 152], ["Q5", "PROTEIN", 113, 115], ["MCP complex", "PROTEIN", 116, 127], ["SGIV-infected cells", "CELL_LINE", 133, 152], ["genistein treatment", "TREATMENT", 22, 41], ["infected cells", "PROBLEM", 138, 152], ["infected cells", "OBSERVATION", 138, 152]]], ["Therefore, we conclude that the entry of SGIV MCP into its host cells is dependent upon cholesterol but does not involve caveolae/raft-dependent endocytosis.DiscussionMacropinocytosis is an endocytotic pathway that has recently drawn increasing attention.", [["cells", "ANATOMY", 64, 69], ["caveolae", "ANATOMY", 121, 129], ["raft", "ANATOMY", 130, 134], ["cholesterol", "CHEMICAL", 88, 99], ["cholesterol", "CHEMICAL", 88, 99], ["SGIV MCP", "GENE_OR_GENE_PRODUCT", 41, 49], ["host cells", "CELL", 59, 69], ["cholesterol", "SIMPLE_CHEMICAL", 88, 99], ["caveolae", "CELLULAR_COMPONENT", 121, 129], ["raft", "CELLULAR_COMPONENT", 130, 134], ["SGIV MCP", "PROTEIN", 41, 49], ["host cells", "CELL_TYPE", 59, 69], ["SGIV", "SPECIES", 41, 45], ["dependent endocytosis", "PROBLEM", 135, 156], ["host cells", "OBSERVATION", 59, 69], ["raft", "OBSERVATION", 130, 134], ["dependent", "OBSERVATION_MODIFIER", 135, 144], ["endocytosis", "OBSERVATION", 145, 156]]], ["It plays a critical role in the cellular uptake of agents (Zhou et al., 2018; Guggenheim et al., 2020), the exchange of extracellular vesicles (such as exosomes and microvesicles) between cells (Costa-Verdera et al., 2017), cellular immune defenses (Hohn et al., 2009), and viral entry (Huang et al., 2017).", [["cellular", "ANATOMY", 32, 40], ["extracellular vesicles", "ANATOMY", 120, 142], ["exosomes", "ANATOMY", 152, 160], ["microvesicles", "ANATOMY", 165, 178], ["cells", "ANATOMY", 188, 193], ["cellular", "ANATOMY", 224, 232], ["cellular", "CELL", 32, 40], ["extracellular vesicles", "CELLULAR_COMPONENT", 120, 142], ["exosomes", "CELL", 152, 160], ["microvesicles", "CELLULAR_COMPONENT", 165, 178], ["cells", "CELL", 188, 193], ["cellular", "CELL", 224, 232], ["exosomes", "CELL_TYPE", 152, 160], ["microvesicles", "CELL_TYPE", 165, 178], ["extracellular vesicles", "PROBLEM", 120, 142], ["extracellular vesicles", "ANATOMY", 120, 142]]], ["Both Na+/H+ exchanger activity and the functional actomyosin network are important in macropinocytosis, and many studies have reported that macropinocytosis requires signaling events and activated protein kinases such as PAK1, PKC, and GTPase Rac1.", [["actomyosin network", "ANATOMY", 50, 68], ["Na+", "CHEMICAL", 5, 8], ["Na+/H+", "CHEMICAL", 5, 11], ["Na+/H+ exchanger", "GENE_OR_GENE_PRODUCT", 5, 21], ["actomyosin network", "MULTI-TISSUE_STRUCTURE", 50, 68], ["PAK1", "GENE_OR_GENE_PRODUCT", 221, 225], ["PKC", "GENE_OR_GENE_PRODUCT", 227, 230], ["Rac1", "GENE_OR_GENE_PRODUCT", 243, 247], ["Na+/H+ exchanger", "PROTEIN", 5, 21], ["protein kinases", "PROTEIN", 197, 212], ["PAK1", "PROTEIN", 221, 225], ["PKC", "PROTEIN", 227, 230], ["GTPase", "PROTEIN", 236, 242], ["Rac1", "PROTEIN", 243, 247], ["exchanger activity", "TREATMENT", 12, 30], ["many studies", "TEST", 108, 120], ["macropinocytosis", "PROBLEM", 140, 156], ["signaling events", "PROBLEM", 166, 182], ["activated protein kinases", "TEST", 187, 212], ["PAK1", "TEST", 221, 225], ["PKC", "TEST", 227, 230]]], ["For example, the entry of SGIV into GS cells (Wang et al., 2014) and of Echovirus 1 into polarized Caco-2 cells (Krieger et al., 2013) depends on PAK1 and PKC and is associated with macropinocytosis.", [["GS cells", "ANATOMY", 36, 44], ["Caco-2 cells", "ANATOMY", 99, 111], ["SGIV", "GENE_OR_GENE_PRODUCT", 26, 30], ["GS cells", "CELL", 36, 44], ["Echovirus 1", "CELL", 72, 83], ["Caco-2 cells", "CELL", 99, 111], ["PAK1", "GENE_OR_GENE_PRODUCT", 146, 150], ["PKC", "GENE_OR_GENE_PRODUCT", 155, 158], ["SGIV", "PROTEIN", 26, 30], ["GS cells", "CELL_LINE", 36, 44], ["polarized Caco-2 cells", "CELL_LINE", 89, 111], ["PAK1", "PROTEIN", 146, 150], ["PKC", "PROTEIN", 155, 158], ["GS cells", "PROBLEM", 36, 44], ["Echovirus", "PROBLEM", 72, 81], ["PAK1", "TEST", 146, 150], ["PKC", "TEST", 155, 158], ["macropinocytosis", "PROBLEM", 182, 198], ["associated with", "UNCERTAINTY", 166, 181], ["macropinocytosis", "OBSERVATION", 182, 198]]], ["Therefore, several inhibitors were used to analyze the role of macropinocytosis in MCP endocytosis during SGIV infection in this study.", [["SGIV", "ANATOMY", 106, 110], ["infection", "DISEASE", 111, 120], ["MCP", "GENE_OR_GENE_PRODUCT", 83, 86], ["SGIV", "CANCER", 106, 110], ["MCP", "PROTEIN", 83, 86], ["SGIV", "SPECIES", 106, 110], ["several inhibitors", "TREATMENT", 11, 29], ["macropinocytosis", "PROBLEM", 63, 79], ["MCP endocytosis", "PROBLEM", 83, 98], ["SGIV infection", "PROBLEM", 106, 120], ["this study", "TEST", 124, 134], ["infection", "OBSERVATION", 111, 120]]], ["ML-7 was used to antagonize the phosphorylation of myosin light chain kinase, to regulate myosin II activity, which blocks the functional actomyosin network involved in macropinocytosis.", [["actomyosin network", "ANATOMY", 138, 156], ["ML-7", "CHEMICAL", 0, 4], ["ML-7", "GENE_OR_GENE_PRODUCT", 0, 4], ["myosin light chain kinase", "GENE_OR_GENE_PRODUCT", 51, 76], ["myosin II", "GENE_OR_GENE_PRODUCT", 90, 99], ["actomyosin network", "MULTI-TISSUE_STRUCTURE", 138, 156], ["myosin light chain kinase", "PROTEIN", 51, 76], ["myosin II", "PROTEIN", 90, 99], ["myosin light chain kinase", "TREATMENT", 51, 76], ["macropinocytosis", "PROBLEM", 169, 185], ["myosin II", "OBSERVATION_MODIFIER", 90, 99]]], ["NSC23766 was used to inhibit Rac1 activity, rottlerin to inhibit PKC activity, and IPA-3 to inhibit PAK1 activity in the host cells (Huang et al., 2017).", [["cells", "ANATOMY", 126, 131], ["NSC23766", "CHEMICAL", 0, 8], ["rottlerin", "CHEMICAL", 44, 53], ["NSC23766", "CHEMICAL", 0, 8], ["rottlerin", "CHEMICAL", 44, 53], ["IPA-3", "CHEMICAL", 83, 88], ["NSC23766", "SIMPLE_CHEMICAL", 0, 8], ["Rac1", "GENE_OR_GENE_PRODUCT", 29, 33], ["rottlerin", "SIMPLE_CHEMICAL", 44, 53], ["PKC", "GENE_OR_GENE_PRODUCT", 65, 68], ["IPA-3", "GENE_OR_GENE_PRODUCT", 83, 88], ["PAK1", "GENE_OR_GENE_PRODUCT", 100, 104], ["cells", "CELL", 126, 131], ["Rac1", "PROTEIN", 29, 33], ["PKC", "PROTEIN", 65, 68], ["PAK1", "PROTEIN", 100, 104], ["host cells", "CELL_TYPE", 121, 131], ["rottlerin", "TREATMENT", 44, 53], ["PKC activity", "TEST", 65, 77], ["IPA", "TEST", 83, 86]]], ["However, even at high concentrations, these macropinocytosis inhibitors caused no statistically significant changes in the entry efficiency of MCP.", [["MCP", "GENE_OR_GENE_PRODUCT", 143, 146], ["MCP", "PROTEIN", 143, 146], ["these macropinocytosis inhibitors", "PROBLEM", 38, 71], ["statistically significant changes", "PROBLEM", 82, 115], ["the entry efficiency of MCP", "PROBLEM", 119, 146], ["entry efficiency", "OBSERVATION", 123, 139]]], ["These results suggest that macropinocytosis is not involved in MCP endocytosis.DiscussionAs reported previously, cellular uptake characteristics are also associated with the cytoskeleton (Al Soraj et al., 2012; He et al., 2018).", [["cellular", "ANATOMY", 113, 121], ["cytoskeleton", "ANATOMY", 174, 186], ["MCP", "GENE_OR_GENE_PRODUCT", 63, 66], ["cellular", "CELL", 113, 121], ["cytoskeleton", "CELLULAR_COMPONENT", 174, 186], ["MCP", "PROTEIN", 63, 66], ["macropinocytosis", "PROBLEM", 27, 43], ["MCP endocytosis", "PROBLEM", 63, 78], ["macropinocytosis", "OBSERVATION", 27, 43], ["not involved", "UNCERTAINTY", 47, 59], ["endocytosis", "OBSERVATION", 67, 78], ["uptake characteristics", "OBSERVATION", 122, 144]]], ["For example, cell-penetrating peptides (CPPs) have been used as vectors for the cellular delivery of therapeutic drugs.", [["cell", "ANATOMY", 13, 17], ["cellular", "ANATOMY", 80, 88], ["cell-penetrating peptides", "GENE_OR_GENE_PRODUCT", 13, 38], ["cellular", "CELL", 80, 88], ["cell-penetrating peptides (CPPs", "TREATMENT", 13, 44], ["therapeutic drugs", "TREATMENT", 101, 118]]], ["They enter cells directly across the plasma membrane and also gain access via endocytosis pathways.", [["cells", "ANATOMY", 11, 16], ["plasma membrane", "ANATOMY", 37, 52], ["cells", "CELL", 11, 16], ["plasma membrane", "CELLULAR_COMPONENT", 37, 52], ["the plasma membrane", "TREATMENT", 33, 52]]], ["Al Soraj et al. (2012) found that the disruption of the actin cytoskeleton with cytoD inhibited CPP entry in the HeLa and A431 epithelial cell lines.", [["cytoskeleton", "ANATOMY", 62, 74], ["HeLa", "ANATOMY", 113, 117], ["A431 epithelial cell lines", "ANATOMY", 122, 148], ["actin", "GENE_OR_GENE_PRODUCT", 56, 61], ["cytoskeleton", "CELLULAR_COMPONENT", 62, 74], ["cytoD", "GENE_OR_GENE_PRODUCT", 80, 85], ["CPP", "SIMPLE_CHEMICAL", 96, 99], ["HeLa", "CELL", 113, 117], ["A431 epithelial cell lines", "CELL", 122, 148], ["actin", "PROTEIN", 56, 61], ["cytoD", "PROTEIN", 80, 85], ["HeLa", "CELL_LINE", 113, 117], ["A431 epithelial cell lines", "CELL_LINE", 122, 148], ["the disruption of the actin cytoskeleton", "PROBLEM", 34, 74], ["CPP entry", "TEST", 96, 105], ["A431 epithelial cell lines", "TREATMENT", 122, 148], ["disruption", "OBSERVATION", 38, 48], ["actin cytoskeleton", "OBSERVATION", 56, 74], ["HeLa", "ANATOMY", 113, 117], ["A431 epithelial cell lines", "OBSERVATION", 122, 148]]], ["By contrast, disruption of the actin cytoskeleton reduced the cellular uptake of dextran by HeLa cells but increased its uptake by A431 cells.", [["cytoskeleton", "ANATOMY", 37, 49], ["cellular", "ANATOMY", 62, 70], ["HeLa cells", "ANATOMY", 92, 102], ["A431 cells", "ANATOMY", 131, 141], ["dextran", "CHEMICAL", 81, 88], ["actin", "GENE_OR_GENE_PRODUCT", 31, 36], ["cytoskeleton", "CELLULAR_COMPONENT", 37, 49], ["cellular", "CELL", 62, 70], ["dextran", "SIMPLE_CHEMICAL", 81, 88], ["HeLa cells", "CELL", 92, 102], ["A431 cells", "CELL", 131, 141], ["actin", "PROTEIN", 31, 36], ["HeLa cells", "CELL_LINE", 92, 102], ["A431 cells", "CELL_LINE", 131, 141], ["the actin cytoskeleton", "PROBLEM", 27, 49], ["dextran", "TREATMENT", 81, 88], ["HeLa cells", "PROBLEM", 92, 102], ["actin cytoskeleton", "OBSERVATION", 31, 49], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["cellular", "OBSERVATION_MODIFIER", 62, 70], ["uptake", "OBSERVATION_MODIFIER", 71, 77], ["HeLa cells", "OBSERVATION", 92, 102], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["uptake", "OBSERVATION_MODIFIER", 121, 127], ["A431 cells", "OBSERVATION", 131, 141]]], ["This indicates that the actin cytoskeleton both promotes and interferes with endocytosis.", [["cytoskeleton", "ANATOMY", 30, 42], ["actin", "GENE_OR_GENE_PRODUCT", 24, 29], ["cytoskeleton", "CELLULAR_COMPONENT", 30, 42], ["actin", "PROTEIN", 24, 29], ["endocytosis", "PROBLEM", 77, 88], ["actin cytoskeleton", "OBSERVATION", 24, 42]]], ["To determine the role of the actin cytoskeleton during MCP endocytosis, cytoD was used to destroy the actin cytoskeleton by inhibiting the elongation of actin filaments.", [["cytoskeleton", "ANATOMY", 35, 47], ["cytoskeleton", "ANATOMY", 108, 120], ["filaments", "ANATOMY", 159, 168], ["actin", "GENE_OR_GENE_PRODUCT", 29, 34], ["cytoskeleton", "CELLULAR_COMPONENT", 35, 47], ["MCP", "GENE_OR_GENE_PRODUCT", 55, 58], ["actin", "GENE_OR_GENE_PRODUCT", 102, 107], ["cytoskeleton", "CELLULAR_COMPONENT", 108, 120], ["actin", "GENE_OR_GENE_PRODUCT", 153, 158], ["filaments", "CELLULAR_COMPONENT", 159, 168], ["actin", "PROTEIN", 29, 34], ["MCP", "PROTEIN", 55, 58], ["cytoD", "PROTEIN", 72, 77], ["actin", "PROTEIN", 102, 107], ["actin filaments", "PROTEIN", 153, 168], ["cytoD", "TREATMENT", 72, 77], ["actin cytoskeleton", "OBSERVATION", 29, 47], ["actin cytoskeleton", "OBSERVATION", 102, 120], ["elongation", "OBSERVATION_MODIFIER", 139, 149], ["actin filaments", "OBSERVATION", 153, 168]]], ["Disruption of the actin cytoskeleton significantly inhibited MCP endocytosis.DiscussionAfter internalization, incoming substances are usually trafficked by the pH-dependent endosomal system, which is responsible for molecular sorting, recycling, degradation, storage, processing, and transcytosis.", [["cytoskeleton", "ANATOMY", 24, 36], ["endosomal system", "ANATOMY", 173, 189], ["actin", "GENE_OR_GENE_PRODUCT", 18, 23], ["cytoskeleton", "CELLULAR_COMPONENT", 24, 36], ["MCP", "GENE_OR_GENE_PRODUCT", 61, 64], ["endosomal", "CELLULAR_COMPONENT", 173, 182], ["actin", "PROTEIN", 18, 23], ["MCP", "PROTEIN", 61, 64], ["Disruption of the actin cytoskeleton", "PROBLEM", 0, 36], ["MCP endocytosis", "PROBLEM", 61, 76], ["actin cytoskeleton", "OBSERVATION", 18, 36], ["MCP endocytosis", "OBSERVATION", 61, 76], ["endosomal system", "OBSERVATION", 173, 189]]], ["CQ and NH4Cl inhibit endocytosis by preventing endosomal acidification (Guo et al., 2011).", [["endosomal", "ANATOMY", 47, 56], ["CQ", "CHEMICAL", 0, 2], ["NH4Cl", "CHEMICAL", 7, 12], ["CQ", "CHEMICAL", 0, 2], ["NH4Cl", "CHEMICAL", 7, 12], ["CQ", "SIMPLE_CHEMICAL", 0, 2], ["NH4Cl", "SIMPLE_CHEMICAL", 7, 12], ["endosomal", "CELLULAR_COMPONENT", 47, 56], ["CQ", "PROBLEM", 0, 2], ["NH4Cl inhibit endocytosis", "PROBLEM", 7, 32], ["endosomal acidification", "PROBLEM", 47, 70], ["endosomal acidification", "OBSERVATION", 47, 70]]], ["Using these inhibitors, we demonstrated that the endocytosis of the Q5-MCP complex is pH dependent.DiscussionIn summary, in this study, we used a highly specific molecular probe, the aptamer Q5, to investigate the crucial events of MCP endocytosis into the host cell during SGIV infection.", [["cell", "ANATOMY", 262, 266], ["SGIV", "ANATOMY", 274, 278], ["infection", "DISEASE", 279, 288], ["Q5-MCP", "GENE_OR_GENE_PRODUCT", 68, 74], ["MCP", "GENE_OR_GENE_PRODUCT", 232, 235], ["host cell", "CELL", 257, 266], ["SGIV", "CANCER", 274, 278], ["Q5", "PROTEIN", 68, 70], ["MCP complex", "PROTEIN", 71, 82], ["aptamer Q5", "PROTEIN", 183, 193], ["MCP", "PROTEIN", 232, 235], ["SGIV", "SPECIES", 274, 278], ["these inhibitors", "TREATMENT", 6, 22], ["the endocytosis", "TEST", 45, 60], ["pH dependent", "PROBLEM", 86, 98], ["this study", "TEST", 124, 134], ["MCP endocytosis", "PROBLEM", 232, 247], ["SGIV infection", "PROBLEM", 274, 288], ["pH dependent", "OBSERVATION", 86, 98], ["host cell", "OBSERVATION", 257, 266], ["infection", "OBSERVATION", 279, 288]]], ["MCP entry into the host cell during SGIV infection is via clathrin-mediated endocytosis and is dependent on dynamin, cholesterol, low pH, and the actin cytoskeleton, but not on caveolae/raft-dependent endocytosis or macropinocytosis.", [["cell", "ANATOMY", 24, 28], ["cytoskeleton", "ANATOMY", 152, 164], ["caveolae", "ANATOMY", 177, 185], ["raft", "ANATOMY", 186, 190], ["infection", "DISEASE", 41, 50], ["cholesterol", "CHEMICAL", 117, 128], ["cholesterol", "CHEMICAL", 117, 128], ["MCP", "GENE_OR_GENE_PRODUCT", 0, 3], ["host cell", "CELL", 19, 28], ["SGIV", "GENE_OR_GENE_PRODUCT", 36, 40], ["clathrin", "GENE_OR_GENE_PRODUCT", 58, 66], ["dynamin", "GENE_OR_GENE_PRODUCT", 108, 115], ["cholesterol", "SIMPLE_CHEMICAL", 117, 128], ["actin", "GENE_OR_GENE_PRODUCT", 146, 151], ["cytoskeleton", "CELLULAR_COMPONENT", 152, 164], ["caveolae", "CELLULAR_COMPONENT", 177, 185], ["raft", "CELLULAR_COMPONENT", 186, 190], ["MCP", "PROTEIN", 0, 3], ["clathrin", "PROTEIN", 58, 66], ["dynamin", "PROTEIN", 108, 115], ["actin", "PROTEIN", 146, 151], ["SGIV", "SPECIES", 36, 40], ["SGIV infection", "PROBLEM", 36, 50], ["clathrin-mediated endocytosis", "PROBLEM", 58, 87], ["cholesterol", "TEST", 117, 128], ["low pH", "PROBLEM", 130, 136], ["the actin cytoskeleton", "TEST", 142, 164], ["dependent endocytosis", "PROBLEM", 191, 212], ["macropinocytosis", "PROBLEM", 216, 232], ["host cell", "OBSERVATION", 19, 28], ["infection", "OBSERVATION", 41, 50], ["endocytosis", "OBSERVATION", 76, 87], ["dependent", "OBSERVATION_MODIFIER", 95, 104], ["low pH", "OBSERVATION_MODIFIER", 130, 136], ["actin cytoskeleton", "OBSERVATION", 146, 164], ["dependent", "OBSERVATION_MODIFIER", 191, 200], ["endocytosis", "OBSERVATION", 201, 212], ["macropinocytosis", "OBSERVATION", 216, 232]]], ["This is the first time that a specific aptamer-based probe has been used to demonstrate the endocytosis of MCP during SGIV infection.", [["infection", "DISEASE", 123, 132], ["MCP", "GENE_OR_GENE_PRODUCT", 107, 110], ["SGIV", "GENE_OR_GENE_PRODUCT", 118, 122], ["MCP", "PROTEIN", 107, 110], ["SGIV", "SPECIES", 118, 122], ["a specific aptamer-based probe", "TREATMENT", 28, 58], ["the endocytosis of MCP", "PROBLEM", 88, 110], ["SGIV infection", "PROBLEM", 118, 132], ["infection", "OBSERVATION", 123, 132]]], ["The strategy developed in this study should be applicable to other types of viral infection, thus providing a convenient strategy for exploring viral pathogenesis and facilitating the development of diagnostic tools for and therapeutic approaches to viral infection.", [["viral infection", "DISEASE", 76, 91], ["viral infection", "DISEASE", 250, 265], ["this study", "TEST", 26, 36], ["viral infection", "PROBLEM", 76, 91], ["a convenient strategy", "TREATMENT", 108, 129], ["viral pathogenesis", "PROBLEM", 144, 162], ["diagnostic tools", "TEST", 199, 215], ["viral infection", "PROBLEM", 250, 265], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 82, 91], ["infection", "OBSERVATION", 256, 265]]], ["This work not only contributes greatly to our understanding of iridovirus pathogenesis but also provides an ideal molecule probe for exploring the behavior of DNA viruses in living cells.Data Availability StatementAll datasets generated for this study are included in the article/Supplementary Material.Author ContributionsPL, QQ, and QZ conceived and designed the experiments.", [["cells", "ANATOMY", 181, 186], ["iridovirus", "CANCER", 63, 73], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["cells", "CELL", 181, 186], ["living cells", "CELL_TYPE", 174, 186], ["iridovirus pathogenesis", "PROBLEM", 63, 86], ["an ideal molecule probe", "TREATMENT", 105, 128], ["DNA viruses in living cells", "PROBLEM", 159, 186], ["this study", "TEST", 241, 251], ["iridovirus", "OBSERVATION", 63, 73]]], ["HX and ShW cultured the cells and performed flow cytometry analysis.", [["cells", "ANATOMY", 24, 29], ["HX", "CELL", 0, 2], ["cells", "CELL", 24, 29], ["HX", "CELL_LINE", 0, 2], ["ShW", "CELL_LINE", 7, 10], ["flow cytometry analysis", "TEST", 44, 67]]], ["YY and HC contributed to the reagents, materials, and analyzed the tools.", [["HC", "PROBLEM", 7, 9]]]], "53d526973a6895ca2394a32fc1171662fc2508a8": [["IntroductionHealth is characterized as a full state of physical, mental, and social well-being and not merely a lack of illness.", [["illness", "DISEASE", 120, 127]]], ["Health is a fundamental element of people's need for a better life.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41]]], ["Unfortunately, the global health problem has created a dilemma because of certain factors, such as poor health services, the presence of large gaps between rural and urban areas, physicians, and nurses unavailability during the hardest time.IntroductionIoT is making any objects internally connected in the recent decade and it has been considered as the next technological revolution.", [["the global health problem", "PROBLEM", 15, 40], ["a dilemma", "PROBLEM", 53, 62], ["large", "OBSERVATION_MODIFIER", 137, 142], ["gaps", "OBSERVATION", 143, 147]]], ["Smart health monitoring mechanism [1, 2] , smart parking [3] , smart home [4] , smart city [5] , smart climate [6] , industrial sites [7] , and agricultural fields [8] are some of the applications of IoT.", [["IoT", "SIMPLE_CHEMICAL", 200, 203], ["industrial sites", "TREATMENT", 117, 133]]], ["The most tremendous use of IoT is in healthcare management which provides health and environment condition tracking facilities.", [["healthcare management", "TREATMENT", 37, 58], ["most", "OBSERVATION_MODIFIER", 4, 8], ["tremendous", "OBSERVATION_MODIFIER", 9, 19]]], ["These connected components can be used on devices for health monitoring.", [["health monitoring", "TEST", 54, 71]]], ["The used sensors then forward the information to distant locations like M2M, which are machinery for computers, machines for people, handheld devices, or smartphones [11] .", [["M2M", "DNA", 72, 75], ["people", "SPECIES", 125, 131]]], ["Nowadays, modern systems are providing a flexible interface [12] , assistant devices [13] , and mental health management [14] to lead a smart life for the human being.IntroductionHeart rate and body temperature are the two most significant indicators for human health.", [["Heart", "ANATOMY", 179, 184], ["body", "ANATOMY", 194, 198], ["human", "ORGANISM", 155, 160], ["Heart", "ORGAN", 179, 184], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["human", "ORGANISM", 255, 260], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 255, 260], ["mental health management", "TREATMENT", 96, 120], ["IntroductionHeart rate", "TEST", 167, 189], ["body temperature", "TEST", 194, 210], ["Heart", "ANATOMY", 179, 184]]], ["Heart rate is the per-minute amount of heartbeats, commonly known as the pulse rate.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart rate", "TEST", 0, 10], ["the pulse rate", "TEST", 69, 83]]], ["To measure the pulse rate, an increase in the blood flow volume can be used by calculating the pulses.", [["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["the pulse rate", "TEST", 11, 25], ["the blood flow volume", "TEST", 42, 63], ["the pulses", "TEST", 91, 101], ["increase", "OBSERVATION_MODIFIER", 30, 38]]], ["Normal heart rate ranges between 60 and 100 beats per minute for healthy people.", [["heart", "ANATOMY", 7, 12], ["heart", "ORGAN", 7, 12], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["heart", "ANATOMY", 7, 12], ["rate ranges", "OBSERVATION", 13, 24]]], ["The typical restful heart for adult males is roughly 70 bpm and for adult females 75 bpm [15] .", [["heart", "ANATOMY", 20, 25], ["heart", "ORGAN", 20, 25], ["heart", "ANATOMY", 20, 25]]], ["Female with 12 years of age and above, typically have higher rates of heart in contrast with males.", [["heart", "ANATOMY", 70, 75], ["heart", "ORGAN", 70, 75], ["heart", "ANATOMY", 70, 75]]], ["The temperature of human body is simply the heat of body and the sum of heat radiated by the body is scientifically determined.", [["body", "ANATOMY", 25, 29], ["body", "ANATOMY", 52, 56], ["body", "ANATOMY", 93, 97], ["human", "ORGANISM", 19, 24], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["body", "ORGANISM_SUBDIVISION", 93, 97], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["The average person's body temperature relies on different factors such as ambient temperature, the person's gender, and his eating habits.", [["body", "ANATOMY", 21, 25], ["body", "ORGANISM_SUBDIVISION", 21, 25], ["person", "SPECIES", 12, 18], ["person", "SPECIES", 99, 105]]], ["Different factors such as flu, low-temperature hypothermia, or any other illness may lead to a change in body temperature.", [["body", "ANATOMY", 105, 109], ["flu", "DISEASE", 26, 29], ["hypothermia", "DISEASE", 47, 58], ["illness", "DISEASE", 73, 80], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["Different factors", "PROBLEM", 0, 17], ["flu", "PROBLEM", 26, 29], ["low-temperature hypothermia", "PROBLEM", 31, 58], ["any other illness", "PROBLEM", 63, 80], ["a change in body temperature", "PROBLEM", 93, 121]]], ["In almost all illnesses, fever is a typical indicator [16] .", [["fever", "DISEASE", 25, 30], ["fever", "PROBLEM", 25, 30], ["all", "OBSERVATION_MODIFIER", 10, 13], ["illnesses", "OBSERVATION", 14, 23], ["fever", "OBSERVATION", 25, 30]]], ["Various methods exist to invasively and noninvasively assess the heart rate and body temperature.", [["heart", "ANATOMY", 65, 70], ["body", "ANATOMY", 80, 84], ["heart", "ORGAN", 65, 70], ["body", "ORGANISM_SUBDIVISION", 80, 84], ["Various methods", "TREATMENT", 0, 15], ["the heart rate", "TEST", 61, 75], ["body temperature", "TEST", 80, 96], ["heart", "ANATOMY", 65, 70]]], ["It is suggested that a healthcare should provide good room conditions to facilitate the patients [18] .", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Some measures like room humidity, level of all gases like CO, and CO 2 can determine the quality of room environment.", [["CO", "CHEMICAL", 58, 60], ["CO 2", "CHEMICAL", 66, 70], ["CO", "SIMPLE_CHEMICAL", 58, 60], ["CO 2", "GENE_OR_GENE_PRODUCT", 66, 70], ["all gases", "TEST", 43, 52], ["CO", "TEST", 58, 60]]], ["The toxic gases and certain levels of humidity are very harmful to patients.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["The toxic gases", "TEST", 0, 15], ["toxic", "OBSERVATION_MODIFIER", 4, 9]]], ["For optimum comfort, the room humidity should be between 30 and 65%.", [["optimum comfort", "TREATMENT", 4, 19], ["the room humidity", "TREATMENT", 21, 38]]], ["Some studies [19, 20] are done only for a smart home, not for dedicated healthcare.IntroductionThere are several fatal diseases like heart disease [21] , diabetes [22] , breast cancer [23, 24] , liver disorder [25] , etc. in medical sector but the main concern of our developed system is to monitor the fundamental signs of all types of patients and the patient's room environment.", [["heart", "ANATOMY", 133, 138], ["breast cancer", "ANATOMY", 170, 183], ["liver", "ANATOMY", 195, 200], ["heart disease", "DISEASE", 133, 146], ["diabetes", "DISEASE", 154, 162], ["breast cancer", "DISEASE", 170, 183], ["liver disorder", "DISEASE", 195, 209], ["heart", "ORGAN", 133, 138], ["breast cancer", "CANCER", 170, 183], ["liver", "ORGAN", 195, 200], ["patients", "ORGANISM", 337, 345], ["patient", "ORGANISM", 354, 361], ["patients", "SPECIES", 337, 345], ["patient", "SPECIES", 354, 361], ["Some studies", "TEST", 0, 12], ["several fatal diseases", "PROBLEM", 105, 127], ["heart disease", "PROBLEM", 133, 146], ["diabetes", "PROBLEM", 154, 162], ["breast cancer", "PROBLEM", 170, 183], ["liver disorder", "PROBLEM", 195, 209], ["several", "OBSERVATION_MODIFIER", 105, 112], ["fatal", "OBSERVATION_MODIFIER", 113, 118], ["diseases", "OBSERVATION", 119, 127], ["heart", "ANATOMY", 133, 138], ["disease", "OBSERVATION", 139, 146], ["breast", "ANATOMY", 170, 176], ["cancer", "OBSERVATION", 177, 183], ["liver", "ANATOMY", 195, 200]]], ["This paper proposes a customized healthcare system that monitors the pulse and body temperature of patients as well as room humidity, CO, and CO 2 gas level of patient's room via sensors and transmits the data through Wi-Fi that enables the medical staffs to get data from the server.", [["body", "ANATOMY", 79, 83], ["CO", "CHEMICAL", 134, 136], ["CO", "CHEMICAL", 142, 144], ["body", "ORGANISM_SUBDIVISION", 79, 83], ["patients", "ORGANISM", 99, 107], ["CO", "SIMPLE_CHEMICAL", 134, 136], ["patient", "ORGANISM", 160, 167], ["Fi", "DNA", 221, 223], ["patients", "SPECIES", 99, 107], ["patient", "SPECIES", 160, 167], ["the pulse", "TEST", 65, 74], ["CO", "TEST", 134, 136], ["CO 2 gas level", "TEST", 142, 156]]], ["The developed system also provides a solution for the problem of maintaining a single database of patients in hospitals using a web server, apart from the personalization of critical health-related criteria.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["a solution", "TREATMENT", 35, 45]]], ["In this system, the gas sensor is used to identify an unexpected occurrence that contrasts the performance with the threshold and produces a PPM signal if the output value crosses the threshold.IntroductionThe rest of the work is organized as follows.", [["the gas sensor", "TEST", 16, 30], ["a PPM signal", "TEST", 139, 151], ["the output value", "TEST", 155, 171]]], ["The major hardware components which are used to develop the prototype are illustrated in \"Major Hardware Components\" section.", [["The major hardware components", "TREATMENT", 0, 29], ["major", "OBSERVATION_MODIFIER", 4, 9], ["hardware", "OBSERVATION", 10, 18], ["Major", "OBSERVATION_MODIFIER", 90, 95], ["Hardware", "OBSERVATION", 96, 104]]], ["\"Conclusion\" section concludes the paper with some future work.Related WorksSome important works have been done in the field of medical science using IoT to monitor patient's health.", [["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172]]], ["The works associated in this field are outlined as follows.Related WorksTamilselvi et al. [26] developed a health monitoring system that can monitor basic symptoms of a patient like heart rate, percentage of oxygen saturation, body temperature, and eye movement in IoT network.", [["heart", "ANATOMY", 182, 187], ["body", "ANATOMY", 227, 231], ["eye", "ANATOMY", 249, 252], ["oxygen", "CHEMICAL", 208, 214], ["oxygen", "CHEMICAL", 208, 214], ["patient", "ORGANISM", 169, 176], ["heart", "ORGAN", 182, 187], ["oxygen", "SIMPLE_CHEMICAL", 208, 214], ["body", "ORGANISM_SUBDIVISION", 227, 231], ["eye", "ORGAN", 249, 252], ["IoT network", "MULTI-TISSUE_STRUCTURE", 265, 276], ["patient", "SPECIES", 169, 176], ["basic symptoms", "PROBLEM", 149, 163], ["heart rate", "TEST", 182, 192], ["oxygen saturation", "TEST", 208, 225], ["body temperature", "TEST", 227, 243], ["eye movement in IoT network", "PROBLEM", 249, 276], ["heart", "ANATOMY", 182, 187], ["oxygen saturation", "OBSERVATION", 208, 225], ["eye", "ANATOMY", 249, 252]]], ["For this purpose, the system used Heartbeat, SpO 2 , Temperature, and Eye blink sensors as capturing elements and Arduino-UNO as a processing device.", [["UNO", "DNA", 122, 125], ["Heartbeat", "TEST", 34, 43], ["SpO", "TEST", 45, 48], ["Temperature", "TEST", 53, 64], ["Eye blink sensors", "TEST", 70, 87], ["a processing device", "TREATMENT", 129, 148], ["Eye", "ANATOMY", 70, 73]]], ["The developed system was implemented but no specific performance measures are described for any patient.", [["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103]]], ["The developed system monitored some basic parameters of human health like Heartbeat, ECG, body temperature, and Respiration.", [["body", "ANATOMY", 90, 94], ["human", "ORGANISM", 56, 61], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["ECG", "TEST", 85, 88], ["body temperature", "TEST", 90, 106], ["Respiration", "TEST", 112, 123]]], ["The major hardware components which are used here are pulse sensor, temperature sensor, BP sensor, ECG sensor, and raspberry pi.", [["raspberry pi.", "SPECIES", 115, 128], ["The major hardware components", "TREATMENT", 0, 29], ["pulse sensor", "TEST", 54, 66], ["temperature sensor", "TEST", 68, 86], ["BP sensor", "TEST", 88, 97], ["ECG sensor", "TEST", 99, 109], ["major", "OBSERVATION_MODIFIER", 4, 9], ["hardware", "OBSERVATION", 10, 18]]], ["The data were collected from sensors and sent it to raspberry pi for processing and again transmitted it to IoT network.", [["IoT network", "MULTI-TISSUE_STRUCTURE", 108, 119], ["The data", "TEST", 0, 8]]], ["The major drawback of the system is that no interfaces for data visualization are developed.Related WorksBanerjee et al. [28] proposed a pulse rate detection system based on a noninvasive technique.", [["data visualization", "TEST", 59, 77], ["a pulse rate detection system", "TREATMENT", 135, 164], ["a noninvasive technique", "TEST", 174, 197]]], ["The proposed system used plethysmography process and correspondingly displayed the output digitally that made it a real-time monitoring device.", [["plethysmography process", "TEST", 25, 48], ["a real-time monitoring device", "TREATMENT", 113, 142], ["output", "OBSERVATION_MODIFIER", 83, 89]]], ["The method has proved as reliable for the patient compared to other invasive techniques.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["other invasive techniques", "TEST", 62, 87]]], ["Gregoski et al. [29] introduced a smartphone-based heart rate monitoring system.", [["heart", "ANATOMY", 51, 56], ["heart", "ORGAN", 51, 56], ["a smartphone", "TREATMENT", 32, 44], ["heart", "ANATOMY", 51, 56]]], ["The system used a mobile light and camera to track finger blood flow and calculated blood flow-based cardiac output.", [["finger", "ANATOMY", 51, 57], ["blood", "ANATOMY", 58, 63], ["blood", "ANATOMY", 84, 89], ["cardiac", "ANATOMY", 101, 108], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["cardiac", "ORGAN", 101, 108], ["a mobile light", "TREATMENT", 16, 30], ["finger blood flow", "TEST", 51, 68], ["calculated blood flow", "TEST", 73, 94], ["based cardiac output", "TEST", 95, 115], ["cardiac", "ANATOMY", 101, 108], ["output", "OBSERVATION", 109, 115]]], ["The developed system described an integrated device that wirelessly transmitted a person's pulse to a computer, empowering people to test their heart rate by merely looking at their phones instead of using hands each time.", [["heart", "ANATOMY", 144, 149], ["people", "ORGANISM", 123, 129], ["heart", "ORGAN", 144, 149], ["person", "SPECIES", 82, 88], ["people", "SPECIES", 123, 129], ["heart", "ANATOMY", 144, 149]]], ["This is an excellent design but it is not feasible if continuous heart monitoring is needed.", [["heart", "ANATOMY", 65, 70], ["heart", "ORGAN", 65, 70], ["continuous heart monitoring", "TEST", 54, 81], ["excellent", "OBSERVATION_MODIFIER", 11, 20], ["design", "OBSERVATION", 21, 27]]], ["Oresko et al. [30] mentioned a fully functional cardiovascular disease sensing system for smartphones, identifying a tool that is developed to be the same given sufficient time and monetary resources.", [["cardiovascular", "ANATOMY", 48, 62], ["cardiovascular disease", "DISEASE", 48, 70], ["cardiovascular", "ANATOMICAL_SYSTEM", 48, 62], ["monetary resources", "TREATMENT", 181, 199]]], ["The developed prototype only tracked coronary rhythm in real-time, did not track heart rate over time, and could not detect any cardiovascular disease.Related WorksTrivedi et al. [31] suggested a mobile device regulated Arduino-based health parameter surveillance framework.", [["coronary", "ANATOMY", 37, 45], ["heart", "ANATOMY", 81, 86], ["cardiovascular", "ANATOMY", 128, 142], ["cardiovascular disease", "DISEASE", 128, 150], ["coronary", "MULTI-TISSUE_STRUCTURE", 37, 45], ["heart", "ORGAN", 81, 86], ["any cardiovascular disease", "PROBLEM", 124, 150], ["a mobile device", "TREATMENT", 194, 209], ["coronary rhythm", "ANATOMY", 37, 52], ["cardiovascular", "ANATOMY", 128, 142], ["disease", "OBSERVATION", 143, 150]]], ["The collected sensor data are analog and sent it to the board of Arduino Uno.", [["The collected sensor data", "TEST", 0, 25]]], ["By the integrated analog to digital converter, the recorded analog values are converted into digital data.", [["the recorded analog values", "TEST", 47, 73]]], ["The Bluetooth device used a module not covering a wide area.", [["The Bluetooth device", "TREATMENT", 0, 20], ["a module", "TREATMENT", 26, 34], ["a wide area", "TREATMENT", 48, 59], ["Bluetooth device", "OBSERVATION", 4, 20], ["wide", "OBSERVATION_MODIFIER", 50, 54]]], ["Kumar et al. [32] developed an adaptive IoT safety monitoring device.", [["an adaptive IoT safety monitoring device", "TREATMENT", 28, 68]]], ["The configuration of the framework is separated into 3 layers such as the control layer, the device layer, and the transport layer.", [["the device layer", "TREATMENT", 89, 105], ["3 layers", "OBSERVATION_MODIFIER", 53, 61], ["layer", "OBSERVATION_MODIFIER", 82, 87], ["device", "OBSERVATION_MODIFIER", 93, 99], ["layer", "OBSERVATION_MODIFIER", 100, 105], ["layer", "OBSERVATION_MODIFIER", 125, 130]]], ["A DS18B20 sensor was used for the measurement of body temperature in the control segment and a pulse sensor is used for the pulse measurement.", [["body", "ANATOMY", 49, 53], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["DS18B20 sensor", "DNA", 2, 16], ["A DS18B20 sensor", "TEST", 0, 16], ["body temperature", "TEST", 49, 65], ["a pulse sensor", "TEST", 93, 107], ["the pulse measurement", "TEST", 120, 141]]], ["The framework layer finally collected the server details.", [["layer", "OBSERVATION_MODIFIER", 14, 19]]], ["Desai et al. [33] developed a wireless sensor network (WSN) to track smart homes and heartbeat.", [["sensor network", "MULTI-TISSUE_STRUCTURE", 39, 53]]], ["Here, Spartan3 is used in parallel data processing with FPGA architecture.", [["Spartan3", "GENE_OR_GENE_PRODUCT", 6, 14], ["Spartan3", "PROTEIN", 6, 14]]], ["The MCU results are shown by an LCD, and all sensors are connected with a microcontroller.", [["an LCD", "TREATMENT", 29, 35], ["a microcontroller", "TREATMENT", 72, 89], ["LCD", "OBSERVATION", 32, 35]]], ["Nevertheless, all machine elements are not integrated in one unit.Major Hardware ComponentsSome sort of hardware components is being used in the proposed system.", [["machine elements", "DNA", 18, 34], ["Major Hardware Components", "TREATMENT", 66, 91], ["hardware components", "TREATMENT", 104, 123], ["Hardware", "OBSERVATION", 72, 80], ["hardware", "OBSERVATION", 104, 112]]], ["The components which are used to develop the system are outlined as follows.ESP32 ProcessorESP32 is one of the main IoT learning tools.", [["ESP32", "CHEMICAL", 76, 81]]], ["ESP32 connects device sensors and actuators through GPIO pins.", [["ESP32", "SIMPLE_CHEMICAL", 0, 5], ["ESP32", "PROTEIN", 0, 5], ["ESP32 connects device sensors and actuators through GPIO pins", "TREATMENT", 0, 61], ["GPIO pins", "OBSERVATION", 52, 61]]], ["ESP32 and IoT merge to be a new technology for creativity in the healthcare system.", [["ESP32", "GENE_OR_GENE_PRODUCT", 0, 5], ["ESP32", "PROTEIN", 0, 5], ["IoT", "PROTEIN", 10, 13]]], ["ESP32 is designed extremely with integrated antenna switches, RF-balun, control amplification, low-noise amplifier, and filters as well as power management modules.", [["ESP32", "SIMPLE_CHEMICAL", 0, 5], ["ESP32", "DNA", 0, 5], ["RF", "PROTEIN", 62, 64], ["integrated antenna switches", "TREATMENT", 33, 60], ["RF", "TEST", 62, 64], ["balun", "TREATMENT", 65, 70], ["low-noise amplifier", "TREATMENT", 95, 114], ["filters", "TREATMENT", 120, 127], ["power management modules", "TREATMENT", 139, 163]]], ["EPS32 can communicate with other Wi-Fi and Bluetooth devices via its SPI/SDIO, or I2C/UART interfaces.", [["EPS32", "SIMPLE_CHEMICAL", 0, 5], ["EPS32", "PROTEIN", 0, 5], ["I2C", "PROTEIN", 82, 85], ["Bluetooth devices", "TREATMENT", 43, 60]]], ["The ESP32 microcontroller is shown in Fig. 1a .Heart Beat SensorThe heartbeat sensor is developed based on the plethysmography theory.", [["ESP32 microcontroller", "DNA", 4, 25], ["The ESP32 microcontroller", "TREATMENT", 0, 25], ["the plethysmography theory", "TEST", 107, 133], ["Fig", "OBSERVATION_MODIFIER", 38, 41], ["Heart", "ANATOMY", 47, 52]]], ["It measures the change in blood volume through anybody's organ that causes the light intensity to move through that organ.", [["blood", "ANATOMY", 26, 31], ["organ", "ANATOMY", 57, 62], ["organ", "ANATOMY", 116, 121], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["organ", "ORGAN", 57, 62], ["organ", "ORGAN", 116, 121], ["the change in blood volume through anybody's organ", "PROBLEM", 12, 62], ["change", "OBSERVATION_MODIFIER", 16, 22], ["blood volume", "OBSERVATION", 26, 38], ["organ", "ANATOMY", 57, 62], ["light intensity", "OBSERVATION_MODIFIER", 79, 94], ["organ", "ANATOMY", 116, 121]]], ["The timing of the pulses is more critical in systems where the heart pulse rate is to be tracked.", [["heart", "ANATOMY", 63, 68], ["heart", "ORGAN", 63, 68], ["the pulses", "TEST", 14, 24], ["the heart pulse rate", "TEST", 59, 79], ["heart", "ANATOMY", 63, 68]]], ["The rate of heartbeats determines the distribution of blood volume, and the signal pulses are equal to the pulses of Fig. 1 The hardware components for the healthcare monitoring system. a ESP32 b heart beat sensor c body temperature sensor d room temperature sensor e CO sensor f CO 2 sensor heartbeat when light is consumed by the blood.", [["blood", "ANATOMY", 54, 59], ["heart", "ANATOMY", 196, 201], ["blood", "ANATOMY", 332, 337], ["CO", "CHEMICAL", 268, 270], ["CO 2", "CHEMICAL", 280, 284], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["heart", "ORGAN", 196, 201], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["blood volume", "TEST", 54, 66], ["the signal pulses", "TEST", 72, 89], ["The hardware components", "TREATMENT", 124, 147], ["a ESP32 b heart beat sensor", "TEST", 186, 213], ["body temperature", "TEST", 216, 232], ["room temperature", "TEST", 242, 258], ["sensor heartbeat", "TEST", 285, 301], ["distribution", "OBSERVATION_MODIFIER", 38, 50], ["blood volume", "OBSERVATION", 54, 66], ["hardware", "OBSERVATION", 128, 136], ["heart", "ANATOMY", 196, 201]]], ["The heart beat sensor is depicted in Fig. 1b .Body Temperature Sensor (LM35)The LM35 series are accurate optimized temperature circuits with output voltage, which is linearly relative to the temperature in centigrade.", [["heart", "ANATOMY", 4, 9], ["heart", "ORGAN", 4, 9], ["Body Temperature Sensor", "TEST", 46, 69], ["The LM35 series", "TEST", 76, 91], ["output voltage", "TEST", 141, 155], ["heart", "ANATOMY", 4, 9]]], ["The LM35 has a vantage point over Kelvin's linear temperature sensors, as a realistic centigrade scaling does not allow the consumer to delete the huge constant voltage from the display.", [["LM35", "CHEMICAL", 4, 8], ["LM35", "SIMPLE_CHEMICAL", 4, 8], ["LM35", "DNA", 4, 8], ["Kelvin's linear temperature sensors", "TREATMENT", 34, 69], ["a realistic centigrade scaling", "TREATMENT", 74, 104]]], ["LM35 is shown in Fig. 1c .Room Temperature Sensor (DHT11)DHT11 is a sensor for temperature and humidity which is commonly used.", [["LM35", "CHEMICAL", 0, 4], ["LM35", "SIMPLE_CHEMICAL", 0, 4], ["LM35", "DNA", 0, 4], ["Fig", "OBSERVATION", 17, 20]]], ["The sensor comes with a dedicated temperature measurement NTC and an 8-bit microcontroller for the processing of temperature and humidity values in series.", [["a dedicated temperature measurement NTC", "TREATMENT", 22, 61], ["an 8-bit microcontroller", "TREATMENT", 66, 90], ["humidity values", "TEST", 129, 144]]], ["The DHT11 sensor is depicted in Fig. 1d .CO Sensor (MQ-9)MQ-9 is appropriate for LPG, CO, and CH 4 detection.", [["MQ-9", "CHEMICAL", 52, 56], ["MQ-9", "CHEMICAL", 57, 61], ["CO", "CHEMICAL", 86, 88], ["CH 4", "CHEMICAL", 94, 98], ["DHT11", "GENE_OR_GENE_PRODUCT", 4, 9], ["LPG", "SIMPLE_CHEMICAL", 81, 84], ["CO", "SIMPLE_CHEMICAL", 86, 88], ["DHT11", "PROTEIN", 4, 9], ["The DHT11 sensor", "TEST", 0, 16], ["CO", "TEST", 86, 88]]], ["Owing to its high sensitivity and fast response time, measurements can be taken fastly.", [["its high sensitivity", "PROBLEM", 9, 29], ["high sensitivity", "OBSERVATION_MODIFIER", 13, 29]]], ["Using the potentiometer, the sensor's sensitivity can be modified.", [["the sensor's sensitivity", "TEST", 25, 49]]], ["The MQ-9 sensor is shown in Fig. 1e .CO 2 Sensor (MQ-135)For air quality control systems, the MQ-135 gas sensors are used for NH 3 , Nicotine, Benzene, Smoke, and CO 2 detection as well as measurement.", [["MQ-9", "CHEMICAL", 4, 8], ["MQ-135", "CHEMICAL", 50, 56], ["Nicotine", "CHEMICAL", 133, 141], ["Benzene", "CHEMICAL", 143, 150], ["1e .CO 2", "CHEMICAL", 33, 41], ["MQ-135", "CHEMICAL", 50, 56], ["MQ-135", "CHEMICAL", 94, 100], ["NH 3", "CHEMICAL", 126, 130], ["Nicotine", "CHEMICAL", 133, 141], ["Benzene", "CHEMICAL", 143, 150], ["CO 2", "CHEMICAL", 163, 167], ["MQ-135", "SIMPLE_CHEMICAL", 50, 56], ["NH 3", "SIMPLE_CHEMICAL", 126, 130], ["Nicotine", "SIMPLE_CHEMICAL", 133, 141], ["Benzene", "SIMPLE_CHEMICAL", 143, 150], ["Smoke", "SIMPLE_CHEMICAL", 152, 157], ["The MQ", "TEST", 0, 6], ["Sensor (MQ", "TEST", 42, 52], ["the MQ", "TEST", 90, 96], ["gas sensors", "TEST", 101, 112]]], ["The MQ-135 sensor module comes with a digital pin that enables this sensor to work even without a microcontroller and is beneficial for detecting specific gases.", [["The MQ", "TEST", 0, 6], ["a digital pin", "TREATMENT", 36, 49], ["a microcontroller", "TREATMENT", 96, 113], ["specific gases", "TEST", 146, 160]]], ["The gasses in PPM are calculated using the analog pins.", [["The gasses in PPM", "TREATMENT", 0, 17], ["the analog pins", "TREATMENT", 39, 54], ["gasses", "OBSERVATION_MODIFIER", 4, 10], ["analog pins", "OBSERVATION", 43, 54]]], ["The analog pin is powered by TTL and works on 5 V, and hence it can be used with most modern microcontrollers.", [["TTL", "PROTEIN", 29, 32], ["The analog pin", "TREATMENT", 0, 14]]], ["The MQ-135 sensor is depicted in Fig. 1f .System DesignContinuous online patient and patient's room condition monitoring is the main idea of the proposed system.", [["MQ-135", "CHEMICAL", 4, 10], ["MQ-135", "CHEMICAL", 4, 10], ["patient", "ORGANISM", 73, 80], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 73, 80], ["patient", "SPECIES", 85, 92], ["The MQ", "TEST", 0, 6]]], ["Therefore, the healthcare monitoring system utilizes the three-stage architectural features, namely (1) Sensor Module (2) Data Processing Module (3) Web User Interface.System DesignThe sensors are wired which are used to collect data from the patient's body and the environment by gathering physiological signs.", [["body", "ANATOMY", 253, 257], ["patient", "ORGANISM", 243, 250], ["body", "ORGANISM_SUBDIVISION", 253, 257], ["patient", "SPECIES", 243, 250], ["the healthcare monitoring system", "TEST", 11, 43], ["architectural features", "OBSERVATION", 69, 91]]], ["The collected data are then processed via an ESP32 module and send to the gateway server.", [["ESP32 module", "DNA", 45, 57], ["The collected data", "TEST", 0, 18]]], ["For the web user interface, ThingSpeak is used for the graphical interpretation, and display of collected results.", [["the graphical interpretation", "TEST", 51, 79]]], ["The HTTP protocol provides easy connectivity for the correspondence between a Wi-Fi module and the web server.", [["Wi-Fi module", "DNA", 78, 90], ["The HTTP protocol", "TEST", 0, 17]]], ["The HTML user interface is updated every 15 s, allowing patients to be tracked in real-time.System DesignThe overall system architecture of the developed system is illustrated in Fig. 2.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Fig", "OBSERVATION_MODIFIER", 179, 182]]], ["The sensors all are connected to a processing unit called ESP32.", [["ESP32", "GENE_OR_GENE_PRODUCT", 58, 63], ["ESP32", "DNA", 58, 63]]], ["Upon attaching these (temperature, heartbeat, gas) sensors, ESP32 works as a heart of the system.", [["heart", "ANATOMY", 77, 82], ["ESP32", "SIMPLE_CHEMICAL", 60, 65], ["heart", "ORGAN", 77, 82], ["ESP32", "PROTEIN", 60, 65], ["heart", "ANATOMY", 77, 82]]], ["ESP32 collects sensor data and then wirelessly transfers them to IoT websites.", [["ESP32", "PROTEIN", 0, 5]]], ["The board uses its Wi-Fi and its own processing unit, which is Xtensa dual-core 32-bit LX6 microprocessor.", [["Wi", "DNA", 19, 21], ["Fi", "DNA", 22, 24], ["bit LX6 microprocessor", "TREATMENT", 83, 105]]], ["The sensor output is then linked to the website of IoT.System DesignThe data are accessed through any network supported device.", [["The sensor output", "TEST", 0, 17], ["any network supported device", "TREATMENT", 98, 126], ["sensor output", "OBSERVATION", 4, 17]]], ["There, the data are graphically shown and it is a channel-based system, and every time while accessing it needs password.Implementation DetailsThe system is implemented using the combination of hardware components.", [["hardware components", "TREATMENT", 194, 213], ["hardware", "OBSERVATION", 194, 202]]], ["All the hardware components are assembled in the implementation phase.", [["All the hardware components", "TREATMENT", 0, 27], ["hardware", "OBSERVATION", 8, 16]]], ["The circuit diagram of the developed system is demonstrated in Fig. 3a .", [["The circuit diagram", "TEST", 0, 19], ["Fig", "OBSERVATION_MODIFIER", 63, 66]]], ["All the sensors are connected with ESP32 using physical pins.", [["ESP32", "GENE_OR_GENE_PRODUCT", 35, 40], ["ESP32", "PROTEIN", 35, 40], ["physical pins", "TREATMENT", 47, 60], ["pins", "OBSERVATION", 56, 60]]], ["ESP32 is used as a processing device as it has a built-in Wi-Fi module.", [["ESP32", "CHEMICAL", 0, 5], ["ESP32", "SIMPLE_CHEMICAL", 0, 5], ["ESP32", "PROTEIN", 0, 5], ["a processing device", "TREATMENT", 17, 36]]], ["For all sensors, the V cc and GND are connected with the V cc and GND pin of ESP32.", [["V cc", "GENE_OR_GENE_PRODUCT", 21, 25], ["ESP32", "GENE_OR_GENE_PRODUCT", 77, 82], ["V cc and GND", "DNA", 21, 33], ["ESP32", "PROTEIN", 77, 82], ["all sensors", "TEST", 4, 15], ["the V cc and GND", "TREATMENT", 17, 33], ["the V cc and GND pin of ESP32", "TREATMENT", 53, 82]]], ["In the case of heart beat sensor, the signal pin is connected with D26 pin of ESP32.", [["heart", "ANATOMY", 15, 20], ["heart", "ORGAN", 15, 20], ["ESP32", "GENE_OR_GENE_PRODUCT", 78, 83], ["D26 pin", "PROTEIN", 67, 74], ["ESP32", "PROTEIN", 78, 83], ["D26 pin of ESP32", "TREATMENT", 67, 83], ["heart", "ANATOMY", 15, 20]]], ["The data pin of LM35 is mapped with D35 pin of microcontroller (ESP32).", [["LM35", "DNA", 16, 20], ["ESP32", "PROTEIN", 64, 69], ["D35 pin of microcontroller", "TREATMENT", 36, 62]]], ["These are the case with a specific patient.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42]]], ["For room condition monitoring, the data pin of DHT11 is linked with ESP32's D14 pin.", [["DHT11", "GENE_OR_GENE_PRODUCT", 47, 52], ["DHT11", "DNA", 47, 52], ["ESP32's D14 pin", "DNA", 68, 83], ["room condition monitoring", "TEST", 4, 29], ["the data pin", "TEST", 31, 43], ["ESP32", "TEST", 68, 73]]], ["In the implementation, DHT11 is only considered for room humidity measurement.", [["DHT11", "SIMPLE_CHEMICAL", 23, 28], ["DHT11", "DNA", 23, 28], ["room humidity measurement", "TEST", 52, 77]]], ["The digital out pin of MQ-9 and MQ-135 are connected with D27 and D34 of ESP32, respectively, for the measurement of toxic gases in room environment.Implementation DetailsThe user prototype is depicted in Fig. 3b where the system is tested with one user.", [["MQ-9", "CHEMICAL", 23, 27], ["MQ-135", "CHEMICAL", 32, 38], ["MQ-9", "CHEMICAL", 23, 27], ["MQ-135", "CHEMICAL", 32, 38], ["MQ-135", "SIMPLE_CHEMICAL", 32, 38], ["ESP32", "GENE_OR_GENE_PRODUCT", 73, 78], ["ESP32", "DNA", 73, 78], ["MQ", "TEST", 23, 25], ["MQ", "TEST", 32, 34], ["D27", "TREATMENT", 58, 61], ["ESP32", "TREATMENT", 73, 78], ["toxic gases", "PROBLEM", 117, 128], ["toxic", "OBSERVATION_MODIFIER", 117, 122]]], ["From Fig. 3b , it can be shown that the hand of one user is attached with body temperature sensor (LM35) and the data are displayed in the web server.Experimental Results AnalysisThe developed system was tested with various subjects of different ages in different conditions.", [["hand", "ANATOMY", 40, 44], ["body", "ANATOMY", 74, 78], ["hand", "ORGANISM_SUBDIVISION", 40, 44], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["body temperature sensor", "TEST", 74, 97]]], ["In the test cases, for heartbeat, body temperature, and room temperature sensors, we manually calculated the actual value and observed value from the developed system.", [["body", "ANATOMY", 34, 38], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["heartbeat", "TEST", 23, 32], ["body temperature", "TEST", 34, 50], ["room temperature sensors", "TEST", 56, 80]]], ["Here, the room temperature sensor is used to measure the humidity only.", [["the room temperature sensor", "TREATMENT", 6, 33]]], ["From the data, we measured error rate to show the effectiveness of the system.", [["error rate", "TEST", 27, 37]]], ["As there is no alternative way to measure the toxic gas level, we just show the data of MQ-9 and MQ-135 in the web server.", [["MQ-9", "CHEMICAL", 88, 92], ["MQ-135", "CHEMICAL", 97, 103], ["MQ-9", "CHEMICAL", 88, 92], ["MQ-135", "CHEMICAL", 97, 103], ["the toxic gas level", "TEST", 42, 61], ["MQ", "TEST", 88, 90], ["MQ", "TEST", 97, 99], ["no", "UNCERTAINTY", 12, 14]]], ["The actual and observed data with error rate for heartbeat, body temperature, and room temperature sensors are demonstrated in Tables 1, 2and 3, respectively.To analyze the deviation of data obtained by the developed system from actual data, Fig. 4 is depicted here.", [["body", "ANATOMY", 60, 64], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["error rate", "TEST", 34, 44], ["heartbeat", "TEST", 49, 58], ["body temperature", "TEST", 60, 76], ["room temperature sensors", "TEST", 82, 106]]], ["From Fig. 4 , it is shown that there is some deviation between the actual and observed data.", [["some deviation", "PROBLEM", 40, 54], ["some", "OBSERVATION_MODIFIER", 40, 44], ["deviation", "OBSERVATION", 45, 54]]], ["Figure 4a represents the data for heart rate which are collected using six different subjects of different ages in hospital environment.", [["heart", "ANATOMY", 34, 39], ["heart", "ORGAN", 34, 39], ["heart rate", "TEST", 34, 44], ["heart", "ANATOMY", 34, 39]]], ["The deviation is occurred due to motion artifact which is caused by the movement of patients during treatment.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["The deviation", "PROBLEM", 0, 13], ["motion artifact", "PROBLEM", 33, 48], ["treatment", "TREATMENT", 100, 109], ["deviation", "OBSERVATION", 4, 13], ["motion artifact", "OBSERVATION", 33, 48], ["movement", "OBSERVATION_MODIFIER", 72, 80]]], ["Sometimes, the sensor is displaced that leads to inaccurate data.", [["displaced", "OBSERVATION", 25, 34]]], ["Moreover, scattering of light from other sources causes deviation.", [["scattering", "OBSERVATION_MODIFIER", 10, 20]]], ["The deviation of body temperature is found due to the miss-positioning of the system and environmental effect that is shown in Fig. 4b .", [["body", "ANATOMY", 17, 21], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["The deviation of body temperature", "PROBLEM", 0, 33], ["deviation", "OBSERVATION", 4, 13]]], ["The discrepancy in the case of room humidity is illustrated in Fig. 4c that is happened due to weather (sunny or rainy) of that day.and 3, respectively.The error rate of the developed system for heart rate, body temperature, and room humidity measurement is demonstrated in Fig. 5a -c, respectively.", [["heart", "ANATOMY", 195, 200], ["body", "ANATOMY", 207, 211], ["heart", "ORGAN", 195, 200], ["body", "ORGANISM_SUBDIVISION", 207, 211], ["heart rate", "TEST", 195, 205], ["body temperature", "TEST", 207, 223], ["room humidity measurement", "TEST", 229, 254], ["heart", "ANATOMY", 195, 200]]], ["The highest error rate for the three cases is 4.28%, 0.81%, and 3.07% individually and the lowest cases are 1.49%, 0.41%, and 1.47%, respectively.", [["The highest error rate", "TEST", 0, 22], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["It is notable that for all every case, the error rate is not more than 5% which is acceptable.and 3, respectively.A snapshot of the continuously collected data in web server (ThingSpeak) is illustrated in Fig. 6 .", [["the error rate", "TEST", 39, 53]]], ["The level toxic gases (CO and CO 2 ) are measured in ppm unit.", [["CO", "CHEMICAL", 23, 25], ["CO 2", "CHEMICAL", 30, 34], ["CO", "SIMPLE_CHEMICAL", 23, 25], ["The level toxic gases", "TEST", 0, 21], ["CO", "TEST", 23, 25], ["CO", "TEST", 30, 32], ["toxic", "OBSERVATION_MODIFIER", 10, 15]]], ["Any medical staff can easily monitor the specific patient as well as the room condition where the patient is now through any type of device which has internet access.", [["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 98, 105], ["any type of device", "TREATMENT", 121, 139]]], ["The patient data here is secure because for accessing data, one needs to pass through a password protected system, i.e., only the authentic staff can monitor the system.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["For a smart health environment, there is some specific level of the threshold for these measurements.", [["these measurements", "TEST", 82, 100]]], ["When the data crosses the level, then the medical staff can easily take necessary steps for healthcare.Actual DataObserved Data Fig. 4 Test results of the actual and calculated value. a Heart rate b body temperature c room humidity Page 8 of 11Actual DataSN Computer ScienceConclusionThe system introduced smart healthcare to monitor the basic important signs of patients like heart rate, body temperature, and some measures of hospital room's condition such as room humidity, the level of CO and CO 2 gases.", [["Heart", "ANATOMY", 186, 191], ["heart", "ANATOMY", 377, 382], ["body", "ANATOMY", 389, 393], ["CO", "CHEMICAL", 490, 492], ["CO 2", "CHEMICAL", 497, 501], ["patients", "ORGANISM", 363, 371], ["heart", "ORGAN", 377, 382], ["body", "ORGANISM_SUBDIVISION", 389, 393], ["CO", "SIMPLE_CHEMICAL", 490, 492], ["CO 2 gases", "SIMPLE_CHEMICAL", 497, 507], ["patients", "SPECIES", 363, 371], ["a Heart rate", "TEST", 184, 196], ["heart rate", "TEST", 377, 387], ["body temperature", "PROBLEM", 389, 405], ["CO 2 gases", "TEST", 497, 507], ["Heart", "ANATOMY", 186, 191], ["heart", "ANATOMY", 377, 382]]], ["The rate of success between the observed data and actual data is approximately greater than 95% for all cases of the developed healthcare system.", [["actual data", "TEST", 50, 61]]], ["Authentic medical staff can view and track the data in real-time even though the patients perform the tests outside of the hospital.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["the tests", "TEST", 98, 107]]], ["The system can also benefit nurses and doctors in situations of epidemics or crises as raw medical data can be analyzed in a short time.", [["epidemics", "PROBLEM", 64, 73], ["crises", "PROBLEM", 77, 83]]], ["The system is very useful in the case of infectious disease like a novel coronavirus (COVID-19) treatment.", [["infectious disease", "DISEASE", 41, 59], ["coronavirus", "DISEASE", 73, 84], ["COVID-19", "CHEMICAL", 86, 94], ["coronavirus", "ORGANISM", 73, 84], ["infectious disease", "PROBLEM", 41, 59], ["a novel coronavirus (COVID", "TREATMENT", 65, 91], ["treatment", "TREATMENT", 96, 105], ["infectious", "OBSERVATION", 41, 51]]], ["The developed system will improve the current healthcare system that may protect lots of lives from death.ConclusionAlthough the system looks somewhat bulky, it will be a tiny device by proper manufacturing in the near future.", [["death", "DISEASE", 100, 105], ["death", "PROBLEM", 100, 105], ["somewhat bulky", "PROBLEM", 142, 156], ["a tiny device", "TREATMENT", 169, 182], ["bulky", "OBSERVATION", 151, 156], ["tiny", "OBSERVATION_MODIFIER", 171, 175], ["device", "OBSERVATION", 176, 182]]], ["The video feature can be added for face to face consultation between the doctors and patients.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93]]], ["Some more measures which are very significant to determine a patient's condition like the level of diabetes, respiration monitoring, etc. can be addressed as future work.", [["diabetes", "DISEASE", 99, 107], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["a patient's condition", "PROBLEM", 59, 80], ["diabetes", "PROBLEM", 99, 107], ["respiration monitoring", "TEST", 109, 131], ["diabetes", "OBSERVATION", 99, 107]]], ["Error Rate (%)Fig. 5The error rate of the developed system for each case. a Heart rate b body temperature c room humidity Page 9 of 11 185 SN Computer Science Fig. 6 A snapshot of web server for data visualization. a Heart rate b body temperature c room humidity d level of CO e level of CO 2", [["Heart", "ANATOMY", 217, 222], ["body", "ANATOMY", 230, 234], ["CO", "CHEMICAL", 274, 276], ["CO 2", "CHEMICAL", 288, 292], ["Error Rate", "TEST", 0, 10], ["a Heart rate", "TEST", 74, 86], ["data visualization", "TEST", 195, 213], ["a Heart rate", "TEST", 215, 227], ["body temperature", "TEST", 230, 246], ["room humidity", "TEST", 249, 262], ["CO e level", "TEST", 274, 284], ["CO", "TEST", 288, 290], ["Heart", "ANATOMY", 76, 81], ["Heart", "ANATOMY", 217, 222]]]], "18c628a5ce11f0907f01ae15f6dc9ab072618773": [["IntroductionIn the world of computer algebra software there are two main categories.", [["main categories", "OBSERVATION", 68, 83]]], ["For an advanced user, interoperability and obtaining fine control of hardware resources is challenging.", [["hardware resources", "TREATMENT", 69, 87]]], ["Axiom [12] is a classic example of such a system.", [["Axiom", "CHEMICAL", 0, 5]]], ["Moreover, these problems are exacerbated by systems being proprietary and closed-source, such as Maple [5] , Magma [6] , and Mathematica [18] .", [["Magma", "TEST", 109, 114]]], ["The second category is computer algebra libraries, which add support for symbolic computation to an existing programming environment.", [["symbolic computation", "TREATMENT", 73, 93]]], ["Since such libraries extend existing environments, and are often free (as in free software), they can have a lower barrier to entry and better accessibility.", [["a lower barrier", "TREATMENT", 107, 122]]], ["Some examples are NTL [14] , FLINT [11] , and CoCoALib [1] .IntroductionThe Basic Polynomial Algebra Subprograms (BPAS) library [2] is a free and open-source computer algebra library for polynomial algebra, and is the subject of this paper.", [["FLINT [11]", "SIMPLE_CHEMICAL", 29, 39], ["CoCoALib [1]", "SIMPLE_CHEMICAL", 46, 58], ["The Basic Polynomial Algebra Subprograms", "TREATMENT", 72, 112]]], ["The BPAS library looks to improve the efficiency of end-users through both usability and performance, providing high-performance code along with an interface which incorporates some of the expressibility of a custom computer algebra system.", [["BPAS library", "DNA", 4, 16], ["The BPAS library", "TEST", 0, 16]]], ["Like any computer algebra software, functionality is highly important, yet usability makes the software practical.IntroductionThe implementation of BPAS is focused on performance for modern computer architectures by optimizing for data locality and through the effective use of parallelization.", [["modern computer architectures", "TREATMENT", 183, 212], ["data locality", "TEST", 231, 244]]], ["These techniques have been applied to our implementations of multi-dimensional FFTs, real root isolation, dense modular polynomial arithmetic, and dense integer polynomial multiplications; see [7] and references therein.", [["root", "ANATOMY", 90, 94], ["multi-dimensional FFTs", "TEST", 61, 83], ["real root isolation", "PROBLEM", 85, 104], ["dense modular polynomial arithmetic", "PROBLEM", 106, 141], ["dense integer polynomial multiplications", "PROBLEM", 147, 187], ["root isolation", "OBSERVATION", 90, 104], ["dense", "OBSERVATION_MODIFIER", 106, 111], ["modular", "OBSERVATION_MODIFIER", 112, 119], ["polynomial arithmetic", "OBSERVATION", 120, 141], ["dense", "OBSERVATION_MODIFIER", 147, 152], ["polynomial multiplications", "OBSERVATION", 161, 187]]], ["Recent works have extended BPAS to include arithmetic over large prime fields [8] and sparse multivariate polynomial arithmetic [3] .", [["BPAS", "PROTEIN", 27, 31]]], ["All of this functionality culminates into a high-performance and parallel polynomial system solver (currently under development) based on the theory of regular chains [4] .", [["parallel polynomial system solver", "TREATMENT", 65, 98]]], ["However, in the present discussion, we look to describe our efforts to make these existing high-performance implementations accessible and practical through user-interface design and improved usability.IntroductionUsability includes many things: ease of use in interfaces, syntax, and semantics; mathematical correctness; accessibility and extensibility for end-users; and maintainability for developers.", [["mathematical correctness", "PROBLEM", 296, 320]]], ["The BPAS library follows two driving principles in its design.", [["BPAS library", "DNA", 4, 16]]], ["The second can be described by a common phrase in user experience design: \"make it hard to do the wrong thing.\"IntroductionThe object-oriented nature of C++, along with its automatic memory management, provides a very natural environment for a user-interface.", [["C++", "CHEMICAL", 153, 156], ["C++", "SIMPLE_CHEMICAL", 153, 156], ["its automatic memory management", "TREATMENT", 169, 200]]], ["While C++ is notoriously difficulty to learn, it remains ubiquitous in industry and scientific computing, making it reasonably accessible, and particularly so, if complexity can be well-encapsualted.", [["C++", "CHEMICAL", 6, 9], ["C++", "SIMPLE_CHEMICAL", 6, 9]]], ["Moreover, C++ being a compiled, staticallyand strongly-typed language, further aids the end-user.", [["C++", "SIMPLE_CHEMICAL", 10, 13]]], ["Meanwhile, statically-typed languages have been shown to be beneficial to usability, and decreases development time, compared to dynamic languages [10] .IntroductionIn the present work, we discuss our early efforts to use C++ metaprogramming to aid in the usability of our interface, for which we hope that BPAS will be easily adopted by other practitioners.", [["C++", "CHEMICAL", 222, 225], ["C++", "SIMPLE_CHEMICAL", 222, 225], ["BPAS", "SIMPLE_CHEMICAL", 307, 311], ["C++ metaprogramming", "TREATMENT", 222, 241]]], ["Doing so while maintaining type safety is difficult; syntactically valid operations may yield mathematically invalid operations between incompatible rings.", [["rings", "MULTI-TISSUE_STRUCTURE", 149, 154], ["syntactically valid operations", "TREATMENT", 53, 83], ["incompatible rings", "TREATMENT", 136, 154], ["incompatible rings", "OBSERVATION", 136, 154]]], ["In particular, we look at polynomials adapting to different ground rings in Sect.", [["ground rings", "OBSERVATION", 60, 72]]], ["We conclude and present future work in Section 5.IntroductionWe note that our techniques are not entirely new; the underlying template metaprogramming constructs have been adopted into the C++ standard since as early as C++11.", [["template metaprogramming constructs", "DNA", 126, 161], ["the underlying template metaprogramming constructs", "PROBLEM", 111, 161], ["not entirely", "UNCERTAINTY", 93, 105], ["new", "OBSERVATION_MODIFIER", 106, 109]]], ["For details on C++, templates, and their capabilities, see [17] .Algebraic Hierarchy as a Class HierarchyIn object-oriented programming (OOP) classes form a fundamental part of software design.", [["C++", "SIMPLE_CHEMICAL", 15, 18]]], ["Through a class hierarchy, or a tree of inheritance, classes have increasing specialization while maintaining all of the functionality of their superclasses.", [["increasing", "OBSERVATION_MODIFIER", 66, 76]]], ["The benefits of a class hierarchy are numerous, including providing a common interface to which all objects should adhere, minimizing code duplication, facilitating incremental design, and of course, polymorphism.", [["polymorphism", "PROBLEM", 200, 212]]], ["For example, the class inclusions of some rings 1 , field \u2282 Euclidean domain \u2282 GCD domain \u2282 integral domain \u2282 ring, would allow rings as the topmost superclass with an incremental design down to fields.", [["Euclidean domain", "PROTEIN", 60, 76], ["GCD domain", "PROTEIN", 79, 89], ["integral domain \u2282 ring", "PROTEIN", 92, 114], ["integral domain \u2282 ring", "TREATMENT", 92, 114], ["the topmost superclass", "TREATMENT", 137, 159], ["some", "OBSERVATION_MODIFIER", 37, 41], ["rings", "OBSERVATION_MODIFIER", 42, 47]]], ["Particularly, we look to implement this hierarchy as a collection of abstract classes for the benefits of code re-use and enforcing a uniform interface across all concrete types (e.g. integers, rational numbers).Algebraic Hierarchy as a Class HierarchyUnfortunately, an encoding of algebraic structures as classes in this way yields incorrect type safety.", [["code re-use", "TREATMENT", 106, 117]]], ["Consider the C++ function declaration which could appear in the topmost Ring class: Ring add(Ring x, Ring y).", [["C++", "CHEMICAL", 13, 16], ["Ring add(Ring x, Ring y)", "TREATMENT", 84, 108]]], ["By polymorphism, any two Ring objects could be passed to this function to produce valid code, but, if those objects are from mathematically incompatible rings, this will certainly lead to errors.", [["rings", "MULTI-TISSUE_STRUCTURE", 153, 158], ["any two Ring objects", "PROBLEM", 17, 37], ["mathematically incompatible rings", "PROBLEM", 125, 158], ["Ring objects", "OBSERVATION", 25, 37]]], ["A more robust system is needed to facilitate strict type safety.Algebraic Hierarchy as a Class HierarchySome libraries (see Sect.", [["A more robust system", "TREATMENT", 0, 20], ["Some libraries", "PROBLEM", 104, 118], ["libraries", "OBSERVATION", 109, 118]]], ["Instead, our main idea is to define the interface of a ring (or a particular subclass, e.g. integral domain) in such a way where a function declaration itself restricts its parameters to be from compatible rings.Algebraic Hierarchy as a Class HierarchyIn our algebraic class hierarchy, function declarations themselves restrict their parameters to be from compatible rings through the use of template parameters.", [["integral domain", "PROTEIN", 92, 107], ["a function declaration", "TREATMENT", 129, 151], ["template parameters", "TREATMENT", 392, 411]]], ["This template parameter identifies the concrete ring(s) with which the one being defined is compatible.", [["This template parameter", "TEST", 0, 23], ["concrete", "OBSERVATION_MODIFIER", 39, 47], ["ring", "OBSERVATION_MODIFIER", 48, 52]]], ["This yields the C++ idiom, the Curiously Recurring Template Pattern (CRTP) (see [17, Ch.", [["idiom", "PROBLEM", 20, 25]]], ["16] ).Algebraic Hierarchy as a Class HierarchyWhile CRTP has several functions, it is used here to facilitate static polymorphism.", [["CRTP", "CHEMICAL", 52, 56], ["CRTP", "GENE_OR_GENE_PRODUCT", 52, 56], ["CRTP", "PROTEIN", 52, 56], ["static polymorphism", "PROBLEM", 110, 129]]], ["That is to say, it forces function resolution to occur at compile-time, instead of dynamically at runtime via virtual tables, providing compile-time errors for incompatibility.", [["incompatibility", "PROBLEM", 160, 175]]], ["For example, the topmost Ring class would become a class template Ring and the add function would become Derived add(Derived x, Derived y).Algebraic Hierarchy as a Class HierarchyThis process works from a key observation when considering simultaneously templates and class inheritance: different template parameter specializations produce distinct classes and thus distinct inheritance hierarchies.", [["a class template Ring", "TREATMENT", 49, 70], ["different template parameter specializations", "TREATMENT", 286, 330], ["distinct", "OBSERVATION_MODIFIER", 365, 373], ["inheritance hierarchies", "OBSERVATION", 374, 397]]], ["Thus, each concrete ring defined via CRTP exists in its own class hierarchy, and dynamic dispatch via polymorphism cannot cause runtime inconsistencies.", [["CRTP", "GENE_OR_GENE_PRODUCT", 37, 41], ["CRTP", "PROTEIN", 37, 41]]], ["The Integer class uses template instantiation where it defines its superclass, specializing the Derived parameter of BPASEuclideanDomain to be Integer, following CRTP.", [["BPASEuclideanDomain", "PROTEIN", 117, 136], ["CRTP", "PROTEIN", 162, 166], ["template instantiation", "TREATMENT", 23, 45], ["BPASEuclideanDomain", "TREATMENT", 117, 136]]], ["For example, arithmetic between integers and rational numbers would be restricted.", [["arithmetic between integers and rational numbers", "PROBLEM", 13, 61]]], ["More generally, natural ring embeddings are neglected.", [["ring embeddings", "OBSERVATION", 24, 39]]], ["A RationalNumber constructor taking an Integer parameter thus allows for automatic and implicit conversion, allowing integers to be used as rational numbers.Algebraic Hierarchy as a Class HierarchyThis design via implicit conversion can be seen as giving permission for compatibility between rings by defining such a constructor.", [["A RationalNumber constructor", "TREATMENT", 0, 28], ["an Integer parameter", "TREATMENT", 36, 56], ["automatic and implicit conversion", "TREATMENT", 73, 106]]], ["For genericity and a common structured interface we wish to parameterize polynomials by their ground ring.", [["genericity", "PROBLEM", 4, 14], ["ground ring", "OBSERVATION", 94, 105]]], ["This can be accomplished with a secondary template parameter in addition to the Derived parameter already included by virtue of polynomials existing in the algebraic class hierarchy (see Listing 2) .Algebraic Hierarchy as a Class HierarchyHowever, this is not fully sufficient, and two issues arise.", [["a secondary template parameter", "TREATMENT", 30, 60]]], ["First, while polynomials do form a ring, they often form more specialized algebraic structures, e.g. a GCD domain.", [["GCD domain", "PROTEIN", 103, 113]]], ["Secondly, there is no restriction on the types which can be used as template parameter specializations of the ground ring.", [["restriction on the types", "PROBLEM", 22, 46], ["no", "UNCERTAINTY", 19, 21], ["restriction", "OBSERVATION_MODIFIER", 22, 33], ["ground ring", "OBSERVATION", 110, 121]]], ["Any type used as a specialization of this ground ring template parameter should truly be a ring and not any other nonsense type.", [["this ground ring template parameter", "TREATMENT", 37, 72]]], ["This class defines a function converting the apparent subclass type to the superclass.", [["subclass type", "OBSERVATION_MODIFIER", 54, 67]]], ["All of these functionalities together create an algebraic hierarchy as a class hierarchy while maintaining strict type safety.", [["algebraic hierarchy", "OBSERVATION", 48, 67]]], ["Yet, our scheme remains flexible enough to support implicit conversions, such as natural ring embeddings, and generic enough to allow, for example, polynomials over user-defined classes, as long as those classes inherit from BPASRing.", [["implicit conversions", "TREATMENT", 51, 71], ["natural ring embeddings", "TREATMENT", 81, 104]]], ["What remains now is to address the issue of polynomial rings sometimes forming different algebraic types depending on their particular ground ring.\"Dynamic\" Type Creation, Conditional ExportIn object-oriented design, the combination of types to create another type is known as composition.", [["polynomial rings", "PROBLEM", 44, 60], ["polynomial rings", "OBSERVATION", 44, 60]]], ["In this section, let us consider univariate polynomial rings; one can always work recursively for multivariate polynomials.", [["univariate polynomial rings", "TREATMENT", 33, 60], ["multivariate polynomials", "PROBLEM", 98, 122]]], ["Viewing a polynomial ring as a ring extension of its ground ring, polynomials can be seen as the composition of some finite number of elements of that ground ring.", [["a polynomial ring", "TREATMENT", 8, 25], ["a ring extension of its ground ring", "TREATMENT", 29, 64], ["polynomial ring", "OBSERVATION", 10, 25], ["ground ring", "OBSERVATION", 53, 64], ["some", "OBSERVATION_MODIFIER", 112, 116], ["finite", "OBSERVATION_MODIFIER", 117, 123], ["number", "OBSERVATION_MODIFIER", 124, 130], ["ground ring", "OBSERVATION", 151, 162]]], ["Moreover, we know that the properties of a polynomial ring depend on the properties of the ground ring.", [["a polynomial ring", "TREATMENT", 41, 58], ["polynomial ring", "OBSERVATION", 43, 58], ["ground ring", "OBSERVATION", 91, 102]]], ["For example, the ring of univariate polynomials over a field is a Euclidean domain while the ring of polynomials over a ring is itself only a ring.", [["Euclidean domain", "PROTEIN", 66, 82], ["ring", "OBSERVATION_MODIFIER", 17, 21], ["univariate polynomials", "OBSERVATION", 25, 47], ["ring", "OBSERVATION_MODIFIER", 93, 97], ["ring", "OBSERVATION_MODIFIER", 120, 124], ["ring", "OBSERVATION_MODIFIER", 142, 146]]], ["Recall from the previous section that our implementation of polynomials are templated by their ground ring.", [["ground ring", "OBSERVATION", 95, 106]]], ["Our goal then is to capture the idea that the position of a polynomial ring in the algebraic class hierarchy changes depending on the particular specialization of this template parameter.\"Dynamic\" Type Creation, Conditional ExportMore generally, we would like that the type resulting from the composition of another type depends on the type being composed.", [["a polynomial ring", "TREATMENT", 58, 75], ["polynomial ring", "OBSERVATION", 60, 75]]], ["This is not truly dynamic, since it is a compile-time operation, but it nonetheless feels dynamic since it is an automatic process by the compiler via template instantiation.", [["a compile-time operation", "TREATMENT", 39, 63], ["the compiler via template instantiation", "TREATMENT", 134, 173], ["not truly", "UNCERTAINTY", 8, 17], ["dynamic", "OBSERVATION", 18, 25]]], ["This technique relies on compile-time introspection and SFINAE.SFINAE and Compile-Time IntrospectionSubstitution Failure Is Not An Error (SFINAE), coined by Vandevoorde in [17] , refers to a fundamental part of C++ templating.", [["C++", "CHEMICAL", 211, 214], ["C++", "SIMPLE_CHEMICAL", 211, 214], ["Failure", "OBSERVATION", 113, 120]]], ["The invalid substitution of a type as a template parameter is itself not an error.", [["a template parameter", "TREATMENT", 38, 58], ["invalid substitution", "OBSERVATION", 4, 24]]], ["Such a principle is required for templates to be practical.", [["templates", "TREATMENT", 33, 42]]], ["Where two or more template specializations exist, it is not required that the substitution of the template parameter fit all of the specializations, but only one.", [["the substitution of the template parameter", "TREATMENT", 74, 116]]], ["This principle, combined with compile-time function overload resolution, provides template metaprogramming its power.", [["overload resolution", "PROBLEM", 52, 71], ["overload", "OBSERVATION_MODIFIER", 52, 60], ["resolution", "OBSERVATION_MODIFIER", 61, 71]]], ["By function overload resolution, if T has a member X the test function chosen will be the first, whose return type has size 1.", [["the test function", "TEST", 53, 70], ["overload", "OBSERVATION_MODIFIER", 12, 20], ["resolution", "OBSERVATION_MODIFIER", 21, 31], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["Otherwise the second function is chosen with return type of size (at least) 2.", [["size", "OBSERVATION_MODIFIER", 60, 64]]], ["1 template < typename T > char test ( typename T :: X const *) ; 2 template < typename T > int test (...); 3 # define type_has_X (T) ( sizeof ( test ( NULL )) == 1);Listing 3.", [["1 template", "TEST", 0, 10]]], ["A simple compile-time introspection to determine if type T has member X.This idea can be generalized to many introspective metaprogramming techniques.", [["many introspective metaprogramming techniques", "TREATMENT", 104, 149]]], ["For example, is base of, a standard feature in C++11, is much like Derived from.", [["base", "OBSERVATION_MODIFIER", 16, 20]]], ["A simple compile-time introspection to determine if type T has member X.Using introspection, one may think that enable if, another standard C++11 template construct, is sufficient.", [["C++11 template construct", "DNA", 140, 164], ["another standard C++11 template construct", "TREATMENT", 123, 164]]], ["The enable if struct template conditionally compiles and exposes a function template based on the value of a Boolean known at compile-time.", [["a function template", "TREATMENT", 65, 84]]], ["Unfortunately, function templates cannot be virtual, thus this solution cannot be used within a class hierarchy.", [["this solution", "TREATMENT", 58, 71]]], ["Conditionally exposing methods in our algebraic class hierarchy requires a different solution.Conditional Inheritance for PolynomialsDefining new types dependent on the value of another type, as well as conditionally exposing member functions, can both be fulfilled by conditional inheritance.", [["Polynomials", "DISEASE", 122, 133], ["a different solution", "TREATMENT", 73, 93], ["new", "OBSERVATION_MODIFIER", 142, 145], ["types dependent", "OBSERVATION_MODIFIER", 146, 161]]], ["Specifically, we implement a compile-time case discussion for inheritance based on introspective values.", [["introspective values", "TEST", 83, 103]]], ["For example: if R is a field, thenConditional Inheritance for Polynomialsis a ring.", [["Polynomialsis a ring", "TREATMENT", 62, 82]]], ["Using is base of to determine the Boolean, conditional chooses one of two types to use as a class's superclass.Conditional Inheritance for PolynomialsAs a simple example, consider Listing 4.", [["PolynomialsAs", "PROBLEM", 139, 152]]], ["The definition of BPASPolynomial tests if the Ring template parameter is a subclass of BPASField.", [["BPASField", "PROTEIN", 87, 96], ["BPASPolynomial tests", "TEST", 18, 38], ["the Ring template parameter", "TREATMENT", 42, 69]]], ["Additionally, a concrete class SparseUnivarPoly is shown, still parameterized by a coefficient ring.", [["a coefficient ring", "TREATMENT", 81, 99]]], ["Notice also that the template parameter of SparseUnivarPoly is enforced to be a subclass of BPASRing on specialization via the Derived from of its superclass.", [["SparseUnivarPoly", "CHEMICAL", 43, 59], ["SparseUnivarPoly", "TREATMENT", 43, 59]]], ["1 template < class Ring , class Derived > 2 class BPASPolynomial : conditional < is_base_of >:: value , 3 BPASEuclideanDomain < Derived >, 4 BPASRing < Derived > >:: type , 5 Derived_from < Ring , BPASRing < Ring > >; 6 7 template < class CoefRing > 8 class SparseUnivarPoly : BPASPolynomial < CoefRing , SparseUnivarPoly < CoefRing >>;Conditional Inheritance for PolynomialsListing 4.", [["value", "TEST", 96, 101], ["BPASRing", "TEST", 141, 149], ["type", "TEST", 166, 170], ["Ring", "TEST", 190, 194], ["BPASRing", "TEST", 197, 205], ["Ring", "TEST", 208, 212], ["CoefRing", "TEST", 239, 247], ["BPASPolynomial", "TEST", 277, 291], ["SparseUnivarPoly", "TREATMENT", 305, 321]]], ["A simple use of conditional to choose between Euclidean domain or ring as the algebraic type of a polynomial based on its template parameter.Conditional Inheritance for PolynomialsThe presented code for BPASPolynomial in Listing 4 is rather simple, showing only a single type check.", [["Euclidean domain", "TREATMENT", 46, 62], ["a polynomial", "TREATMENT", 96, 108], ["a single type check", "TEST", 262, 281]]], ["To implement a chain of type checks, the \"else\" branch of a conditional should simply be another conditional.", [["type checks", "TEST", 24, 35]]], ["Instead, we create two symmetric class hierarchies, one representing the true algebraic class inclusions while the other is a \"tester\" hierarchy.Conditional Inheritance for PolynomialsThis tester hierarchy uses one conditional to determine if a property holds and, if so, chooses the corresponding class from the algebraic hierarchy as superclass.", [["symmetric", "OBSERVATION_MODIFIER", 23, 32], ["class hierarchies", "OBSERVATION", 33, 50], ["algebraic class", "OBSERVATION", 78, 93], ["inclusions", "OBSERVATION", 94, 104]]], ["Otherwise, the next tester in the hierarchy is chosen as superclass to trigger the evaluation of the next conditional.", [["the evaluation", "TEST", 79, 93]]], ["Finally, all concrete polynomial classes inherit from BPASPolynomial to automatically determine their correct interface based on their ground ring.", [["ground ring", "OBSERVATION", 135, 146]]], ["This structure is shown in Fig. 1 , with the algebraic hierarchy on the left, and the tester hierarchy on the right.", [["left", "ANATOMY", 72, 76], ["Fig", "OBSERVATION_MODIFIER", 27, 30], ["algebraic", "OBSERVATION_MODIFIER", 45, 54], ["hierarchy", "OBSERVATION", 55, 64], ["left", "ANATOMY_MODIFIER", 72, 76], ["tester", "OBSERVATION_MODIFIER", 86, 92], ["hierarchy", "OBSERVATION_MODIFIER", 93, 102], ["right", "ANATOMY_MODIFIER", 110, 115]]], ["For example, based on the specialization of a template parameter, the definition of a class template can be changed automatically and dynamically.", [["a template parameter", "TREATMENT", 44, 64], ["a class template", "TREATMENT", 84, 100]]], ["Not only does this enforce a proper class interface, but it allows the possibility of choosing between several different abstract implementations in order to best support the new type (i.e. the result of a composition).Discussion and Related WorkFor decades, computer algebra systems have worked towards type safety.", [["several different abstract implementations", "TREATMENT", 103, 145]]], ["Axiom [12] is a pioneering work on that front, but has grown out of popularity.", [["Axiom", "CHEMICAL", 0, 5]]], ["However, while powerful, functional languages can be seen as an obscure and inaccessible programming paradigm compared to the mainstream imperative paradigm.Discussion and Related WorkConsidering other C/C++ computer algebra libraries, there are many examples with interesting mechanisms for handling algebraic structures.", [["C/C++ computer algebra libraries", "DNA", 202, 234], ["inaccessible programming paradigm", "PROBLEM", 76, 109]]], ["The Singular library [9] perhaps has the most simple mechanism: a single class represents all rings, using a number of enum and Boolean variables to determine properties of instances at runtime.", [["enum", "SIMPLE_CHEMICAL", 119, 123]]], ["While rings are subclasses of RingBase, elements of a ring are an entirely different class.", [["RingBase", "GENE_OR_GENE_PRODUCT", 30, 38], ["RingBase", "PROTEIN", 30, 38], ["subclasses", "OBSERVATION_MODIFIER", 16, 26]]], ["LinBox [15] also has separate classes for rings and their elements.", [["LinBox", "CHEMICAL", 0, 6]]], ["There, ring properties are encoded as class templates where concrete rings use explicit template specialization to define properties.Discussion and Related WorkMuch like the previous cases, the Mathemagix system requires instances (i.e. elements) of a ring to have a specific reference to a separate entity encoding the ring itself.", [["concrete rings", "TREATMENT", 60, 74], ["explicit template specialization", "TREATMENT", 79, 111], ["the Mathemagix system", "TREATMENT", 190, 211]]], ["Notably, Mathemagix also includes a scheme to import and export C++ code to and from the Mathemagix language [16].", [["C", "PROTEIN", 64, 65]]], ["This uses templates to allow, for example, a ring specified in the Mathemagix language to be used as the coefficient ring for polynomials defined in C++.Discussion and Related WorkIn all of these cases there is some limiting factor.", [["a ring", "TREATMENT", 43, 49], ["the Mathemagix language", "TREATMENT", 63, 86]]], ["In some cases this is implemented by separating rings themselves from elements of a ring, a process counterintuitive to object-oriented design where one class should define the behaviour of all instances of that type.Discussion and Related WorkOn the contrary, our scheme does not rely on runtime checks.", [["runtime checks", "TEST", 289, 303]]], ["Instead, a function declaration itself restricts its arguments to be mathematically compatible at compile-time via the use of template parameters and the Curiously Recurring Template Pattern.", [["a function declaration", "TREATMENT", 9, 31], ["template parameters", "TREATMENT", 126, 145], ["Template Pattern", "OBSERVATION", 174, 190]]], ["The symmetry between the algebraic hierarchy and our class hierarchy hopes to make our interfaces natural and approachable to an end-user.", [["symmetry", "OBSERVATION_MODIFIER", 4, 12], ["algebraic", "ANATOMY_MODIFIER", 25, 34], ["hierarchy", "ANATOMY_MODIFIER", 35, 44]]], ["This symmetry comes at the price of creating a deep class hierarchy, and thus strong coupling within the class hierarchy.", [["deep class", "OBSERVATION_MODIFIER", 47, 57], ["hierarchy", "OBSERVATION", 58, 67]]], ["Yet, this price is worth the symmetry and comprehensibility of the class hierarchy with the algebraic hierarchy.Discussion and Related WorkIn contrast with our class hierarchy solution to type safety, a different compile-time solution could be crafted through further use of type traits (see, e.g., [17, Ch.", [["a different compile-time solution", "TREATMENT", 201, 234], ["algebraic hierarchy", "OBSERVATION", 92, 111]]], ["Type traits are template metaprogramming constructs for type introspection and modification, some of which have already been seen, such as is base of, and conditional.", [["template metaprogramming constructs", "DNA", 16, 51], ["Type traits", "PROBLEM", 0, 11], ["template metaprogramming constructs", "TREATMENT", 16, 51], ["base", "OBSERVATION_MODIFIER", 142, 146]]], ["Type traits are arguably more flexible, however, template metaprogramming is already rather difficult, and is essentially limited to C++.", [["Type traits", "PROBLEM", 0, 11], ["template metaprogramming", "PROBLEM", 49, 73], ["more flexible", "OBSERVATION_MODIFIER", 25, 38]]], ["Class hierarchies, on the other hand, are present in every object-oriented language and should therefore be more accessible to end-users.", [["hierarchies", "OBSERVATION", 6, 17]]], ["The use of class hierarchies, in addition to encapsulating much of the template metaprogramming in our design, should provide better extensibility to end-users in general.Conclusion and Future WorkIn this work we have explored part of the implementation and design of the C++ interface of the BPAS library.", [["BPAS library", "DNA", 293, 305], ["the template metaprogramming", "TREATMENT", 67, 95]]], ["Through the use of template metaprogramming we have devised a so-called algebraic class hierarchy which directly models the algebraic hierarchy while providing compile-time type safety.", [["template metaprogramming", "TREATMENT", 19, 43]]], ["This hierarchy is type-safe both in the programming language sense and the mathematical sense.Conclusion and Future WorkUsing inheritance throughout the algebraic abstract class hierarchy, the interface of algebraic types is constructed incrementally.", [["algebraic types", "OBSERVATION", 206, 221]]], ["Through additional templating techniques, we can automatically infer, at compile-time, the correct superclass (and thus interface) of new types created by template parameter specialization (e.g. polynomials).", [["additional templating techniques", "TREATMENT", 8, 40]]], ["The result is a consistent and enforced interface for all classes modelling algebraic types.Conclusion and Future WorkWe are currently working to extend our algebraic class hierarchy to include multivariate power series, polynomials with power series coefficients, and polynomials in prime characteristic.", [["multivariate power series", "TEST", 194, 219], ["power series coefficients", "TEST", 238, 263]]], ["This more capable hierarchy will be used within our library to implement a sophisticated solver for systems of polynomial equations, a prototype of which is already available in recent releases of BPAS.", [["BPAS", "GENE_OR_GENE_PRODUCT", 197, 201], ["BPAS", "PROTEIN", 197, 201], ["polynomial equations", "PROBLEM", 111, 131]]], ["Finally, we hope to create a Python interface to the BPAS library (i.e. an extension module) to further improve the accessibility and ease of use of our library.", [["BPAS library", "DNA", 53, 65], ["an extension module", "TREATMENT", 72, 91], ["our library", "TREATMENT", 149, 160]]]], "PMC7264612": [["INTRODUCTIONThe COVID\u201019 pandemic, caused by SARS\u2010CoV\u20102, has been implicated in over 800 000 cases in the United States alone and has been found to affect as many as 28% of HCW worldwide.1, 2 Physicians across specialties have had to make rapid decisions about personal protective equipment (PPE), patient care triaging, and navigating national and international guidelines that continue to evolve.", [["SARS", "DISEASE", 45, 49], ["SARS\u2010CoV\u20102", "ORGANISM", 45, 55], ["patient", "ORGANISM", 298, 305], ["patient", "SPECIES", 298, 305], ["SARS\u2010CoV", "SPECIES", 45, 53]]], ["These decisions are not uniform and vary within the context of individual location's infection rate and available resources.INTRODUCTIONThis is of special concern to otolaryngologists, who are among the highest risk specialties for COVID\u201019 exposure from nasal and mucosal procedures and examinations.3, 4 The highest concentration of viral particles is found in the nasopharynx and routine procedures performed by otolaryngologists can easily aerosolize viral particles and allow for airborne trasmission.5, 6 In these early days of the pandemic, recommendations to keep both patients and providers safe were made based on data from Wuhan, China; Northern Italy; and extrapolations from the SARS\u2010CoV\u20101 epidemic.", [["nasal", "ANATOMY", 255, 260], ["mucosal", "ANATOMY", 265, 272], ["nasopharynx", "ANATOMY", 367, 378], ["infection", "DISEASE", 85, 94], ["SARS", "DISEASE", 692, 696], ["nasal", "MULTI-TISSUE_STRUCTURE", 255, 260], ["mucosal", "MULTI-TISSUE_STRUCTURE", 265, 272], ["nasopharynx", "ORGAN", 367, 378], ["patients", "ORGANISM", 577, 585], ["patients", "SPECIES", 577, 585], ["SARS\u2010CoV", "SPECIES", 692, 700], ["individual location's infection rate", "PROBLEM", 63, 99], ["nasal and mucosal procedures", "TEST", 255, 283], ["examinations", "TEST", 288, 300], ["viral particles", "PROBLEM", 335, 350], ["routine procedures", "TREATMENT", 383, 401], ["airborne trasmission", "TREATMENT", 485, 505], ["nasal", "ANATOMY", 255, 260], ["mucosal", "ANATOMY", 265, 272], ["viral particles", "OBSERVATION", 335, 350], ["nasopharynx", "ANATOMY", 367, 378]]], ["Givi et al distilled these recommendations into specifics regarding protective equipment (PPE) and practice considerations for head and neck surgeons during the COVID\u201019 pandemic.7The implementation of these recommendations has been variable across institutions, likely based upon regional COVID19 case load and resource availability.INTRODUCTIONAs a subspecialty, head and neck cancer surgeons have had to balance infection risk with patient care.", [["head", "ANATOMY", 127, 131], ["neck", "ANATOMY", 136, 140], ["head and neck cancer", "ANATOMY", 365, 385], ["head and neck cancer", "DISEASE", 365, 385], ["infection", "DISEASE", 415, 424], ["head", "ORGANISM_SUBDIVISION", 127, 131], ["head and neck cancer", "CANCER", 365, 385], ["patient", "ORGANISM", 435, 442], ["patient", "SPECIES", 435, 442], ["protective equipment", "TREATMENT", 68, 88], ["head and neck surgeons", "TREATMENT", 127, 149], ["pandemic", "PROBLEM", 170, 178], ["head and neck cancer", "PROBLEM", 365, 385], ["neck", "ANATOMY", 136, 140], ["head", "ANATOMY", 365, 369], ["neck", "ANATOMY", 374, 378], ["cancer", "OBSERVATION", 379, 385]]], ["Surgery remains a mainstay for head and neck cancer treatment, but poses a high risk of viral exposure.", [["head and neck cancer", "ANATOMY", 31, 51], ["head and neck cancer", "DISEASE", 31, 51], ["head and neck cancer", "CANCER", 31, 51], ["Surgery", "TREATMENT", 0, 7], ["head and neck cancer treatment", "TREATMENT", 31, 61], ["viral exposure", "PROBLEM", 88, 102], ["neck", "ANATOMY", 40, 44], ["cancer", "OBSERVATION", 45, 51], ["viral exposure", "OBSERVATION", 88, 102]]], ["Surgical treatment delays have been shown to significantly increase the risk of recurrence and reduce overall survival.8, 9 Thus, head and neck surgeons are tasked with triaging patient care and balancing their decisions with the safety of themselves, their team, and support staff.", [["head", "ANATOMY", 130, 134], ["neck", "ANATOMY", 139, 143], ["head", "ORGANISM_SUBDIVISION", 130, 134], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["Surgical treatment delays", "TREATMENT", 0, 25], ["recurrence", "PROBLEM", 80, 90], ["triaging patient care", "TREATMENT", 169, 190], ["recurrence", "OBSERVATION", 80, 90], ["head", "ANATOMY", 130, 134], ["neck", "ANATOMY", 139, 143]]], ["Patients with cancer have significantly higher rates of morbidity and mortality if infected with the novel coronavirus, but a cohesive approach to testing patients and weighing the risks of patient exposure with resource utilization and patient survival is lacking.10", [["cancer", "ANATOMY", 14, 20], ["cancer", "DISEASE", 14, 20], ["coronavirus", "DISEASE", 107, 118], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 14, 20], ["coronavirus", "ORGANISM", 107, 118], ["patients", "ORGANISM", 155, 163], ["patient", "ORGANISM", 190, 197], ["patient", "ORGANISM", 237, 244], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 155, 163], ["patient", "SPECIES", 190, 197], ["patient", "SPECIES", 237, 244], ["cancer", "PROBLEM", 14, 20], ["the novel coronavirus", "PROBLEM", 97, 118], ["resource utilization", "TREATMENT", 212, 232], ["cancer", "OBSERVATION", 14, 20]]]], "64b8a7e0e340693c3071f728769ee162fa217270": [["I. INTRODUCTIONT HIS PAPER describes the model repository (MREP) of models of infectious disease agent study (MIDAS), which is a tool developed to organize and catalog the models, results, and suggestions for using results of the MIDAS and store them in a relational database for future use and reference.", [["infectious disease", "DISEASE", 78, 96], ["infectious disease agent study", "TEST", 78, 108], ["infectious", "OBSERVATION", 78, 88]]], ["The database is a repository of epidemiological-based infectious disease models and their derivatives (e.g., inputs, parameters, and outputs).", [["infectious disease", "DISEASE", 54, 72], ["their derivatives", "TREATMENT", 84, 101], ["infectious", "OBSERVATION", 54, 64]]], ["These products will be stored to allow easy retrieval via a query method.", [["a query method", "TREATMENT", 58, 72]]], ["This section gives a brief explanation of the MIDAS and the rationale for the MREP, and identifies other related tools in the literature.", [["the MREP", "TEST", 74, 82]]], ["Section II presents the architecture and design of the MREP.", [["MREP", "DNA", 55, 59], ["the MREP", "TEST", 51, 59]]], ["The MREP's key design elements include the ability to link all related model components together and to include a version control tool as part of the relational data base management system (RDBMS) data model.", [["MREP", "DNA", 4, 8], ["a version control tool", "TREATMENT", 112, 134]]], ["Section III describes the content of the MREP, including the information about the MIDAS models and the studies they comprise.", [["the studies", "TEST", 100, 111]]], ["Section IV summarizes key features of the MREP and discusses future enhancements.A. MIDASThe MIDAS is a research partnership between the National Institutes of Health (NIH) and the scientific community to develop computational models for policymakers, public health workers, and researchers to help them make better-informed decisions about emerging infectious diseases-both man made and naturally occurring.", [["infectious diseases", "DISEASE", 350, 369], ["man", "ORGANISM", 375, 378], ["MREP", "DNA", 42, 46], ["man", "SPECIES", 375, 378]]], ["The MIDAS researchers are working to develop models that can assist the public health community understand how best to respond during outbreaks and epidemics.", [["epidemics", "PROBLEM", 148, 157]]], ["The MIDAS consists of seven research groups and one centralized informatics group.A. MIDAS1) MIDAS Objectives: The MIDAS Research Groups develop epidemiological models that represent host-pathogen relationships, disease epidemiology and forecasting systems, and pandemic response strategies.", [["forecasting systems", "TEST", 237, 256], ["pandemic response strategies", "TREATMENT", 262, 290], ["MIDAS", "OBSERVATION_MODIFIER", 4, 9]]], ["As a collaborative network of scientists, the MIDAS investigates using computational and mathematical models that will prepare the nation to respond to outbreaks of infectious diseases by providing policymakers and public health officials with reliable and timely information that can be used to prepare for infectious disease outbreaks.A. MIDAS2) Epidemiological Models: Epidemic models represent powerful tools for gaining insight into how the dynamics of an epidemic are affected by interventions.", [["infectious diseases", "DISEASE", 165, 184], ["infectious disease outbreaks", "DISEASE", 308, 336], ["infectious diseases", "PROBLEM", 165, 184], ["infectious disease outbreaks", "PROBLEM", 308, 336], ["Epidemic models", "PROBLEM", 372, 387]]], ["In order to understand and control the spread of pathogens, it is essential to establish some of the key parameters associated with disease transmission.", [["pathogens", "PROBLEM", 49, 58], ["disease transmission", "PROBLEM", 132, 152]]], ["Fundamental to the dynamics of an epidemic are two quantities: the basic reproduction number (R0) and the generation time (Tg) of the pathogen [1] .", [["epidemic", "OBSERVATION", 34, 42]]], ["The R0 is the average number of secondary cases produced by each primary case at the start of an epidemic in a previously unaffected population.", [["average", "OBSERVATION_MODIFIER", 14, 21], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["The Tg is the average time between infection of index cases and the secondary cases they produce.", [["infection", "DISEASE", 35, 44], ["infection of index cases", "PROBLEM", 35, 59]]], ["The R0 is a measure of the transmissibility of the strain in the population, and largely determines the proportion of the population that will be infected in a pandemic.", [["the strain", "PROBLEM", 47, 57], ["strain", "OBSERVATION_MODIFIER", 51, 57], ["population", "OBSERVATION_MODIFIER", 65, 75], ["infected", "OBSERVATION", 146, 154]]], ["The ratio R0/Tg is a measure of an epidemic's rate of growth.A. MIDASMany epidemiological models are based on a compartmental, Sampling Importance Resampling (SIR) framework; the host population is partitioned into those that are susceptible, infected, or immune to a particular pathogen.", [["The ratio", "TEST", 0, 9], ["infected", "PROBLEM", 243, 251], ["a particular pathogen", "PROBLEM", 266, 287], ["infected", "OBSERVATION", 243, 251]]], ["These models assume that the rate at which new infections are acquired is proportional to the number of encounters between susceptible and infected individuals, and leads to an effective reproductive ratio that depends on a threshold density of susceptibles.", [["infections", "DISEASE", 47, 57], ["the rate", "TEST", 25, 33], ["new infections", "PROBLEM", 43, 57], ["susceptible and infected individuals", "PROBLEM", 123, 159], ["an effective reproductive ratio", "PROBLEM", 174, 205], ["a threshold density of susceptibles", "PROBLEM", 222, 257], ["new", "OBSERVATION_MODIFIER", 43, 46], ["infections", "OBSERVATION", 47, 57], ["infected", "OBSERVATION_MODIFIER", 139, 147], ["effective", "OBSERVATION_MODIFIER", 177, 186], ["reproductive", "OBSERVATION", 187, 199]]], ["Thus, the models depend not only on parameters intrinsic to the disease such as latent and infectious periods, but also on contacts between infectious and susceptible hosts.", [["the disease", "PROBLEM", 60, 71], ["latent and infectious periods", "PROBLEM", 80, 109], ["disease", "OBSERVATION", 64, 71], ["latent", "OBSERVATION_MODIFIER", 80, 86], ["infectious", "OBSERVATION_MODIFIER", 91, 101]]], ["Compartmental models of this kind implicitly assume that the host population is well mixed, such that the probability of infection is equal for all.A. MIDASHowever, social network structures are clearly not always well mixed, and the complexities of host interactions may have profound implications for the interpretation of epidemiological models and clinical data.", [["infection", "DISEASE", 121, 130], ["network structures", "MULTI-TISSUE_STRUCTURE", 172, 190], ["infection", "PROBLEM", 121, 130], ["clinical data", "TEST", 352, 365], ["infection", "OBSERVATION", 121, 130]]], ["Agent-based models (ABMs) represent an important new approach for describing interacting heterogeneous agents.", [["interacting heterogeneous agents", "TREATMENT", 77, 109]]], ["The heterogeneous aspect of agents enables more sophisticated and complex environments to be described by ABMs approaches.", [["heterogeneous", "OBSERVATION_MODIFIER", 4, 17]]], ["Thus, every ABM run identifies infected persons where they live and work in general, and their movements within groups (referred to as social networks) that influence disease spread.", [["persons", "ORGANISM", 40, 47], ["persons", "SPECIES", 40, 47], ["influence disease spread", "PROBLEM", 157, 181], ["infected", "OBSERVATION", 31, 39]]], ["ABMs have been used to describe phenomena from social systems to immune systems, both of which are distributed collections of interacting entities (agents) that function without a leader.", [["ABMs", "CELL_TYPE", 0, 4], ["ABMs", "TREATMENT", 0, 4]]], ["An ABM consists of a set of agents that encapsulate the behaviors of the individuals that make up the system, and model execution consists of emulating these behaviors [2] .A. MIDAS3) Models of Influenza Transmission: The major focus of the MIDAS research partnership has been pandemic influenza.", [["Influenza", "DISEASE", 194, 203], ["influenza", "DISEASE", 286, 295], ["An ABM", "TEST", 0, 6], ["a set of agents", "TREATMENT", 19, 34], ["pandemic influenza", "PROBLEM", 277, 295]]], ["In response to the MIDAS mission (see http://grants.nih.gov/ grants/guide/notice-files/NOT-GM-06-106.html), a number of large ABMs describing influenza transmission were developed.", [["influenza transmission", "DISEASE", 142, 164], ["ABMs", "CANCER", 126, 130], ["large ABMs describing influenza transmission", "PROBLEM", 120, 164], ["large", "OBSERVATION_MODIFIER", 120, 125]]], ["The main purpose of the models was to examine possible intervention strategies that would protect the general public from morbidity and mortality should an influenza pandemic strike.", [["influenza pandemic", "DISEASE", 156, 174], ["intervention strategies", "TREATMENT", 55, 78], ["an influenza pandemic strike", "PROBLEM", 153, 181], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["One of the initial objectives in all disease transmission studies is to determine the basic R0 value.", [["all disease transmission studies", "TEST", 33, 65]]], ["The goal of intervention is to reduce R0 below the self-sustaining threshold of R0 = 1.", [["intervention", "TREATMENT", 12, 24], ["R0", "TREATMENT", 38, 40]]], ["The R0 of a future newly emergent influenza strain is unknown, but estimates for previous pandemics are available.", [["influenza", "DISEASE", 34, 43], ["a future newly emergent influenza strain", "PROBLEM", 10, 50], ["previous pandemics", "PROBLEM", 81, 99], ["influenza", "OBSERVATION", 34, 43]]], ["For example, an estimate of 1.89 was obtained for the pandemic of 1968 in Hong Kong [3] , and the pandemic of 1957 in Great Britain (GB) was estimated to be between 1.5-1.7 [4] .", [["an estimate", "TEST", 13, 24], ["the pandemic", "TEST", 94, 106]]], ["There is historical evidence that these three influenza pandemics were explosive.", [["influenza pandemics", "DISEASE", 46, 65], ["these three influenza pandemics", "PROBLEM", 34, 65]]], ["The results reported by the MIDAS also suggest that the pandemics can be controlled to some degree.", [["the pandemics", "PROBLEM", 52, 65]]], ["By comparison, childhood diseases such as rubella, pertussis, and measles have R0 values in most populations in the range 7-15 [6] , and consequently, are much less controllable.A. MIDASTo estimate the effect of various interventions on the spread of pandemic influenza, the effect of specific interventions on transmission rates needs to be quantified.", [["rubella, pertussis", "DISEASE", 42, 60], ["measles", "DISEASE", 66, 73], ["influenza", "DISEASE", 260, 269], ["childhood diseases", "PROBLEM", 15, 33], ["rubella", "PROBLEM", 42, 49], ["pertussis", "PROBLEM", 51, 60], ["measles", "PROBLEM", 66, 73], ["R0 values", "TEST", 79, 88], ["various interventions", "TREATMENT", 212, 233], ["pandemic influenza", "PROBLEM", 251, 269], ["specific interventions", "TREATMENT", 285, 307], ["transmission rates", "TREATMENT", 311, 329], ["diseases", "OBSERVATION", 25, 33]]], ["Generally, estimates of the proportion of infections that occur in the various social contexts such as households, schools, workplaces, and communities have been reported.", [["infections", "DISEASE", 42, 52], ["infections", "PROBLEM", 42, 52], ["infections", "OBSERVATION", 42, 52]]], ["Then, estimates of relative effect of intervention measures on transmission in each context will need to be established.", [["intervention measures", "TREATMENT", 38, 59]]], ["For example, we would like to know the extent to which household and community contacts are increased when schools are closed.A. MIDASThere is scant information on the proportion of transmission that occurs in different social contexts.", [["scant", "OBSERVATION", 143, 148]]], ["Therefore, while models can give some insight into the likely benefit of single or combined interventions, that insight is somewhat limited by this lack of data.", [["single or combined interventions", "TREATMENT", 73, 105]]], ["To some extent, the results depend on the assumptions made by the modelers about transmission in the different contexts.", [["some extent", "OBSERVATION_MODIFIER", 3, 14]]], ["The degree of uncertainty does depend on the specific control measures.", [["degree", "OBSERVATION_MODIFIER", 4, 10], ["uncertainty", "OBSERVATION", 14, 25]]], ["Modelers can arguably better project the possible effects of antiviral and vaccine use, case isolation, and household quarantine than the effects of school closure, mask use, banning of mass-gatherings, or nonspecific social distancing measures.A. MIDASThe most recent MIDAS study examined the effectiveness of a set of proposed targeted, layered containment strategies that combined a number of transmission interventions currently available to public health planners in the United States [9] .", [["antiviral and vaccine", "TREATMENT", 61, 82], ["case isolation", "TREATMENT", 88, 102], ["school closure", "TREATMENT", 149, 163], ["mass", "PROBLEM", 186, 190], ["MIDAS study", "TEST", 269, 280], ["layered containment strategies", "TREATMENT", 339, 369], ["transmission interventions", "TREATMENT", 396, 422], ["mass", "OBSERVATION", 186, 190]]], ["These include nonpharmaceutical social distancing measures and antiviral treatment and prophylaxis.", [["nonpharmaceutical social distancing measures", "TREATMENT", 14, 58], ["antiviral treatment", "TREATMENT", 63, 82], ["prophylaxis", "TREATMENT", 87, 98]]], ["All three MIDAS models examined the same set of interventions, although each of the three implemented the interventions using different approaches.", [["interventions", "TREATMENT", 48, 61], ["the interventions", "TREATMENT", 102, 119], ["different approaches", "TREATMENT", 126, 146]]], ["The three sets of models also examined the sensitivity of the effectiveness of the intervention combinations to thresholds for triggering the interventions, levels of case ascertainment and compliance, and the transmissibility of the circulating pandemic strain.", [["the intervention combinations", "TREATMENT", 79, 108], ["the interventions", "TREATMENT", 138, 155], ["the circulating pandemic strain", "PROBLEM", 230, 261], ["pandemic strain", "OBSERVATION", 246, 261]]], ["The intervention scenarios examined reflect those being considered now by the United States Homeland Security Council and Department of Health and Human Services (DHHS).B. Model RepositoryAn important goal of MIDAS was creating a repository for storing and managing the computerized models, model results, model parameters, and the specifications used to develop the models.", [["Human", "ORGANISM", 147, 152], ["Human", "SPECIES", 147, 152]]], ["To support ease of access, the MREP is implemented using relational database management technology and a Webbased interface.B. Model RepositoryIn addition, there are other compelling reasons for developing the MREP, including promoting quality assurance and enhancing productivity during day-to-day activities.", [["MREP", "DNA", 31, 35], ["relational database management technology", "TREATMENT", 57, 98], ["enhancing productivity", "PROBLEM", 258, 280], ["enhancing", "OBSERVATION_MODIFIER", 258, 267], ["productivity", "OBSERVATION_MODIFIER", 268, 280]]], ["By imposing a structure that links together all model components, houses these connected components in a centralized database, and annotates those components, we can preserve and reuse essential linkages.B. Model RepositoryIn summary, the MREP provides the following capabilities to the MIDAS: first, a process for responding to an emergency event.", [["MREP", "DNA", 239, 243], ["a centralized database", "TEST", 103, 125]]], ["Characteristics of MIDAS models across all modeling groups can be quickly identified and linked to relevant documentation.", [["MIDAS models", "PROBLEM", 19, 31], ["MIDAS", "OBSERVATION_MODIFIER", 19, 24]]], ["Second, a quality assurance mechanism for registering models into the MREP.", [["MREP", "DNA", 70, 74]]], ["The registration system is consistent with the process identified by Le Nov\u00e8re et al. [10] .", [["The registration system", "TEST", 0, 23], ["consistent with", "UNCERTAINTY", 27, 42]]], ["Third, a tracking mechanism that catalogs, locates, and identifies the different versions of the models involved in different experiments that comprise MIDAS studies.", [["MIDAS studies", "TEST", 152, 165]]], ["Fourth, the MREP has productivity features that allow modelers to efficiently locate previous model versions and reuse the code in new models.", [["MREP", "DNA", 12, 16], ["previous model versions", "TREATMENT", 85, 108]]], ["Fifth, the MREP maintains inventories of work developed by the research groups in a locatable form.B. Model Repository1) MREP Scope: A repository is a collection of resources that can be accessed to retrieve information.", [["MREP", "DNA", 11, 15], ["a collection of resources", "TREATMENT", 149, 174]]], ["The MREP consists of a collection of infectious disease models and pertinent information about those models including: model specifications, inputs (static), parameters, results, source code, object code, scripts for compiling the object code, scripts for executing the model, user manuals, and other model documentation including published manuscripts.B. Model RepositoryEach element in the MREP is part of a relational database.", [["MREP", "DNA", 4, 8], ["MREP", "DNA", 392, 396], ["infectious disease models", "PROBLEM", 37, 62], ["infectious", "OBSERVATION", 37, 47]]], ["Therefore, one major feature of the MREP is tracking and connecting all of the components of a model, which allows researchers to revisit previously generated results.", [["MREP", "DNA", 36, 40]]], ["This enables a query engine to present information to a user without having to browse irrelevant information.B. Model RepositoryIn summary, the MREP is important to the MIDAS scientific research environment because it links specific model runs with the explicit model code and input data with the corresponding output data.", [["MREP", "DNA", 144, 148], ["input data", "TEST", 277, 287], ["the corresponding output data", "TEST", 293, 322]]], ["If researchers wish to identify how specific interventions were implemented and rerun a particular model or analyze it in any way after the run is completed, the MREP provides all the information necessary.C. Other Computerized Model RepositoriesThe MIDAS MREP appears to be unique among computerized epidemiological model repositories.", [["C", "GENE_OR_GENE_PRODUCT", 206, 207], ["MREP", "DNA", 162, 166], ["appears to be", "UNCERTAINTY", 261, 274]]], ["However, a number of quantitative biology-based model repositories exist and provide a useful point of comparison.C. Other Computerized Model RepositoriesWe performed a literature search and identified other model repositories similar in some degree to the MREP.", [["C", "GENE_OR_GENE_PRODUCT", 114, 115], ["MREP", "DNA", 257, 261], ["a literature search", "TEST", 167, 186], ["some degree", "OBSERVATION_MODIFIER", 238, 249]]], ["A number of online archives and/or data repositories from a number of nonmodeling applications were also identified.C. Other Computerized Model RepositoriesThe repositories described later offer information about a specific class of models to their user communities, and, in this context, they are similar in their capabilities to the MREP.", [["MREP", "DNA", 335, 339], ["C.", "SPECIES", 116, 118], ["C.", "SPECIES", 116, 118], ["nonmodeling applications", "TREATMENT", 70, 94]]], ["None of them, however, catalogs infectious disease models and none of them attempts to maintain a version-controlled environment that offers code to the users from a stable, documented environment provided by a version-managed system.", [["infectious disease", "DISEASE", 32, 50], ["infectious", "OBSERVATION", 32, 42], ["stable", "OBSERVATION_MODIFIER", 166, 172]]], ["Nevertheless, all of the examples offer their users annotated models, and all are concerned about providing reliable programs with usable documentation.C. Other Computerized Model Repositories1) Biomodels Database: The BioModels.net project describes itself as an international effort to: 1) define standards for model curation; 2) define vocabularies for annotating models with connections to biological data resources; and 3) provide a free, centralized, publicly accessible database of annotated computational models in Systems Biology Markup Language (SBML) and other structured formats [11] (for detail, see http:// www.ebi.ac.uk/biomodels/).C. Other Computerized Model RepositoriesThe database component of BioModels.net is especially designed for working with annotated computational models: each model is carefully reviewed and augmented by human annotators on the BioModels.net team to add metadata linking the model elements to other biological databases and resources.", [["C", "GENE_OR_GENE_PRODUCT", 152, 153], ["human", "ORGANISM", 849, 854], ["human", "SPECIES", 849, 854], ["human", "SPECIES", 849, 854], ["annotating models", "TEST", 356, 373]]], ["The BioModels database at the European Bioinformatics Institute (EBI) system is a true database, featuring browsing, crossreferencing, searching, and facilities for visualization, exporting models in different formats, and remote application programming interface (API) access.C. Other Computerized Model RepositoriesThe BioModels Database is a data resource that allows biologists to store, search, and retrieve published mathematical models of biological content.", [["C.", "SPECIES", 277, 279], ["C.", "SPECIES", 277, 279], ["visualization", "TEST", 165, 178], ["remote application programming interface (API) access", "TREATMENT", 223, 276], ["biological content", "OBSERVATION", 446, 464]]], ["All models use SBML as their standard form of representation.C. Other Computerized Model RepositoriesThe premise of this tool is that researchers must be able to exchange and share their results.", [["C", "GENE_OR_GENE_PRODUCT", 61, 62]]], ["The development and broad acceptance of common model representation formats such as SBML is a crucial step in that direction, allowing researchers to exchange and build upon each other's work with greater ease and accuracy.C. Other Computerized Model RepositoriesTo make assembling useful collections of quantitative models of biological phenomena easier, establishing standards for the vocabularies used in model annotations as well as criteria for minimum quality levels of those models is crucial.", [["C", "GENE_OR_GENE_PRODUCT", 223, 224], ["biological phenomena", "PROBLEM", 327, 347], ["broad", "OBSERVATION_MODIFIER", 20, 25], ["biological phenomena", "OBSERVATION", 327, 347]]], ["The BioModels.net project aims to bring together a community of interested researchers to address these issues.C. Other Computerized Model Repositories2) CellML-A Biological Model-Based Repository: This application is similar to the BioModels Database application and uses a markup language called CellML developed specifically for describing biological processes contained in CellML [12] .", [["CellML", "PROTEIN", 298, 304], ["C.", "SPECIES", 111, 113], ["C.", "SPECIES", 111, 113], ["CellML", "TEST", 154, 160]]], ["The repository is a Web site that stores and exchanges computer-based mathematical models.", [["Web site", "DNA", 20, 28]]], ["The CellML also includes information about model structure (how the parts of a model are related to one another), model mathematics (equations that describe the underlying biological processes), and metadata (additional information about the model that allows scientists to search for specific models or model components in a database or other repository).C. Other Computerized Model Repositories3) AnyBody-A Repository for Models That Describe Musculoskeletal Processes:The premise behind this MREP is taken from the AnyBody Web site [13] .", [["CellML", "PROTEIN", 4, 10], ["MREP", "DNA", 495, 499], ["this MREP", "TEST", 490, 499]]], ["The site describes how the cost of musculo-skeletal injuries is rapidly increasing, while fundamental understanding of the mechanical functions of the body is increasing at a dramatic rate.", [["musculo-skeletal", "ANATOMY", 35, 51], ["body", "ANATOMY", 151, 155], ["musculo-skeletal injuries", "DISEASE", 35, 60], ["skeletal", "ORGAN", 43, 51], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["musculo-skeletal injuries", "PROBLEM", 35, 60], ["skeletal", "ANATOMY", 43, 51], ["injuries", "OBSERVATION", 52, 60], ["rapidly", "OBSERVATION_MODIFIER", 64, 71], ["increasing", "OBSERVATION_MODIFIER", 72, 82], ["body", "ANATOMY", 151, 155], ["increasing", "OBSERVATION_MODIFIER", 159, 169]]], ["For example, the AnyBody Web site indicates that the number of ergonomic-based injuries caused by excessive use of the computer mouse is exploding, yet the actual cause of many of these injuries remains a mystery.", [["injuries", "DISEASE", 79, 87], ["injuries", "DISEASE", 186, 194], ["mouse", "ORGANISM", 128, 133], ["AnyBody Web site", "DNA", 17, 33], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["the AnyBody Web site", "PROBLEM", 13, 33], ["ergonomic-based injuries", "PROBLEM", 63, 87], ["these injuries", "PROBLEM", 180, 194], ["injuries", "OBSERVATION", 79, 87], ["excessive", "OBSERVATION_MODIFIER", 98, 107], ["injuries", "OBSERVATION", 186, 194]]], ["Policymakers and others, therefore, find it difficult to issue guidelines to reduce the problems.", [["the problems", "PROBLEM", 84, 96]]], ["Also, research into human locomotion has historically been relegated to experimental studies (for detail, see http://anybody.auc. dk/).)", [["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["experimental studies", "TEST", 72, 92]]], ["AnyBody-A Repository for Models That Describe Musculoskeletal Processes:The stated purpose of the AnyBody project is to develop mechanical models of different elements of the human body, and then, perform detailed studies of the behavior of these models.)", [["body", "ANATOMY", 181, 185], ["human", "ORGANISM", 175, 180], ["body", "ORGANISM_SUBDIVISION", 181, 185], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["detailed studies", "TEST", 205, 221], ["human body", "ANATOMY", 175, 185]]], ["AnyBody-A Repository for Models That Describe Musculoskeletal Processes:Typical model examples include the analysis and optimization of tools and workplace layout, and designing sports equipment and hand tools for maximum efficiency.", [["hand", "ANATOMY", 199, 203], ["hand", "ORGANISM_SUBDIVISION", 199, 203], ["the analysis", "TEST", 103, 115], ["maximum efficiency", "PROBLEM", 214, 232]]], ["A unique software system called the AnyBody Modeling System was developed to conduct necessary research into causes and treatments of musculo-skeletal injuries.)", [["musculo", "ANATOMY", 134, 141], ["skeletal", "ANATOMY", 142, 150], ["musculo-skeletal injuries", "DISEASE", 134, 159], ["skeletal", "ORGAN", 142, 150], ["musculo-skeletal injuries", "PROBLEM", 134, 159], ["skeletal", "ANATOMY", 142, 150], ["injuries", "OBSERVATION", 151, 159]]], ["AnyBody-A Repository for Models That Describe Musculoskeletal Processes:There are four major aims of the AnyBody project.", [["Musculoskeletal", "ANATOMY", 46, 61]]], ["The first is to develop methods for analyzing movement strategies and tendon, muscle, and joint forces in humans performing specific manual tasks.", [["tendon", "ANATOMY", 70, 76], ["muscle", "ANATOMY", 78, 84], ["joint", "ANATOMY", 90, 95], ["tendon", "TISSUE", 70, 76], ["muscle", "ORGAN", 78, 84], ["joint", "MULTI-TISSUE_STRUCTURE", 90, 95], ["humans", "ORGANISM", 106, 112], ["humans", "SPECIES", 106, 112], ["humans", "SPECIES", 106, 112], ["analyzing movement strategies and tendon, muscle, and joint forces in humans", "PROBLEM", 36, 112], ["tendon", "ANATOMY", 70, 76], ["muscle", "ANATOMY", 78, 84], ["joint", "ANATOMY", 90, 95]]], ["The second is to investigate what numerical simulation can teach us about the function of the human body.", [["body", "ANATOMY", 100, 104], ["human", "ORGANISM", 94, 99], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["human", "ANATOMY", 94, 99], ["body", "ANATOMY_MODIFIER", 100, 104]]], ["The third is to use the analysis for ergonomic optimization of tools, workplaces, and man/machine interfaces.", [["the analysis", "TEST", 20, 32], ["ergonomic optimization of tools", "TEST", 37, 68]]], ["The fourth is to provide an MREP to enable interested researchers to share the models.", [["an MREP", "TREATMENT", 25, 32]]], ["Overall, AnyBody identifies useful information and models that can be shared by researchers interested in studying musculo-skeletal injuries.4) Probabilistic-Logical MREP:This repository contains software for manipulating and learning probabilistic-logical models [14] .", [["musculo-skeletal", "ANATOMY", 115, 131], ["musculo-skeletal injuries", "DISEASE", 115, 140], ["skeletal", "ORGAN", 123, 131], ["skeletal", "ANATOMY", 123, 131], ["injuries", "OBSERVATION", 132, 140]]], ["The aim is to construct an MREP that will allow dissemination of software for probabilistic-logical models and facilitate comparisons among competing approaches (for detail, see http://www.informatik.uni-freiburg.de/\u223ckersting/plmr/).4) Probabilistic-Logical MREP:The site notes that probability models are important methods for representing uncertainty, and mentions that various probabilistic frameworks include Bayesian networks, hidden Markov models, and stochastic context-free languages, along with other popular tools for describing appropriate scenarios exhibiting uncertainty.", [["MREP", "DNA", 27, 31], ["Logical MREP", "DNA", 250, 262]]], ["It notes that these types of models have been applied to problems in diagnosis, forecasting, automated vision, sensor fusion, manufacturing control, speech recognition, and computational biology.", [["sensor fusion", "TREATMENT", 111, 124], ["manufacturing control", "TREATMENT", 126, 147]]], ["However, traditional approaches have a major drawback-they have a rigid structure, and therefore, lack of versatility in representing complex models.4) Probabilistic-Logical MREP:To overcome these limitations, the site states that various researchers have recently proposed logical extensions of classical probabilistic models incorporating the notions of objects and object interconnections.4) Probabilistic-Logical MREP:This repository consists of a database of software, documentation, and links to developers.", [["rigid structure", "OBSERVATION", 66, 81], ["complex models", "OBSERVATION", 134, 148]]], ["The potential scope for the models in this repository is huge, with many different methods for defining and describing probabilistic-logical models.5) Cancer Intervention and Surveillance Modeling Network (CISNET):The cancer intervention and surveillance modeling network (CISNET) is a consortium of investigators sponsored by the National Cancer Institute \"whose focus is using modeling to improve our understanding of the impact of cancer control interventions (e.g., prevention, screening treatment, etc.) on population trends in incidence and mortality\" [15] .", [["Cancer", "ANATOMY", 151, 157], ["cancer", "ANATOMY", 218, 224], ["cancer", "ANATOMY", 434, 440], ["Cancer", "DISEASE", 151, 157], ["cancer", "DISEASE", 218, 224], ["Cancer", "DISEASE", 340, 346], ["cancer", "DISEASE", 434, 440], ["Cancer", "CANCER", 151, 157], ["cancer", "CANCER", 218, 224], ["cancer", "CANCER", 434, 440], ["Cancer Intervention", "TREATMENT", 151, 170], ["The cancer intervention", "TREATMENT", 214, 237], ["surveillance modeling network", "TEST", 242, 271], ["cancer control interventions", "TREATMENT", 434, 462], ["screening treatment", "TREATMENT", 482, 501], ["Cancer", "OBSERVATION", 151, 157], ["cancer", "OBSERVATION", 218, 224], ["cancer", "OBSERVATION", 434, 440]]], ["They use models to project future trends and help determine optimal cancer control strategies (for detail, see http://cisnet.cancer.gov/about/).", [["cancer", "ANATOMY", 68, 74], ["cancer", "DISEASE", 68, 74], ["cancer", "CANCER", 68, 74], ["optimal cancer control strategies", "TREATMENT", 60, 93]]], ["The CISNET also describes using a comparative modeling approach in which each modeler focuses on an individual area.", [["CISNET", "DNA", 4, 10], ["a comparative modeling approach", "TREATMENT", 32, 63]]], ["However, whenever possible, they develop a common \"base\" question that allows comparison across all models using a set of common population inputs.", [["a common \"base\"", "PROBLEM", 41, 56]]], ["Then, they develop a common set of intermediate and final outputs.5) Cancer Intervention and Surveillance Modeling Network (CISNET):To aid in this process of model description and comparison, the CISNET has developed the Model Profiler, an Internet-based application.", [["Cancer", "ANATOMY", 69, 75], ["Cancer", "DISEASE", 69, 75], ["Cancer", "CANCER", 69, 75], ["Cancer Intervention", "TREATMENT", 69, 88], ["Cancer", "OBSERVATION", 69, 75]]], ["The system allows modelers to describe their models, and allows interested readers to read about, compare, and contrast simulation models.5) Cancer Intervention and Surveillance Modeling Network (CISNET):The sites described earlier we believed were fairly representative of the repositories available to researchers.", [["Cancer", "ANATOMY", 141, 147], ["Cancer", "DISEASE", 141, 147], ["Cancer", "CANCER", 141, 147], ["Cancer Intervention", "TREATMENT", 141, 160], ["Cancer", "OBSERVATION", 141, 147]]], ["Our literature search indicated that other sites are available.", [["Our literature search", "TEST", 0, 21]]], ["SigPath is described by Campagne et al. [16] as an information management system that stores both quantitative information on cellular components and their interactions, and the basic reactions governing those interactions; EcoCyc, which is described as a comprehensive database resource for Escherichia coli by Keseler et al. [17] ; JWS Online, described by Olivier and Snoep as a repository of kinetic models describing biological systems that can be interactively run and interrogated over the Internet [18] ; and the Database of Quantitative Cellular Signaling, which Sivakumaran et al. describe as a repository of models of signaling pathways [19] .D. SummaryA number of model repositories are identified in the literature.", [["cellular", "ANATOMY", 126, 134], ["EcoCyc", "CHEMICAL", 224, 230], ["cellular", "CELL", 126, 134], ["EcoCyc", "GENE_OR_GENE_PRODUCT", 224, 230], ["Escherichia coli", "ORGANISM", 292, 308], ["Escherichia coli", "SPECIES", 292, 308], ["Escherichia coli", "SPECIES", 292, 308], ["the basic reactions", "PROBLEM", 174, 193], ["Escherichia coli", "PROBLEM", 292, 308], ["signaling pathways", "PROBLEM", 629, 647], ["Cellular Signaling", "OBSERVATION", 546, 564]]], ["One manifestation of sophistication is using a markup language based on XML concepts that imposes a standard method for describing and representing models common to a repository.", [["a markup language", "TREATMENT", 45, 62]]], ["We assert that ABMs are conceptually less mature than computational biology models, and broader in their scope (i.e., agents can represent genes, proteins, and cis-regulatory elements at one end of the spectrum, and represent people, states, and countries at the other end).", [["ABMs", "CELL_TYPE", 15, 19], ["cis-regulatory elements", "DNA", 160, 183], ["people", "SPECIES", 226, 232], ["genes, proteins", "PROBLEM", 139, 154]]], ["Rather, we focused on building a repository that captures ABMs in whatever form they were developed and creates a common set of documentation and annotations, so that the model can be understood (at some level) and reused should the need arise.A. ScopeThe MREP is designed to house, manage, and allow users to run infectious disease models from an access-controlled disease MREP.", [["infectious disease", "DISEASE", 314, 332], ["infectious disease models", "PROBLEM", 314, 339], ["controlled disease MREP", "PROBLEM", 355, 378]]], ["The MREP contains source code of disease models that have been developed by external developers and tested in a production environment.", [["MREP", "DNA", 4, 8], ["disease models", "PROBLEM", 33, 47], ["source code", "OBSERVATION", 18, 29]]], ["Different versions of models used to describe various aspects of the same disease are housed in the repository.", [["the same disease", "PROBLEM", 65, 81]]], ["The annotations captured during the model registration process also identify a model's purpose, specifications, and relevant features.A. ScopeThe MREP also houses, manages, and controls access to a disease model results warehouse, which consists of output generated by the models contained in the MREP database.", [["MREP", "PROTEIN", 297, 301], ["the model registration process", "TREATMENT", 32, 62], ["a model's purpose", "TEST", 77, 94], ["the MREP database", "TEST", 293, 310]]], ["They will also be stored in a relational database to permit them to be easily identified, categorized, and downloaded.A. ScopeThe MREP includes a version control system (also referred to in the literature as a configuration control system) as one of its core elements.", [["MREP", "DNA", 130, 134], ["a version control system", "TREATMENT", 144, 168]]], ["Version-control software provides a database that is used to keep track of the revisions made to a program by all the programmers and developers involved in it.A. ScopeThe MREP uses Subversion as its version control system [20] .", [["MREP", "DNA", 172, 176], ["the revisions", "TREATMENT", 75, 88], ["Subversion", "TREATMENT", 182, 192], ["revisions", "OBSERVATION", 79, 88]]], ["Subversion is a free, open-source application that is licensed under the Creative Commons Attribution License (see http://svnbook.red-bean. com/en/1.0/).", [["open-source application", "TREATMENT", 22, 45], ["free", "OBSERVATION_MODIFIER", 16, 20]]], ["The GUI allows the user access to the model source code, provides an interface to input data sets, permits results to be viewed directly or downloaded to a user workstation, and provides a mechanism to submit the models for rerunning.A. ScopeThe MREP is comprised of the following major components: 1) a source code repository and version control system; 2) a model documentation tree; 3) a data warehouse (input and output data sets); and 4) an application interface (API) consisting of a database, browser, and graphics user interface components that allow the model user to develop input data sets, run the codes, and browse output results.A. ScopeA standard system development approach was used creating the initial version of the MREP using approximately two fulltime equivalents (FTEs) over a 13-month period.A. ScopeB.", [["MREP", "DNA", 246, 250], ["output data sets", "TEST", 417, 433], ["browse output", "TEST", 621, 634]]], ["These features include: 1) a version control system that provides configuration control over model source code and 2) complete flexibility regarding output formats.", [["a version control system", "TREATMENT", 27, 51], ["output formats", "TEST", 149, 163]]], ["The most common model development languages represented in the MREP are anticipated to be C, C++, Java, and Matlab.", [["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["To maintain control in a language-free environment, using a version control element was deemed essential.A. ScopeThe second feature was the ability to support a common output format.", [["version control element", "DNA", 60, 83], ["a version control element", "TREATMENT", 58, 83]]], ["The MREP offers these results to users in the received format.", [["MREP", "DNA", 4, 8]]], ["Fig. 1 represents a high-level logical data model for the MREP.", [["MREP", "DNA", 58, 62]]], ["Five primary components comprise the architecture, including the MIDAS Compute Server; a File System; a relational database management system (RDBMS); a Version Control System; and an External Systems Gateway.", [["a relational database management system", "TREATMENT", 102, 141], ["a Version Control System", "TREATMENT", 151, 175]]], ["Additionally, code maintainers/developers will have full access to all of the Linux system's features as needed to make changes to the code.A. ScopeThe MIDAS cluster is managed by Cluster Resource's MOAB (see http://www.clusterresources.com/pages/products/ moab-cluster-suite.php) [21] , an advanced cluster scheduler capable of optimizing scheduling and node allocations.", [["node", "ANATOMY", 355, 359], ["node", "MULTI-TISSUE_STRUCTURE", 355, 359], ["optimizing scheduling and node allocations", "TREATMENT", 329, 371], ["node", "OBSERVATION", 355, 359]]], ["MOAB allows site administrators to control job scheduling, priority, and where jobs are run.A. Scope3) File System: The file system is part of the MIDAS cluster resource and is an integral part of the cluster system.", [["MOAB", "CHEMICAL", 0, 4], ["cluster system", "OBSERVATION", 201, 215]]], ["A second system element is primarily used to archive study results in the MREP warehouse.", [["archive study", "TEST", 45, 58]]], ["At present, the archival file system is configured with 2 terabytes (TB) of disk storage that will eventually be expanded to 14 TB.", [["TB", "DISEASE", 69, 71], ["TB", "DISEASE", 128, 130], ["disk storage", "PROBLEM", 76, 88]]], ["4) Relational Database System: The database management system platform will be housed by the MIDAS Web portal, which serves as the interface for electronic information exchange for the MIDAS network.", [["The database management system platform", "TREATMENT", 31, 70], ["portal", "ANATOMY", 103, 109]]], ["The MIDAS portal is accessible to the public, but only registered users can access and provide information to the private section of the portal.A. ScopeThe MIDAS portal runs on RTI's Oracle Application Server 10 g (v. 9.0.4.1.0) server farm and uses Oracle technology [22] to manage the information within the repository (see www.oracle.com/appserver/index.html).A. ScopeThe database system tags metadata that reference specific simulation run results with the input and output data sets and source code associated with those runs.", [["portal", "MULTI-TISSUE_STRUCTURE", 137, 143], ["the input", "TEST", 457, 466], ["output data sets", "TEST", 471, 487], ["MIDAS", "ANATOMY_MODIFIER", 4, 9], ["portal", "ANATOMY", 10, 16], ["portal", "ANATOMY", 137, 143], ["MIDAS", "OBSERVATION_MODIFIER", 156, 161], ["portal", "ANATOMY", 162, 168]]], ["The database system will allow users to perform keyword searches to identify repository elements assigned to those metadata. a) Data model-hierarchal design: The database design will maintain tables of metadata that describe the following entities:A. ScopeProjects-a collection of studies with a common set of objectives; Studies-a collection of runs that were produced by one or more models; Models-the core code that is designed to describe computer environments that generate the runs; Model versions-a specific instance of a model to handle the production of runs having a specific set of attributes; and Runs-a set of information referred to as results that describe a single realization of a simulated epidemic.A. ScopeEach realization is associated with a unique set of parameter values or alternatively is associated with a repeated set of parameter values.", [["repository elements", "DNA", 77, 96], ["A.", "SPECIES", 717, 719], ["Studies", "TEST", 322, 329], ["a collection of runs", "PROBLEM", 330, 350], ["a simulated epidemic", "PROBLEM", 696, 716]]], ["Fig. 2 defines the interconnections between the entities.", [["entities", "OBSERVATION", 48, 56]]], ["A study is either linked to a published manuscript that defines project aims and study results or to a document that describes an MIDAS study that is part of a larger MIDAS project effort to examine specific hypotheses about disease spread and containment.", [["A study", "TEST", 0, 7], ["an MIDAS study", "TEST", 127, 141], ["containment", "OBSERVATION_MODIFIER", 244, 255]]], ["For example, the DHHS project examined the problem of whether influenza could be stopped at its source (i.e., South East [SE] Asia), and if so, what methods of containment are important.", [["influenza", "DISEASE", 62, 71], ["influenza", "PROBLEM", 62, 71]]], ["Two studies from this project are part of the MREP: the Emory SE Asia Study and the Imperial SE Asia Study.A. ScopeIn a second example, the combined project focus is to address the problem of \"what can be done to mitigate pandemic influenza if it gets established in the U.S.\"", [["influenza", "DISEASE", 231, 240], ["Two studies", "TEST", 0, 11], ["pandemic influenza", "PROBLEM", 222, 240]]], ["The specific objectives of the combined study are to assess the feasibility and effectiveness of different types of interventions strategies.", [["the combined study", "TEST", 27, 45], ["interventions strategies", "TREATMENT", 116, 140]]], ["The types of interventions specifically exclude prepandemic vaccines and limit the available quantity of a partially efficacious vaccine, but utilize as much antiviral treatment as required.", [["interventions", "TREATMENT", 13, 26], ["prepandemic vaccines", "TREATMENT", 48, 68], ["a partially efficacious vaccine", "TREATMENT", 105, 136], ["much antiviral treatment", "TREATMENT", 153, 177]]], ["Two paradigms are the focus of this study: the entire United States and a large city (Chicago).", [["this study", "TEST", 31, 41], ["large", "OBSERVATION_MODIFIER", 74, 79]]], ["Six studies (and corresponding models) examine this problem.", [["Six studies", "TEST", 0, 11]]], ["Two of these models simulate transmission in the continental United States, three others represent transmission in the city of Chicago, and the sixth presents the results of a historical review of the 1918 Spanish influenza epidemic.", [["influenza", "DISEASE", 214, 223]]], ["The last study helped justify the design of the intervention strategies.A. ScopeEach model is composed of one or more model versions.", [["The last study", "TEST", 0, 14], ["the intervention strategies", "TREATMENT", 44, 71]]], ["Usually, a modeler attempts to describe the complete set of simulations through parameter manipulation.", [["parameter manipulation", "TREATMENT", 80, 102]]], ["However, in many instances, it is likely that new and novel interventions will not be anticipated by the code developer.", [["is likely", "UNCERTAINTY", 31, 40], ["new", "OBSERVATION_MODIFIER", 46, 49]]], ["In these instances, it is common for the developer to create a different version of the model to handle a subset of the simulated interventions.", [["the simulated interventions", "TREATMENT", 116, 143]]], ["One of the explicit objectives of the MREP is to track the different model versions and to link them to the results they produce.A. ScopeThe run is the lowest unit of analysis of the MREP.", [["MREP", "DNA", 38, 42], ["MREP", "DNA", 183, 187], ["the MREP", "TREATMENT", 179, 187]]], ["Each run constitutes a single replicate of a single set of parameters or a summary run over all replicates having a common set of parameters.A. Scopeb) Query engine: The overall plan is to populate the MREP with models that are initially in accordance with MIDAS goals, which are currently limited to infectious disease models.", [["infectious disease", "DISEASE", 301, 319], ["infectious disease models", "PROBLEM", 301, 326]]], ["For example, the MIDAS ABMs use synthetic population data that describe a specific geographical region.", [["synthetic population data", "TEST", 32, 57]]], ["The model results identify individuals that influence disease spread within that region.", [["influence disease spread", "PROBLEM", 44, 68]]], ["Then, by using the geospatial identifiers that are tagged to individual model results, users can drill down into subregions and neighborhoods that are affected by epidemics.", [["epidemics", "PROBLEM", 163, 172]]], ["Please note that it is possible to use the search keys to identify the studies that focus on a particular type of intervention strategy, and then, by examining Model Version details, determine the implementation details to decide a target computer to rerun the model.", [["the studies", "TEST", 67, 78], ["intervention strategy", "TREATMENT", 114, 135]]], ["This could be done to replicate earlier results or to begin the process of modifying parameters to assess new interventions.A. Scope5) Version Control: The version control system maintains the various model version source codes and executables.", [["modifying parameters", "TREATMENT", 75, 95], ["new interventions", "TREATMENT", 106, 123], ["The version control system", "TREATMENT", 152, 178]]], ["Each model version in the MREP is maintained in Subversion, the free, open-source version control system that manages files and directories over time.", [["MREP", "DNA", 26, 30], ["open-source version control system", "TREATMENT", 70, 104]]], ["A tree of files is placed into a central database.", [["tree", "OBSERVATION_MODIFIER", 2, 6], ["central", "ANATOMY_MODIFIER", 33, 40]]], ["This allows people to use Subversion on different computers and fosters collaboration by allowing various people to modify and manage the same set of data from their respective locations.", [["people", "ORGANISM", 12, 18], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 12, 18], ["people", "SPECIES", 106, 112]]], ["Furthermore, progress can occur more quickly because there is no single conduit through which all modifications must occur.", [["single conduit", "TREATMENT", 65, 79], ["no", "UNCERTAINTY", 62, 64], ["conduit", "OBSERVATION", 72, 79]]], ["Because the work is versioned, we prevent the possibility of losing that conduit if an incorrect change is made to the data, in that the change can be easily undone.A. ScopeSubversion is a full version control system.", [["a full version control system", "TREATMENT", 187, 216]]], ["The MREP only uses a small subset of Subversion's functionality.", [["MREP", "DNA", 4, 8], ["Subversion's functionality", "TREATMENT", 37, 63], ["small", "OBSERVATION_MODIFIER", 21, 26]]], ["The MREP Subversion server is hosted on a virtual Linux host using VMWare Server software.", [["MREP Subversion server", "DNA", 4, 26]]], ["6) External Applications: An important component of Fig. 1 , referred to as External Systems, is a general set of tools that are available outside of the MREP.", [["MREP", "DNA", 154, 158], ["External Applications", "TREATMENT", 3, 24], ["Fig", "TREATMENT", 52, 55]]], ["These tools are used to visualize, process, and analyze results from the MREP.", [["MREP", "DNA", 73, 77], ["the MREP", "TEST", 69, 77]]], ["The data from the MREP are served up via a HyperText Markup Language (HTML) portal.", [["MREP", "DNA", 18, 22], ["portal", "ANATOMY", 76, 82]]], ["These data can be downloaded to the user's workstation or can be visualized directly from the MREP.", [["MREP", "DNA", 94, 98]]], ["For example, many of the data files in the MREP are stored as PDF, text, or.xls files, and can be viewed directly from the repository using Adobe Acrobat Reader, a text editor, or Microsoft Excel, respectively.", [["MREP", "CANCER", 43, 47], ["MREP", "DNA", 43, 47]]], ["Other files can be downloaded and imported into external systems available to specific users.C. Model RegistrationThe results/outputs of production runs will also be housed in the MREP.", [["C.", "SPECIES", 93, 95], ["C.", "SPECIES", 93, 95], ["production runs", "PROBLEM", 137, 152]]], ["If it has not been developed under version control, it will be moved to Subversion, tested, and moved to the MREP data warehouse.1) Source and Object Code:The model code will be annotated with the following set of metadata: name of model, link to model description, contact information, date of model creation, distribution terms, model specifications, model implementation of those specifications, disease, region of analysis, types of intervention strategies, computer resource requirements, user's manual (link), validation measures (link to supporting manuscript), and compile and/or run scripts.", [["disease", "PROBLEM", 399, 406], ["intervention strategies", "TREATMENT", 437, 460], ["validation measures", "TREATMENT", 516, 535]]], ["For example, if an implementation strategy calls for a reduction of 50% in model contacts, it is plausible to implement the strategy by halving the number of people contacted or alternatively maintaining the same number of persons in the contact network while halving the number of contacts with each person.", [["people", "ORGANISM", 158, 164], ["people", "SPECIES", 158, 164], ["persons", "SPECIES", 223, 230], ["person", "SPECIES", 301, 307], ["a reduction", "TREATMENT", 53, 64]]], ["Each result unit is tagged to a second set of metadata that includes model name, version number, developer, intervention, parameter file, fixed input file, and script used to generate results.1) Source and Object Code:3) Model Inputs: Model inputs are also placed in the repository and linked to the model that uses the inputs and the corresponding results that are generated.", [["Model inputs", "TREATMENT", 235, 247]]], ["Each set of inputs is tagged to a set of metadata defined at the model version level: model name, version number, developer, intervention, and parameter location (including name, type, and range of values).D. Information RetrievalEither a query tool is used to locate repository results or a complete list of models is displayed, and the user selects from the list.", [["intervention", "TREATMENT", 125, 137]]], ["The process proceeds according to the following five steps.D. Information RetrievalIn step 1, query keys are specified: the study and/or model and/or results are selected that meet the user-specified search criteria.", [["the study", "TEST", 120, 129]]], ["For example, disease, geographic description, objective of study, model name and version number, and model developer.D. Information RetrievalIn step 2, the query tool identifies the model in the repository with the specified attributes and displays the information.", [["disease", "PROBLEM", 13, 20], ["objective of study", "TEST", 46, 64], ["disease", "OBSERVATION", 13, 20]]], ["At this point, the user can either access the annotations or drill down to lower-level (run-level) linked results (results are displayed and/or downloaded if desired), or identify input data files and scripts that run the model.D. Information RetrievalIn step 3, the model identified by the earlier steps can be checked out of Subversion.", [["the annotations", "TEST", 42, 57], ["drill", "TEST", 61, 66]]], ["Please note that all version updates are performed by the MREP administrator and that model development occurs under version control.", [["version control", "TREATMENT", 117, 132]]], ["The modified model is then entered into the repository.D. Information RetrievalIn step 4, the model is loaded into the MREP.", [["MREP", "DNA", 119, 123]]], ["This step annotates the model with both descriptive text and model metadata as part of the check-in process.", [["the check", "TEST", 87, 96]]], ["An HTML file is created that connects the model, results, and input data; it also creates directories for source code, object code, inputs, results, and scripts.D. Information RetrievalIn step 5, model results are loaded into the model result warehouse and metadata specified at the run level, including model name, version number, developer, result category, replicate, link to parameter list, and location of results.III. RESULTSCurrently, four projects, 12 studies, five models, six model versions, and 538 runs are loaded into the MREP.III. RESULTSThe vaccine project is a single study project that uses a single influenza-based model of a medium-sized city in the United States.", [["MREP", "DNA", 535, 539], ["a single study", "TEST", 575, 589], ["a single influenza", "TREATMENT", 608, 626], ["sized", "OBSERVATION_MODIFIER", 651, 656]]], ["The study consists of six runs generated from a single epidemiological model of disease spread.", [["The study", "TEST", 0, 9], ["six runs", "PROBLEM", 22, 30], ["disease spread", "PROBLEM", 80, 94], ["disease", "OBSERVATION", 80, 87]]], ["The main hypothesis behind the vaccine distribution study is to assess whether targeted antiviral prophylaxis (TAP), taken prophylactically, is effective in containing influenza.", [["influenza", "DISEASE", 168, 177], ["the vaccine distribution study", "TEST", 27, 57], ["targeted antiviral prophylaxis (TAP)", "TREATMENT", 79, 115], ["influenza", "PROBLEM", 168, 177], ["main", "OBSERVATION_MODIFIER", 4, 8], ["influenza", "OBSERVATION", 168, 177]]], ["The authors conclude that TAP is nearly as effective as vaccinating 80% of the population, and further, that vaccinating 80% of children less than 19 years of age is almost as effective as vaccinating 80% of the entire study population.III. RESULTSThe Influenza Containment-SE Asia was developed by the MIDAS network and was completed in September 2005.", [["Influenza Containment-SE", "DISEASE", 252, 276], ["TAP", "GENE_OR_GENE_PRODUCT", 26, 29], ["children", "ORGANISM", 128, 136], ["TAP", "PROTEIN", 26, 29], ["children", "SPECIES", 128, 136], ["Influenza", "SPECIES", 252, 261], ["TAP", "TREATMENT", 26, 29]]], ["It consists of two studies and two models.", [["two studies", "TEST", 15, 26]]], ["Both studies simulated disease transmission in regions that included some part of Thailand.", [["Both studies", "TEST", 0, 12], ["simulated disease transmission in regions", "PROBLEM", 13, 54], ["disease", "OBSERVATION", 23, 30]]], ["The overall hypothesis of the project was to examine if it is possible to contain Avian Influenza in the place of origin before it becomes a pandemic.", [["Influenza", "DISEASE", 88, 97], ["Avian Influenza", "PROBLEM", 82, 97], ["a pandemic", "PROBLEM", 139, 149], ["Influenza", "OBSERVATION", 88, 97], ["pandemic", "OBSERVATION", 141, 149]]], ["However, the developers used a special version (the second) of the model that simulates the impact of geographically targeted antiviral prophylaxis (GTAP) to produce two other runs.", [["a special version", "TREATMENT", 29, 46], ["antiviral prophylaxis", "TREATMENT", 126, 147], ["GTAP", "TREATMENT", 149, 153], ["antiviral prophylaxis", "OBSERVATION", 126, 147]]], ["All runs are loaded in the MREP.", [["MREP", "DNA", 27, 31]]], ["The Imperial model represented all of Thailand plus a perimeter region around its border that extended into its four border countries.", [["Thailand plus a perimeter region", "TREATMENT", 38, 70], ["Imperial model", "OBSERVATION_MODIFIER", 4, 18], ["all", "OBSERVATION_MODIFIER", 31, 34], ["perimeter", "OBSERVATION_MODIFIER", 54, 63], ["border", "ANATOMY_MODIFIER", 82, 88], ["four", "OBSERVATION_MODIFIER", 112, 116], ["border", "OBSERVATION_MODIFIER", 117, 123]]], ["Only the baseline (no intervention) run, produced by the Imperial SE Asia model, is loaded into the MREP at this time.III. RESULTSThe Influenza Containment-United States and Great Britain project examined whether pandemic flu could be mitigated in the United States, assuming containment in SE Asia failed.", [["flu", "DISEASE", 222, 225], ["SE", "DISEASE", 291, 293], ["pandemic flu", "TREATMENT", 213, 225]]], ["This project was developed in collaboration with the DHHS and consisted of three studies: the Imperial Assessment study, the Epicast assessment, and the EpiSims assessment.", [["the Imperial Assessment study", "TEST", 90, 119], ["the Epicast assessment", "TEST", 121, 143], ["the EpiSims assessment", "TEST", 149, 171]]], ["The Imperial Assessment study consisted of two models: one describing disease transmission in the United States and the second describing transmission in GB.", [["The Imperial Assessment study", "TEST", 0, 29], ["GB", "ANATOMY", 154, 156]]], ["The GB model served as a counterpoint for the United States model, suggesting some interesting influences of geography and national patterns of behavior on disease spread.III. RESULTSThe Epicast DHHS experiment described disease in the United States and examined influences on the spread of disease on a population derived from the U.S. 2000 Census data.", [["disease spread", "PROBLEM", 156, 170], ["disease", "PROBLEM", 291, 298]]], ["The principal investigator of the Imperial assessment study is Ferguson et al. [4] .", [["the Imperial assessment study", "TEST", 30, 59]]], ["The MIDAS principal investigator of the Epicast assessment study is Ira Longini [25] .III. RESULTSThe EpiSims assessment study simulated disease behavior in a mid-size city in the United States and used the same type of containment strategies that were used by the other two U.S. experiments.", [["disease behavior", "DISEASE", 137, 153], ["the Epicast assessment study", "TEST", 36, 64], ["EpiSims assessment study", "TEST", 102, 126], ["simulated disease behavior", "PROBLEM", 127, 153], ["containment strategies", "TREATMENT", 220, 242], ["MIDAS", "OBSERVATION_MODIFIER", 4, 9]]], ["The EpiSims DHHS experiment consisted of a single model and generated 516 runs, involving a complete factorial design of nine binary variables and a partial design that examined the influence of three more variables.", [["The EpiSims DHHS experiment", "TREATMENT", 0, 27], ["nine binary variables", "PROBLEM", 121, 142], ["partial", "OBSERVATION_MODIFIER", 149, 156]]], ["A complete set of 516 runs is loaded in the MREP for this study.", [["MREP", "DNA", 44, 48], ["this study", "TEST", 53, 63]]], ["The baseline GB run is also loaded into the MREP.", [["MREP", "DNA", 44, 48], ["The baseline GB run", "TEST", 0, 19]]], ["Four national U.S. Epicast runs are currently loaded in the MREP.III. RESULTSThe Combined project is also a U.S.-based study.", [["MREP", "DNA", 60, 64], ["based study", "TEST", 113, 124]]], ["It represents a refinement of the Influenza Containment-U.S. and GB project.", [["Influenza Containment", "OBSERVATION", 34, 55], ["GB", "ANATOMY", 65, 67]]], ["Specifically, it examines a more complete set of social distancing interventions with the goal of determining practical strategies for implementation at the state and local level.", [["social distancing interventions", "TREATMENT", 49, 80], ["practical strategies", "TREATMENT", 110, 130]]], ["This is an ongoing study that consists of six sets of experiments: two U.S. experiments, three Chicago-based experiments, and a historic study that examined certain characteristics of the 1918 influenza pandemic.", [["influenza pandemic", "DISEASE", 193, 211], ["an ongoing study", "TEST", 8, 24], ["a historic study", "TEST", 126, 142]]], ["Each study is associated with a single model with a single version per model.", [["Each study", "TEST", 0, 10]]], ["The objective of the combined study is to simulate a set of scenarios at the city and the national level.", [["the combined study", "TEST", 17, 35]]], ["The entire study amounts to about 150 distinct scenarios, each with multiple (thousands of) runs.", [["multiple", "OBSERVATION_MODIFIER", 68, 76]]], ["This is an ongoing study that will be loaded into the MREP.", [["MREP", "DNA", 54, 58], ["an ongoing study", "TEST", 8, 24]]], ["Currently, only the principle results are loaded into the MREP; the code that generated the results has not yet been loaded.III. RESULTSA set of economic runs has also been generated as part of this study.", [["MREP", "DNA", 58, 62], ["economic runs", "TEST", 145, 158], ["this study", "TEST", 194, 204]]], ["The economic models involve assessments of cost-effective interventions with respect to containing disease spread.IV. DISCUSSIONThe MREP represents a one-of-a-kind resource for housing and cataloging infectious disease models.", [["infectious disease", "DISEASE", 200, 218], ["cost-effective interventions", "TREATMENT", 43, 71], ["disease spread", "PROBLEM", 99, 113], ["disease", "OBSERVATION", 99, 106]]], ["The strength of the MREP's design is its data model hierarchy that accurately portrays the stages of a study and its derivatives, at least from the MIDAS perspective.", [["MREP", "DNA", 20, 24], ["a study", "TEST", 101, 108]]], ["This data model begins with a high-level study as represented by an overall set of study objectives and design specifications and culminates at a low level with a set of runs (results) that contribute to assessing those objectives.", [["a high-level study", "TEST", 28, 46]]], ["In between the studies and the runs linked to those studies are the experiments that represent the different and independent points of view characterized by different research groups and the models those groups used to generate their results.", [["the studies", "TEST", 11, 22], ["those studies", "TEST", 46, 59]]], ["The final data model design element is based on the assumption that containment strategies are not always accommodated within a single model; a change in the model code is sometimes the favored approach for representing simulated behavior differences, that is, the containment strategy responses.IV. DISCUSSIONA second important element of the MREP is its use of a recognized code versioning application to house different model versions.", [["MREP", "DNA", 344, 348], ["containment strategies", "TREATMENT", 68, 90]]], ["Using Subversion fosters a highly controlled environment that promotes quality assurance/quality control (QA/QC) activities through a rigorous association among different model versions-their inputs and the results the input data set and model version generate.IV. DISCUSSIONA final feature of the MREP is the absence of standards associated with including models results.", [["Subversion fosters", "TREATMENT", 6, 24], ["QA/QC) activities", "TREATMENT", 106, 123], ["the input data", "TEST", 215, 229]]], ["The MREP permits Statistical Analysis Software (SAS), text, Excel, images, and virtually any output format for which a reader exists.", [["MREP", "DNA", 4, 8], ["Statistical Analysis", "TEST", 17, 37], ["images", "TEST", 67, 73]]], ["This tool will identify all models within the MREP (using the ontology information) that reference specific model parameters and connect those parameters to the values assigned by the study developers.", [["MREP", "DNA", 46, 50], ["the study", "TEST", 180, 189]]], ["This will provide a convenient mechanism for identifying and comparing assumptions across models within the MREP.", [["MREP", "DNA", 108, 112]]]], "PMC7486671": [["IntroductionWe are in the midst of the coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has resulted in thousands of deaths worldwide [1,2].", [["coronavirus disease", "DISEASE", 39, 58], ["COVID-19) pandemic", "DISEASE", 60, 78], ["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["deaths", "DISEASE", 187, 193], ["coronavirus", "ORGANISM", 39, 50], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 90, 137], ["SARS-CoV-2", "ORGANISM", 139, 149], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["SARS-CoV-2", "SPECIES", 139, 149], ["IntroductionWe", "TREATMENT", 0, 14], ["the coronavirus disease", "PROBLEM", 35, 58], ["COVID", "TEST", 60, 65], ["pandemic", "PROBLEM", 70, 78], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 90, 135], ["coronavirus disease", "OBSERVATION", 39, 58], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome", "OBSERVATION", 103, 123]]], ["Increased age and underlying health conditions, including diabetes, cardiovascular disease, obesity, and hypertension, significantly increase the risk of COVID-19 infection [3,4].", [["cardiovascular", "ANATOMY", 68, 82], ["diabetes", "DISEASE", 58, 66], ["cardiovascular disease", "DISEASE", 68, 90], ["obesity", "DISEASE", 92, 99], ["hypertension", "DISEASE", 105, 117], ["infection", "DISEASE", 163, 172], ["COVID-19", "CHEMICAL", 154, 162], ["COVID-19", "GENE_OR_GENE_PRODUCT", 154, 162], ["Increased age and underlying health conditions", "PROBLEM", 0, 46], ["diabetes", "PROBLEM", 58, 66], ["cardiovascular disease", "PROBLEM", 68, 90], ["obesity", "PROBLEM", 92, 99], ["hypertension", "PROBLEM", 105, 117], ["COVID-19 infection", "PROBLEM", 154, 172], ["health conditions", "OBSERVATION", 29, 46], ["cardiovascular", "ANATOMY", 68, 82], ["disease", "OBSERVATION", 83, 90], ["obesity", "OBSERVATION", 92, 99], ["hypertension", "OBSERVATION", 105, 117], ["increase", "OBSERVATION_MODIFIER", 133, 141], ["infection", "OBSERVATION", 163, 172]]], ["Similarly, disease severity may be worsened, and deaths are overrepresented in people with diabetes [4,5].", [["deaths", "DISEASE", 49, 55], ["diabetes", "DISEASE", 91, 99], ["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["disease severity", "PROBLEM", 11, 27], ["diabetes", "PROBLEM", 91, 99], ["disease", "OBSERVATION", 11, 18], ["may be", "UNCERTAINTY", 28, 34], ["worsened", "OBSERVATION_MODIFIER", 35, 43]]], ["Evidence shows poor glycemic control is both associated with and a consequence of COVID-19 infection, the latter demonstrated in older persons with type 2 diabetes [3,5,6].", [["infection", "DISEASE", 91, 100], ["type 2 diabetes", "DISEASE", 148, 163], ["COVID-19", "GENE_OR_GENE_PRODUCT", 82, 90], ["persons", "SPECIES", 135, 142], ["poor glycemic control", "PROBLEM", 15, 36], ["COVID-19 infection", "PROBLEM", 82, 100], ["type 2 diabetes", "PROBLEM", 148, 163], ["poor", "OBSERVATION_MODIFIER", 15, 19], ["glycemic control", "OBSERVATION", 20, 36], ["infection", "OBSERVATION", 91, 100]]], ["More recently, evidence has shown that Black, Asian, and minority ethnic groups are more severely affected, with higher death rates observed from COVID-19 infection in this population; high prevalence of diabetes and comorbidities in this subgroup likely contributes to this increased risk [7].", [["death", "DISEASE", 120, 125], ["COVID-19", "CHEMICAL", 146, 154], ["infection", "DISEASE", 155, 164], ["diabetes", "DISEASE", 204, 212], ["COVID-19", "ORGANISM", 146, 154], ["Black, Asian, and minority ethnic groups", "PROBLEM", 39, 79], ["severely affected", "PROBLEM", 89, 106], ["higher death rates", "PROBLEM", 113, 131], ["COVID-19 infection", "PROBLEM", 146, 164], ["diabetes", "PROBLEM", 204, 212], ["comorbidities", "PROBLEM", 217, 230], ["this increased risk", "PROBLEM", 270, 289], ["Black", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 155, 164], ["diabetes", "OBSERVATION", 204, 212]]], ["Despite the challenges for people with diabetes, the COVID-19 pandemic has presented a valuable opportunity to digitalize diabetes care.", [["diabetes", "DISEASE", 39, 47], ["diabetes", "DISEASE", 122, 130], ["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["diabetes", "PROBLEM", 39, 47], ["diabetes care", "TREATMENT", 122, 135]]], ["Given the importance of maintaining and improving well-being and glycemic control during this time, evaluation of novel methods to support self-management remotely is critically important.IntroductionThe aims of this paper are (1) to explore the evidence for the role of telemedicine to support people with diabetes during the COVID-19 pandemic and beyond; (2) to outline the benefits and challenges presented by virtual diabetes care; (3) to present our experience of virtual consultations in clinical settings during the COVID-19 pandemic; and (4) to share lessons learned to assist researchers, clinicians, and people with diabetes when integrating technology in diabetes care.Impact of Social Distancing/Shielding on Diabetes Care and Well-BeingWith diabetes being classed as a high-risk group by the government, it is important that people with diabetes take care of their health now more than ever.", [["diabetes", "DISEASE", 307, 315], ["diabetes", "DISEASE", 421, 429], ["diabetes", "DISEASE", 626, 634], ["diabetes", "DISEASE", 666, 674], ["Diabetes", "DISEASE", 721, 729], ["diabetes", "DISEASE", 754, 762], ["diabetes", "DISEASE", 850, 858], ["people", "ORGANISM", 295, 301], ["people", "ORGANISM", 614, 620], ["people", "ORGANISM", 838, 844], ["people", "SPECIES", 295, 301], ["people", "SPECIES", 614, 620], ["people", "SPECIES", 838, 844], ["glycemic control", "TREATMENT", 65, 81], ["evaluation", "TEST", 100, 110], ["novel methods", "TREATMENT", 114, 127], ["self-management", "TREATMENT", 139, 154], ["diabetes", "PROBLEM", 307, 315], ["the COVID", "TEST", 323, 332], ["virtual diabetes care", "TREATMENT", 413, 434], ["diabetes", "PROBLEM", 626, 634], ["diabetes care", "TREATMENT", 666, 679], ["Diabetes Care", "TREATMENT", 721, 734]]], ["People with diabetes are advised to practice social distancing (eg, working from home or self-isolating), adhere to national recommendations on frequent handwashing, and abstain from nonessential travel to avoid infectious contacts [8].", [["diabetes", "DISEASE", 12, 20], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["diabetes", "PROBLEM", 12, 20], ["diabetes", "OBSERVATION", 12, 20]]], ["In some cases, extremely vulnerable people with diabetes are advised to undertake \u201cshielding.\u201d", [["diabetes", "DISEASE", 48, 56], ["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["diabetes", "PROBLEM", 48, 56]]], ["Additional guidance, specifically for people with diabetes, focuses on self-management strategies, which help to boost innate immunity for primary prevention [8,9].", [["diabetes", "DISEASE", 50, 58], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["diabetes", "PROBLEM", 50, 58], ["self-management strategies", "TREATMENT", 71, 97], ["primary prevention", "TREATMENT", 139, 157]]], ["The American Association of Diabetes Educators recommends the following seven self-care activities: keeping physically active, healthy diet, following medication regimen, blood glucose monitoring and problem solving, reducing risk of complications, and self-empathy; all of these are endorsed for people with diabetes to reduce their risk and severity of COVID-19 [10].Impact of Social Distancing/Shielding on Diabetes Care and Well-BeingInterestingly, for people with diabetes, their engagement with these self-care activities has been highly variable during the pandemic, with some being able to focus more time on their diabetes management and undertake increasing amounts of self-care.", [["blood", "ANATOMY", 171, 176], ["Diabetes", "DISEASE", 28, 36], ["glucose", "CHEMICAL", 177, 184], ["diabetes", "DISEASE", 309, 317], ["Diabetes", "DISEASE", 410, 418], ["diabetes", "DISEASE", 469, 477], ["diabetes", "DISEASE", 623, 631], ["glucose", "CHEMICAL", 177, 184], ["COVID-19", "CHEMICAL", 355, 363], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["glucose", "SIMPLE_CHEMICAL", 177, 184], ["people", "ORGANISM", 297, 303], ["people", "ORGANISM", 457, 463], ["people", "SPECIES", 297, 303], ["people", "SPECIES", 457, 463], ["medication regimen", "TREATMENT", 151, 169], ["blood glucose monitoring", "TEST", 171, 195], ["problem solving", "TREATMENT", 200, 215], ["complications", "PROBLEM", 234, 247], ["self-empathy", "PROBLEM", 253, 265], ["diabetes", "PROBLEM", 309, 317], ["COVID", "TEST", 355, 360], ["Diabetes Care", "TREATMENT", 410, 423], ["diabetes", "PROBLEM", 469, 477], ["their diabetes management", "TREATMENT", 617, 642], ["complications", "OBSERVATION", 234, 247]]], ["For example, Bonora et al [11] showed in a small study that glycemic control improved for people with type 1 diabetes during lockdown who self-isolated compared to those who continued working [11].", [["type 1 diabetes", "DISEASE", 102, 117], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["a small study", "TEST", 41, 54], ["type 1 diabetes", "PROBLEM", 102, 117], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["However, for others, the significant change in lifestyle presented by lockdown has been detrimental to their health and well-being.", [["significant", "OBSERVATION_MODIFIER", 25, 36], ["change", "OBSERVATION", 37, 43]]], ["Barriers specifically for people with diabetes have included difficulty accessing healthy foods because of restricted shopping and bulk buying; inability to access medications; restricting physical activity to once per day in the local area; and being unable to attend face-to-face appointments with their diabetes care providers [8,9].", [["diabetes", "DISEASE", 38, 46], ["diabetes", "DISEASE", 306, 314], ["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32], ["diabetes", "PROBLEM", 38, 46], ["medications", "TREATMENT", 164, 175]]], ["With this in mind, diabetes health care professionals (HCPs) have valid concerns that glycemic control, quality of life, self-management, and well-being can be significantly jeopardized during social distancing and shielding, posing considerable risks to people with diabetes, both in the short and long term.", [["diabetes", "DISEASE", 19, 27], ["diabetes", "DISEASE", 267, 275], ["people", "ORGANISM", 255, 261], ["people", "SPECIES", 255, 261], ["glycemic control", "TREATMENT", 86, 102], ["self-management", "TREATMENT", 121, 136], ["diabetes", "PROBLEM", 267, 275]]], ["Lockdown, social distancing, shielding, and the abundance of misinformation in the media also present additional stressors, which may further exacerbate underlying depression and anxiety [12], conditions that are already highly prevalent in the diabetes population [13].Digital Consultations ::: Digitalization of Diabetes Care: Benefits and ChallengesTechnology has been increasingly integrated into diabetes education and care in modern times, for example, through apps, computer-based or web-based education, and telemedicine [14].", [["depression", "DISEASE", 164, 174], ["anxiety", "DISEASE", 179, 186], ["diabetes", "DISEASE", 245, 253], ["Diabetes", "DISEASE", 314, 322], ["diabetes", "DISEASE", 401, 409], ["underlying depression", "PROBLEM", 153, 174], ["anxiety", "PROBLEM", 179, 186], ["diabetes education", "TREATMENT", 401, 419]]], ["This non\u2013face-to-face activity may be synchronous or asynchronous, meaning a direct or indirect line of communication with an HCP, respectively [17,18].", [["asynchronous", "PROBLEM", 53, 65]]], ["Synchronous activity would be a video or telephone consultation, whereas asynchronous may involve monitoring an email or tracking system and responding to patients\u2019 questions through these platforms.", [["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163]]], ["The benefits of non\u2013face-to-face appointments are multifactorial and include the opportunity for better care and more connected patient care pathways, as well as cost savings and a reduced environmental impact.Digital Consultations ::: Digitalization of Diabetes Care: Benefits and ChallengesStudies evaluating virtual clinics prior to the COVID-19 pandemic have demonstrated feasibility, accessibility, safety, and effectiveness comparable to in-person consultations [19].", [["Diabetes", "DISEASE", 254, 262], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["a reduced environmental impact", "PROBLEM", 179, 209], ["the COVID", "TEST", 336, 345]]], ["A multicenter mixed methods study evaluating video consultations in diabetes care showed that video consultations were shorter in duration and people with diabetes did relatively more talking than the HCP [20,21].", [["diabetes", "DISEASE", 68, 76], ["diabetes", "DISEASE", 155, 163], ["people", "SPECIES", 143, 149], ["A multicenter mixed methods study", "TEST", 0, 33], ["diabetes", "PROBLEM", 155, 163]]], ["Although from a management perspective, video consultations were favored, there were significant barriers to uptake from the teams implementing them because of the significant changes introduced to their usual way of working and the care processes, systems, and pathways [21].", [["video consultations", "TEST", 40, 59]]], ["A Cochrane review analyzed 21 low-to-high-quality studies comparing telemedicine to usual care in people with diabetes and found that improvement in glycemic control was variable, but low-density lipoprotein (LDL) levels and blood pressure were more effectively lowered by telemedicine approaches compared to usual care [22].", [["blood", "ANATOMY", 225, 230], ["diabetes", "DISEASE", 110, 118], ["people", "ORGANISM", 98, 104], ["low-density lipoprotein", "SIMPLE_CHEMICAL", 184, 207], ["LDL", "SIMPLE_CHEMICAL", 209, 212], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["LDL", "PROTEIN", 209, 212], ["people", "SPECIES", 98, 104], ["A Cochrane review", "TEST", 0, 17], ["diabetes", "PROBLEM", 110, 118], ["low-density lipoprotein (LDL) levels", "PROBLEM", 184, 220], ["blood pressure", "TEST", 225, 239]]], ["Further studies have evaluated virtual clinics for diabetes care in type 1 and type 2 diabetes and have reported improved biochemical parameters, including glycated hemoglobin (HbA1c) [23].", [["diabetes", "DISEASE", 51, 59], ["type 2 diabetes", "DISEASE", 79, 94], ["glycated hemoglobin", "GENE_OR_GENE_PRODUCT", 156, 175], ["HbA1c", "SIMPLE_CHEMICAL", 177, 182], ["glycated hemoglobin", "PROTEIN", 156, 175], ["HbA1c", "PROTEIN", 177, 182], ["Further studies", "TEST", 0, 15], ["diabetes care", "TREATMENT", 51, 64], ["type 2 diabetes", "PROBLEM", 79, 94], ["glycated hemoglobin", "TEST", 156, 175], ["HbA1c", "TEST", 177, 182]]], ["However, many of these studies combined interventions, such as synchronous and asynchronous programs, rendering it difficult to delineate the efficacy of the individual interventions [23].", [["these studies", "TEST", 17, 30], ["synchronous and asynchronous programs", "TREATMENT", 63, 100], ["the individual interventions", "TREATMENT", 154, 182]]], ["Additionally, how these findings relate to virtual clinics being implemented during and due to a global pandemic must be considered.Digital Consultations ::: Digitalization of Diabetes Care: Benefits and ChallengesDuring the COVID-19 pandemic, telemedicine has been widely adopted globally in order to reduce exposure and need for people with diabetes to come into a hospital, while maintaining care standards for people with chronic conditions.", [["Diabetes", "DISEASE", 176, 184], ["diabetes", "DISEASE", 343, 351], ["people", "ORGANISM", 331, 337], ["people", "ORGANISM", 414, 420], ["people", "SPECIES", 331, 337], ["people", "SPECIES", 414, 420], ["a global pandemic", "PROBLEM", 95, 112], ["diabetes", "PROBLEM", 343, 351], ["chronic conditions", "PROBLEM", 426, 444], ["global", "OBSERVATION_MODIFIER", 97, 103], ["pandemic", "OBSERVATION", 104, 112]]], ["For example, virtual consultations have been implemented to triage patients suspected of COVID-19 in primary care and to initiate a hospital visit [25-27].", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["There have been other examples of successful virtual care adoption for people with newly diagnosed type 1 diabetes [28], and for people with long-standing type 1 diabetes.", [["type 1 diabetes", "DISEASE", 99, 114], ["type 1 diabetes", "DISEASE", 155, 170], ["people", "ORGANISM", 71, 77], ["people", "ORGANISM", 129, 135], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 129, 135], ["successful virtual care adoption", "TREATMENT", 34, 66], ["newly diagnosed type 1 diabetes", "PROBLEM", 83, 114], ["long-standing type 1 diabetes", "PROBLEM", 141, 170], ["diabetes", "OBSERVATION", 162, 170]]], ["A small Italian study showed that for people with type 1 diabetes who were not working during the pandemic and using continuous glucose monitoring, their time in range significantly improved from 54% to 65%, and this was attributed to decreased hyperglycemia [11].", [["type 1 diabetes", "DISEASE", 50, 65], ["glucose", "CHEMICAL", 128, 135], ["hyperglycemia", "DISEASE", 245, 258], ["glucose", "CHEMICAL", 128, 135], ["people", "ORGANISM", 38, 44], ["glucose", "SIMPLE_CHEMICAL", 128, 135], ["people", "SPECIES", 38, 44], ["A small Italian study", "TEST", 0, 21], ["type 1 diabetes", "PROBLEM", 50, 65], ["continuous glucose monitoring", "TEST", 117, 146], ["decreased hyperglycemia", "PROBLEM", 235, 258], ["small", "OBSERVATION_MODIFIER", 2, 7], ["decreased", "OBSERVATION_MODIFIER", 235, 244], ["hyperglycemia", "OBSERVATION", 245, 258]]], ["Blood glucose variability and average glucose readings from continuous glucose monitoring also significantly improved in this study.", [["Blood", "ANATOMY", 0, 5], ["glucose", "CHEMICAL", 38, 45], ["glucose", "CHEMICAL", 6, 13], ["glucose", "CHEMICAL", 38, 45], ["glucose", "CHEMICAL", 71, 78], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["glucose", "SIMPLE_CHEMICAL", 38, 45], ["glucose", "SIMPLE_CHEMICAL", 71, 78], ["Blood glucose variability", "TEST", 0, 25], ["average glucose", "TEST", 30, 45], ["continuous glucose monitoring", "TEST", 60, 89], ["this study", "TEST", 121, 131], ["glucose variability", "OBSERVATION", 6, 25], ["significantly", "OBSERVATION_MODIFIER", 95, 108], ["improved", "OBSERVATION_MODIFIER", 109, 117]]], ["In contrast to patients who continued working, there was no difference in glycemic control [11].", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Early reports suggest that virtual clinics are feasible, with some centers increasing virtual clinic consultations from 1% of all consultations prior to COVID-19 to 70% afterwards, and it is technology that has made this rapid transformation possible [29-31].Digital Consultations ::: Digitalization of Diabetes Care: Benefits and ChallengesA recent linguistic ethnographic study has shown that video consultations among people with a long-term condition and their clinician was found to be effective [26].", [["Diabetes", "DISEASE", 303, 311], ["people", "ORGANISM", 421, 427], ["people", "SPECIES", 421, 427], ["COVID", "TEST", 153, 158], ["this rapid transformation", "PROBLEM", 216, 241], ["linguistic ethnographic study", "TEST", 350, 379], ["Diabetes", "OBSERVATION", 303, 311]]], ["When patients experienced technical or operational issues with their video equipment or internet connection, they generally found a solution to resolve the problem.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["a solution", "TREATMENT", 130, 140]]], ["Technical interruptions and delays of connectivity either on patient or clinician device were clearly evident in the study; nevertheless, remote physical examinations were conducted, allowing the patient and/or carer to take an active role in the consultation [26].Patient Safety ::: Benefits of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesIn line with social distancing advice and minimizing risk for people with diabetes, virtual clinics bring specialist care to the home of the patient.", [["Diabetes", "DISEASE", 334, 342], ["diabetes", "DISEASE", 446, 454], ["patient", "ORGANISM", 61, 68], ["patient", "ORGANISM", 196, 203], ["people", "ORGANISM", 434, 440], ["patient", "ORGANISM", 513, 520], ["patient", "SPECIES", 61, 68], ["patient", "SPECIES", 196, 203], ["Patient", "SPECIES", 265, 272], ["people", "SPECIES", 434, 440], ["patient", "SPECIES", 513, 520], ["Technical interruptions", "TREATMENT", 0, 23], ["clinician device", "TREATMENT", 72, 88], ["the study", "TEST", 113, 122], ["remote physical examinations", "TEST", 138, 166], ["diabetes", "PROBLEM", 446, 454], ["Diabetes", "OBSERVATION", 334, 342]]], ["The virtual clinic is the ideal solution to enable patients to access specialist care but without unnecessarily exposing themselves to a high-risk environment, or come in close contact with staff or other patients.", [["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 205, 213], ["specialist care", "TREATMENT", 70, 85]]], ["This is particularly pertinent given the new data supporting the number of COVID-19 infections developed while being in hospital [32].Reduced Burden of Treatment: Improved Accessibility and Overall Experience ::: Benefits of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesVirtual clinics increase accessibility to specialist diabetes care.", [["infections", "DISEASE", 84, 94], ["Diabetes", "DISEASE", 263, 271], ["diabetes", "DISEASE", 354, 362], ["COVID-19 infections", "PROBLEM", 75, 94], ["specialist diabetes care", "TREATMENT", 343, 367], ["infections", "OBSERVATION", 84, 94], ["Burden", "OBSERVATION_MODIFIER", 142, 148], ["Diabetes", "OBSERVATION", 263, 271]]], ["In our experience, we have found that patients who regularly did not attend appointments are now attending their virtual clinic appointments.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["The virtual clinic may also provide an improved patient experience because people with diabetes are not required to spend additional time traveling to the hospital for regular appointments, which can significantly reduce the burden of treatment that some may experience with their diabetes care.", [["diabetes", "DISEASE", 87, 95], ["diabetes", "DISEASE", 281, 289], ["patient", "ORGANISM", 48, 55], ["people", "ORGANISM", 75, 81], ["patient", "SPECIES", 48, 55], ["people", "SPECIES", 75, 81], ["diabetes", "PROBLEM", 87, 95], ["treatment", "TREATMENT", 235, 244], ["their diabetes care", "TREATMENT", 275, 294]]], ["The virtual clinics may provide a solution\u2014video or phone calls may provide a relaxed environment for some people with diabetes, as they are within their own familiar surroundings, which may create a more relaxed atmosphere for their virtual appointment.", [["diabetes", "DISEASE", 119, 127], ["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113], ["diabetes", "PROBLEM", 119, 127]]], ["From our clinic team experience of using virtual consultations with people with diabetes, it is evident that some patients feel comfortable showing the HCP their house environment and exercise regimen, and introduce them to their family members, within professional boundaries.", [["diabetes", "DISEASE", 80, 88], ["people", "ORGANISM", 68, 74], ["patients", "ORGANISM", 114, 122], ["people", "SPECIES", 68, 74], ["patients", "SPECIES", 114, 122], ["diabetes", "PROBLEM", 80, 88], ["exercise regimen", "TREATMENT", 184, 200]]], ["This offers a unique insight into environmental or interpersonal factors, which may influence the self-care activities of people with diabetes.", [["diabetes", "DISEASE", 134, 142], ["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128], ["diabetes", "PROBLEM", 134, 142]]], ["Long-term, these factors may be considered when discussing the care plan and treatment goals of people with diabetes.", [["diabetes", "DISEASE", 108, 116], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["diabetes", "PROBLEM", 108, 116]]], ["The opportunities presented in virtual clinics for delivering increasingly person-centered and individualized care cannot be underestimated.Improved Therapeutic Alliance and Consultation Dynamics ::: Benefits of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesVirtual consultations could significantly shift the locus of control of people with diabetes, which would complement the philosophy around the importance of self-management and self-care in diabetes.", [["Diabetes", "DISEASE", 250, 258], ["diabetes", "DISEASE", 372, 380], ["diabetes", "DISEASE", 478, 486], ["people", "ORGANISM", 360, 366], ["people", "SPECIES", 360, 366], ["diabetes", "PROBLEM", 372, 380], ["self-management", "TREATMENT", 445, 460], ["diabetes", "PROBLEM", 478, 486], ["Diabetes", "OBSERVATION", 250, 258]]], ["Virtual consultations could provide an opportunity for shared care between people with diabetes and the HCP.", [["diabetes", "DISEASE", 87, 95], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["diabetes", "PROBLEM", 87, 95]]], ["Multiple members of the diabetes multidisciplinary team (MDT) may come together for the video consultation, to make collaborative decisions with patients.", [["diabetes", "DISEASE", 24, 32], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153]]], ["People with diabetes benefit from MDT input, with reduced time commitment for patients and professionals alike.", [["diabetes", "DISEASE", 12, 20], ["People", "ORGANISM", 0, 6], ["patients", "ORGANISM", 78, 86], ["People", "SPECIES", 0, 6], ["patients", "SPECIES", 78, 86], ["diabetes", "PROBLEM", 12, 20], ["MDT input", "TREATMENT", 34, 43]]], ["Physical examination (eg, conducting a diabetes foot examination) can also be performed.", [["diabetes", "DISEASE", 39, 47], ["Physical examination", "TEST", 0, 20], ["a diabetes foot examination", "TEST", 37, 64]]], ["This is particularly important in the context of diabetes foot disease, where people with diabetes can be triaged in virtual clinic to determine the need for hospital admission based on the video examination findings.", [["foot", "ANATOMY", 58, 62], ["diabetes foot disease", "DISEASE", 49, 70], ["diabetes", "DISEASE", 90, 98], ["foot", "ORGANISM_SUBDIVISION", 58, 62], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84], ["diabetes foot disease", "PROBLEM", 49, 70], ["diabetes", "PROBLEM", 90, 98], ["the video examination findings", "TEST", 186, 216], ["foot", "ANATOMY", 58, 62], ["disease", "OBSERVATION", 63, 70]]], ["Technical barriers would be expected when setting up virtual consultations; thus, we have shared a checklist that we developed for setting up a virtual clinic (Figure 1).Societal and Psychosocial Benefits ::: Benefits of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesVirtual clinics reduce the need for travel to and from hospitals, which is a significant benefit since 20% of traffic in the United Kingdom is attributed to health care\u2013related travel [15,16].", [["Diabetes", "DISEASE", 259, 267], ["Diabetes", "OBSERVATION", 259, 267]]], ["Additionally, virtual clinics mean less time is missed from work, which can be a recurrent issue for people with diabetes, so this reduction in treatment burden is highly advantageous.Societal and Psychosocial Benefits ::: Benefits of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesWith social isolation becoming more prevalent than ever during the current climate, it is imperative to acknowledge the positive impact that remote consultations may have on individuals who are required to practice social distancing and shielding.", [["diabetes", "DISEASE", 113, 121], ["Diabetes", "DISEASE", 273, 281], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["diabetes", "PROBLEM", 113, 121], ["this reduction", "TREATMENT", 126, 140], ["treatment burden", "TREATMENT", 144, 160], ["Diabetes", "OBSERVATION", 273, 281]]], ["Virtual consultations, whether these are conducted by telephone or video, provide people with diabetes the opportunity to virtually connect with their HCP, mitigating the psychological effects of social isolation.Patient Preference ::: Overcoming the Challenges of Virtual Care ::: Digitalization of Diabetes Care: Benefits and ChallengesPeople with diabetes can choose whether to have a telephone or video consultation, to reflect variability in access to technology and systems for video recording and to ensure access to care services.", [["diabetes", "DISEASE", 94, 102], ["Diabetes", "DISEASE", 300, 308], ["diabetes", "DISEASE", 350, 358], ["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88], ["Patient", "SPECIES", 213, 220], ["People", "SPECIES", 338, 344], ["social isolation", "TREATMENT", 196, 212], ["diabetes", "PROBLEM", 350, 358], ["video consultation", "TEST", 401, 419], ["video recording", "TEST", 484, 499], ["Diabetes", "OBSERVATION", 300, 308]]], ["However, virtual care is a significant change from the usual hospital attendance for their diabetes care, thus, some people with diabetes would still prefer a face-to-face consultation.", [["diabetes", "DISEASE", 91, 99], ["diabetes", "DISEASE", 129, 137], ["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["their diabetes care", "TREATMENT", 85, 104], ["diabetes", "PROBLEM", 129, 137]]], ["However, in light of the COVID-19 pandemic, people with diabetes have readily transitioned to virtual methods, and it is hoped that through familiarization with these new consultation methods, this may increase uptake of virtual care in the longer term.", [["diabetes", "DISEASE", 56, 64], ["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["diabetes", "PROBLEM", 56, 64], ["virtual methods", "TREATMENT", 94, 109], ["virtual care", "TREATMENT", 221, 233]]], ["There are also concerns that people with diabetes may find it difficult to build rapport with their HCP in a virtual clinic, but in our experience, the opposite is true.", [["diabetes", "DISEASE", 41, 49], ["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["diabetes", "PROBLEM", 41, 49]]], ["People with diabetes have been far more relaxed in the virtual clinic and able to speak more openly with their diabetes team, which is essential to improve their diabetes management.", [["diabetes", "DISEASE", 12, 20], ["diabetes", "DISEASE", 111, 119], ["diabetes", "DISEASE", 162, 170], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["diabetes", "PROBLEM", 12, 20], ["their diabetes management", "TREATMENT", 156, 181], ["diabetes", "OBSERVATION", 12, 20]]], ["But this is dependent on high-quality video image and sound, highlighting the essential role of technology to optimize communication between people with diabetes and their HCP.Engaging the Multidisciplinary Team ::: Overcoming the Challenges of Virtual Care ::: Digitalization of Diabetes Care: Benefits and ChallengesEngaging professionals and the wider team with virtual care can be a challenge in itself.", [["diabetes", "DISEASE", 153, 161], ["Diabetes", "DISEASE", 280, 288], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["diabetes", "PROBLEM", 153, 161], ["virtual care", "TREATMENT", 365, 377], ["dependent", "OBSERVATION_MODIFIER", 12, 21], ["Diabetes", "OBSERVATION", 280, 288]]], ["This is a significant change for the diabetes team as well as the patient, and new processes and pathways have needed to develop rapidly to manage the care of people with diabetes remotely (Figure 2 [33]).", [["diabetes", "DISEASE", 37, 45], ["diabetes", "DISEASE", 171, 179], ["patient", "ORGANISM", 66, 73], ["people", "ORGANISM", 159, 165], ["patient", "SPECIES", 66, 73], ["people", "SPECIES", 159, 165], ["diabetes", "PROBLEM", 171, 179], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["change", "OBSERVATION", 22, 28]]], ["It is essential that the whole team is committed to the virtual care approach, because this ensures the delivery of safe, high-quality care.", [["safe, high-quality care", "TREATMENT", 116, 139]]], ["It is anticipated that with increased familiarity and established systems, HCPs will be more open to adopt virtual care into their routine practice and overcome the natural aversion to change of how it has always been.The Future of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesAnecdotally, in our experience virtual clinics have been feasible and accessible, with high patient satisfaction.", [["Diabetes", "DISEASE", 270, 278], ["patient", "ORGANISM", 400, 407], ["patient", "SPECIES", 400, 407], ["Diabetes", "OBSERVATION", 270, 278]]], ["Virtual clinical consultations offer a different kind of benefit compared to conventional face-to-face appointments, particularly around convenience, logistics, cost-effectiveness, and clinician-patient dynamic/relationship [26].", [["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202]]], ["However, we must acknowledge the pitfalls of these new modes of communication and the challenges that may lie ahead with the clinical quality and safety of appointments.The Future of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesBuilding on these developments, we are looking to make virtual clinics sustainable for the long term.", [["Diabetes", "DISEASE", 221, 229], ["Diabetes", "OBSERVATION", 221, 229]]], ["In a time of a pandemic, individualized care is more important than ever and virtual clinics provide a readily accessible solution to facilitate this.", [["a readily accessible solution", "TREATMENT", 101, 130]]], ["Having applied virtual clinics in our setting for the last 2 months, lessons we have learned include: (a) the importance of integrating multiple members of the MDT into the one virtual consultation; (b) avoiding the checklist approach and instead focusing on an individualized, person-centered consultation; (c) and acknowledging that video consultation may be preferred to telephone because of the additional benefits of human contact, body language, and the opportunity to gain better insight into the lifestyle and livelihood of people with diabetes in order to tailor medical support accordingly.", [["body", "ANATOMY", 437, 441], ["diabetes", "DISEASE", 544, 552], ["human", "ORGANISM", 422, 427], ["body", "ORGANISM_SUBDIVISION", 437, 441], ["people", "ORGANISM", 532, 538], ["person", "SPECIES", 278, 284], ["human", "SPECIES", 422, 427], ["people", "SPECIES", 532, 538], ["human", "SPECIES", 422, 427], ["diabetes", "PROBLEM", 544, 552], ["medical support", "TREATMENT", 572, 587]]], ["In our experience, virtual clinics may be better suited to individuals with longstanding diabetes and where possible should be performed by a professional with whom they have already built a strong rapport.The Future of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesAlthough virtual clinics can be an alternative option, there are key elements that must be considered to make the consultation as efficient as possible.", [["diabetes", "DISEASE", 89, 97], ["Diabetes", "DISEASE", 258, 266], ["longstanding diabetes", "PROBLEM", 76, 97], ["Diabetes", "OBSERVATION", 258, 266]]], ["Secondly, logistical and administrative factors must be integrated within the NHS system, a system which for so many years has been based on delivering face-to-face patient services.", [["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172]]], ["We are programmed to deliver our outpatient services in a \u201ctraditional\u201d way, and therefore would anticipate a colossal challenge adapting this existing pathway to a more digital-focused platform.The Future of Virtual Clinics ::: Digitalization of Diabetes Care: Benefits and ChallengesBy acknowledging the complexity of integrating virtual consultations, we also acknowledge the challenges that may come with technology, in terms of the security and safety of every patient and HCP.", [["Diabetes", "DISEASE", 247, 255], ["patient", "ORGANISM", 466, 473], ["patient", "SPECIES", 466, 473], ["a colossal challenge", "TREATMENT", 108, 128], ["Diabetes", "OBSERVATION", 247, 255]]], ["Data protection and privacy is of critical importance; the technology, software, and programs used in virtual clinics must be encrypted and adhere to the General Data Protection Regulation and information governance standards to maintain patient confidentiality at all times.", [["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 238, 245], ["governance standards", "TREATMENT", 205, 225]]], ["We acknowledge that virtual consultations are not for everyone; however, providing options to people enables them to choose an approach that is tailored to their diabetes needs and lifestyle demands, with the aim of reducing the burden of treatment that so many people with diabetes may be experiencing.", [["diabetes", "DISEASE", 162, 170], ["diabetes", "DISEASE", 274, 282], ["people", "ORGANISM", 94, 100], ["people", "ORGANISM", 262, 268], ["people", "SPECIES", 94, 100], ["people", "SPECIES", 262, 268], ["an approach", "TREATMENT", 124, 135], ["treatment", "TREATMENT", 239, 248], ["diabetes", "PROBLEM", 274, 282]]], ["We aim to not only prepare our patients to attend virtual consultations, by creating a safe environment and respecting their safety (Figure 3), but to also create a digital platform that would integrate within the current NHS system.ConclusionVirtual consultations may become a necessity following this pandemic.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["this pandemic", "PROBLEM", 298, 311]]], ["The current system pressures due to COVID-19 have led to numerous challenges to the delivery of routine diabetes care and education.", [["COVID-19", "CHEMICAL", 36, 44], ["diabetes", "DISEASE", 104, 112], ["COVID-19", "CHEMICAL", 36, 44], ["The current system pressures", "TEST", 0, 28], ["COVID", "TEST", 36, 41], ["routine diabetes care", "TREATMENT", 96, 117]]], ["Despite the relative lack of data to support virtual care, in the face of adversity, these virtual measures have been imperative to maintain a line of communication with people with diabetes and to support self-management and self-care remotely.", [["diabetes", "DISEASE", 182, 190], ["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176], ["virtual care", "TREATMENT", 45, 57], ["diabetes", "PROBLEM", 182, 190], ["self-management", "TREATMENT", 206, 221]]], ["With the right infrastructure and systems in place, technology is the key to evolution in diabetes care, and virtual consultations can be effectively embedded into routine diabetes care at the national level in the United Kingdom.", [["diabetes", "DISEASE", 90, 98], ["diabetes", "DISEASE", 172, 180], ["diabetes care", "TREATMENT", 90, 103], ["routine diabetes care", "TREATMENT", 164, 185], ["right", "ANATOMY_MODIFIER", 9, 14], ["infrastructure", "OBSERVATION", 15, 29]]], ["At present, virtual clinics may be an ideal platform to reduce social isolation, encourage self-management remotely and in a less intrusive manner, and reduce burden of treatment.", [["social isolation", "TREATMENT", 63, 79], ["self-management", "TREATMENT", 91, 106], ["treatment", "TREATMENT", 169, 178]]], ["The COVID-19 outbreak will shift the culture of health care across the world and the way we interact within clinical settings will gradually change to ensure that care can be delivered within social distancing rules", [["The COVID", "TEST", 0, 9]]]]}